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Section 1: Introduction
During the past three decades, catheter and surgical ablation of atrial
fibrillation (AF) have evolved from investigational procedures to their
current role as effective treatment options for patients with AF.
Surgical ablation of AF, using either standard, minimally invasive, or
hybrid techniques, is available in most major hospitals throughout the
world. Catheter ablation of AF is even more widely available, and is
now the most commonly performed catheter ablation procedure.
In 2007, an initial Consensus Statement on Catheter and Surgical
AF Ablation was developed as a joint effort of the Heart Rhythm
Society (HRS), the European Heart Rhythm Association (EHRA), and
the European Cardiac Arrhythmia Society (ECAS).1 The 2007 docu-
ment was also developed in collaboration with the Society of
Thoracic Surgeons (STS) and the American College of Cardiology
(ACC). This Consensus Statement on Catheter and Surgical AF
Ablation was rewritten in 2012 to reflect the many advances in AF
ablation that had occurred in the interim.2 The rate of advancement
in the tools, techniques, and outcomes of AF ablation continue to in-
crease as enormous research efforts are focused on the mechanisms,
outcomes, and treatment of AF. For this reason, the HRS initiated an
effort to rewrite and update this Consensus Statement. Reflecting
both the worldwide importance of AF, as well as the worldwide per-
formance of AF ablation, this document is the result of a joint part-
nership between the HRS, EHRA, ECAS, the Asia Pacific Heart
Rhythm Society (APHRS), and the Latin American Society of Cardiac
Stimulation and Electrophysiology (Sociedad Latinoamericana de
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Estimulacio´n Cardı´aca y Electrofisiologı´a [SOLAECE]). The purpose
of this 2017 Consensus Statement is to provide a state-of-the-art re-
view of the field of catheter and surgical ablation of AF and to report
the findings of a writing group, convened by these five international
societies. The writing group is charged with defining the indications,
techniques, and outcomes of AF ablation procedures. Included within
this document are recommendations pertinent to the design of clin-
ical trials in the field of AF ablation and the reporting of outcomes,
including definitions relevant to this topic.
The writing group is composed of 60 experts representing 11 or-
ganizations: HRS, EHRA, ECAS, APHRS, SOLAECE, STS, ACC,
American Heart Association (AHA), Canadian Heart Rhythm Society
(CHRS), Japanese Heart Rhythm Society (JHRS), and Brazilian
Society of Cardiac Arrhythmias (Sociedade Brasileira de Arritmias
Cardı´acas [SOBRAC]). All the members of the writing group, as well
as peer reviewers of the document, have provided disclosure state-
ments for all relationships that might be perceived as real or potential
conflicts of interest. All author and peer reviewer disclosure informa-
tion is provided in Appendix A and Appendix B.
In writing a consensus document, it is recognized that consensus
does not mean that there was complete agreement among all the
writing group members. Surveys of the entire writing group were
used to identify areas of consensus concerning performance of AF
ablation procedures and to develop recommendations concerning
the indications for catheter and surgical AF ablation. These recom-
mendations were systematically balloted by the 60 writing group
members and were approved by a minimum of 80% of these mem-
bers. The recommendations were also subject to a 1-month public
comment period. Each partnering and collaborating organization
then officially reviewed, commented on, edited, and endorsed the
final document and recommendations.
The grading system for indication of class of evidence level was
adapted based on that used by the ACC and the AHA.3,4 It is import-
ant to state, however, that this document is not a guideline. The indi-
cations for catheter and surgical ablation of AF, as well as
recommendations for procedure performance, are presented with a
Class and Level of Evidence (LOE) to be consistent with what the
reader is familiar with seeing in guideline statements. A Class I recom-
mendation means that the benefits of the AF ablation procedure
markedly exceed the risks, and that AF ablation should be performed;
a Class IIa recommendation means that the benefits of an AF ablation
procedure exceed the risks, and that it is reasonable to perform AF
ablation; a Class IIb recommendation means that the benefit of AF ab-
lation is greater or equal to the risks, and that AF ablation may be
considered; and a Class III recommendation means that AF ablation is
of no proven benefit and is not recommended.
The writing group reviewed and ranked evidence supporting cur-
rent recommendations with the weight of evidence ranked as Level
A if the data were derived from high-quality evidence from more
than one randomized clinical trial, meta-analyses of high-quality
randomized clinical trials, or one or more randomized clinical trials
corroborated by high-quality registry studies. The writing group
ranked available evidence as Level B-R when there was moderate-
quality evidence from one or more randomized clinical trials, or
meta-analyses of moderate-quality randomized clinical trials. Level B-
NR was used to denote moderate-quality evidence from one or
more well-designed, well-executed nonrandomized studies,
observational studies, or registry studies. This designation was also
used to denote moderate-quality evidence from meta-analyses of
such studies. Evidence was ranked as Level C-LD when the primary
source of the recommendation was randomized or nonrandomized
observational or registry studies with limitations of design or execu-
tion, meta-analyses of such studies, or physiological or mechanistic
studies of human subjects. Level C-EO was defined as expert opinion
based on the clinical experience of the writing group.
Despite a large number of authors, the participation of several
societies and professional organizations, and the attempts of the
group to reflect the current knowledge in the field adequately, this
document is not intended as a guideline. Rather, the group would like
to refer to the current guidelines on AF management for the purpose
of guiding overall AF management strategies.5,6 This consensus docu-
ment is specifically focused on catheter and surgical ablation of AF,
and summarizes the opinion of the writing group members based on
an extensive literature review as well as their own experience. It is
directed to all health care professionals who are involved in the care
of patients with AF, particularly those who are caring for patients
who are undergoing, or are being considered for, catheter or surgical
ablation procedures for AF, and those involved in research in the field
of AF ablation. This statement is not intended to recommend or pro-
mote catheter or surgical ablation of AF. Rather, the ultimate judg-
ment regarding care of a particular patient must be made by the
health care provider and the patient in light of all the circumstances
presented by that patient.
The main objective of this document is to improve patient care by
providing a foundation of knowledge for those involved with catheter
ablation of AF. A second major objective is to provide recommenda-
tions for designing clinical trials and reporting outcomes of clinical tri-
als of AF ablation. It is recognized that this field continues to evolve
rapidly. As this document was being prepared, further clinical trials of
catheter and surgical ablation of AF were under way.
Section 2: Definitions,
Mechanisms, and Rationale for AF
Ablation
Definition
AF is a common supraventricular arrhythmia that is characterized by
rapid and irregular activation in the atria without discrete P waves on
the surface electrocardiogram (ECG). AF can be diagnosed with a
surface ECG, an intracardiac atrial electrogram, or both. An arrhyth-
mia that has the ECG characteristics of AF and lasts sufficiently long
for a 12-lead ECG to be recorded, or is otherwise documented to
last for at least 30 seconds, should be considered to be an AF epi-
sode. The 30-second duration was selected based on previous pub-
lished consensus statements and is used as the minimal duration to
define recurrence of AF after catheter ablation.1,7 This duration of AF
has not been linked to a specific outcome of AF. In addition to the
duration requirements listed above, the diagnosis of AF requires an
ECG or rhythm strip demonstrating: (1) “absolutely” irregular R-R
intervals (in the absence of complete atrioventricular [AV] block); (2)
no distinct P waves on the surface ECG; and (3) an atrial cycle length
(when visible) that is usually less than 200 ms.2,7
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Although there are several classification systems for AF, for this
consensus document, we have adopted in large part the classification
system that was presented in the 2014 AHA/ACC/HRS Guideline for
the Management of Patients with Atrial Fibrillation.5 We recommend
that this classification system be used for future studies of catheter
and surgical ablation of AF. Paroxysmal AF (PAF) is defined as AF that
terminates spontaneously or with intervention within 7 days of onset
(Table 1); persistent AF is defined as continuous AF that is sustained
beyond 7 days; and long-standing persistent AF is defined as continuous
AF of greater than 12 months’ duration. Early persistent AF is a new
term we have defined as continuous AF of more than 7 days’ duration
but less than 3 months’ duration. Within the context of AF ablation
and clinical trials of AF ablation, early persistent AF defines a population
of patients in whom better outcomes of AF ablation are anticipated
as compared with persistent AF of more than 3 months’ duration.
The term permanent AF is defined as AF in which the presence of the
AF is accepted by the patient and physician, and no further attempts
will be made to either restore or maintain sinus rhythm. It is import-
ant, therefore, to recognize that the term permanent AF represents a
therapeutic attitude on the part of a patient and their physician rather
than on any inherent pathophysiological attribute of the AF. Such de-
cisions can change as symptoms, the efficacy of therapeutic interven-
tions, and patient and physician preferences evolve. If a rhythm
control strategy is recommended after reevaluation, the AF should
be redesignated as paroxysmal, persistent, or long-standing persistent
AF. Within the context of any rhythm control strategy, including
catheter and surgical AF ablation, the term permanent AF is not mean-
ingful and should not be used. Silent AF is defined as asymptomatic AF
diagnosed by an opportune ECG or rhythm strip. Paroxysmal, per-
sistent, and long-standing persistent AF can be silent. We recognize
that a particular patient might have AF episodes that fall into one or
more of these categories; therefore, we recommended that patients
be categorized by their most frequent pattern of AF during the
6 months prior to performance of an ablation procedure. Lone AF is a
descriptor that has been applied to younger patients without clinical
or echocardiographic evidence of cardiac disease. Because the defin-
itions are variable, the term lone AF is potentially confusing, and
should not be used to describe populations of patients with AF nor
to guide therapeutic decisions.5 The term chronic AF also has variable
definitions and should not be used to describe populations of patients
with AF.
The writing group recognizes that these definitions of AF are very
broad, and that additional details should be provided when describing
a population of patients undergoing AF ablation. With the increased
use of implantable loop recorders (ILRs), pacemakers, and implant-
able cardioverter-defibrillators for rhythm diagnosis, we urge the in-
vestigators to specify the duration of time patients have spent in
continuous AF prior to an ablation procedure, including the 24-hour
AF burden, when data are available. The investigators should also
specify whether patients undergoing AF ablation have previously
failed pharmacological therapy, electrical cardioversion, catheter and/
or surgical ablation. Shown in Table 1 are a series of definitions of AF
types that can be used for future trials of AF ablation and in the litera-
ture to help standardize reporting of patient populations and
outcomes.
Demographic Profile of Patients with AF
and Risk Factors for Development of AF
AF is an exceedingly common age-related arrhythmia. Among people
of European descent, the lifetime risk of developing AF after age 40 is
26% for men and 23% for women.8 There are multiple risk factors
for development of AF.5,7 Some of these risk factors are modifiable,
including hypertension, obesity, endurance exercise, obstructive
sleep apnea (OSA), thyroid disease, and alcohol consumption,
whereas many others are not.5,7,9,10,11 Nonmodifiable risk factors
Table 1 Atrial fibrillation definitions
AF episode An AF episode is defined as AF that is docu-
mented by ECG monitoring or intracardiac
electrogram monitoring and has a duration of
at least 30 seconds, or if less than 30 seconds,
is present throughout the ECG monitoring
tracing. The presence of subsequent episodes
of AF requires that sinus rhythm be docu-
mented by ECG monitoring between AF
episodes.
Chronic AF Chronic AF has variable definitions and should
not be used to describe populations of AF
patients undergoing AF ablation.
Early persistent AF Early persistent AF is defined as AF that is sus-
tained beyond 7 days but is less than
3 months in duration.
Lone AF Lone AF is a historical descriptor that is poten-
tially confusing and should not be used to de-
scribe populations of patients with AF
undergoing AF ablation.
Long-standing
persistent AF
Long-standing persistent AF is defined as con-
tinuous AF of greater than 12 months’
duration.
Paroxysmal AF Paroxysmal AF is defined as AF that terminates
spontaneously or with intervention within 7
days of onset.
Permanent AF Permanent AF is defined as the presence of AF
that is accepted by the patient and physician,
and for which no further attempts to restore
or maintain sinus rhythm will be undertaken.
The term permanent AF represents a thera-
peutic attitude on the part of the patient and
physician rather than an inherent patho-
physiological attribute of AF. The term per-
manent AF should not be used within the
context of a rhythm control strategy with
antiarrhythmic drug therapy or AF ablation.
Persistent AF Persistent AF is defined as continuous AF that is
sustained beyond 7 days.
Silent AF Silent AF is defined as asymptomatic AF diag-
nosed with an opportune ECG or rhythm
strip.
AF, atrial fibrillation; ECG, electrocardiogram.
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include age, sex, family history, race, tall stature, and other types of
heart and valvular disease.5,7 Among the many risk factors for devel-
opment of AF, age is perhaps the most powerful.8,9 The relative risks
(RRs) of AF development associated with a number of risk factors
are provided in a recent systematic review.12 It is rare to develop AF
prior to age 50; and by age 80, approximately 10% of individuals are
diagnosed with AF. The precise pathophysiological basis of this link
between AF and age is not completely understood; however, age-
related fibrosis likely plays a key role.9 AF risk factors have also been
shown to be of value in predicting progression of paroxysmal to per-
sistent AF.13 It is notable that many of the risk factors that have been
associated with development of AF also contribute to AF progres-
sion, recurrences of AF following ablation, and complications associ-
ated with AF (e.g., stroke).
Natural History of AF
The concept of “AF begets AF” remains a cornerstone in the
understanding of the natural history of AF progression.14
Increasing AF burden is associated with progressive atrial re-
modeling and the development of atrial fibrosis, which can con-
tribute to the long-term persistence of AF.15 A wealth of
experimental data exist regarding structural and functional atrial
changes that contribute to the development, maintenance, and
progression of AF. In contrast, considerably less data exist regard-
ing the natural history of AF.16,17 This is in large part related to the
difficulty in accurately assessing the underlying burden of AF in in-
dividuals and large populations. Thus, estimates of the prevalence
of clinical AF subtypes and their progression have evolved with
the changes in population characteristics, associated comorbid-
ities, and development of modern arrhythmia monitoring technol-
ogy. For example, the rate of progression appears to be very low
in individuals with an initial diagnosis of AF who are younger than
60 years of age and who have no concomitant heart disease.
Among 97 individuals followed over three decades, 21% had an
isolated AF event without further recurrence, 58% had recurrent
AF, and 22% developed persistent AF.18 Other longitudinal studies
have demonstrated a much higher rate of AF progression. One re-
cent study examined the rate of progression to persistent AF
among 1219 paroxysmal patients with AF.13 Progression to per-
sistent AF was observed in 15% of the patients over 12 months of
follow-up. Predictors of progression included age, hypertension,
prior transient ischemic attack (TIA) or stroke, and chronic ob-
structive pulmonary disease. Similar results were reported in an-
other recent study that examined AF progression while waiting
for an AF ablation procedure.19 Among 564 patients with PAF,
11% progressed to persistent AF during a 10-month follow-up
period. In this study, heart failure (HF) and a left atrial (LA) diam-
eter >45 mm were predictive of progression. These findings raise
the possibility that the clinical progression of AF could be driven
by the development of associated comorbidities as opposed to
the arrhythmia itself. Moreover, recent studies using pacemaker-
documented AF burden have demonstrated a more complex nat-
ural history of the arrhythmia, with persistent AF reverting to par-
oxysmal forms, without intervention.20 This highlights our
incomplete understanding of the natural history of clinical AF and
the need for larger studies focusing on the accurate assessment of
AF progression and regression.
Genetic Contribution to AF
It is now well recognized that AF is heritable.21,22,23 Individuals having
a first-degree relative with AF have approximately a 40% increased
risk for development of AF after accounting for established clinical
AF risk factors.23 In the last decade, great progress has been made in
identifying the genetic determinants of AF. Although studies of fami-
lies with AF have led to the identification of mutations in a series of
ion channels and molecules, these mutations are typically family-
specific, rare, and do not explain a significant portion of the heritabil-
ity of AF.24 Therefore, population-based or genome-wide studies
have been used to identify many AF risk loci.25,26,27,28,29,30 The genes
at these loci encode transcription factors and ion channels, and many
are without a clear relation to AF at the present time.
There is interest in trying to use genetics to predict the onset of
AF, to stratify the risk of AF outcomes such as stroke and HF, and to
identify the response to treatments including antiarrhythmic medica-
tions or catheter ablation procedures. Interestingly, a genetic risk
score consisting of the top 12 loci for AF can be used to identify as
much as a 5-fold gradient in the risk of AF or those at greatest risk for
a stroke.31,32 However, similar to other common diseases, the gen-
etic risk for AF provides minimal additional predictive value after con-
sidering basic clinical risk factors such as age and sex.33,34 Future
studies will be directed at using a comprehensive panel of genetic
variants to identify those at greatest risk for AF, and also to predict
stroke risk and outcomes to AF therapy, including AF ablation.35
Whether genetic testing will ultimately prove to be an important clin-
ical marker of AF risk will become clear over time. An alternative
and/or complementary strategy, which might be easier for clinicians
to employ, will be the use of a clinical risk score.
Genetic Determinants of Ablation
Outcome
Because many genetic determinants of AF have been identified, a lo-
gical question would be to ask whether genetics can help predict the
outcome of an ablation procedure.35 At the present time, however,
whether genetics will help predict outcomes remains an unanswered
question. Although there have been a number of studies exploring
the relation between a genetic variant or single nucleotide poly-
morphism (SNP) and AF ablation outcome, these studies have been
challenged by small sample sizes, testing of a limited number of SNPs,
and variable endpoints.
One recent study pooled ablation data from three different sites
consisting of 991 individuals of European ancestry.36 They tested rep-
resentative SNPs at the top three loci (PITX2, ZFHX3, and KCNN3)
identified for AF in genome-wide association studies and related
these SNPs to ablation outcome. The primary finding was that an
SNP, rs2200733, at the chromosome 4q25 or the PITX2 locus for AF
was associated with a 1.4-fold increased risk of late AF recurrence. In
contrast, another recent study found differing results in a large
Korean population of 1068 individuals undergoing catheter ablation
for AF.37 This second study tested a similar set of SNPs, representing
the PITX2, ZFHX3, and KCNN3 loci, yet they did not observe any
long-term difference in AF recurrence after an ablation.
It is possible that the different outcomes noted in these two stud-
ies are due to a racial difference in the genetic influence on ablation
outcome, although future studies will be necessary to resolve this
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issue. Larger, prospective, multiethnic studies that test a comprehen-
sive number of SNPs will be necessary before genetic data can be
considered clinically useful when considering AF ablation procedures.
Significance of AF
AF is an important arrhythmia for many reasons. First, it is common:
current estimates reveal that more than 33 million individuals world-
wide have AF.38 In the United States alone, it is estimated that be-
tween 3 and 5 million people have AF, and that by 2050 this number
will exceed 8 million.39 Second, AF increases risk of stroke by an
average of 5-fold.40 AF-related strokes are more severe than those
not related to AF.41 Third, AF increases mortality, and has been
linked to an increased risk of sudden death.42,43 Consistent with these
prior studies, a recent Framingham study reported that those with re-
current or sustained AF had a higher multivariable-adjusted mortality
compared with those with an isolated AF episode.44 Fourth, AF in-
creases the risk of HF.45 Fifth, recent studies have linked AF with the
development of dementia.46 Finally, AF causes a wide variety of symp-
toms, including fatigue and reduced exercise tolerance, and signifi-
cantly impairs quality of life (QOL).47 It is notable that asymptomatic
status is associated with similar (or worse) prognosis compared with
symptomatic status.48 AF is also important when considered in terms
of use of health care resources and cost. In the United States, AF ac-
counts for more than 450,000 hospitalizations yearly and has contrib-
uted to more than 99,000 deaths.49,50 AF has been reported to
increase annual health care costs by $8700 per patient, resulting in a
$26 billion annual increase in U.S. health care costs. Although studies
have not been performed to address the question of whether AF
control with catheter ablation impacts the morbidity and mortality
associated with AF, it is notable that emerging data have revealed
that persistent forms of AF are associated with a significant increase
in thromboembolism and death compared with PAF.51
The morbidity and mortality associated with AF provide a rationale
to maintain sinus rhythm. Given the anticipated enormous public
health impact of AF, proven interventions to reduce the risk of
stroke, HF, cognitive impairment, and mortality are direly needed.
Large, prospective, multicenter, randomized clinical trials will help ad-
dress whether sinus rhythm achieved with ablation techniques low-
ers morbidity and mortality compared with rate control alone or
treatment with antiarrhythmic therapy. These studies will also best
define the patient population that will derive the most benefit. Until
the results of these types of clinical trials are available, it must be rec-
ognized that the only proven benefit of AF ablation remains the re-
duction of symptoms and an improvement in QOL.
Relationship Between Presence and Type
of AF and Symptoms
During the past 15 years, multiple studies have investigated the im-
pact of rate vs rhythm control on stroke risk and mortality.52,53,54,55
These studies have demonstrated no difference in these endpoints.
When interpreting the results of these studies, it is important to keep
in mind the population of patients who were enrolled, the approach
used for rhythm control, and the duration of follow-up. These studies
enrolled predominantly elderly, minimally symptomatic patients with
AF in whom either a rate or rhythm control strategy would be ac-
ceptable; the mean duration of follow-up was less than 4 years. The
primary indication for catheter ablation is to reduce patient symp-
toms and improve QOL. Therefore, prior to undergoing catheter ab-
lation, it is important to confirm that the patient’s symptoms
(palpitations, fatigue, or effort intolerance) result from AF and to as-
sess their severity. In some patients with PAF, arrhythmia-monitoring
tools (e.g., transtelephonic monitoring, Holter) are useful to establish
the correlation between symptoms and rhythm. In patients with per-
sistent AF who initially appear to be asymptomatic, a reassessment of
symptoms after restoration of sinus rhythm with cardioversion often
reveals that the patient does in fact feel better when in sinus rhythm.
Because of this observation, many experienced clinicians routinely
recommend cardioversion with a reassessment of symptoms in ap-
parently asymptomatic patients with persistent AF. If the patient is ul-
timately demonstrated to be symptomatic, a rhythm control strategy
becomes an attractive therapeutic approach. Conversely, if there is
no change in symptoms postrestoration of sinus rhythm, a rate con-
trol strategy could be preferable.
Several AF ablation studies evaluated the relationship between pa-
tient characteristics and the presence of AF symptoms.56,57,58 It is
well recognized that patients’ perception of AF varies widely. One of
the first studies to examine AF symptoms prior to and following abla-
tion found that among 114 patients who underwent 7-day Holters
prior to and following ablation, 38% of the patients had only symp-
tomatic AF episodes, 57% had both symptomatic and asymptomatic
episodes, and 5% of the patients had only asymptomatic episodes.
Following the ablation, the percentage of patients with only asymp-
tomatic episodes of AF increased to 37%.56 Asymptomatic AF is
more frequent in men than in women.48,59,60 In two prospective
registries and in one recent retrospective study, older age was associ-
ated with asymptomatic AF.48,60,61 Inconsistent results have been re-
ported for the association between asymptomatic AF and cardiac
and noncardiac comorbidities.48,59,60 Although any type of AF can be
asymptomatic, asymptomatic AF is more common in patients with
continuous persistent AF.48 In approximately half of the patients with
highly symptomatic AF referred for catheter ablation, asymptomatic
episodes are also present.45,50,57,62 Arrhythmia episodes are more
likely to be asymptomatic following, as compared with prior to, AF
ablation. Therefore, assessment of freedom from AF postablation
cannot be based on freedom from symptoms alone.63
Anatomic and Electrophysiological
Features of the Atria, Coronary Sinus,
and Pulmonary Veins
In recent decades, the development of catheter ablation of AF and
other atrial arrhythmias has made it necessary to have a sound under-
standing of cardiac anatomy (Figure 1). Figure 1 shows the cardiac
anatomy relevant for AF ablation when viewed from the anterior
(Figure 1A), right lateral (Figure 1B), left lateral (Figure 1C), and poster-
ior projections (Figure 1D, 1E).64 Viewed from the front, the right
atrium (RA) is right and anterior, while the LA is situated to the left
and mainly posteriorly, with the right pulmonary veins (PVs) adjacent
to the intercaval area of the RA.65,66 Consequently, the plane of the
atrial septum lies at an angle to the sagittal plane of the body. The
front of the LA and the medial wall of the RA lie just behind the aortic
root, separated only by the transverse pericardial sinus. The poster-
ior wall of the LA is just in front of the tracheal bifurcation and the
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esophagus, with the fibrous pericardium separating the heart from
these structures.
PV anatomy is highly variable between patients (Figure 2). Four dis-
tinct PV ostia are present in approximately 60% of patients, whereas
variant anatomy is observed in 40% of patients undergoing ablation.67
In approximately 80% of cases, the anterior part of the ostium of the
left PVs is common, separated from the appendage by a ridge.68,69
The most frequent type of variant anatomy is a left common PV, and
the second most frequent variant anatomy is a right middle PV.
Anomalous PVs can also be observed arising from the roof of the
atrium. The orifices of the left PVs are located more superior than
those of the right PVs. The right superior (RS) PV and the left super-
ior (LS) PV project forward and upward, whereas the right inferior
(RI) PV and the left inferior (LI) PV project backward and downward.
The RSPV lies just behind the superior vena cava (SVC) or RA, and
the left PVs are positioned between the left atrial appendage (LAA)
and the descending aorta.
Nathan and Eliakim first drew attention to the presence of sleeves
of cardiac tissue that extend onto the PVs (Figure 1E).70 Myocardial
muscle fibers extend from the LA into all the PVs for 1–3 cm; the
thickness of the muscular sleeve is highest at the proximal ends (1–
1.5 mm), and then gradually decreases distally.16,64,71 The orientation
of the major atrial muscular bundles (e.g., Bachmann’s bundle or
Crista terminalis) has been recognized from anatomical dissections,
with mostly circular bundles around the ostia of the PVs, AV valves,
and LAA.72 Studies have described how premature firing from the
PVs can initiate AF by interacting with tissue mechanisms, using diffu-
sion tensor imaging (at present, in vitro).73,74 These findings have been
Figure 1 Anatomical drawings of the heart relevant to AF ablation. This series of drawings shows the heart and associated relevant structures
from four different perspectives relevant to AF ablation. This drawing includes the phrenic nerves and the esophagus. (A) The heart viewed from the
anterior perspective. (B) The heart viewed from the right lateral perspective. (C) The heart viewed from the left lateral perspective. (D) The heart
viewed from the posterior perspective. (E) The left atrium viewed from the posterior perspective. Illustration: Tim Phelps VC 2017 Johns Hopkins
University, AAM.
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reproduced by cardiac magnetic resonance imaging (MRI), highlight-
ing the very variable individual pattern of fiber orientation.75 Future
in vivo implementation (in addition to identification of fibrosis), com-
bined with simultaneous mapping techniques, could allow individual
tailoring of interruption of potential reentrant “pathways.”76,77
The greater coronary venous system drains approximately 85% of
the venous flow into the RA, with the most proximal part being called
the coronary sinus (CS). The great cardiac vein ascends into the left
AV groove, where it passes close to the circumflex artery and under
the cover of the LAA. The juncture between the great cardiac vein
and the CS is marked by the entrance of the vein of Marshall (which
is typically obliterated in adults and is referred to as the ligament of
Marshall), which descends along the epicardium between the LAA
and the LSPV and can contain sympathetic nerves and ganglia.78
Especially around the CS itself, muscular bundles are present that
interconnect to the LA, thereby serving as additional interatrial elec-
trical “conductors.”79,80
PV focal firing can trigger AF or act as a rapid driver to maintain the
arrhythmia. During embryological development of the heart, the lo-
cation of the precursors of the conduction system is defined by the
looping process of the heart tube.81,82 Cell markers common to pre-
cursors of specialized conduction tissue derived from the heart tube
have been found within myocardial sleeves.83 The presence of P cells,
transitional cells, and Purkinje cells has been demonstrated in human
PVs.84,85 PV-sleeve cardiomyocytes have discrete ion channel and ac-
tion potential properties that predispose them to arrhythmogene-
sis.84,85 They have small background IK1, which could favor
spontaneous automaticity,84 as could their reduced coupling to atrial
tissue, a property common to pacemaking structures.86 Other stud-
ies show susceptibility to Ca2þ-dependent arrhythmia mechanisms,87
possibly due to cells of melanocyte origin.88 Some, but not all, studies
have reported that isolated cardiomyocytes from rabbit and canine
PVs show abnormal automaticity and triggered activity during ma-
nipulations that enhance Ca2þ loading.87,88,89 These properties might
explain the electrical activity within the PVs that is commonly
observed after electrical disconnection of the PVs from the atrium.90
Other studies have provided evidence to suggest that the PVs and
the posterior LA are also preferred sites for reentrant arrhyth-
mias.90,91 One important factor could be the shorter action potential
duration (APD) of the PVs vs the atrium84 due to larger delayed-
rectifier Kþ currents and smaller inward Ca2þ currents in the
PV.89,92,93 In addition, PVs demonstrate conduction abnormalities
that promote reentry due to abrupt changes in fiber orientation as
well as Naþ channel inactivation by reduced resting potentials due to
small IK1.
84 Yet another study examined the impact of increasing atrial
pressure on PV activation, finding that as LA pressure was increased
above 10 cm H2O, the PV–LA junction became the source of domin-
ant rotors.94 These observations help explain the clinical link be-
tween AF and increased atrial pressure. Several clinical studies have
reported shorter refractory periods (RPs) inside PVs compared to
the LA, decremental conduction inside PVs, and easy induction of PV
reentry with premature stimulation from the PVs. Accordingly, rapid
reentrant activity with entrainment phenomena have been described
inside PVs after successful PV isolation (PVI).95,96 Electrophysiological
evaluation of the PVs using multielectrode basket catheters has re-
vealed effective refractory period (ERP) heterogeneity and
Figure 2 This figure includes six CT or MR images of the left atrium and pulmonary veins viewed from the posterior perspective. Common and un-
common variations in PV anatomy are shown. (A) Standard PV anatomy with 4 distinct PV ostia. (B) Variant PV anatomy with a right common and a
left common PV. (C) Variant PV anatomy with a left common PV with a short trunk and an anomolous PV arising from the right posterior left atrial
wall. (D) and (E) Variant PV anatomy with a common left PV with a long trunk. (F) Variant PV anatomy with a massive left common PV.
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anisotropic conduction properties within the PV and at the PV–LA
junction, which can provide a substrate for reentry.97 The response
of PV activity to adenosine administration in patients with PAF is
more consistent with a reentrant than a focal-ectopic type of mech-
anism.98,99 In addition, dominant frequency analysis points to an evo-
lution of mechanisms in patients with AF, with PV sources becoming
less predominant as AF becomes more persistent and atrial remodel-
ing progresses.95
Autonomic Nervous System and How It
Relates to AF and AF Ablation
The cardiac autonomic nervous system (ANS) can be divided into
the extrinsic and intrinsic ANS.100 The extrinsic cardiac ANS consists
of sympathetic and parasympathetic components,101,102 and includes
neurons in the brain and spinal cord and nerves directed to the heart.
The intrinsic ANS primarily includes thousands of autonomic neu-
rons and nerves located in ganglionated plexi (GP), which are transi-
tioned to the epicardial fat pads outside the heart and along the great
vessels in the thorax.100,103,104 There are 7 major GP, including 4
located in the LA around the PVs.103,105 The ligament of Marshall,
which also contains GP, plays a coordination role between the ex-
trinsic and intrinsic ANS.106 The GP predominantly contain parasym-
pathetic neurons, but also sympathetic neurons. In humans,
numerous autonomic nerves are located at the PV–LA junction. The
nerve densities are much more pronounced within 5 mm of the PV–
LA junction and are higher in the epicardial surface than in the endo-
cardium.107,108 These data reveal that the areas of LA endocardial
surface most suitable for ANS modification are located in the imme-
diate vicinity of the PV–LA junction. Due to close relationship of the
sympathetic and parasympathetic ANS components, it is difficult to
perform selective radiofrequency (RF) ablation of a particular part of
the ANS,109 and ablation of these sites can destroy both adrenergic
and cholinergic nerves.
In an animal model of PAF, injection of parasympathomimetics into
the fat pad adjacent to the PV-atrial junctions resulted in spontaneous
or easily induced sustained AF, suggesting that a hyperactive ANS can
play an important role in patients with focal AF arising from the
PV.110,111 Stimulation of GP by pacing at the base of the PV can also
provide a substrate of AF initiation from PV firing.112,113 Studies have
shown that the intrinsic ANS has a potential impact on acute atrial
electrical remodeling induced by rapid atrial pacing.113 Other studies
have shown that synergic actions of both the sympathetic and para-
sympathetic neurotransmitters promote rapid PV firing in an experi-
mental system.114 Another study demonstrated that stimulation of the
right anterior GP converts isolated premature depolarization from the
RSPV into AF-inducing premature depolarizations,115 indicating a link
between GP activity and AF inducibility. The authors proposed a
model of a highly integrated atrial neural network in which a GP hyper-
active state could release a gradient of locally excessive concentrations
of neurotransmitters that initiate AF, whereas activation of the axons
can “retrogradely” excite the GP at a distance to cause the release of
neurotransmitters to induce AF. Several studies have identified a link
between the intrinsic cardiac nervous system and complex fractio-
nated atrial electrograms (CFAEs) and AF triggers.113,116
The effectiveness of catheter ablation of GP in patients with AF re-
mains controversial. One of the major challenges has been the lack of
a sensitive and specific means to localize the GP in pa-
tients.117,118,119,120 Whereas several small studies have reported im-
proved outcomes using an anatomically based approach to localize
autonomic ganglia, these findings have not been replicated by other
investigators.121,122 A recent prospective randomized surgical AF ab-
lation study reported no improvement of outcomes by ablation of
autonomic ganglia.123
The most commonly used approach to localize the major atrial GP
is to apply high-frequency stimulation (HFS) to the presumed GP
areas to elicit AV block. This method has low specificity and sensitiv-
ity because endocardial GP can be embedded in epicardial fat
pads.106,124 Some investigators have suggested that HFS mainly re-
veals the afferent link of the ANS, suggesting that sites eliciting vagal
responses do not coincide with sites where GP clusters and efferent
autonomic nerves are located.125 Another issue is reinnervation of
the ANS during follow-up.108,114 Whether reinnervation causes re-
current AF postablation remains uncertain. One study has reported
that reinnervation of the ANS in patients after RF ablation is not dir-
ectly related to AF recurrence.126
In summary, there is considerable evidence that the ANS contrib-
utes to the initiation and maintenance of AF. Whether ablation of the
ANS impacts the outcomes of AF ablation remains uncertain. In the
future, novel approaches for ANS modulation could increase the effi-
cacy of AF ablation treatment.127,128,129
Cardiac Fibrosis: Etiology and How It
Relates to AF
Atrial fibrosis is a common finding in patients with AF. The question
of whether atrial fibrosis stems from AF itself, from AF-related risk
factors, or from a specific fibrotic atrial cardiomyopathy (FACM) is
under debate.130,131,132,133,134 Recently, a subgroup of patients with
recent onset persistent AF have been described with a diffuse abnor-
mal substrate and with poor outcome after ablation.135 There is great
variability in the amount of fibrosis in patients with AF, in which some
patients with PAF have massive fibrosis and some patients with per-
sistent AF show mild fibrosis.134,136 Some morphological studies have
shown that fibrosis in humans is related to the underlying disease ra-
ther than being caused by AF.73,137,138 The specific role of age and AF
risk factors in atrial fibrosis was questioned by an autopsy study, in
which only small amounts of fibrofatty tissue were described in atrial
specimens from patients with a high mean CHA2DS2-VASc score of
4.3 but no AF.139 In addition, a low correlation between risk factors
and the fibrotic substrate as estimated from electroanatomic voltage
mapping in patients with non-PAF has been described.140 Similarly,
cardiovascular risk factors were found to be equally distributed in
various classes of LA fibrosis as described by MRI studies, and struc-
tural atrial remodeling was the same in patients with and without car-
diovascular risk factors.130 On the other hand, there is extensive
evidence that many AF risk factors do substantially increase atrial fi-
brosis content, and that AF itself might have a profibrotic ef-
fect.141,142,143 One study reported that elevated serum markers of
collagen synthesis were associated with postsurgical AF, compared
with those who stayed in sinus rhythm.144
It is possible that the fibrotic atrial substrate could be a result of a
specific FACM.131,133,140 FACM has been described as a specific dis-
ease with various expressions, from mild, to moderate, to severe
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atrial fibrosis, and with a potentially progressive disease process.
Consequently, AF—and other arrhythmias such as reentrant atrial
tachycardia (AT) and sinus node disease—can be understood as a
manifestation of the preexisting FACM.131,133,145,146
Atrial Electrical and Structural
Remodeling
The pathophysiology of AF is complex, involving interaction among
multiple factors, including triggers, which are responsible for AF initi-
ation; substrate, which is necessary for AF maintenance; and perpetu-
ators, which underlie the progression of the arrhythmia from
paroxysmal to the persistent forms.146,147 The recently published
EHRA/HRS/APHRS/SOLAECE expert consensus document on atrial
cardiomyopathies provides a detailed review of the important topic
of atrial cardiomyopathies and their interrelationship with AF.148 It is
generally believed that some degree of structural remodeling must
predate electrical remodeling. The trigger mechanisms can include
focal enhanced automaticity or triggered activity. Initiation of AF can
be favored by both parasympathetic and sympathetic activation,
which also appear to play a role in maintaining AF.149 However, the
central mechanisms governing AF initiation and perpetuation are
poorly understood, which explains in part why treatment of patients
with all forms of AF, and particularly long-standing persistent AF, re-
mains suboptimal. Although AF usually starts with paroxysmal epi-
sodes, it can evolve to a persistent form in a significant number of
patients.150 A few clinical factors have been associated with transition
from paroxysmal to persistent AF.20,151,152 The transition likely
reflects progressive structural and electrophysiological remodeling
in both atria, making the sources of the arrhythmia more stable
by fundamental mechanisms that have been incompletely
explored.153,154,155,156
AF-Related Extracellular Matrix
Remodeling
Persistent AF itself leads to electrical remodeling and fibrosis of the
atria.157,158 Experimental and clinical data point to a complex patho-
physiology involving diverse factors, including oxidative stress, cal-
cium overload, atrial dilatation, microRNAs, inflammation, and
myofibroblast activation.141,159,160,161,162 In a recent study of tran-
scriptional changes associated with AF, susceptibility to the arrhyth-
mia was associated with decreased expression of targets of several
transcription factors related to inflammation, oxidation, and cellular
stress responses.163 However, it is unknown to what extent and at
which time points such alterations influence the remodeling process
that perpetuates AF. Moreover, rapid atrial rates activate fibroblasts
to increase collagen-gene activity, and AF in isolation might promote
cardiac fibrosis.131,133,134
Cardiac fibrosis is part of the maladaptive cardiac remodeling in re-
sponse to cardiac injury164,165 and has been implicated in initiation
and maintenance of AF.166 The mechanisms that are responsible for
fibrosis and its consequences comprise many phenomena occurring
at various scales, including molecular, organelle, cellular, and tissue
scales.167 At the molecular scale are dynamics changes in the genome,
the transcriptome, and the signaling pathways underlying the gener-
ation of profibrotic molecules168; cellular changes involve interactions
among the various cardiac cells, including myocytes, fibroblasts or
myofibroblasts, and inflammatory cells such as macrophages and neu-
trophils169; and tissue changes relate to the dynamics of scar, angio-
genesis, electrical conduction, and contractility.153 Fibrosis can
certainly act as an electrically insulating obstacle. Profibrotic stimuli
promote differentiation of fibroblasts into activated myofibroblasts,
which electronically couple to myocytes in vitro20,150,151,152; whether
this occurs to a significant extent in AF atria in vivo remains uncertain.
Fibrosis affects electrical propagation through slow, discontinuous
conduction with “zigzag” propagation,170,171 reduced regional cou-
pling,172 abrupt changes in fibrotic bundle size,173 interruption of bun-
dle continuity, and micro-anatomical reentry.174
Another potentially important factor in AF-related atrial remodel-
ing is fatty infiltration, which is known to increase in a number of myo-
cardial pathophysiological conditions and is regarded as
arrhythmogenic.175,176,177 Obesity is a known AF risk factor, and the
increasing incidence of AF could be related to increasing rates of
obesity.177,178 Obesity frequently coexists with other AF risk factors
that improve in response to weight loss, emphasizing the importance
of weight loss in AF risk factor management.179 Epicardial fatty infil-
tration occurs with obesity180 and has been associated with AF.177
Biofactors released from fat might promote fibrosis and myocardial
remodeling.
Atrial Amyloidosis
Over the past decade, a number of studies have called attention to a
link between atrial amyloidosis and AF.74,181,182 Amyloidosis is char-
acterized by the presence of extracellular proteinaceous deposits
showing characteristic structural and tinctorial properties. The vari-
ous types of amyloidosis are distinguished based on the fibril protein
deposited and the clinical presentation. Amyloidosis can affect the
heart as part of a systemic process, as in immunoglobulin-derived
light-chain amyloidosis. Amyloid can also be deposited in the heart as
a manifestation of aging (senile amyloidosis), with amyloid observed
in cardiac vessels, in the ventricular interstitium, and in the atria. The
heart can also be affected by an organ-limited variant called isolated
atrial amyloidosis. The incidence of isolated atrial amyloidosis ex-
ceeds 90% in the ninth decade. Studies have shown that isolated atrial
amyloidosis affects atrial conduction and increases the risk of AF.
Notably, there is an inverse correlation between isolated atrial amyl-
oidosis and atrial fibrosis.
Role of Intracellular Ca2þ Dysregulation
Spontaneous Ca2þ release promoting triggered activity is likely to be
an important mechanism of AF initiation.183 During AF, the exceed-
ingly high frequency of atrial excitation is expected to lead to RyR2
refractoriness184 and downregulation of Ca2þ handling proteins,158
acting to prevent triggered activity in the presence of persistent AF.
RyR2 leakiness is therefore unlikely to contribute to persistent AF.185
However, such considerations do not apply in PAF, in which ectopic
activity likely related to Ca2þ-dependent ectopy could play an im-
portant role. There is evidence that Ca2þ released from the leaky
RyR2 receptors in the sarcoplasmic reticulum (SR) is exchanged by
the Naþ-Ca2þ exchanger (NCX), which produces an arrhythmo-
genic depolarizing current that induces atrial ectopic activity.186,187 In
a mouse model characterized by progressive AF, SR Ca2þ leak is
enhanced in association with Ca2þ/calmodulin-dependent protein
kinase II (CaMKII)-dependent hyperphosphorylation of the ryanodine
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receptor.188 Genetic inhibition of the Ca2þ leak reduced structural
remodeling and prevented the development of persistent AF.188
However, in isolated remodeled rabbit and human atrial myocytes,
Ca2þ signaling was silenced through a variety of mechanisms.185 The
authors suggested that Ca2þ silencing might be a protective mechan-
ism against the Ca2þ overload that occurs during chronic AF, and
challenged the notion that aberrant Ca2þ release contributes to the
pathophysiology of persistent AF. However, during AF, the exceed-
ingly high frequency of atrial excitation is expected to lead to RyR2
refractoriness and downregulation of Ca2þ-handling proteins, acting
to prevent triggered activity. Therefore, whether RyR2 leakiness con-
tributes to persistent AF is now being disputed.158,184,185 A popular
concept that had been promoted by some investigators over the last
several years was that both initiation and maintenance of AF could be
related to increased activity of protein kinase A (PKA) and/or Ca2þ/
CaMKII, with subsequent uncontrolled diastolic Ca2þ release from
the SR.186 The idea is that Ca2þ released from the “leaky” RyR2 re-
ceptors in the SR would overactivate the NCX to extrude Ca2þ and
produce an arrhythmogenic depolarizing current, thereby explaining
both the contractile dysfunction and the high recurrence rate of the
arrhythmia.186,187 In a recent study in mice with a mutation causing
progressive AF, SR Ca2þ leak was reported to be enhanced in associ-
ation with Ca2þ/CaMKII–dependent hyperphosphorylation of the
ryanodine receptor.188 Genetic inhibition of Ca2þ/CaMKII-mediated
RyR2-S2814 suppressed the Ca2þ leak, reduced structural remodel-
ing, and prevented the development of persistent AF.188 However,
recent studies in large animals and in humans have challenged the
idea that Ca2þ dysfunction underlies AF maintenance and perpetu-
ation. In isolated rabbit atrial myocytes, remodeling in response to
sustained tachycardia for up to 5 days was shown to silence Ca2þ sig-
naling through a failure of subcellular propagated Ca2þ release.185
The authors suggested that Ca2þ silencing might be a protective
mechanism against the massive Ca2þ overload that occurs during
chronic AF. In another study in human atrial myocytes, although
CaMKII appeared to facilitate catecholamine-evoked arrhythmias in
the atrial myocardium of patients with sinus rhythm, the same agon-
ists failed to elicit arrhythmias in the atrial myocardium of patients
with chronic AF, likely related to atrial remodeling, which included
decreases in CaMKII-mediated processes.189
The above results in patients are consistent with data derived from
western blot analyses in sheep, designed to test whether remodeling
was related to altered intracellular calcium dysfunction.158 Although
the Naþ-Ca2þ exchange was increased in the LAA of animals with
persistent AF, both total RyR2 and phosphorylated RyR2 proteins
were decreased, and the ratio of phosphorylated RyR2 to total RyR2
phosphorylation was unaffected. Thus, the transition from paroxys-
mal to persistent AF in the sheep model of atrial tachypacing did not
appear to depend on Ca2þ leak or delayed afterdepolarizations
(DADs).
Ion Channels and Electrical Remodeling
Electrical remodeling, manifested as shortening of atrial refractori-
ness, develops within the first few days of AF.13,153,154,190 A number
of ion channel modifications underlying such electrical changes have
been described in animal models and humans.17,190,191,192 A recent
study158 used a clinically relevant ovine model of intermittent RA
tachypacing and demonstrated that, after the first AF episode, the
dominant excitation frequency (DF) increased gradually during a
2-week period in both LA and RA until it stabilized at a time that coin-
cided with the onset of persistent AF. The DF changes were associ-
ated with downregulation of ICaL and INa and upregulation of IK1,
along with corresponding mRNA or protein changes, as described in
extensive previous studies of atrial remodeling.17 Interstitial fibrosis
developed at 6–12 months and coincided with persistent AF. This
study highlighted progressive forms of atrial remodeling in the
increasing tendency of AF to persist over time. Consistent with these
findings, another study recently demonstrated that AF persistence
was associated with numerous transcriptional changes in ion channel
expression.163 Such changes included upregulation of KCNJ2 and
KCNJ4 (encoding Kir2.1 and Kir2.3 subunits, respectively, which con-
tribute to IK1) and downregulation of CACNA1C (encoding the ICaL
a-subunit) and CACNAB2 (an ICaL b-subunit).
163,193 Therefore, the
progressive DF increase during PAF is also consistent with the fact
that AF frequency is usually higher in patients with persistent than
with PAF,98 a difference that is now clearly due to sustained AF-
related electrical remodeling. Sustained AF shortens APD and the
ERP, decreasing the wavelength and facilitating the acceleration and
stabilization of sustained reentry. The primary determinants of APD
shortening are the decrease in ICaL and increase in IK1.
158
Mechanisms of AF: Multiple Wavelet
Hypothesis, Reentry, Spiral Waves,
Rotational Activity, and Focal Triggers
from the Pulmonary Veins and Other
Sites
For many years, three concepts competed to explain the mechanism
of AF: multiple reentrant wavelets (Figure 3A), rapidly discharging
automatic foci (Figure 3B), and a single reentrant circuit with fibrilla-
tory conduction (Figure 3C).194,195,196 Considerable progress has
been made in defining the mechanisms underlying initiation, perpetu-
ation, and progression of AF (Figures 3, 4).16,17 A key breakthrough
was the recognition that in some patients, AF is triggered and/or
maintained by rapidly firing foci and can be “cured” by local catheter
ablation.197 This crucial observation focused attention on the PV car-
diomyocyte sleeves. Subsequent work confirmed the key role of the
PVs in AF, particularly paroxysmal forms, and showed that the PVs
have features that make them favored zones to harbor both focal
automatic and microreentrant activity.157
The multiple wavelet concept was initially proposed by Garrey
(Figure 3A), was later refined by Moe, and for at least 50 years became
the dominant mechanistic framework for AF. Engelmann had earlier
suggested that AF was maintained by rapidly discharging atrial ectopic
foci,198,199,200 a notion that was subsequently rejected only to period-
ically resurface.201 Finally, Thomas Lewis suggested that a single rap-
idly rotating primary reentrant circuit (a “mother wave”) was the
most likely mechanism underlying AF.202 For AF due to a single ec-
topic focus or a rapidly rotating single circuit, fibrillatory conduction
is required to account for the irregular activation typical of AF.203 All
three of these classical mechanisms were proposed in the early 20th
century and continue to underlie much of the contemporary thinking
about AF mechanisms.195
As mentioned above, the observations of early investigators who
recognized the importance of the PVs in AF were critical. Their initial
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observations pointed to a critical role for very rapidly discharging PV
foci in maintaining AF. Subsequent experimental studies indicated
that the PVs could indeed represent sites of very rapid automatic ac-
tivity, which is enhanced by the rapid activation caused by AF.204
Subsequent detailed studies of PV cardiomyocyte ion-current func-
tion84 and structure91 indicated that the PVs also have properties
favoring local microreentry, which likely contribute to their participa-
tion in AF. Recent studies have implicated abnormal Ca2þ handling
and DAD related to spontaneous ectopic activity of patients with
paroxysmal or long-standing persistent AF.186,205 However, more re-
cent studies strongly suggest that during long-term sustained AF, one
should not expect an increase in the spontaneous release of Ca2þ
from the SR, nor that DADs or triggered activity is involved in AF
maintenance or in the progression to stable forms of the arrhyth-
mia.158,206,207 Subsequent to recognition of the importance of the
PVs, a variety of sites other than the PVs have been shown to poten-
tially harbor AF-maintaining sources,208 but the critical importance of
the PVs has withstood the test of time.
Allessie et al induced and mapped electrically induced tachycardia
in isolated rabbit atria and documented the circular movement reen-
try in that model.209 Using a limited number of electrodes, the au-
thors detected an activation sequence that suggested centripetal
direction of wavelet propagation. The authors proposed that these
centripetal wavelets activated tissue at the center of the circuit,
resulting in double responses (double potentials) of subnormal ampli-
tude. Because the centripetal wavelets were unable to propagate be-
yond the center, they prevented the impulse from shortcutting the
circuit, resulting in the maintenance of reentry. This mechanism of
reentry was named leading circle reentry by Allessie et al.209 Building
on ideas put forward initially by Mines and later quantified by Wiener
and Rosenblueth, Allessie et al suggested that functional reentry nat-
urally establishes itself in the shortest circuit that can maintain reen-
try, defined by the distance a cardiac impulse travels during the
RP.210,211,212 This distance determines the length of the shortest
reentrant cardiac excitation wave (wavelength, WL) and is equal to
the product of conduction velocity (CV) and RP (e.g., WL = CV 
RP). If AF is maintained by multiple simultaneous reentrant waves,
the likelihood of spontaneous termination is greatest when the atria
are only large enough to maintain one reentrant wave; if the wave-
length is shortened so that multiple waves can be maintained simul-
taneously, the chances of spontaneous termination will be greatly
reduced and AF is likely to be sustained. Evidence to support this no-
tion was obtained in a dog model by varying autonomic tone and ad-
ministering antiarrhythmic drugs (AADs).211 However, some clinical
observations were incompatible with the leading circle mechanism,
notably the effectiveness of Naþ channel blockers in AF. According
to the leading circle notion, Naþ channel blockers should decrease
the wavelength by reducing CV and thereby promote, rather than
Figure 3 Schematic drawing showing various hypotheses and proposals concerning the mechanisms of atrial fibrillation. (A) Multiple wavelets
hypothesis. (B) Rapidly discharging automatic foci. (C) Single reentrant circuit with fibrillatory conduction. (D) Functional reentry resulting from rotors
or spiral waves. (E) AF maintenance resulting from dissociation between epicardial and endocardial layers, with mutual interaction producing multi-
plying activity that maintains the arrhythmia.
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terminate, AF. Furthermore, for many years, multiple numerical stud-
ies and high-density mapping studies in cardiac tissues have failed to
confirm the idea of the leading circle or the presence of centripetal
wavelets in the maintenance of reentrant excitation.
Computer simulations and experiments in multiple mammalian
species suggest that functional reentry is better explained by rotors
or spiral waves (Figure 3D). This idea was first conceptualized by
Russian scientists in the 1960s, and later popularized by Arthur
Winfree to explain the reentry in all excitable media.213,214,215 The
rotor is the organizing center of the reentrant excitation215; it spins
at exceedingly high frequencies, radiating spiral wavefronts with out-
wardly decreasing curvature, forming an Archimedean spiral, and re-
sulting in wave fragmentation in its periphery.216,217 Because CV
decreases as the wavefront curvature becomes steeper toward the
center tip, it follows that at that site (sometimes called the phase sin-
gularity [PS]) the curvature reaches a critical value, the velocity be-
comes zero, and the PS follows a circular trajectory.215,218 At each
point the direction of propagation is perpendicular to the wavefront
and the velocity increases toward the periphery. The PS is a unique
point where the wavefront and the wavetail converge and velocity is
zero, preventing the impulse from extending toward the center of
the rotation. Instead, the PS becomes the rotor, circling around a
small center of unexcited but excitable tissue.218 The concept of
rotor can also be applicable to anatomical reentry in the atria; a pec-
tinate muscle or the orifice of a PV can stabilize a reentrant
rotor.156,219 Unlike leading-circle reentry, spiral-wave reentry is not
determined by the wavelength, but rather by the source-sink rela-
tionship between the activation wavefront and the tissue that must
be excited in front of it to maintain activity. The rotor concept has
been applied to AF, and subsequent studies have confirmed its ability
to account for the AF-suppressing actions of Naþ channel
blockers.119
Recent advances in electrophysiological recording and analysis
have led to important advances in appreciating AF-maintaining mech-
anisms in patients. Interestingly, they have also led to new controver-
sies. The application of advanced computing technology to the
definition of detailed intracardiac electrical activity based on highly
sophisticated body surface mapping (BSM), a technique called
Figure 4 Structure and mechanisms of atrial fibrillation. (A) Schematic drawing of the left and right atria as viewed from the posterior perspective.
The extension of muscular fibers onto the PVs can be appreciated. Shown in yellow are the five major left atrial autonomic ganglionic plexi (GP) and
axons (superior left GP, inferior left GP, anterior right GP, inferior right GP, and ligament of Marshall). Shown in blue is the coronary sinus, which is
enveloped by muscular fibers that have connections to the atria. Also shown in blue is the vein and ligament of Marshall, which travels from the
coronary sinus to the region between the left superior PV and the left atrial appendage. (B) The large and small reentrant wavelets that play a role in
initiating and sustaining AF. (C) The common locations of PV (red) and also the common sites of origin of non-PV triggers (shown in green).
(D) Composite of the anatomic and arrhythmic mechanisms of AF. Adapted with permission from Calkins et al. Heart Rhythm 2012; 9:632–696.e21.2
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electrocardiographic imaging (ECGI), has led to the noninvasive ana-
lysis of underlying mechanisms in patients with AF.220,221 Both focal
and reentrant rotor sources were visualized and tended to become
more numerous as AF was maintained for longer periods.221
Detailed analysis of patients undergoing AF ablation indicates that
rotors are localized to specific atrial regions and tend to be short-
lasting, with rotor cores tending to occur at the interface between fi-
brotic tissue and more normal atria.222 Investigators have also applied
intra-atrial basket catheters and complex mathematical analysis to de-
fine AF mechanisms and target them in the electrophysiology labora-
tory with a technique called focal impulse and rotor modulation
(FIRM).77 FIRM procedures have identified rotational activity in pa-
tients with AF. A number of studies have shown the superiority of
FIRM-based ablation over conventional ablation strategies.223
However, the success of targeted rotational activity ablation, as well
as the meaning of rotors detected by FIRM technology, have been
disputed in recent clinical studies. A prospective randomized clinical
trial is now underway. It is notable that conventional mapping tech-
niques using isochronal mapping have not been able to identify con-
tinuous rotational activation.224,225 It is also notable that detailed
human atrial mapping studies have not observed discrete rotors, but
rather suggest that AF is maintained by dissociation between epicar-
dial and endocardial layers, with mutual interaction producing multi-
plying activity that maintains the arrhythmia (Figure 3E).226,227,228,229
Investigators have recorded more than 500 epicardial electrograms
from both atria during cardiac surgery in patients with persistent AF
and were unable to identify reentrant activity.229 They interpreted
their results as suggesting predominance of focal activity and break-
throughs. Potential unifying findings were recently presented by
investigators, who performed high-resolution endocardial and epicar-
dial optical mapping in explanted diseased human hearts.227 They
noted that AF was driven by stable transmural reentrant sources an-
chored to anatomical complexities and fibrotic regions. One limita-
tion of their studies was a need for an action potential abbreviating
drug (pinacidil) to observe AF, limiting the applicability of their find-
ings to spontaneous AF.
In summary, although the presently available data leave a number
of questions open, they do indicate that both ectopic activity and
reentry play important roles in AF. The specific mechanisms and de-
terminants remain to be elucidated, along with their implications for
therapy.
Mechanisms of Atrial Tachycardia and
Atrial Flutter
Atrial arrhythmias can be broadly classified as focal, small circuit, or
macroreentry (Figure 5A–F). Focal ATs can originate from anywhere
within the atria or venous structures but do have a classical anatomic
Figure 5 Schematic drawing showing mechanisms of atrial flutter and atrial tachycardia. (A) Isthmus-dependent reverse common (clockwise) atrial
flutter. (B) Isthmus-dependent common (counter clockwise) atrial flutter. (C) Focal atrial tachycardia with circumferential spread of activation of the
atria (can arise from multiple sites within the left and right atrium). (D) Microreentrant atrial tachycardia with circumferential spread of activation of
the atria. (E) Perimitral atrial flutter. (F) Roof-dependent atrial flutter.
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distribution (Figures 4, 5C). In the absence of a prior LA catheter or
surgical ablation procedure, approximately two-thirds of focal tachy-
cardias have an RA origin and one-third occur from the LA. In the
RA, the most common anatomic locations are the crista terminalis,
tricuspid annulus, CS ostium, and perinodal regions. In the LA, the
pulmonary venous ostia and mitral annulus are most common. Focal
tachycardias also can arise from the LA and RA appendages, but these
sites of origin are rare.
Macroreentry is a broad term that encompasses what have been
considered to be typical and atypical atrial flutters (AFLs). The hall-
mark of macroreentry is that two sites >_2 cm apart demonstrate en-
trainment with a postpacing interval–tachycardia cycle length
of <_ 20 ms (i.e., within the circuit). The most common forms of atrial
macroreentry are variants of classical common and reverse common
cavotricuspid isthmus-dependent flutter (Figure 5A,B). These include
both counterclockwise (common) and clockwise (reverse common)
variants, with the circuit originally described as a broad active wave-
front rotating around the tricuspid annulus. However, it is now rec-
ognized that many variants exist, such as lower loop reentry and
forms in which the active wavefront crosses immediately anterior or
posterior to the inferior vena cava. Rarely, intraisthmus reentry can
occur. Classical AFL almost invariably coexists with AF. Studies of
AFL onset and termination have demonstrated that both invariably
require transitional AF, indicating that flutter is largely a downstream
arrhythmia. Attempts to modify the natural history of AF by ablation
of AFL have thus far largely been unsuccessful. Nevertheless, cavotri-
cuspid isthmus ablation is a simple procedure with high efficacy and
low risk that can provide good arrhythmia palliation in the appropri-
ately selected patient. However, long-term follow-up studies follow-
ing flutter ablation have demonstrated increasing prevalence of AF
during long-term follow-up.230
Atypical forms of macroreentry can occur in both the LA and RA
and are most common in the setting of prior atrial surgery or prior
ablation for AF. They can also occur spontaneously. In the RA, these
can occur in the free wall, where a surgical or spontaneous scar cre-
ates the central obstacle; or in the form of upper loop reentry in
which the SVC is the central obstacle, often with some anchoring
scar. Circuits have also been described around segments of the crista
terminalis, which acts as a central barrier and creates regions of slow
conduction. Reentrant circuits on the right septum, even in the con-
text of surgical scars or prosthetic material, are uncommon. In the
LA, macroreentry is most common in the context of prior ablation.
The type of circuit varies according to the nature of prior ablation
and to the underlying structural heart disease. Patients with more
advanced atrial remodeling, such as those with persistent AF, will be
more likely to have regions of slow conduction. Linear ablation par-
ticularly induces macroreentry due to the propensity for gaps in lines
to develop. At the gap site, conduction can also be slowed due to the
presence of damaged tissue. Common reentrant circuits are perimi-
tral- or mitral isthmus-dependent or, alternately, roof-dependent cir-
cuits (Figure 5E,F), which occur around either the left- or right-sided
PVs. Ablation of these circuits can be accomplished by creation of a
linear ablation lesion in the form of a mitral or an anterior line
for perimitral flutter or a roof line for roof-dependent flutters.
Microreentrant AFL can be ablated with a focal lesion (Figure 5D).
When flutter occurs through a gap in a preexisting line, focal ablation
at that gap can often be sufficient to create complete conduction
block. With the diminished use of linear ablation for persistent AF
treatment, the prevalence of these circuits is expected to diminish.
Whenever linear ablation is required for ablation of a macroreen-
trant circuit it is important to check for bidirectional conduction
block. Macroreentrant circuits can also occur in the LA around large
regions of scar. These can either occur spontaneously, particularly in
the setting of structural heart disease and atrial enlargement, or be
due to prior ablation. Simultaneous dual-loop reentry can also be
observed in this situation. Left septal flutter has been described, but is
an uncommon arrhythmia. When patients present with macroreen-
trant arrhythmias following AF ablation, it is important to also identify
and ablate the trigger causing onset. Common sources of triggers in-
clude the PVs, reflecting PV reconnection, or non-PV triggers.
Small circuit reentry has been described more recently, and most
classically occurs in the context of a prior catheter or surgical abla-
tion procedure due to islands of scar that form a central obstacle and
regions of slow conduction (Figure 5D). The definition of a small circuit
as being less than 2 cm in diameter creates a rather arbitrary distinc-
tion from macroreentry, but it does have clinical relevance. In the ma-
jority of small circuits, a single focal isthmus of slow conduction can
be found in which focal ablation eliminates the circuit.
Potential Benefits and Rationale for
Eliminating AF with Ablation
As described earlier in this document, AF is associated with many ad-
verse outcomes, including stroke, dementia, HF, impaired QOL,
increased medical costs, and mortality. Understanding the effect of
catheter ablation of AF on these outcomes is important in the overall
assessment of the role of ablation in the long-term management of
patients with AF. There have been a number of studies that have
examined long-term outcomes with AF ablation. To date, however,
none have prospectively randomized patients to ablation vs medical
management and followed them longitudinally for more than 1 to
2 years. There are some long-term prospective registries of patients
who have undergone AF ablation, with patients matched to those
treated medically. Despite rigorous propensity matching, there could
still be unrecognized differences in the populations treated with abla-
tion compared with those receiving medical management. Thus,
most of the evidence we have, while suggestive of benefit from abla-
tion, cannot be taken as definitive with respect to major health out-
comes. This lack is the rationale behind the Catheter Ablation vs
Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA)
(ClinicalTrials.gov identifier NCT00911508), which is a prospective,
randomized trial of ablation vs medical management of AF. The trial
has completed enrollment, but it will be some time before the results
are known.
It is widely recognized that AF ablation is effective in controlling AF
and its associated symptoms. Multiple studies have demonstrated
that AF ablation improves QOL in a patient with symptomatic AF,
including those with HF.231,232 Many patients with AF have HF with
reduced ejection fraction (EF). Multiple studies have examined the ef-
fect of ablation on EF.63,76,233,234,235,236 In a meta-analysis of nine stud-
ies of AF ablation in patients with HF, mean EF improved 11% (95%
confidence interval [CI] 6.9–15.3, P <.001).237 The effect of ablation
on the future risk of stroke is of great interest, partly because of the
morbidity and mortality associated with stroke, but also because of
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the need to inform decisions regarding continuing anticoagulation in
patients with apparently successful ablations. A number of studies,
but not all, have reported a low stroke rate in patients who have
undergone AF ablation when followed long term.238,239,240,241,242
Although the results of these studies taken as a whole report a lower
than expected stroke rate, these results can be considered prelimin-
ary data because many of these trials enrolled patients with a
CHA2DS2-VASc score of < 2, in whom stroke rates will be antici-
pated to be low. This reflects the fact that very few patients with a
high stroke risk profile were followed long term after suspension of
anticoagulation. Notably, it has recently been shown that patients
with PAF have a lower stroke rate than those with persistent AF.51
These observations, while preliminary, are supportive of the emerg-
ing belief that AF ablation could in fact reduce stroke risk. The ultim-
ate proof that elimination of AF by ablation lowers stroke risk will
require a large, prospective, randomized clinical trial such as
CABANA. Limited studies have evaluated the effect of ablation on
the risk of dementia. Prior studies have reported that Alzheimer’s de-
mentia occurred in 0.2% of AF ablation patients compared with 0.9%
of patients with AF who did not have ablation and 0.5% of patients
without AF (P <.0001). Other types of dementia were also reduced
significantly in patients who had undergone ablation.239 Although
these findings are of interest, they must be considered preliminary
because this was not a prospective randomized trial. The impact of
AF ablation on mortality is also uncertain. Although a number of pre-
liminary studies have reported encouraging results, not all studies
have reported a reduction in mortality. These results must also be
considered preliminary due to their study design.232,239,241
In summary, there is strong evidence that AF ablation improves
QOL, and reasonable evidence that AF ablation improves ventricular
function in those patients with AF who have HF. The impact of AF
control with ablation on other endpoints, including stroke risk, de-
mentia, and mortality, will require further study.
Electrophysiological Basis of AF Ablation
It is generally accepted that development of AF requires both a trig-
ger and a susceptible substrate. Figures 3 and 4 summarize the many
mechanisms of AF. Over time, AF progresses from a trigger-driven to
a more substrate-mediated arrhythmia due to structural remodeling
of the atria.153,243 Ablative therapy is therefore aimed at either elimi-
nating the trigger initiating AF or modifying the arrhythmogenic sub-
strate. The most commonly employed ablation strategy consists of
electrical isolation of the PVs by creation of circumferential lesions
around the right and the left PV.197,244,245 A schematic overview of
common lesion sets created during an AF ablation procedure is
shown in Figure 6. The effects of these lesions have been attributed to
isolation of AF triggering PV foci, elimination of non-PV triggering
foci, and/or as the result of modification of the arrhythmogenic sub-
strate.246 The latter might include interruption of crucial pathways of
conduction between pulmonary-atrial junctions, which play a role in
sustenance of AF, reduction of the amount of mass available for the
number of simultaneously circulating wavelets (atrial debulking), or
partial vagal denervation by interruption of vagal stimulation from the
autonomic ganglia.109,247,248,249 Adjuvant substrate modification is
targeted at patient-specific AF sources in the RA and LA.250 AF recur-
rences after an initially successful AF ablation procedure are typically
associated with PVI reconnection. A more recent strategy for AF
ablation involves mapping and ablation of rotational activity.222,223
The Mechanisms of AF Recurrence After
Catheter Ablation or Surgical AF
Ablation
Although its efficacy has been established, both catheter and surgical
ablation of AF are associated with a substantial risk of AF recur-
rence.251,252 It is important to recognize that late recurrences are
often asymptomatic.56 Recurrences of AF after ablation are generally
classified into three types according to the phase after ablation in
which they appear: (1) early recurrence (within 3 months); (2) late re-
currence (from 3 months to 1 year); and (3) very late recurrence
(more than 1 year). The characteristics and optimal managements dif-
fer according to the type of recurrence.
Early recurrence, which is defined as recurrence within the first
3 months after the procedure, is observed in 50% or more of pa-
tients.253,254,255 Although its precise mechanisms have not been fully
elucidated, the possible causes include (1) a transient stimulatory ef-
fect of the tissue inflammatory response to the application of RF256;
(2) a transient imbalance of the ANS257; and (3) a delayed effect of
the application of RF, likely due to the maturation of the ablation le-
sion soon after the procedure.258 A “blanking period” of 3 months
after the procedure, during which reintervention should be avoided,
is recommended because up to half of the patients with early recur-
rence remain AF-free during long-term follow-up.254,255,259 It has re-
cently been shown that patients who experience multiple early
recurrences, especially more than a month postablation, are more
likely to have an unsuccessful response to AF ablation at 1-year
follow-up. It is for this reason that some electrophysiologists recom-
mend early reablation in this subset of patients.260
Late recurrence, during the first 9 months after the blanking
period, occurs in 25%–40% of cases261,262; however, the incidence
differs depending on the patient population (ratio of paroxysmal to
persistent form) and the manner in which recurrence is screened for
and detected. Studies have shown that the mechanism for late-term
recurrence is predominantly linked to the recovery of electrical con-
duction between the PVs and the LA, irrespective of the type of
AF.261,263 Accordingly, ongoing efforts are focused on identifying
techniques to achieve permanent PVI during an initial AF ablation
procedure.264,265
The incidence of very late recurrence (after more than 12 months
postablation) has been shown to be higher than previously expected.
Multiple studies of long-term follow-up data (more than 5 years)
have demonstrated that the longer the follow-up postablation, the
higher the recurrence rate.266,267,268 The predominant mechanism of
very late recurrence includes PV reconnection, the development of
non-PV triggers, and development and maturation of sub-
strate.267,269,270 The predictors of the very late recurrence of AF ap-
pear to be the nonparoxysmal form of AF at baseline, organic heart
disease (valvular heart disease and cardiomyopathy), advanced age,
and obesity.268,271
One study investigated the relationship between time to recur-
rence of AF following AF ablation, response to therapy, and out-
come.272 This study found that time to recurrence is a major
determinant of outcome. Patients with later recurrences were more
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likely to have sporadic episodes and respond better to AADs and re-
peat ablation. This observation suggests pathophysiological differ-
ences based on time to recurrence, and have implications for clinical
management.
Section 3: Modifiable Risk Factors
for AF and Impact on Ablation
AF Risk Factors and Their Interaction
with AF Management and Ablation
Management of patients with AF has traditionally consisted of three
main components: (1) anticoagulation for stroke prevention; (2) rate
control; and (3) rhythm control. With the emergence of large
amounts of data, which have both defined and called attention to the
interaction between modifiable risk factors and the development of
AF and outcomes of AF management, we believe it is time to include
risk factor modification as the fourth pillar of AF manage-
ment.7,10,273,274,275 In this section of the document, we will review
the link between modifiable risk factors and both the development of
AF and their impacts on the outcomes of AF ablation.
Obesity
Data from population studies have demonstrated a significant dose
relationship between increasing risk of developing AF and increasing
severity of obesity.8 This relationship holds true even after multivari-
ate adjustment for other known risk factors, with 3%–7% increased
AF risk per unit increment of body mass index (BMI).8,276,277,278
Obesity is an important contributor to the burden of AF, explaining
one-fifth of all AF cases.279
Obesity results in significant atrial remodeling, which predisposes
an individual to the development of AF. Progressive weight gain has
Figure 6 Schematic of common lesion sets employed in AF ablation. (A) The circumferential ablation lesions that are created in a circumferential
fashion around the right and the left PVs. The primary endpoint of this ablation strategy is the electrical isolation of the PV musculature. (B) Some of
the most common sites of linear ablation lesions. These include a “roof line” connecting the lesions encircling the left and/or right PVs, a “mitral isth-
mus” line connecting the mitral valve and the lesion encircling the left PVs at the end of the left inferior PV, and an anterior linear lesion connecting ei-
ther the “roof line” or the left or right circumferential lesion to the mitral annulus anteriorly. A linear lesion created at the cavotricuspid isthmus is
also shown. This lesion is generally placed in patients who have experienced cavotricuspid isthmus-dependent atrial flutter clinically or have it induced
during EP testing. (C) Similar to 6B, but also shows additional linear ablation lesions between the superior and inferior PVs resulting in a figure of eight
lesion sets as well as a posterior inferior line allowing for electrical isolation of the posterior left atrial wall. An encircling lesion of the superior vena
cava (SVC) directed at electrical isolation of the SVC is also shown. SVC isolation is performed if focal firing from the SVC can be demonstrated. A
subset of operators empirically isolates the SVC. (D) Representative sites for ablation when targeting rotational activity or CFAEs are targeted.
Modified with permission from Calkins et al. Heart Rhythm 2012; 9:632–696.e21.2
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been associated with increasing atrial size, interstitial fibrosis, pericar-
dial fat, heterogeneous and slowed conduction, and infiltration of the
atrial myocardium by the adjacent pericardial fat.180,280,281 As a con-
sequence of these changes, AF is more frequently induced and
sustained.
There is increasing recognition that obesity can influence the risk
of AF recurrence after catheter ablation procedures.268,282,283,284,285,
286,287,288,289,290,291,292,293,294,295,296,297,298 A recent meta-analysis
identified 16 studies involving 5864 individuals reporting on the
link between obesity and recurrence of AF after catheter ablation,
identifying that there was a 3.1% greater risk of recurrent AF
postablation for every one unit increase in BMI (RR 1.03; 95% CI
1.00–1.07).299
Much less information is available on the effect of weight manage-
ment on reducing the risk of developing AF and on the impact of
weight management on AF burden and the outcomes of ablation in
those with AF. In light of the above discussion, it was somewhat sur-
prising that the 5067-patient Action for Health in Diabetes (Look
AHEAD) randomized trial of an intensive lifestyle intervention failed
to reduce the risk of developing AF in individuals with type 2 dia-
betes.300 In a recent, randomized, controlled clinical study, patients
with highly symptomatic AF were randomized to either physician-
directed weight and cardiometabolic risk factor management or
standard of care. Weight and risk factor management were associ-
ated with a reduction in AF symptom burden and reduced number
and duration of AFs on ambulatory monitoring. Indeed, a dose-
dependent improvement in arrhythmia-free survival has been
observed in obese individuals with AF who underwent weight loss in
the Long-Term Effect of Goal Directed Weight Management on an
Atrial Fibrillation Cohort (LEGACY) study, with the best outcomes
being observed in those having a linear loss of weight >_10% and with-
out weight fluctuation. The Aggressive Risk Factor Reduction Study
for Atrial Fibrillation and Implications for the Outcome of Ablation
(ARREST-AF) cohort study evaluated the impact of weight and risk
factor management in the context of patients undergoing AF ablation.
In this observational study, adjunctive weight and risk factor manage-
ment resulted in improvement in AF symptoms and a 5-fold greater
likelihood of maintaining sinus rhythm after ablation; at a 42-month
follow-up, 87% in the intervention group, compared with 18% in the
control group, were in sinus rhythm (P <.001).301
Although there are randomized data demonstrating the impact of
weight and cardiometabolic risk factor management, data after cath-
eter ablation remain observational and require confirmation. A sur-
vey of the writing group shows that 96% recommend weight loss as
part of a comprehensive risk factor management strategy for patients
with AF, including those who are being evaluated for an AF ablation
procedure. Eighty-eight percent of the writing group consider a pa-
tient’s BMI when discussing the risks, benefits, and outcomes of AF
ablation with a patient being evaluated for an AF ablation procedure.
One limitation to enacting a weight loss program is that only 34% of
the writing group members currently have ready access to a weight
loss clinic at their center.
Sleep Apnea
Types, Assessment, and Treatment of Apnea
Sleep-disordered breathing includes OSA, central sleep apnea (CSA),
periodic breathing (including Cheyne-Stokes breathing), and sleep-
related hypoventilation. OSA affects approximately 24% of men and
9% of women between 30 and 60 years of age. Several studies re-
vealed that the prevalence of OSA is substantially higher among pa-
tients with AF (ranging from 32% to 39%), indicating that OSA could
be contributing to the initiation and progression of AF.
OSA is caused by repeated upper airway collapse leading to oxy-
gen desaturation and disrupted sleep. Pathogenesis varies; predispos-
ing factors include small upper airway lumen, unstable respiratory
control, low arousal threshold, and dysfunctional upper airway dila-
tor muscles. Risk factors include obesity, male sex, age, menopause,
fluid retention, adenotonsillar hypertrophy, and smoking. Continuous
positive airway pressure (CPAP) is the treatment of choice for OSA,
with adherence of 60%–70%. The positive pressure keeps the pha-
ryngeal area from collapsing, and thus helps alleviate the airway
obstruction.
Bi-level positive airway pressure or adaptive servoventilation can be
used for patients who are intolerant of CPAP. Other treatments in-
clude mandibular advancement devices, upper airway surgery, and life-
style modification (weight loss, avoidance of alcohol and sedatives).
AF Mechanisms in Sleep Apnea
A variety of mechanisms have been implicated in the pathogenesis of
OSA-associated AF.302 Exposure of rats over 35 days to episodic
hypoxia of the type caused by OSA causes a sustained increase in
blood pressure (BP) due to activation of sympathetic nerves and the
renin-angiotensin-aldosterone system.303 Although intrinsic endothe-
lial sensitivity appears unaltered in OSA, the vasoconstrictor re-
sponse to angiotensin is enhanced.304
A variety of lines of evidence point to an important role of the
ANS. Prolonged apneic episodes in dogs (2 min) enhance ganglion-
ated plexus neural activity and increase AF inducibility.305 Strong
negative intrathoracic pressure applied to pigs during 2-minute apneic
episodes reduces the atrial ERP and enhances AF inducibility, effects
reversed by atropine or vagotomy.306 Renal denervation suppresses
postapneic BP increases, AF inducibility and neurohumoral activation
in pigs.307,308
That altered autonomic nerve activity is not the entire explanation
for the influence of sleep apnea in AF occurrence was shown in a
study of sleep apnea in a rat model of obesity.309 Obstructive apnea
promoted AF induction in obese rats much more than in lean rats,
with only partial protection (<50%) by autonomic blockade. On the
other hand, obstructive episodes caused LA dilation that was
enhanced in obese rats by obesity-associated left-ventricular diastolic
dysfunction. Prevention of LA dilation fully prevented apnea-
associated AF. In this model, neither obstructive apnea nor obesity
was enough to cause significant AF vulnerability; the interaction ap-
peared necessary to cause the degree of LA dilation needed to allow
for AF induction.
Subsequent studies evaluated the effects of repeated obstructive
apnea, as occurs in patients with OSA, on cardiac structure, function,
and electrophysiology.310 In a rat model of repeated OSA for
4 weeks, atrial conduction slowed considerably in association with
connexin downregulation and atrial fibrosis. Left ventricular dilation,
hypertrophy, and diastolic dysfunction also occurred. In addition to
the remodeling-induced AF substrate caused by repeated apneic epi-
sodes, AF inducibility was further enhanced by superimposed epi-
sodes of acute obstructive apnea in over 80% of the rats.310 The role
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of atrial remodeling by repeated OSA is supported by electroana-
tomical studies in the clinical electrophysiology lab, with OSA associ-
ated with prolonged atrial conduction times, slower conduction,
reduced electrogram amplitudes, and widespread complex atrial
electrograms.311
Finally, experiments in sheep demonstrated that hypercapnia per
se causes profound atrial conduction slowing and increased AF indu-
cibility, which persists following the return of CO2 levels to nor-
mal.312 This effect was independent of oxygen levels. Taken together,
the results suggest that acute OSA episodes enhance AF vulnerability
via a combination of LA dilation and autonomic and electrophysiolo-
gical changes; however, these abnormalities alone are not enough to
significantly enhance AF risk in normal hearts. Repeated nocturnal
OSA activates neurohormonal systems that over time produce sus-
tained hypertension and cardiac structural and electrophysiological
remodeling. These render the atria susceptible to AF, particularly
during an acute OSA episode.
Sleep Apnea Treatment and AF Ablation Outcomes
Several studies have observed associations between AF and OSA.
Epidemiological data suggest AF prevalence and progression are
linked with OSA severity,313,314 whereas observational data have
linked OSA with a more severely remodeled atrial substrate.311
Treatment of OSA with CPAP, however, appears to favorably impact
AF management, regardless of the rhythm control strategy
adopted.315,316
Several studies have examined the impact of CPAP intervention
on arrhythmia-free survival following catheter ablation of
AF.283,289,290,291,316,317,318,319 Although OSA has been associated with
poorer outcomes, CPAP appears to attenuate the deleterious impact
of OSA. Pooled analysis suggests that although OSA increases the
risk of AF recurrence following ablation (RR 1.31; 95% CI 1.16–1.48;
P <.001), CPAP therapy improves ablation success to rates compar-
able with non-OSA populations (RR 1.25; 95% CI 0.77–2.03;
P= .37).320 Nonuse of CPAP increases the risk of recurrent AF after
ablation by 57% (RR 1.57; 95% CI 1.36–1.81; P <.001).320 One study
demonstrated an increased prevalence of non-PV triggers in patients
with OSA.290
The observational nature of the literature that evaluates CPAP use
in OSA, however, limits its generalizability and precision. In most
studies, formal sleep studies were not used to systematically screen
all patients for sleep apnea. Clinical history or diagnostic question-
naires (e.g., Berlin questionnaire) formed the basis of OSA diagnosis
in some, whereas the diagnosis was rarely excluded by sleep study in
non-OSA groups.283,289,290,291,316 Similarly, treatment efficacy was as-
sessed by self-reported CPAP use.289,290,291,316 These study deficien-
cies lead to a poorly defined treatment effect of CPAP on AF
recurrence after ablation.
A survey of the writing group shows that 80% of the writing group
members screen for signs and symptoms of sleep apnea when evalu-
ating patients for an AF ablation procedure. This survey also revealed
that 94% refer patients being evaluated for an AF ablation procedure,
in whom signs and symptoms of sleep apnea are detected, to a sleep
center for evaluation and management of sleep apnea. Eighty-six per-
cent of the writing group members currently have ready access to a
sleep program at their center.
Hypertension
Hypertension is a well-established, independent risk factor for
AF,9,279,321,322 and this risk increases in patients with uncontrolled
systolic BP,323 particularly in those with EF less than 40%.324 Even BPs
that are near the upper limit of normal (systolic 130–139 mm Hg, dia-
stolic 85–89 mm Hg) predict risk for AF in healthy middle-aged
men325 and women.326 Hypertensive animal models have shown that
elevated systolic and diastolic BP promote the development of the
atrial substrate for AF by increasing LA pressure, promoting intersti-
tial fibrosis and inflammatory infiltrates.327
Following AF ablation, hypertension has been shown to be an inde-
pendent predictor of recurrence.268,328,329,330 Conversely, patients
with pharmacologically controlled hypertension could have similar risk
of AF recurrence postablation as those without hypertension.279
Pooled analysis of two small studies demonstrated that renal artery de-
nervation resulted in both sustained lowering of BP and reduction in
AF recurrence postablation.127,331 However, the antiarrhythmic effect
of renal denervation is not well established, and whether it is mediated
by remodeling of the hypertension-associated atrial substrate or de-
crease in neurohormonal activation remains uncertain.129 Whereas
upstream therapy with angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers might be effective for primary preven-
tion of AF in patients with systolic LV dysfunction or left ventricular
hypertrophy,332 their effect on secondary prevention postablation of
AF is uncertain. Numerous, mostly retrospective, studies have shown
that modulation of the renin-angiotensin-aldosterone system does not
improve ablation outcome.289,290,291,333,334
In summary, studies have shown that hypertension predicts AF re-
currence after AF ablation; however, it is not well established
whether aggressive BP reduction with antihypertensive therapy,
modulation of the autonomic system, or inhibition of the renin-
angiotensin-aldosterone system is required for reducing AF reoccur-
rence in patients with hypertension undergoing AF ablation. Despite
this, aggressive treatment of hypertension is warranted in all patients
with AF due to the well-established link between hypertension and
stroke risk.
Diabetes
Diabetes promotes atrial remodeling characterized by diffuse inter-
stitial fibrosis and conduction slowing,335 and has been shown to be
an independent risk factor for development of AF.9,336,337 At least 10
studies have evaluated whether diabetes or impaired glucose metab-
olism predicts AF recurrence following ablation, with varying results.
A systematic review and meta-analysis reported that the risk of AF
postablation was not elevated in patients with diabetes.338
Overall, studies have not consistently demonstrated differences in
AF ablation outcomes in patients with diabetes, and whether aggres-
sive glucose control is effective for secondary AF prevention follow-
ing ablation is uncertain.
Alcohol
Alcohol consumption at varying degrees could increase the likelihood
of incident AF and might also elevate the risk of thromboembolic
events and postablation recurrence in patients with AF.339,340,341,342
Fibrotic changes in the myocardium caused by alcohol toxicity poten-
tially facilitate development of LA scar and origin of non-PV
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triggers.301,343 A recent observational study demonstrated a lower
AF ablation success rate in moderate and heavy drinkers.342
Furthermore, binge drinking has been reported to be associated with
increase in the risk of postablation AF recurrence. Finally, the
ARREST-AF study demonstrated significant reduction in symptom
severity, burden, and recurrence rate in patients with risk factor man-
agement that included lowering alcohol intake to <_ 30 g per week.344
Thus, limiting alcohol intake is a potential target to increase the suc-
cess rate in AF ablation, but definitive evidence is required before
stronger conclusions can be made.
Exercise
Recent studies have observed a U-shaped risk relationship of physical
activity to AF. At one end of the spectrum, a large observational study
of 64,561 people showed that those at the lowest levels of physical
fitness had a 5-fold increased risk of AF.345 Increasing the physical ac-
tivity of sedentary patients could help reduce the risk or burden of
AF. For example, one randomized study demonstrated that just
12 weeks of moderate-intensity physical activity decreased the AF
burden by 41%.346 Of the physically inactive with AF, the obese might
benefit the most from moderate levels of physical activity.345 In con-
trast, a meta-analysis of 655 endurance athletes also demonstrated a
5-fold increased risk of AF.347 Of these studies, increased AF risk was
generally only observed with the highest levels of physical activity
over a prolonged period of time.348,349 One explanation for the exer-
cise paradox is that both long-term endurance training and a seden-
tary lifestyle increase chronic systemic inflammation.
The risk of AF from sustained high levels of physical activity is likely
modulated by age, given studies of young athletes have failed to show
an increased risk.350,351 Indeed, AF is the primary arrhythmia
observed in middle-aged athletes.352 AF in athletes tends to be par-
oxysmal, vagally mediated, and highly symptomatic.353 Risk is aug-
mented in athletes who are better conditioned, participate more
often, and have faster performance times.354
The mechanism of increased AF risk at either end of the physical
activity spectrum likely includes autonomic, structural, inflammatory,
and fibrotic changes to the heart. For example, increased vagal tone,
which is often observed in the endurance athlete, has been shown to
result in a short atrial RP, and thus initiates AF.355 Most studies have
shown structural changes in endurance athletes, which have resulted
in the term athlete’s heart. These changes include dilatation of all four
heart chambers, increase in left ventricular mass, and mild right ven-
tricular hypertrophy.356 Initially, these adaptive changes were felt to
be benign; however, emerging evidence suggests otherwise, with en-
durance athletes experiencing higher-than-expected rates of coron-
ary artery calcium scores, myocardial fibrosis, AF, and sinus node
dysfunction.357
Long-term endurance training, as well as a sedentary lifestyle,358 in-
crease chronic systemic inflammation,359 which in turn could also fa-
cilitate AF.360 Studies show that moderate physical activity might
reduce inflammatory markers.361,362,363
Extreme levels of exercise are a known cause of cardiac fibrosis,
particularly in hinge point locations of the heart, such as the right ven-
tricle; however, the significance of MRI-detected fibrosis remains con-
troversial.349 Athletes who experience higher levels of fibrosis also
have higher levels of coronary calcium.364 In turn, fibrosis is a well-
established risk factor of AF.365 In one study, the fibrotic changes
caused by vigorous exercise were reversed after an 8-week period of
physical activity cessation.366 One study showed an increase in colla-
gen and other fibrosis biomarkers in athletes.367 Murine models have
found that losartan reduces all fibrosis biomarkers and the histologic
findings of fibrosis induced by long-term intensive exercise.368
Although increasing physical activity might reduce AF in sedentary
patients, decreasing physical activity levels in elite endurance athletes
could also reduce AF.350 Professional athletes represent a unique
treatment dilemma because medical therapy for AF might not only
reduce athletic performance but it could also be prohibited in some
sports.369
Furthermore, many athletes have marked resting bradycardia, lim-
iting use of AAD therapy. Because most high-level endurance athletes
are unwilling to give up or reduce their level of their sports participa-
tion, AF ablation might be the only viable treatment option for these
patients. Although there are limited data on the efficacy of AF abla-
tion in athletes, two small studies involving a total of 276 patients sug-
gested equal benefit of ablation compared with AAD therapy for the
endurance athlete.370,371 However, caution should be exercised
when interpreting these data because a third small study reported
that, although ablation can result in a durable arrhythmia-free benefit,
athletes typically require multiple procedures—an average of 2.3—
to achieve a long-term benefit.372
Although moderate levels of physical activity have not been inde-
pendently shown to improve AF ablation outcomes in the sedentary
patient, one observational study of 308 patients showed that
increased physical fitness was associated with a dose-dependent re-
duction in AF burden. Moreover, the AF benefit of physical fitness
provided a 12% incremental gain over weight loss, resulting in an im-
proved AF risk factor profile, inflammatory state, and cardiac re-
modeling.373 These observed beneficial changes of moderate physical
activity would predict a better AF ablation outcome in the sedentary
patient. Given that interventions aimed at increasing physical activity
could be more successful than those targeting weight loss,374 increas-
ing physical activity could be an attractive option to prevent or treat
AF. To date, however, definitive evidence of the impact of physical ac-
tivity on ablation outcomes is lacking.
Section 4: Indications
Recommendations and General
Considerations
Shown in Table 2, and summarized in Figures 7 and 8 of this document,
are the Consensus Indications for Catheter and Surgical Ablation of
AF. As outlined in the introduction section of this document, these
indications are stratified as Class I, Class IIa, Class IIb, and Class III indi-
cations. The evidence supporting these indications is provided, as
well as a selection of the key references supporting these levels of
evidence. In making these recommendations, the writing group con-
sidered the body of published literature that has defined the safety
and efficacy of catheter and surgical ablation of AF. Also considered
in these recommendations is the personal lifetime experience in the
field of each of the writing group members. Both the number of clin-
ical trials and the quality of these trials were considered. In consider-
ing the class of indications recommended by this writing group, it is
important to keep several points in mind. First, these classes of
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Table 2 Indications for catheter (A and B) and surgical (C, D, and E) ablation of atrial fibrillation
Recommendation Class LOE References
Indications for catheter ablation of atrial fibrillation
A. Indications for catheter ablation of atrial fibrillation
Symptomatic AF refractory
or intolerant to at least
one Class I or III antiar-
rhythmic medication
Paroxysmal: Catheter ablation is recommended. I A 261,262,462,489,503,
655,673,684,709,
1027–1029
Persistent: Catheter ablation is reasonable. IIa B-NR 245,262,515,527,733,
1015,1025–1030
Long-standing persistent: Catheter ablation may be
considered.
IIb C-LD 245,262,515,527,733,
1015,1025–1030
Symptomatic AF prior to ini-
tiation of antiarrhythmic
therapy with a Class I or
III antiarrhythmic
medication
Paroxysmal: Catheter ablation is reasonable. IIa B-R 370,372,377–383
Persistent: Catheter ablation is reasonable. IIa C-EO
Long-standing persistent: Catheter ablation may be
considered.
IIb C-EO
B. Indications for catheter atrial fibrillation ablation in populations of patients not well represented in clinical trials
Congestive heart failure It is reasonable to use similar indications for AF ablation
in selected patients with heart failure as in patients
without heart failure.
IIa B-R 233–237,384,386–395,
1042
Older patients (>75 years of
age)
It is reasonable to use similar indications for AF ablation
in selected older patients with AF as in younger
patients.
IIa B-NR 396–398,401–404
Hypertrophic
cardiomyopathy
It is reasonable to use similar indications for AF ablation
in selected patients with HCM as in patients without
HCM.
IIa B-NR 385,1043,1044
Young patients (<45 years of
age)
It is reasonable to use similar indications for AF ablation
in young patients with AF (<45 years of age) as in
older patients.
IIa B-NR 405,1045
Tachy-brady syndrome It is reasonable to offer AF ablation as an alternative to
pacemaker implantation in patients with tachy-brady
syndrome.
IIa B-NR 381–383
Athletes with AF It is reasonable to offer high-level athletes AF as first-
line therapy due to the negative effects of medications
on athletic performance.
IIa C-LD 370–372
Asymptomatic AF** Paroxysmal: Catheter ablation may be considered in se-
lect patients.**
IIb C-EO 416,418
Persistent: Catheter ablation may be considered in se-
lect patients.
IIb C-EO 417
Indications for surgical ablation of atrial fibrillation
C. Indications for concomitant open (such as mitral valve) surgical ablation of atrial fibrillation
Symptomatic AF refractory
or intolerant to at least
one Class I or III antiar-
rhythmic medication
Paroxysmal: Surgical ablation is recommended. I B-NR 1290,1326–1338
Persistent: Surgical ablation is recommended. I B-NR 1290,1326–1338
Long-standing persistent: Surgical ablation is
recommended.
I B-NR 1290,1326–1338
Symptomatic AF prior to ini-
tiation of antiarrhythmic
therapy with a Class I or
III antiarrhythmic
medication
Paroxysmal: Surgical ablation is recommended. I B-NR 1290,1326–1338
Persistent: Surgical ablation is recommended. I B-NR 1290,1326–1338
Long-standing persistent: Surgical ablation is
recommended.
I B-NR 1290,1326–1338
Continued
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indications only define the indications for catheter and surgical abla-
tion of AF when performed by an electrophysiologist or a surgeon
who has received appropriate training and/or who has a certain level
of experience and is performing the procedure in an experienced
center (Section 11). Catheter and surgical ablation of AF are highly
complex procedures, and a careful assessment of the benefit and risk
must be considered for each patient. Second, these indications strat-
ify patients based only on the type of AF and whether the procedure
is being performed prior to or following a trial of one or more Class I
or III antiarrhythmic medications. This document for the first time in-
cludes indications for catheter ablation of select asymptomatic pa-
tients. As detailed in Section 9, there are many other additional
clinical and imaging-based variables that can be used to further define
the efficacy and risk of ablation in a given patient. Some of the
variables that can be used to define patients in whom a lower success
rate or a higher complication rate can be expected include the pres-
ence of concomitant heart disease, obesity, sleep apnea, LA size, pa-
tient age and frailty, as well as the duration of time the patient has
been in continuous AF. Each of these variables needs to be con-
sidered when discussing the risks and benefits of AF ablation with a
particular patient. In the presence of substantial risk or anticipated dif-
ficulty of ablation, it could be more appropriate to use additional
AAD options, even if the patient on face value might present with a
Class I or IIa indication for ablation. Third, it is important to consider
patient preference and values. Some patients are reluctant to con-
sider a major procedure or surgery and have a strong preference for
a pharmacological approach. In these patients, trials of antiarrhythmic
agents including amiodarone might be preferred to catheter ablation.
....................................................................................................................................................................................................................
Table 2 Continued
Recommendation Class LOE References
D. Indications for concomitant closed (such as CABG and AVR) surgical ablation of atrial fibrillation
Symptomatic AF refractory
or intolerant to at least
one Class I or III antiar-
rhythmic medication
Paroxysmal: Surgical ablation is recommended. I B-NR 1339–1344
Persistent: Surgical ablation is recommended. I B-NR 1339–1344
Long-standing persistent: Surgical ablation is
recommended.
I B-NR 1339–1344
Symptomatic AF prior to ini-
tiation of antiarrhythmic
therapy with a Class I or
III antiarrhythmic
medication
Paroxysmal: Surgical ablation is reasonable. IIa B-NR 1339–1344
Persistent: Surgical ablation is reasonable. IIa B-NR 1339–1344
Long-standing persistent: Surgical ablation is reasonable. IIa B-NR 1339–1344
E. Indications for stand-alone and hybrid surgical ablation of atrial fibrillation
Symptomatic AF refractory
or intolerant to at least
one Class I or III antiar-
rhythmic medication
Paroxysmal: Stand-alone surgical ablation can be con-
sidered for patients who have failed one or more at-
tempts at catheter ablation and also for those who
are intolerant or refractory to antiarrhythmic drug
therapy and prefer a surgical approach, after review
of the relative safety and efficacy of catheter ablation
versus a stand-alone surgical approach.
IIb B-NR 123,601,1306,1339–
1341,1349,1351–
1361
Persistent: Stand-alone surgical ablation is reasonable
for patients who have failed one or more attempts at
catheter ablation and also for those patients who pre-
fer a surgical approach after review of the relative
safety and efficacy of catheter ablation versus a stand-
alone surgical approach.
IIa B-NR 123,601,1306,1339–
1341,1349,1351–
1361
Long-standing persistent: Stand-alone surgical ablation is
reasonable for patients who have failed one or more
attempts at catheter ablation and also for those pa-
tients who prefer a surgical approach after review of
the relative safety and efficacy of catheter ablation
versus a stand-alone surgical approach.
IIa B-NR 123,601,1306,1339–
1341,1349,1351–
1361
It might be reasonable to apply the indications for stand-
alone surgical ablation described above to patients
being considered for hybrid surgical AF ablation.
IIb C-EO 1361–1366
AF, atrial fibrillation; LOE, Level of Evidence; HCM, hypertrophic cardiomyopathy.
**A decision to perform AF ablation in an asymptomatic patient requires additional discussion with the patient because the potential benefits of the procedure for the patient
without symptoms are uncertain.
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On the other hand, some patients prefer a nonpharmacological ap-
proach. Fourth, it is important to recognize that some patients early
in the course of their AF journey might have only infrequent episodes
for many years and/or could have AF that is responsive to well-
tolerated AAD therapy. And finally, it is important to bear in mind
that a decision to perform catheter or surgical AF ablation should
only be made after a patient carefully considers the risks, benefits,
and alternatives to the procedure.
As demonstrated in a large number of published studies, the primary
clinical benefit from catheter ablation of AF is an improvement in QOL
resulting from elimination of arrhythmia-related symptoms, such as pal-
pitations, fatigue, or effort intolerance (see Section 9). Thus, the pri-
mary selection criterion for catheter ablation should be the presence
of symptomatic AF. The indications for catheter and surgical ablation
of symptomatic AF shown in Table 2, and summarized in Figures 7
and 8, are for the most part consistent with the indications for AF abla-
tion recommended in the recently published 2016 ESC Guidelines for
the Management of AF, as well as in the 2014 ACC/AHA/HRS
Guidelines for AF management.5,6 These recommendations for AF ab-
lation present the indications for AF ablation as second-line therapy,
after failure of a Class I or III antiarrhythmic agent and also the
Figure 7 Indications for catheter ablation of symptomatic atrial
fibrillation. Shown in this figure are the indications for catheter abla-
tion of symptomatic paroxysmal, persistent, and long-standing per-
sistent AF. The Class for each indication based on whether ablation
is performed after failure of antiarrhythmic drug therapy or as first-
line therapy is shown. Please refer to Table 2B and the text for the
indications for catheter ablation of asymptomatic AF.
Figure 8 Indications for surgical ablation of atrial fibrillation. Shown in this figure are the indications for surgical ablation of paroxysmal, persistent,
and long-standing persistent AF. The Class for each indication based on whether ablation is performed after failure of antiarrhythmic drug therapy or
as first-line therapy is shown. The indications for surgical AF ablation are divided into whether the AF ablation procedure is performed concomitantly
with an open surgical procedure (such as mitral valve replacement), a closed surgical procedure (such as coronary artery bypass graft surgery), or as
a stand-alone surgical AF ablation procedure performed solely for treatment of atrial fibrillation.
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Table 3 Atrial fibrillation ablation: strategies, techniques, and endpoints
Recommendation Class LOE References
PV isolation by catheter ablation Electrical isolation of the PVs is recommended
during all AF ablation procedures.
I A 245,261,262,456,462,489,503,515,527,
655,673,684,709,733,1015,1025,1026,1027,1030
Achievement of electrical isolation requires, at a
minimum, assessment and demonstration of
entrance block into the PV.
I B-R 245,261,262,456,462,489,503,515,527,655,673,
684,709,733,1015,1025,1026,1027,1030
Monitoring for PV reconnection for 20 minutes
following initial PV isolation is reasonable.
IIa B-R 263,265,448,450,451,452,457–461,462
Administration of adenosine 20 minutes follow-
ing initial PV isolation using RF energy with
reablation if PV reconnection might be
considered.
IIb B-R 265,448,449–451,454,456,461,463–468
Use of a pace-capture (pacing along the ablation
line) ablation strategy may be considered.
IIb B-R 264,472–475
Demonstration of exit block may be considered. IIb B-NR 445,477–481
Ablation strategies to be
considered for use in
conjunction with PV isolation
If a patient has a history of typical atrial flutter or
typical atrial flutter is induced at the time of
AF ablation, delivery of a cavotricuspid isth-
mus linear lesion is recommended.
I B-R 230,504,511,1397
If linear ablation lesions are applied, operators
should use mapping and pacing maneuvers to
assess for line completeness.
I C-LD 245,504,506–508,510–513,1397
If a reproducible focal trigger that initiates AF is
identified outside the PV ostia at the time of
an AF ablation procedure, ablation of the focal
trigger should be considered.
IIa C-LD 96,197,208,257,530,531,533–535,537–539
When performing AF ablation with a force-sens-
ing RF ablation catheter, a minimal targeted
contact force of 5 to 10 grams is reasonable.
IIa C-LD 453,468,668,670–686
Posterior wall isolation might be considered for
initial or repeat ablation of persistent or long-
standing persistent AF.
IIb C-LD 522–529
Administration of high-dose isoproterenol to
screen for and then ablate non-PV triggers
may be considered during initial or repeat AF
ablation procedures in patients with paroxys-
mal, persistent, or long-standing persistent AF.
IIb C-LD 96,197,208,257,530,531,533–535,537–539
DF-based ablation strategy is of unknown useful-
ness for AF ablation.
IIb C-LD 587–594
The usefulness of creating linear ablation lesions
in the right or left atrium as an initial or repeat
ablation strategy for persistent or long-stand-
ing persistent AF is not well established.
IIb B-NR 245,507–521
The usefulness of linear ablation lesions in the
absence of macroreentrant atrial flutter is not
well established.
IIb C-LD 245,507–521
The usefulness of mapping and ablation of areas
of abnormal myocardial tissue identified with
voltage mapping or MRI as an initial or repeat
ablation strategy for persistent or long-stand-
ing persistent AF is not well established.
IIb B-R 140,522,553–561
The usefulness of ablation of complex fractio-
nated atrial electrograms as an initial or repeat
ablation strategy for persistent and long-
standing persistent AF is not well established.
IIb B-R 245,514–517,540,545–552
Continued
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indications for AF ablation as first-line therapy. As shown in Table 2,
catheter ablation is recommended for patients with symptomatic PAF
who have failed AAD therapy (Class I, LOE A). For patients with symp-
tomatic persistent AF who have failed AAD therapy, catheter ablation
has a Class IIa, LOE B-NR indication, and for patients with symptomatic
long-standing persistent AF who have failed drug therapy, catheter ab-
lation has a Class IIb, LOE C-LD indication.
In preparing this document, the writing group has chosen to ad-
dress for the first time the important issue of catheter ablation of AF
in select asymptomatic patients. We have also addressed the import-
ant issues of AF ablation as first-line therapy, the role of AF ablation
in patients with HF, and the role of AF ablation in subgroups of pa-
tients not well represented in clinical trials. Each of these important
considerations is addressed in detail below.
....................................................................................................................................................................................................................
Table 3 Continued
Recommendation Class LOE References
The usefulness of ablation of rotational activity
as an initial or repeat ablation strategy for per-
sistent and long-standing persistent AF is not
well established.
IIb B-NR 76,221–226,562–575
The usefulness of ablation of autonomic ganglia
as an initial or repeat ablation strategy for par-
oxysmal, persistent, and long-standing persist-
ent AF is not well established.
IIb B-NR 103,105,114,116,122–124,245,355,576–586
Nonablation strategies
to improve outcomes
Weight loss can be useful for patients with AF,
including those who are being evaluated to
undergo an AF ablation procedure, as part of
a comprehensive risk factor management
strategy.
IIa B-R 8,180,268,276–301
It is reasonable to consider a patient’s BMI when
discussing the risks, benefits, and outcomes of
AF ablation with a patient being evaluated for
an AF ablation procedure.
IIa B-R 8,180,268,276–301
It is reasonable to screen for signs and symptoms
of sleep apnea when evaluating a patient for
an AF ablation procedure and to recommend
a sleep evaluation if sleep apnea is suspected.
IIa B-R 283,289–291,302–320
Treatment of sleep apnea can be useful for pa-
tients with AF, including those who are being
evaluated to undergo an AF ablation
procedure.
IIa B-R 283,289–291,302–320
The usefulness of discontinuation of antiarrhyth-
mic drug therapy prior to AF ablation in an ef-
fort to improve long-term outcomes is
unclear.
IIb C-LD 617–621
The usefulness of initiation or continuation of
antiarrhythmic drug therapy during the posta-
blation healing phase in an effort to improve
long-term outcomes is unclear.
IIb C-LD 617–621
Strategies to reduce
the risks of AF ablation
Careful identification of the PV ostia is manda-
tory to avoid ablation within the PVs.
I B-NR 434,505,778,927,928,1143–1160
It is recommended that RF power be reduced
when creating lesions along the posterior wall
near the esophagus.
I C-LD 341,417,637,806,866,900,906–911,920,1162–1178,1398
It is reasonable to use an esophageal tempera-
ture probe during AF ablation procedures to
monitor esophageal temperature and help
guide energy delivery.
IIa C-EO 341,417,910,1398
AF, atrial fibrillation; LOE, Level of Evidence; PV, pulmonary vein; RF, radiofrequency; MRI, magnetic resonance imaging; BMI, body mass index.
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Catheter Ablation of AF as First-Line
Therapy
The role of catheter ablation as first-line therapy, prior to a trial of a
Class I or III antiarrhythmic agent, is an appropriate indication for
catheter ablation of AF in patients with symptomatic paroxysmal or
persistent AF. These recommendations are consistent with the indi-
cations for AF ablation recommended in the recently published 2016
ESC guidelines for the management of AF as well as in the 2014
ACC/AHA/HRS Guidelines for AF management.5,6,375,376 For pa-
tients with paroxysmal symptomatic AF who have not failed drug
therapy, catheter ablation has a Class IIa, LOE B-R indication; for pa-
tients with persistent symptomatic AF who have not failed drug ther-
apy, catheter ablation has a Class IIa, LOE C-EO indication; and for
patients with long-standing persistent AF who have not failed drug
therapy, catheter ablation has a Class IIb, LOE C-EO indication.
There have been three prospective randomized clinical trials that
have examined the relative efficacy and safety of first-line AF ablation
vs pharmacological therapy.377,378,379 The outcomes of these three
trials have recently been summarized in a meta-analysis.380 A total of
491 young, generally healthy patients with predominantly PAF were
randomized to AF ablation vs pharmacological therapy. Catheter ab-
lation of AF was associated with a significantly higher freedom from
AF recurrence, as compared with drug therapy. The difference in the
rate of symptomatic AF recurrences was not significant. There was
one procedure-related death due to a stroke in the ablation arm. The
main major complication was cardiac tamponade which occurred in
1.7% of patients in the ablation arm. Taken as a whole, these findings
provide evidence to support the role of AF ablation as first-line
therapy.
It is important to recognize that there are certain situations in
which first-line AF ablation is a preferred treatment option. For ex-
ample, first-line AF ablation is often recommended in patients with
PAF who have symptomatic pauses (tachy-brady syndrome). For
these patients, initiation of pharmacological therapy would be in-
appropriate in the absence of a permanent pacemaker. Over the past
15 years, a body of literature has been published demonstrating that
catheter ablation is effective, without concomitant need of a perman-
ent pacemaker in the great majority of patients with tachy-brady syn-
drome.381,382,383 Based on this body of literature and the cumulative
experience of the writing group, we believe that it is appropriate to
consider AF ablation as first-line therapy in this clinical situation.
Another specific population of patients in whom first-line AF ablation
is often recommended as an initial approach are high-level competi-
tive athletes with paroxysmal or persistent AF. These individuals
often are strongly against taking a medication, which could potentially
reduce their peak heart rate and/or impair cardiac function; they
often have a marked resting bradycardia. Several studies have re-
ported favorable outcomes of AF ablation in this subgroup of
patients.371,372,373
Catheter Ablation of AF in Patients with
Heart Failure and Reduced Cardiac
Function
AF and HF are closely related conditions. HF can predispose an indi-
vidual to the occurrence of AF through various mechanisms, such as
the increase of the left ventricular filling pressure or LA dilatation and
fibrosis, each of which can lead to atrial structural and electrical re-
modeling. Conversely, AF with the loss of atrial contraction and po-
tential uncontrolled heart rate secondary to arrhythmia can
predispose an individual to the development of HF, thus leading to
impaired contractility and reduced cardiac output. AF can increase
mortality in patients with left ventricular dysfunction; therefore, the
treatment of AF in this subset of patients is of pivotal importance.
Much controversy still exists regarding how to maintain sinus
rhythm in patients with HF; undoubtedly, however, maintenance of
sinus rhythm is beneficial in restoring atrial-ventricular coordination,
thus favoring an improved left ventricular performance and a better
QOL.
The published literature describing the safety and efficacy of AF
ablation in patients with HF and/or a reduced EF is considerable.
When viewed cumulatively, these published results describe the
outcomes of AF ablation in more than 1000 patients with
HF.233,234,235,236,237,384,385,386,387,388,389,390,391,392,393,394 Included
within this large body of literature are four prospective, randomized
clinical trials, the results of which were recently summarized in a
meta-analysis.235,236,237,390,392 A total of 224 patients were random-
ized, among whom 83% had persistent AF. AF ablation resulted in an
increase in left ventricular ejection fraction (LVEF) by a mean of 8.5%
compared with rate control alone. AF ablation also was superior to
rate control in improving QOL. Peak oxygen consumption and 6-mi-
nute walk test distance increased in ablation compared with rate con-
trol patients. Major adverse events were not different in the two
treatment arms. The meta-analysis of these four studies concluded
that catheter ablation is superior to rate control in improving LVEF,
QOL, and functional capacity. This conclusion is consistent with
other data that reveal that adequate rate control alone is insufficient
to prevent AF-mediated cardiomyopathy in a subset of AF pa-
tients.395 Prior to accepting a rate control strategy, patients with HF
and persistent AF or drug-refractory AF should be advised to con-
sider AF ablation.
Based on this growing body of data, the writing group believes that
catheter ablation of AF is a safe, effective, and clinically acceptable
therapeutic option in patients with AF and HF. This applies both to
patients suspected of having a cardiomyopathy that is strongly sus-
pected to be due to AF, with a rapid ventricular response, as well as
to other populations of patients with AF. The writing group recom-
mends that it is reasonable to use similar indications for AF ablation
in selected patients with HF as for patients without HF (Class IIa,
LOE B-R).
Catheter Ablation in Older People
AF is in large part a disease of the older person. During the past dec-
ade, there have been a number of studies that have specifically
focused on reporting the outcomes of AF ablation in older individ-
uals.396,397,398,399,400,401,402,403,404 The age cutoff for defining elderly
varied between age >_70 years, age >_75 years,397,402,404 and age
>_80 years.398,399,400,401 The number of older people in these studies
was small, with five of the seven studies enrolling fewer than 100 pa-
tients and the largest reporting outcomes on 261 older people.
Taken as a whole, the results of these studies provide evidence that
catheter ablation of AF has an acceptable safety and efficacy profile in
selected older individual over the age of 75 or 80 years. However, as
shown in analysis of the relationship between age and 5-year
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outcomes of AF ablation,403 age significantly impacts long-term out-
comes of AF ablation. This study reported that for every 10-year in-
crease in age there was a higher multivariate-adjusted risk of AF
recurrence, death, and major cardiac events.
The writing group recommends that it is reasonable to use similar
indications for AF ablation in selected older people with AF as in
younger patients (Class IIa, LOE B-NR). It is important to note that
the complications of the procedure are somewhat increased in older
individuals, the need for concomitant antiarrhythmic therapy posta-
blation is greater, and the efficacy is somewhat reduced.396,405 It is
also important to recognize that amiodarone, although not a good
long-term pharmacological option in younger individuals, is an appro-
priate treatment strategy in older people.
Catheter Ablation in Other Populations
of Patients Not Well Represented in
Clinical Trials
Shown in Table 2 are indications for AF ablation in several additional
subgroups of patients not well represented in clinical trials. These
subgroups include patients with hypertrophic dilated cardiomyop-
athy, young patients (<45 years of age), high-level athletes, and pa-
tients with tachy-brady syndrome. The references supporting the
recommendations of the writing group are shown.
Catheter Ablation to Reduce Stroke Risk
Patients with AF might seek catheter ablation to avoid long-term oral
anticoagulation (OAC) therapy. Multiple studies reported a low
thromboembolic risk in patients who discontinued OAC after suc-
cessful AF ablation.238,406,407,408,409,410,411 However, an important
limitation of these studies is the fact that only a small subset of pa-
tients had a CHA2DS2-VASc score >_2, and almost no patients were
at extreme increased stroke risk due to a prior stroke or TIA and/or
age >_75 years. Recent data from the German Ablation Registry412
showed a high thromboembolic risk after ablation in high-stroke-risk
patients. Furthermore, it is well recognized that both symptomatic
and asymptomatic AF can recur after AF ablation procedures,56,58,413
and late recurrence of AF is observed in 50% or more patients by
5 years. Absence of symptomatic AF after ablation does not necessar-
ily indicate an absence of asymptomatic AF or a low risk of stroke.414
The writing group also recommends that systemic anticoagulation
with warfarin or a novel oral anticoagulant (NOAC) is recommended
for at least 2 months post-catheter ablation of AF (Class I, LOE
C-EO). The writing group recommends that decisions regarding con-
tinuation of systemic anticoagulation more than 2 months postabla-
tion should be based on the patient’s stroke risk profile and not on
the perceived success or failure of the ablation procedure (Class I,
LOE C-EO, Table 4). Anticoagulation is recommended for patients
with a CHA2DS2-VASc score of 2 in men or 3 in women. For patients
with one stroke risk factor (e.g., CHA2DS2-VASc 1 in men or 2 in
women), the role of OAC is borderline, and can “be considered.”
Anticoagulation is generally not recommended 2 or more months
post-AF ablation in patients with a low stroke risk profile (e.g.,
CHA2DS2-VASc 0 in men or 1 in women) unless cardioversion is
anticipated or has recently been performed.415
The writing group also recommends that adherence to AF anticoa-
gulation guidelines is recommended for patients who have
undergone an AF ablation procedure, regardless of the apparent suc-
cess or failure of the procedure (Class I, LOE C-EO, Table 4).
Patients in whom discontinuation of anticoagulation is being con-
sidered based on patient values and preferences should consider
undergoing continuous or frequent ECG monitoring to screen for
AF recurrence (Class IIb, LOE C-EO, Table 4).414 A patient’s desire
to eliminate the need for long-term anticoagulation by itself should
not be considered an appropriate selection criterion for AF ablation.
In arriving at this recommendation, the writing group recognizes that
patients who have undergone catheter ablation of AF represent a
new and previously unstudied population in trials of OAC therapy.
Clinical trials are therefore needed to define the stroke risk of this pa-
tient population and to determine whether the risk factors identified
in the CHA2DS2-VASc or other scoring systems apply to these pa-
tients. Please refer to Section 7 for a more detailed discussion of this
topic and the writing group recommendations for long-term
anticoagulation.
Catheter Ablation in Patients with
Asymptomatic AF
The writing group believes that AF ablation may be considered in se-
lect asymptomatic patients with paroxysmal or persistent AF when
performed by an experienced operator and following a detailed dis-
cussion of the risks and benefits of undergoing the procedure (Class
IIb, LOE C-EO). It is recognized that a decision to perform AF abla-
tion in an asymptomatic patient requires additional discussion with
the patient, given the potential benefits of the procedure for the pa-
tient without symptoms are uncertain. AF ablation is not recom-
mended for patients with asymptomatic long-standing persistent AF.
The justification for making this recommendation is as follows. First, it
is well established that the duration of time a patient is in continuous
AF directly impacts the outcomes of AF ablation or other rhythm
control strategies. Whereas AF ablation in patients with symptomatic
PAF is associated with high efficacy, the efficacy of AF ablation in pa-
tients who have been in continuous AF for 2 or more years is dramat-
ically reduced. Second, it is well established that AF is associated with
an increased risk of stroke, HF, dementia, and mortality. It is also not-
able that asymptomatic status is associated with similar (or worse)
prognosis compared with symptomatic status.48 Furthermore, the
risk of stroke has been shown to be lower in patients with paroxys-
mal rather than continuous AF. Although large-scale, prospective,
randomized clinical trials have not been performed to evaluate the
impact of AF ablation on stroke risk, dementia, HF, and mortality, it is
plausible that maintenance of sinus rhythm will ultimately be shown
to reduce these risks. While awaiting the results of these trials, it is
important to recognize that if a physician makes a decision to leave a
patient with apparent asymptomatic continuous AF in AF rather than
to pursue restoration of sinus rhythm, it will be extremely difficult or
impossible to restore and maintain sinus rhythm later in this patient’s
life.
There have been three small studies that have described the safety
and efficacy of AF ablation in patients with asymptomatic
AF.416,417,418 The first compared the outcomes of 54 patients with
asymptomatic subclinical AF with 486 patients with drug-refractory
symptomatic AF.416 No difference in safety or efficacy of the proced-
ure was observed at the 24-month follow-up. The second study
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Table 4 Anticoagulation strategies: pre-, during, and postcatheter ablation of AF
Recommendation Class LOE References
Preablation For patients undergoing AF catheter ablation who have been thera-
peutically anticoagulated with warfarin or dabigatran, performance of
the ablation procedure without interruption of warfarin or dabiga-
tran is recommended.
I A 400,532,829,830,833,834,837,841
For patients undergoing AF catheter ablation who have been thera-
peutically anticoagulated with rivaroxaban, performance of the abla-
tion procedure without interruption of rivaroxaban is
recommended.
I B-R 842
For patients undergoing AF catheter ablation who have been thera-
peutically anticoagulated with a NOAC other than dabigatran or
rivaroxaban, performance of the ablation procedure without with-
holding a NOAC dose is reasonable.
IIa B-NR 1395
Anticoagulation guidelines that pertain to cardioversion of AF should
be adhered to in patients who present for an AF catheter ablation
procedure.
I B-NR 5,6
For patients anticoagulated with a NOAC prior to AF catheter ablation,
it is reasonable to hold one to two doses of the NOAC prior to AF
ablation with reinitiation postablation.
IIa B-NR 835–840
Performance of a TEE in patients who are in AF on presentation for AF
catheter ablation and who have been receiving anticoagulation thera-
peutically for 3 weeks or longer is reasonable.
IIa C-EO 5,6
Performance of a TEE in patients who present for ablation in sinus
rhythm and who have not been anticoagulated prior to catheter ab-
lation is reasonable.
IIa C-EO 5,6
Use of intracardiac echocardiography to screen for atrial thrombi in pa-
tients who cannot undergo TEE may be considered.
IIb C-EO 768,820–824
During ablation Heparin should be administered prior to or immediately following
transseptal puncture during AF catheter ablation procedures and ad-
justed to achieve and maintain an ACT of at least 300 seconds.
I B-NR 768,802–804,820,830,840,846–849
Administration of protamine following AF catheter ablation to reverse
heparin is reasonable.
IIa B-NR 851
Postablation In patients who are not therapeutically anticoagulated prior to catheter
ablation of AF and in whom warfarin will be used for anticoagulation
postablation, low molecular weight heparin or intravenous heparin
should be used as a bridge for initiation of systemic anticoagulation
with warfarin following AF ablation.*
I C-EO
Systemic anticoagulation with warfarin* or a NOAC is recommended
for at least 2 months postcatheter ablation of AF.
I C-EO 1,2
Adherence to AF anticoagulation guidelines is recommended for pa-
tients who have undergone an AF ablation procedure, regardless of
the apparent success or failure of the procedure.
I C-EO 5,6
Decisions regarding continuation of systemic anticoagulation more than
2 months post ablation should be based on the patient’s stroke risk
profile and not on the perceived success or failure of the ablation
procedure.
I C-EO 5,6
In patients who have not been anticoagulated prior to catheter ablation
of AF or in whom anticoagulation with a NOAC or warfarin has
been interrupted prior to ablation, administration of a NOAC 3 to
5 hours after achievement of hemostasis is reasonable postablation.
IIa C-EO 835–840
Patients in whom discontinuation of anticoagulation is being considered
based on patient values and preferences should consider undergoing
continuous or frequent ECG monitoring to screen for AF
recurrence.
IIb C-EO
AF, atrial fibrillation; LOE, Level of Evidence; NOAC, novel oral anticoagulant; TEE, transesophageal electrocardiogram; ACT, activated clotting time.
*Time in therapeutic range (TTR) should be > 65% – 70% on warfarin.
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reported the outcomes of 61 patients with asymptomatic long-
standing persistent AF.417 At 50 ± 5 months’ follow-up, 57% re-
mained AF recurrence-free after removal from drugs. QOL im-
proved, with the physical component summary and the mental
component summary demonstrating substantial improvement.
Improvement was also noted on metabolic stress testing. A third
study compared the outcomes of 61 patients with asymptomatic per-
sistent AF with 132 otherwise matched symptomatic patients with
AF.418 In this study, the outcomes of ablation were superior in the
symptomatic patients compared with the asymptomatic patients
(71% vs 27% freedom from AF). Also of note was the fact that 16 pa-
tients (37%) in the asymptomatic group developed symptomatic AT.
Perhaps not surprisingly, the asymptomatic patients showed less im-
provement in QOL than the symptomatic patients. The study con-
cludes that the outcomes of AF ablation are worse in asymptomatic
patients, predominantly due to the risk of developing a symptomatic
AT postablation of asymptomatic AF. There are no prospective
randomized clinical trials that determine the benefit and risk ratio of
ablation in patients with asymptomatic AF.
While considering the issues of rhythm control and AF ablation in
apparently asymptomatic AF patients, the writing group of this docu-
ment feels it is important to note that many patients with apparently
asymptomatic AF are in fact symptomatic once an assessment of how
the patient feels in sinus rhythm has been carried out. It has become
common practice, when faced with a relatively young person with ap-
parently asymptomatic persistent AF, to cardiovert the patient, with
or without concomitant use of antiarrhythmic medications, and then
reassess the patients’ symptom status while in sinus rhythm. In our
experience, many patients subjected to this “trial of sinus rhythm”
recognize that they feel better in sinus rhythm. This finding is import-
ant because a rhythm control strategy and/or catheter ablation then
becomes a more acceptable therapeutic strategy.
At the end of the day, the writing group believes that in selected
patients, after a careful discussion of the risks, benefits, and alterna-
tives, that AF ablation may be considered in patients with asymptom-
atic paroxysmal or persistent AF (Class IIb, LOE C-EO) (Table 2).
Patients in whom this management strategy should be entertained in-
clude patients whose clinical profile would be associated with a high
efficacy and safety of AF ablation.
Indications for Surgical Ablation of AF
Indications for surgical ablation of AF are also shown in Table 2 and
are summarized in Figure 8. Safety and efficacy of AF ablation have
been well supported for a surgical approach, either performed in
conjunction with another cardiac surgical procedure or when carried
out as a stand-alone procedure. The rationale and detailed indications
for surgical ablation of AF are discussed in more detail in Section 12.
Section 5: Strategies, Techniques,
and Endpoints
Historical Considerations
Cox and colleagues are credited with developing and demonstrating
the efficacy of surgical ablation of AF.419,420 Subsequent surgeons
evaluated the efficacy of surgical approaches that limit the lesion set
to PVI.421,422 The final iteration of the procedure developed by Cox,
which is referred to as the MAZE-3 procedure, was based on a
model of AF in which maintenance of the arrhythmia was shown to
require a critical number of circulating wavelets for reentry. The suc-
cess of the Maze-3 procedure in the early 1990s led some cardiac
electrophysiologists to attempt to reproduce the procedure with RF
catheter ablation. Swartz and colleagues reported replication of the
MAZE-1 lesion set in a small series of patients using specially designed
sheaths and standard RF ablation catheters.423 The efficacy was mod-
est, the complication rate was high, and the procedure and fluoros-
copy times were long. As a result, this approach was quickly
abandoned. This report demonstrated a proof of concept that moti-
vated others to try to improve catheter-based ablative treatment of
AF. Subsequently, a large number of investigators attempted to repli-
cate the surgical MAZE procedure through the use of either three-
dimensional (3D) mapping systems or the use of multipolar ablation
catheters. These clinical trials had limited success.424,425,426,427,428,429
Based on these observations and the rapid advances in ablation of AF
targeting focal triggers that initiate AF in the PVs, electrophysiologists
lost interest in linear non-PV-based approaches to catheter ablation
of AF that attempted to replicate various aspects of the surgical
MAZE procedure.
The identification by Haissaguerre and colleagues of triggers that
initiate AF within the PVs led to prevention of AF recurrence by cath-
eter ablation at the site of the origin of the trigger.197,430,431,432,433
Direct catheter ablation of the triggers was limited by the infrequency
with which AF initiation could be reproducibly triggered. To over-
come these limitations, an ablation approach was introduced433 that
was designed to electrically isolate the PVs. This segmental PVI tech-
nique involved the sequential identification and ablation of the PV ost-
ium close to the earliest sites of activation of the PV musculature. An
ablation strategy of encircling the PVs guided by 3D electroanatomi-
cal mapping (EAM) was subsequently developed by Pappone
et al.244,432
The recognition of PV stenosis as a complication of RF delivery
within a PV, as well as the recognition that sites of AF initiation and/
or maintenance were frequently located within the PV antrum, re-
sulted in a shift in ablation strategies to target the atrial tissue located
in the antrum rather than in the PV itself.434,435 Ablation at these sites
was either performed segmentally, guided by a circular mapping cath-
eter433,436 positioned close to the PV ostium, the so-called segmental
PV ablation, or by wider continuous circumferential ablation lesions
created to surround the right or left PVs,244,432 the so-called wide-
area circumferential ablation (WACA). The circumferential ablation
or isolation line was either guided by 3D EAM,244,437,438 by fluoros-
copy,439 or by intracardiac echocardiography (ICE).435,440 Studies
comparing these two procedures reported contradictory data.441,442
A subsequent randomized study compared isolation of each individ-
ual PV vs isolation of large areas around both ipsilateral PVs. This
study reported that isolation of a large circumferential area around
both ipsilateral PVs with verification of conduction block is a more ef-
fective treatment of AF than segmental isolation of each PV.443 The
endpoint for this procedure was either amplitude reduction within
the ablated area,244,437 elimination (or dissociation) of the PV poten-
tials recorded from either one or two circular mapping catheters, or
a basket catheter within the ipsilateral PVs435,438,439,441,442,444 and/or
exit block from the PV.445
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PVI is now widely accepted as the cornerstone of AF ablation pro-
cedures (Table 3).2 Electrical isolation of the PVs is recommended
during all AF ablation procedures (Class I, LOE A). Elimination (or
dissociation) of the PV potentials recorded from a multipolar elec-
trode catheter is the primary endpoint for AF ablation procedures
for 95% of the writing group members. A single-catheter approach to
AF ablation, without employing a circular multipolar electrode cath-
eter as an ablation endpoint, is used by 5% of the writing group mem-
bers, whereas 95% employ both an ablation catheter and a mapping
catheter in the LA when performing AF ablation using either RF en-
ergy or cryoballoon (CB) ablation (CBA). Due to the high recurrence
rate observed in patients with persistent and long-standing persistent
AF with PVI alone, efforts continued to identify additive strategies to
improve the outcomes of AF ablation. These strategies have included
linear RF lesions in the LA and RA, ablation of autonomic ganglia, ab-
lation by CFAE, ablation of non-PV foci, isolation of the LAA, ablation
of scar identified by voltage mapping or MRI, and most recently, abla-
tion of rotational activity. Whether any or all of these strategies will
emerge as standard proven components to AF ablation procedures
will be determined over time. The results of the recent randomized
Substrate and Trigger Ablation for Reduction of AF Trial Part II
(STAR AF II) trial failed to demonstrate any reduction in AF recur-
rence by adding either linear or CFAE ablation to PVI in patients with
persistent AF.245 This study represented a sobering landmark in the
field of AF ablation, which has served to remind those in the field that
rigorous clinical trials are needed to define the safety and efficacy of a
particular ablation strategy before it is adopted widely as part of rou-
tine clinical care. Other advancements in the field include the intro-
duction of the CBA system, as well as the introduction of force-
sensing ablation catheters. In the following sections of this document
we will go through the data supporting each of these approaches and
technologies in detail. We will also provide input as to the import-
ance of these approaches as assessed by this large international writ-
ing group.
Ablation Approaches Targeting the PVs
and Techniques to Obtain Permanent
PVI Using RF Energy
Permanent electrical isolation of the PVs is well established as the
cornerstone of AF ablation. Despite the importance of this ablation
endpoint, permanent electrical isolation of the PVs can rarely be
achieved.263,446,447,448,449,450,451,452,453,454,455,456 Among patients re-
turning to the electrophysiology laboratory for a repeat ablation pro-
cedure after failing an initial ablation procedure, most studies report
that recurrence of PV conduction is observed in one or more PVs in
more than 80% of patients.263,446,447,452,454
Studies have also been performed to define the rate of PV recon-
duction among patients who are AF-free after an initial PVI proced-
ure. Although several of these series reported rates of PV
reconduction less than 20%,263,447 most studies have reported far
higher reconduction rates, varying from 62% to 90%.449,454,456 The
time course of electrical reconduction appears to be rapid, with stud-
ies reporting acute reconduction rates of 33% at 30 minutes448,450,451
and 50% at 60 minutes.457 In this section of the document, we will re-
view techniques that have been developed in attempt to improve the
rate of permanent PVI. We will also provide input concerning which
approaches are most widely used by the writing group members of
this document.
Optimal Initial Lesion Creation and Waiting Phase
It is widely recognized that the likelihood of obtaining permanent PVI is
related to the quality of ablation energy delivery and lesion formation.
There are many factors that play a role in determination of lesion size.
With RF energy it is well recognized that important variables that im-
pact lesion size and transmurality include catheter stability, contact
force (CF), power output, temperature, and duration of RF output.
Please refer to Section 6 of this document for a more detailed discus-
sion of these topics. Each of these variables is of importance. The writ-
ing group recommends that when performing AF ablation with a
force-sensing RF catheter, that a minimum targeted CF of 5 to 10
grams is reasonable (Class IIa, LOE C-LD) (Table 3).
The writing group also recommends that it is reasonable to use an
esophageal temperature probe during RF ablation procedures to
monitor esophageal temperature and help guide energy delivery
(Class IIa, LOE C-EO) (Table 3). In contrast to these two topics on
which consensus was achieved, there is much less consensus regard-
ing power output and the duration of energy delivery because a wide
variety of approaches are used by members of the writing group.
One of the approaches that has been proposed as a technique to
increase the rate of permanent PVI is to incorporate a 20- to 30-mi-
nute waiting period following initial isolation of each PV. The preva-
lence of time-induced PV reconnection is most frequent at
30 minutes, with a significant proportion of patients having further re-
connection at 60 minutes and very few between 60 and 90 mi-
minutes.265,448,450,451,457,459,460,461 In a retrospective study including
patients undergoing a repeat ablation procedure for recurrent AF, re-
ceiver operating characteristic analysis revealed a strong negative
correlation between the observation time after complete PVI during
the initial procedure and chronic PV reconnection.452 The optimal
cutoff value was 35 minutes, although the diagnostic accuracy was
not high (sensitivity 66.9%, specificity 60.6%). A small, prospective
randomized trial comparing the outcomes of AF ablation in which no
waiting period, a 30-minute, and a 60-minute waiting period was
incorporated into the ablation procedure revealed a clear benefit of
incorporating a 30-minute or longer waiting phase (60.7%, 84.3%, and
86.7%, respectively).457 It is notable that reevaluation of the need for
a waiting phase has not been reassessed since the widespread avail-
ability of contact force-sensing (CFS) ablation catheters. The need
for a waiting phase has been less completely assessed with CB AF ab-
lation. The Sustained Treatment of Paroxysmal Atrial Fibrillation
(STOP-AF) Trial did require a 30-minute waiting period before ter-
mination of the observation period. It is unclear whether this contrib-
uted to the 69.9% success rate in elimination of AF, although those
outcomes are similar to equivalent studies during that time frame.462
The above data would suggest that a 20- to 30-minute waiting
phase is reasonable to incorporate into an AF ablation procedure. A
limitation of a longer observation period is the impact on the total
procedure duration and work flow in the electrophysiology labora-
tory. A survey of the writing group members shows that 80% incorp-
orate at least a 20-minute waiting period following initial isolation of
the PVs when performing AF ablation with RF energy. Based on this
information, the published literature, and the experience of this writ-
ing group, the writing group recommends that monitoring for PV
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reconnection for 20 minutes following initial PVI “is reasonable”
(Class IIa, LOE B-R) during AF ablation using RF energy (Table 3).
Adenosine Testing
Intravenous adenosine (or adenosine triphosphate [ATP]) can transi-
ently restore cellular excitability and differentiate permanent conduc-
tion block from dormant conduction (e.g., viable but latently
nonconducting tissue) across circumferential PV ablation (CPVA)
lines.463,464,465,466,467 The ability of adenosine to unmask dormant PV
reconnection is impacted by the adenosine dose as well as by the
waiting time since initial documentation of PVI.466,467 The results of
one recent study suggest that the demonstration of a physiological ef-
fect of adenosine (e.g., sinus tachycardia, hypotension) is inadequate,
and that sufficient adenosine needs to be administered to demon-
strate transient AV block.467 There have been more than a dozen
studies that have investigated the role of adenosine as an adjunct to
achieving permanent PVI and improving the outcomes of AF ablation;
these are summarized in a recent review article.466 Among these
studies are two large, prospective, randomized clinical trials.
The first study was a prospective, randomized clinical trial involving
534 patients with PAF. All the patients were administered adenosine
20 minutes following initial PVI. The initial dose was 12 mg, which was
titrated until at least one blocked P wave or a 3-second pause was
observed.265 The presence of dormant PV conduction was associ-
ated with an increased risk of arrhythmia recurrence. Patients with
dormant PV conduction were randomly assigned to additional
adenosine-guided or to no further ablation. Elimination of dormant
PV conduction by additional targeted ablation significantly reduced
recurrent atrial tachyarrhythmias (ATAs) by 56% during follow-up
(P <.0001).265 The most recent study enrolled 2113 patients with
paroxysmal, persistent, and long-standing persistent AF.461 In this
study, 0.4 mg per kg of adenosine was administered after a variable
waiting time (median time 43 minutes). Early reconduction after the
waiting time alone was observed in 42% of the patients in both
groups. Subsequent administration of adenosine demonstrated fur-
ther reconduction in an additional 27% of the patients. Further abla-
tion was then performed to eliminate dormant conduction. At the
end of 1 year of follow-up, no difference in outcome was observed,
with a success rate of approximately 65% in each group. Of note,
given the lower observed 27.6% prevalence of dormant conduction
in the latter trial, a risk reduction of 72.4% in those patients with dor-
mant conduction would have been required to detect a significant
overall difference.466 It is also notable that the use of force-sensing
ablation catheters is associated with a significant reduction in the
prevalence of dormant conduction, therefore limiting the impact of
an adenosine-guided ablation strategy on clinical outcome.468
Although the above data would suggest that administration of ad-
enosine 20 minutes after initial PVI at a dose titrated to achieve AV
block or a 3-second pause could improve outcomes of AF ablation,
the impact of such a strategy is limited. Furthermore, the addition of
an adenosine testing strategy prolongs procedure time and increases
costs. A survey of the writing group members shows that 61% rou-
tinely incorporate use of adenosine into their ablation procedure
when using RF energy and 25% incorporate this approach into their
ablation strategy when using CB. Based on this information, the pub-
lished literature, and the experience of this writing group, the writing
group recommends that administration of adenosine 20 minutes after
initial PVI phase “may be considered” (Class IIb, LOE B-R) during AF
ablation (Table 3).
Isoproterenol Infusion
Some studies reported the use of adenosine during isoproterenol in-
fusion to unmask dormant PV conduction.460,469,470 A prospective
clinical and experimental evaluation of various pharmacological strat-
egies found that adenosine was superior to an isoproterenol infusion,
with no significant additional value of combining the two.471
Therefore, although isoproterenol infusion can be used to identify
non-PV triggers in paroxysmal and persistent AF, there is only a lim-
ited role of isoproterenol infusion alone to reveal dormant PV con-
duction after PVI. A survey of writing group members shows that less
than one-third administer isoproterenol to search for PV
reconnection.
Loss of Pace Capture on the Ablation Line
The use of a pace capture-guided ablation strategy as an additional
endpoint in PVI procedures has been proposed as another method
to improve the durability of PVI.264,472,473,474,475 Using this approach,
after completion of PVI, high-output pacing (10 mA) from the abla-
tion catheter’s distal bipole is performed during sinus rhythm while
slowly moving the catheter along the entire circumference of the ipsi-
lateral PVI lines.264,472 Where local LA capture is identified, additional
ablation is performed until loss of capture, with the goal of closure of
the residual gaps. In a recent randomized study involving 102 patients
at two centers, this technique significantly improved arrhythmia-free
survival compared with conventional PVI.474 Another study com-
pared an ablation strategy of loss of pace capture vs adenosine ad-
ministration to identify dormant conduction. The outcomes were no
different in the two groups.473 Another study revealed that a strategy
of pace-capture-guided PVI was found to be associated with a signifi-
cant reduction in dormant PV conduction revealed by adenosine.475
It is also notable that reevaluation of value of pace capture has not
been reassessed since the widespread availability of CFS ablation
catheters.
Although the above data would suggest that using pace capture
might improve outcomes of AF ablation, the data are somewhat lim-
ited and have been published from a very small number of centers.
Like other strategies to improve outcomes of AF ablation, this strat-
egy also prolongs procedure time. A survey of the writing group
members shows that 24% routinely incorporate the strategy of pace
capture when using RF energy. This strategy is not applicable for the
CB approach. Based on this information, the published literature, and
the experience of this writing group, the writing group recommends
that pace-capture-guided ablation strategy may be considered follow-
ing PVI with RF energy (Class IIb, LOE B-R) (Table 3).
Exit Block
Although the demonstration of entrance conduction block is the
standard endpoint of PVI procedures, permanent PV exit conduction
block (or the “stable absence of PV-LA conduction”) is the ultimate
goal for prevention of PV-induced AF. Exit block can be demon-
strated either by spontaneous discharges recorded circumferentially
around the PV or by continuing arrhythmia within the PV, which are
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dissociated from sinus rhythm or by pacing from within the PV.476 In
the case of PV pacing, it is imperative to demonstrate local PV cap-
ture without conduction to the LA to prove exit block. It is also im-
portant to avoid inadvertent capture of adjacent far-field structures,
which would result in misinterpretation of apparent exit conduc-
tion.477,478 The presence of entrance block appears to be effective in
predicting bidirectional block across CPVA lines.141,142,143
Mechanistically, the most likely explanation is source–sink mismatch,
which is defined as delay or block of conduction observed when the
size of a given excited region supplying depolarizing current (the cur-
rent source) is insufficient for the amount of depolarizing current ne-
cessary to excite the regions ahead (the current sink).479 Although an
initial report has observed unidirectional entrance block in more
than 40% of PVs,445 the incidence was much lower in more recent
studies (1.5%–16%).477,479,480,481 Interestingly, in one of these studies,
the presence of PV discharges conducted to the LA (exit conduction)
was followed by recovery of entrance conduction during a 30-minute
waiting period.480 None of the reported studies compared success
rates of PVI using only verification of PV entrance block vs bidirec-
tional PV conduction block.
The above data would suggest that demonstration of exit block is
feasible, and is a reasonable endpoint for AF ablation when combined
with the presence of exit block. A survey of the writing group mem-
bers shows that 60% routinely pace in the PV and employ exit block
as an endpoint during AF ablation using RF energy, and 46% routinely
pace in the PV and employ exit block as an endpoint during CBA.
Based on this information, the published literature, and group experi-
ence, the writing group recommends that demonstration of exit
block may be considered following PVI with RF or CB energy (Class
IIb, LOE B-NR) (Table 3).
Techniques for Obtaining Permanent PVI
with Balloon Technologies
PVI is the cornerstone of all ablation strategies in AF. However, it is
still challenging, and there exists a considerable learning curve to de-
velop the skills needed to safely and effectively perform RF AF under
3D electroanatomical guidance. Therefore, novel catheter designs
with alternative energy sources have been developed. These cath-
eter technologies are balloon-based ablation systems using various
energy modalities, such as cryoenergy (Arctic Front, Medtronic,
Inc., Minneapolis, MN, USA), laser (Heartlight, CardioFocus,
Marlborough, MA, USA), and radiofrequency catheter (RFC) (Hot
Balloon Catheter, Hayama Arrhythmia Institute, Kanagawa, Japan).
These technologies will be discussed in detail in the technologies sec-
tion of this document. The present section will focus on some of the
strategies that have been developed to facilitate the endpoint of
achieving permanent PVI.
Obtaining Permanent PVI with the Cryoballoon
The first-generation CB was introduced approximately 10 years ago
and consisted of a noncompliant balloon with two different diam-
eters (23 mm and 28 mm), using N2O as the refrigerant. A stiff wire
or a spiral mapping catheter (Achieve, Medtronic, Inc.) is inserted via
a central lumen of the catheter shaft. Applying the first-generation
CB and freeze cycle durations of 300 seconds, successful PVI was
routinely followed by a bonus freeze cycle of the same duration. The
1-year success rate was approximately 70%–73%.462,482 More than
80% of the patients with AF recurrence after first-generation CB-
based PVI demonstrated recurrence of conduction at the time of a re-
peat ablation procedure.483 The second-generation CB (Arctic Front
Advance, Medtronic, Inc.) was introduced in 2012 and incorporates a
modified refrigerant injection system characterized by 8 injection jets
in a more distal balloon position. Thus, a more homogeneous cooling
of the complete distal balloon hemisphere, including the distal tip,
was achieved. Multiple studies have demonstrated clinical success
rates of 65% or greater.484,485,486,487,488,489,490,491,492,493 The recently
published FIRE AND ICE trial was the first to compare the acute
and long-term efficacy as well as the safety profile of the second-
generation CB with conventional RFC ablation in a prospective,
randomized, multicenter fashion.489 The study demonstrated the
noninferiority of CBA compared with RF-based ablation with re-
spect to efficacy and safety of patients with drug-refractory
PAF.494 However, secondary endpoints, such as the rate of reho-
spitalization and reablations, or the necessity of electrical cardio-
version during follow-up were in favor of CB.490 Among patients
who fail AF ablation with the CB2 system, recurrent PV conduc-
tion is observed in 27% to 65% of patients.487,491 The role of ad-
enosine in revealing dormant conduction has also been evaluated.
One study reported that administration of 12 mg or more of ad-
enosine (titrated to AV block) 30 minutes postablation resulted in
an 11% incidence of recurrent PV conduction.495 A second study
reported similar findings, with a 12% incidence of recurrent con-
duction after a waiting phase plus adenosine administration. This
small study of 90 patients reported a higher success rate (84% vs
79%) when a strategy of reablation based on adenosine-induced
dormant conduction was targeted.495
A survey of the writing group shows that only 51% of the writing
group members employ a 20-minute or longer waiting phase when
using CBA. This survey also revealed that 46% of operators routinely
pace in the PV and employ exit block as a secondary endpoint during
AF ablation using CB energy.
Endoscopic Laser Balloon PVI
The endoscopic laser balloon is a recently introduced balloon-based
ablation system incorporating a titratable laser source and a 2F endo-
scope. This ablation system received U.S. Food and Drug
Administration (FDA) approval in the United States for ablation of
PAF in 2016. It consists of a compliant balloon (9–35 mm) that can be
adapted according to the individual PV diameter. The laser arc covers
30 of a complete circle and allows energy titration in five steps, from
5.5 W to a maximum of 12 W. The rate of acute PVI when applying
this system is 98%–100%.496,497,498,499 A study in which 52 patients
underwent chronic reassessment of PV conduction revealed that
14% of PVs demonstrated reconnection, translating to 38% of pa-
tients with reconduction of one or more veins.497 The application of
higher energy levels (8.5 W or 10 W) was associated with a significant
increase in the rate of acute PVI after a purely visually guided ablation
circle.500,501,502 At the same time, the application of higher energy
settings did not compromise the safety profile. One-year clinical
follow-up data from two prospective, multicenter studies in pa-
tients with PAF demonstrated a single-procedure clinical success
rate of 63% and 60% with no anti-arrhythmic medication.498,499
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A prospective comparison with RF ablation revealed equivalent 1-
year outcomes, with a success rate of 61%.503 There have been no
studies that have examined how often vein reconnection is observed
within the first 60 minutes post-PVI. There are also no data on the
role of adenosine.
Adjunctive Ablation Strategies to Be
Performed in Addition to PVI During AF
Ablation
Cavotricuspid Isthmus Ablation
Catheter ablation of typical AFL involving the cavotricuspid isthmus is
a safe, effective, and well-established ablation procedure. For patients
undergoing AF ablation, creation of a cavotricuspid isthmus line can
be performed safely, easily, and with only a slight prolongation in pro-
cedure time. A survey of the writing group members shows that abla-
tion of the cavotricuspid isthmus is performed by 94% of the writing
group members in patients undergoing AF ablation who have previ-
ously been documented by ECG to have experienced isthmus-
dependent AFL, as well as those with inducible cavotricuspid
isthmus-dependent AFL at the time of the ablation procedure. This is
based on decades of experience demonstrating the safety and efficacy
of catheter ablation of AFL as well as data from clinical trials compar-
ing ablation with AAD therapy.230,504,511,1397 The writing group rec-
ommends that if a patient has a history of typical AFL or typical AFL is
induced at the time of AF ablation, delivery of a cavotricuspid isthmus
linear lesion is recommended (Class I, LOE B-R, Table 3).
Linear Lesions Not Involving the Cavotricuspid Isthmus
Circumferential isolation of PVs has become the standard therapy for
PAF. However, due to the high recurrence rate observed in patients
with persistent and long-standing persistent AF with PVI alone, con-
tinued efforts are underway to identify additive strategies to improve
outcome. One of these strategies is to create additional linear lesions
in the LA similar to those that are a part of that advocated with the
Cox-Maze III lesion set (Figure 6).505,506 The most common sites for
linear ablation are the LA “roof” connecting the superior aspects of
the left and right upper PVI lesions, the region of tissue between the
mitral valve and the LIPV (the mitral isthmus), and anteriorly between
the roof line near the left or right circumferential lesion and the mitral
annulus. A prior randomized, prospective trial of catheter ablation of
PAF comparing segmental PVI vs CPVA plus LA linear ablation
(CPVA-LALA) at the LA roof and myocardial infarction showed that
significantly more patients had LA flutter in the CPVA-LALA
group.507 A survey of the writing group shows that only 2% perform
linear ablation during an initial AF ablation in patients with PAF. For
redo ablation procedures in PAF, only 10% of the writing group
members routinely employ linear ablation. Based on this information,
the published literature, and the experience of this writing group, we
recommend that creation of linear lesions not be performed during
initial or redo AF ablation for PAF unless a macroreentrant AT is
induced. The role of additional lines in cases of persistent AF remains
controversial.508 The recently completed STAR-AF study of ablation
strategies for persistent AF showed no improvement in ablation effi-
cacy for linear lesions plus PVI vs PVI alone.245 The Catheter Ablation
of Persistent Atrial Fibrillation (CHASE-AF) study also revealed that
the addition of linear lesions and defragmentation of PVI did not
improve outcomes for ablation of persistent AF compared with PVI
alone.509 For patients with persistent or long-standing persistent AF,
25% of the writing group members perform linear ablation at the
time of an initial ablation procedure, increasing to 45% when redo
procedures are performed in patients with persistent and long-
standing persistent AF. The writing group recognizes that the useful-
ness of linear ablation lesions in the absence of macroreentrant AFL
is not well established (Class IIb, LOE C-LD). For patients with PAF,
linear ablation should not be performed. The usefulness of creation
of linear ablation lesions in the RA or LA as an initial or repeat abla-
tion strategy for persistent or long-standing persistent AF is not well
established (Class IIb, LOE B-NR) (Table 3). It has been widely dem-
onstrated that incomplete block across the ablation lines can be re-
sponsible for AT recurrence.510,511,512,513 Therefore, if linear ablation
lesions are applied, operators should use mapping and pacing maneu-
vers to assess for line completeness (Class I, LOE C-LD) (Table 3).
Well-designed, prospective, randomized clinical trials must be the ul-
timate test of linear ablation techniques.
In patients with long-standing persistent AF, the stepwise approach
has been proposed.514,515 The strategy starts by pulmonary isolation,
followed by ablation of CFAE, looking for reversion to sinus rhythm or
AT. If this endpoint is not achieved, additional linear lesions are de-
ployed.514,516,517 Whether the endpoint of AF termination is associated
with improved long-term results remains controversial.518 Despite
encouraging acute outcomes, with termination of AF in 80% of patients,
the follow-up data were less impressive with a 1-year single procedure
efficacy of 35% and a 5-year efficacy of 17%. Arrhythmia-free survival
rates after the last procedure (mean 2.1 ± 1.0 procedures) were
89.7% ± 2.5%, 79.8% ± 3.4%, and 62.9% ± 4.5%, at 1, 2, and 5 years, re-
spectively.515 More recent data also suggest that linear ablation does
not improve outcomes compared with PVI alone.245,515,519,520,521 The
recently completed CHASE-AF study also reported no improvement in
efficacy for ablation of persistent AF with PVI plus linear lesions and de-
fragmentation compared with PVI alone.509 The clinical significance of
these data, which appear to be contrary to our understanding of the
mechanisms of AF, predicting that AF is less likely to be sustained in
electrophysiologically smaller, segmented atria, is of clinical importance.
Potential explanations for this discrepancy might be that the linear le-
sions are incomplete, are in the wrong place, or that our understanding
of the AF mechanism is incorrect.
Posterior Wall Isolation
Some patients with PAF can be undertreated with PVI alone, and PVI
might not be enough to control persistent and long-standing persist-
ent AF. Further modification of the atrial substrate might be required.
One of the strategies that has been proposed is electrical isolation of
the posterior wall. This can be performed by creating a linear ablation
of the LA roof joining the superior PVs and the LA floor joining the in-
ferior PVs or by point-by-point ablation of the entire posterior wall
(Figure 6). Entrance block of the box lesion is confirmed by lack of po-
tentials in the box. Exit block of the box lesion is confirmed by pacing
in the box and demonstrating exit block during sinus rhythm. Gaps
along the ablation lines, if present, are mapped and ablated.522,523,524
With lack of LA capture outside the box, the lines are considered
complete. The endpoint of box isolation is defined as bidirectional
conduction block, i.e., both lack of potentials in the box and lack of
LA capture.
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Although some studies have been published that report improved
outcomes,525,526 with posterior wall isolation, other clinical trials re-
port no improvement on outcomes.527 The recently published
BELIEF trial reported at 28% efficacy of an extensive ablation strategy,
including ablation of the posterior wall, in patients with long-standing
persistent AF.528,529 A survey of the writing group shows that 15% of
the writing group members perform posterior wall isolation in pa-
tients with PAF during an initial AF ablation procedure, and 18% iso-
late the posterior wall during a repeat ablation procedure in a patient
with PAF. The role of posterior wall isolation in cases of persistent
AF also remains controversial.508 For patients with persistent or
long-standing persistent AF, 22% of the writing group members per-
form posterior wall isolation at the time of an initial AF ablation pro-
cedure and 38% of the writing group members perform posterior
wall isolation for repeat AF ablation procedures in patients with per-
sistent and long-standing persistent AF. Based on this information and
a review of the literature, the writing group recommends that poster-
ior wall isolation might be considered during an initial or repeat AF
ablation for paroxysmal, persistent, or long-standing persistent AF
(Class IIb, LOE C-LD, Table 3).
Nonpulmonary Vein Triggers
Non-PV “triggers” can be identified in 10%–33% of unselected pa-
tients referred for catheter ablation of AF.96,197,208,257,530,
531,532,533,534 The prevalence of non-PV triggers in different studies
varies with the specific definition adopted, which ranges from repeti-
tive atrial premature depolarizations without definitive AF initi-
ation532,533 to reproducible sustained AF triggering.534
Supraventricular tachycardias, such as AV nodal reentry or accessory
pathway-mediated AV reciprocating tachycardia, can also be identi-
fied in up to 4% of unselected patients referred for AF ablation and
can serve as a triggering mechanism for AF.458 Non-PV triggers can
be provoked in patients with both paroxysmal and more persistent
forms of AF.531,534 In selected patients with reproducible non-PV trig-
gers and without provocable PV AF triggers with high-dose iso-
proterenol, elimination of only the non-PV triggers has resulted in
elimination of AF.96,458,535
The most common sites of origin for non-PV atrial triggers include
the posterior wall of the LA, the SVC, the crista terminalis, the fossa
ovalis, the CS, the eustachian ridge, the ligament of Marshall, and adja-
cent to the AV valve annuli (Figure 4).96,208,458,530,531,536 More re-
cently, frequent and repetitive atrial premature depolarizations have
been identified in the LAA in patients with more persistent AF, which
have been targeted by LAA isolation techniques.532,533
Isoproterenol is the most commonly used agent to provoke non-
PV triggers. Withholding of antiarrhythmic agents for five half-lives
and withholding beta-blockers for at least 24 hours is important
when a strategy of searching for non-PV triggers is employed. A typ-
ical protocol for initiating non-PV triggers includes:
(1) Baseline infusion of a vasoconstrictor (e.g., phenylephrine) to main-
tain mean arterial pressure (MAP) >70 mm Hg and increase the
bolus vasoconstrictor throughout infusion to maintain adequate
perfusion. This is particularly important under general anesthesia.
Careful titration of a vasoconstrictor allows for higher doses of iso-
proterenol infusion.
(2) Graded infusion of isoproterenol using up to 20–30lg per minute
for at least 10 minutes is recommended. Most members of the non-
PV trigger writing group felt that lower-dose isoproterenol infusion
was frequently ineffective.
(3) If no effect with isoproterenol infusion, burst pacing into AF and
then cardioversion during low-dose isoproterenol infusion (2–6lg
per minute) may be considered.
(4) Use of adenosine bolus or burst atrial pacing during lower-dose iso-
proterenol infusion to attempt to identify repetitive triggers after
the drive train is an adjunctive technique employed by a subset of
the non-PV trigger writing group. Localization of non-PV AF triggers
can be challenging, particularly when only the first triggering beat is
being targeted, and typically involves recognition of specific intra-
atrial activation patterns on multipolar catheters placed in the RA
and CS, together with information from the surface ECG to help re-
gionalize an area of interest.458,534,535 Moving the circular mapping
or ablation catheters around the LA and reinitiating AF can be useful
to localize AF triggers, taking care to minimize ectopy with catheter
manipulation. Placement of a multipolar catheter inside the SVC is
important for identifying SVC triggers. The majority of the writing
committee members perform SVC isolation if an SVC trigger is
identified. To isolate the SVC, a circular mapping catheter is placed
inside the SVC to identify SVC potentials. Ablation is performed
proximally at the SVC/RA junction. While isolating the SVC, high-
voltage pacing (at least 20 mA) is used before each RF application to
check for phrenic nerve (PN) stimulation. Ablation is avoided in
areas of PN capture, even if incomplete isolation is the result. SVC
isolation should ideally be performed in sinus rhythm after iso-
proterenol infusion has worn off to avoid sinus node injury. RF ap-
plication is ceased if sinus node acceleration or pauses are
observed. The endpoint of SVC isolation is entry and exit block into
the SVC, as is typically seen with PVI. Dissociated firing of the SVC
can also be observed. In contrast to wide-area PVI and because of
phrenic capture or risk of sinus node injury, a segmental approach
targeting the earliest breakthrough on the circular mapping catheter
is most commonly employed.
While ablating AF triggers on the LA posterior wall, the RF power
is typically decreased to <_ 30 W. An esophageal temperature probe
is frequently used. The writing group also recommends that it is rea-
sonable to use an esophageal temperature probe during RF ablation
procedures to monitor esophageal temperature and to help guide
energy delivery (Class IIa, LOE C-EO, Table 3). Some committee
members isolate the entire posterior wall if numerous or multifocal
posterior wall triggers are identified. This can be accomplished using
a “box” lesion set, including a roof line (RSPV to LSPV) and floor line
(RIPV to LIPV) after PVI. If triggers are observed to be originating
from the CS or the LAA, some writing committee members perform
isolation of these structures, while most prefer focal ablation. LAA
triggers can be identified by observing far field LAA activity on a circu-
lar mapping catheter placed in the LSPV; placing the ablation catheter
into the LAA should be avoided to minimize risk of perforation or
catheter-induced ectopy. Isolation of the LAA should be performed
only after prior discussion with the patient and consideration of the
long-term need for thromboembolic prophylaxis, with consideration
given to LAA closure by one of the available methods. For other
non-PV triggers, such as AT, AV nodal reentry tachycardia or AV
reentrant tachycardia, focal ablation is performed. Inability to pro-
voke the trigger with repeat isoproterenol infusion is considered as
the endpoint. Observational studies have shown improved
arrhythmia-free survival when non-PV triggers are targeted for abla-
tion and effectively eliminated at the time of PVI.537,538
e38 Guidelines
Downloaded from https://academic.oup.com/europace/article-abstract/20/1/e1/4158475
by Erasmus University Rotterdam user
on 29 January 2018
In some redo ablation cases, if non-PV triggers cannot be pro-
voked, empiric ablation of non-PV trigger sites may be attempted.
The empiric targeting of frequently defined non-PV trigger sites can
have more value in persistent forms of AF when triggers are not
observed with provocative maneuvers.539 The most common em-
piric non-PV trigger ablation is SVC isolation. Other common sites
for empiric non-PV trigger ablation include the mitral annulus, limbus
of the crista terminalis, mid to inferior crista terminalis, and eusta-
chian ridge.539 Some investigators also advocate empiric LAA and CS
isolation.
Despite the suggested improved outcome with elimination of non-
PV triggers, the minority of operators according to a recent
European survey routinely perform non-PV trigger initiation and abla-
tion.540 Ablation of non-PV triggers might be more important for pa-
tients with persistent forms of AF and for those patients who
undergo repeat ablation procedures in whom all PVs are found to be
isolated.
Additional investigation is needed on the optimum method for ini-
tiating and mapping infrequent non-PV triggers. Furthermore, the
value of routine non-PV trigger identification and ablation with the
initial ablation procedure and at the time of repeat procedure follow-
ing recurrence warrants further study.
A survey of the writing group members shows that when ablating
PAF with the CB system, 18% also search for non-PV triggers.
Among those who use RF energy for AF ablation in patients with
PAF, 41% routinely employ a strategy including administration of
high-dose isoproterenol to screen for and then ablate non-PV trig-
gers. When performing a repeat procedure in a patient with PAF,
57% of the writing group members search for non-PV triggers. When
ablating persistent and long-standing persistent AF with RF energy,
the percentage of the writing group members who use a non-PV trig-
ger protocol are 35%, and 46% for first-time and redo AF ablation
procedures, respectively. Based on this information and a review of
the literature, the writing groups recommends that administration of
high-dose isoproterenol to screen for and then ablate non-PV trig-
gers may be considered during initial or repeat AF ablation proced-
ures in patients with paroxysmal, persistent, or long-standing
persistent AF (Class IIb, LOE C-LD).
LAA Focal Ablation, Isolation, and
Ligation or Resection
A relatively new non-PV-based strategy for ablation of AF involves
targeting non-PV triggers and reentrant tachycardias that arise from
the LAA.541 Over the past 5 years, new information has been pub-
lished showing promising outcomes using a variety of non-PV-based
ablation strategies that target the LAA. These strategies include focal
ablation of non-PV triggers arising in the appendage,541 electrical iso-
lation of the LAA,541,542,543,544 and most recently, ligation of the LAA,
although this approach is an off-label use of LA tissue liga-
tion.532,533,535,536 LAA isolation has been described using a technique
similar to that of PVI: with the circular mapping catheter positioned
at the level of the LAA ostium, addressing the earliest LAA activation
site (preferably during sinus rhythm). Care should be taken not to ab-
late inside the LAA (risk of perforation and PN injury). After LAA iso-
lation, patients should be kept on long-term OAC or considered for
LAA occlusion. This reflects the results of a recent study that has
reported an increased stroke risk following LAA electrical isola-
tion.544 The recently published BELIEF trial randomized 173 patients
to start AF ablation or to start standard AF ablation with empirical
electrical isolation of the LAA. After an average of 1.3 procedures,
the cumulative success at 24 months’ follow-up was 76% in the com-
bined group vs 56% with standard AF ablation.528,529 One approach
to address this potential issue is to combine LAA electrical isolation
with placement of a Watchman Device.542,543 Recent animal and
human studies have also reported the feasibility of this combined
strategy.542,543 Currently, a prospective randomized clinical trial is
being performed to determine if LAA ligation with the LARIAT de-
vice will improve the efficacy of PVI in patients with persistent AF.
The outcome of this trial will be required to provide a clear indication
for this approach. A survey of the writing group members shows
LAA focal ablation, isolation, or ligation as an initial ablation strategy
in patients with PAF is used by 2% of the writing group members, and
4% use the above for repeat AF ablation procedures in patients with
PAF. For patients with persistent and long-standing persistent AF,
LAA focal ablation, isolation, or ligation was used by 9% of the writing
group members as an initial ablation strategy in patients with PAF,
and was used by 11% of the writing group members for repeat AF ab-
lation procedures in patients with persistent and long-standing per-
sistent AF. There is need for additional well-performed, prospective,
multicenter randomized trials in order to determine the safety and ef-
ficacy of this approach.
Complex Fractionated Atrial
Electrogram Ablation
More than a decade ago, CFAEs were reported to potentially repre-
sent AF substrate sites and became target sites for AF.516,545 CFAEs
are electrograms with highly fractionated potentials or with a very
short cycle length (<120 ms). CFAEs are typically low-voltage mul-
tiple potential signals between 0.06 and 0.25 mV. The primary end-
points using this approach during RF catheter ablation strategies for
AF are either complete elimination of the areas identified with
CFAEs, conversion of AF to sinus rhythm (either directly or first to
an AT), and/or noninducibility of AF. In patients with persistent AF,
the endpoint of ablation with this approach is AF termination.
Although use of the AF termination endpoint has been reported to
be associated with improved short-term outcomes, the long-term re-
sults have been disappointing.245,515,517,546 When the areas identified
with CFAEs are completely eliminated, but the arrhythmias continue
as organized AFL or AT, the ATAs are mapped and ablated. In pa-
tients with long-standing persistent AF, a step-wise approach to abla-
tion has been reported to successfully convert AF to either sinus
rhythm or AT in greater than 80% of patients.514,547 Despite these
encouraging acute outcomes, the follow-up data were disappointing,
with a 1-year single procedure efficacy of 35% and a 5-year efficacy of
17%.515
One of the limitations of ablation targeting with CFAEs has been
the extensive amount of ablation needed. As a result, some strategies
for differentiating “active” from “passive” sites have been described.
These include pharmacological interventions, the use of monophasic
action potentials, limiting ablation to areas of continuous electrical ac-
tivity, and activation mapping of AF.540,548,549,550,551 Unfortunately,
improved outcomes with CFAE ablation in patients with persistent
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AF have not been uniformly reported, and the scientific basis for
CFAE ablation is not universally accepted. Moreover, results from
the STAR AF II trial have shown that the addition of further ablation
(lines or CFAEs) to PVI increased ablation time but did not reduce
the recurrence of AF in 589 patients with persistent AF.245 At
18 months, the percentage of patients who were free from AF recur-
rence after one procedure without antiarrhythmic medication did
not significantly differ among groups. Similar findings were reported
in the CHASE-AF trial, which reported that the addition of defrag-
mentation and linear ablation to PVI did not improve ablation out-
comes for persistent AF compared with PVI alone.509 This suggests
that CFAE has clearly lost momentum, perhaps in favor of less exten-
sive approaches for AF ablation.552
None of the writing group members routinely employ CFAE-
based ablation as part of an initial ablation strategy in patients with
PAF, and only 4% of the writing group members employ CFAE abla-
tion during repeat procedures. Ten percent of the writing group
members routinely employ CFAE-based ablation as part of an initial
ablation strategy in patients with persistent and long-standing persist-
ent AF, and 26% incorporate CFAE-based ablation for redo proced-
ures in this subset of patients. Based on this information and a review
of the literature, the writing group recognizes that the usefulness of
CFAE-based ablation as an initial or repeat ablation strategy for per-
sistent and long-standing persistent AF is not well established (Class
IIb, LOE B-R). Focal ablation of sites targeted by CFAE without an-
choring the lesion to a nonconducting neighboring area might simply
lead to formation of a substrate prone to produce future AFLs. CFAE
ablation is not recommended for ablation of PAF.
Ablation of Fibrosis Identified by Voltage
Mapping and/or MRI Mapping
Another new ablation strategy that has been developed to improve
the outcomes of ablation involves targeting detected areas of fibrosis,
based either on voltage mapping or on MRI. The regional and individ-
ual extent of the fibrotic LA substrate in patients with AF can be
visualized during ablation intervention in sinus rhythm by applying
electroanatomical voltage mapping (EAVM). This technique led to
the use of a patient-tailored ablation strategy called box isolation of fi-
brotic areas (BIFA), with circumferential isolation of the severely af-
fected fibrotic areas (e.g., <0.5 mV), and with complete isolation
confirmed by a circular mapping catheter.140,553 Early pilot data using
this approach combined with PVI was encouraging.
This approach involves first isolating the PVs. A voltage map is then
recorded during sinus rhythm, and the low voltage areas are identi-
fied and subsequently isolated according to the individual localization
and extent. Efforts are made to connect these BIFA ablation lines to
the initial PVI lines to prevent the production of small channels, such
as is possible with CFAE or GP ablation. Using this approach, ap-
proximately one-third of the patients with persistent AF were identi-
fied as not having substantial LA fibrosis and, accordingly, only PVI
was performed. This limited approach led to freedom from AF at
12 months with a single procedure in 69% of the patients and with
only 1.2 procedures per patient in 85%.140 These results were com-
parable to patients with substantial fibrosis and subsequent BIFA abla-
tion. In addition, in a small portion of patients with massive fibrosis
(the strawberry), failure of the initial ablation was likely, and further
ablation procedures were discouraged.140 Other investigators have
also described a tailored substrate modification based on low-voltage
areas.554 They used several strategies, including linear lines encircling
of low-voltage areas, with demonstration of a significant reduction in
local electrograms, defractionation, and/or loss of capture. Even ear-
lier, isolation of the posterior wall at the level of the PVs without
prior EAVM was introduced522; however, this strategy did not ad-
dress the individual localization of the fibrotic disease at that time.
Several other groups have recently reported on voltage-guided sub-
strate modification in patients with persistent AF.555,556,557 The dur-
ability of RFC-induced isolating lesions is clearly still an issue. The
same holds true for BIFA lines for substrate modification guided by
EAVM. Recent technology improvements of point-by-point catheter
approaches (e.g., CF measurement) could further pave the way for
improving these approaches. However, the realization of the pro-
posed strategies for BIFA substrate modification requires of the oper-
ator extensive manual skills and experience.
The methods to describe the fibrotic substrate with EAVM are
also under intensive investigation, and several limitations yet remain.
The voltage maps using point-by-point mapping not only take time,
but the measured voltage also depends on the rhythm (sinus rhythm
vs extrasystole or AF), the contact of the electrode to the tissue, the
thickness of the atrial myocardium, the size of the mapping elec-
trodes, interelectrode distance, and other variables. Investigators
described preexistent LA scarring in patients undergoing PVI as an in-
dependent predictor of procedural failure.558 Low voltage for abnor-
mal areas in their study was also defined as an amplitude <_0.5 mV,
and scar <_0.05 mV, indistinguishable from noise. Other investigators
recently described contact EAM-derived voltage criteria for charac-
terizing LA scar in patients undergoing ablation for AF.559 In their
study, a voltage range of 0.2 to 0.45 mV was found to delineate scar.
Others used 0.2 to 0.5 mV as diseased and >0.5 mV as healthy.554 This
differs from the experience of another investigator, in whose studies
0.5 to 1.5 mV presented an intermediate zone that did not denote sub-
stantial fibrosis but that also did not provide clear evidence for a nor-
mal atrial myocardium.140,553 The fragmented electrogram
appearance of voltages in the range of 0.5 and 1.5 mV frequently
argue in favor of mild fibrosis. Certainly, there is no “yes or no” with
respect to atrial fibrosis, but various grades can be observed. In sum-
mary, atrial scar is proposed for sites with no discrete electrograms
(apart from potential far-field electrograms) and no local capture dur-
ing pacing, dense fibrosis for sites with voltages <_0.5 mV, an intermedi-
ate zone of mild fibrosis for sites with voltages >0.5 to 1.5 mV, and
normal for sites with voltages >1.5 mV. However, with some excep-
tions, mild fibrosis is even assumed at sites with voltages between 1.5
and 2.5 mV. Furthermore, criteria need to be developed when other
diagnostic catheters are used for EAVM, e.g., the circular mapping
catheter or the Pentaray catheter. Overall, these initial single-center
observational studies on ablation or isolation of fibrotic areas need to
be confirmed and extended in multicenter randomized studies.
Recently, the utility of delayed enhancement (DE) MRI has been
introduced for detecting, quantifying, and localizing atrial fibrosis,
including the definition of four categories of structural changes (Utah
stages I–IV).130,560,561 The tissue characterization of the LA wall on
DE MRI correlated with EAVM and with histology from surgical bi-
opsy specimens.560,561 The association of atrial tissue fibrosis and AF
catheter ablation outcomes, with more extensive fibrosis associated
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with lower efficacy, was confirmed in the multicenter Delayed
Enhancement MRI and Atrial Fibrillation Catheter Ablation
(DECAAF) study.365 On the other hand, these MRI findings at this
point in time require extensive MRI experience, including specifica-
tion of image contrast and continuity, required to set boundaries for
the various degrees of fibrosis. The reproducibility of this approach is
still under investigation. A major limitation of this approach is that the
degree of scar identified depends strongly on the above thresholds
used to define scar. At the present time, no uniform standard has
been developed. This limitation hinders the reader-to-reader and
day-to-day reproducibility of MRI-determined measurements of atrial
scar. Once established, however, the DE MRI quantification and local-
ization of atrial fibrosis might be used effectively to guide individually
tailored substrate elimination comparable to EAVM-guided substrate
modification. Finally, tissue visualization before and also during and
directly after RF catheter ablation is the target for introducing real-
time MRI into the clinical electrophysiological laboratory. Currently,
the DECAAF-2 trial has been launched to test the hypothesis that ab-
lation of scar detected on MRI improves ablation outcomes for per-
sistent AF compared with PVI alone.
A survey of the writing group members shows that for patients
undergoing an initial AF ablation for PAF, 7% of the writing group
members employ an ablation strategy based in part on MRI or voltage
mapping-detected scar, and 9% of the writing group members em-
ploy this strategy for repeat AF ablation procedures in patients with
PAF. For an initial ablation procedure in patients with persistent and
long-standing persistent AF, 15% of the writing group members em-
ploy an ablation strategy based in part on MRI or voltage mapping-
detected scar. The proportion increases to 22% for repeat ablation
in patients with persistent or long-standing persistent AF. Based on
this information and a review of the literature, the writing group rec-
ognizes that the usefulness of mapping and ablation of areas of abnor-
mal myocardial tissue identified with voltage mapping or MRI as an
initial or repeat ablation strategy for persistent and long-standing per-
sistent AF is not well established (Class IIb, LOE B-R, Table 3).
Mapping and Ablation of Rotational
Activity
Several approaches have been developed to identify areas of rota-
tional activity in the atria. The first identification and targeted ablation
of rotational activity with fibrillatory activities was reported in 2005,
using the noncontact mapping technique by Lin et al.562 The next sys-
tem that was developed for clinical use employed two 64-pole basket
catheters to obtain simultaneous unipolar endocardial electrograms
from 128 locations in both atria of patients undergoing AF abla-
tion.563 A computational mapping system (RhythmView, Topera,
Inc.) was used to process the electrograms and generate activation
movies of the atrial electrical activity. After considerable processing
and interpolation, evidence was found for rotational activity in pa-
tients with paroxysmal, persistent, and long-standing persistent
AF.564 MAPs established the minimum repolarization interval and
provided physiologically feasible sequential activation paths. Movies
of activation patterns and isochronal maps from individual cycles
showed circulating activity around a center of rotation that was iden-
tified as rotational activity.564 Focal (centrifugal) activations were also
identified. Both were considered drivers only if they sustained for
>_50 rotations or focal discharges.563 This approach has recently
been validated by linking FIRM simultaneously with optically mapped
rotational activity in the same human hearts.76 Although early reports
documented findings showing that this approach to mapping and
ablating rotational activity improved outcomes of AF abla-
tion,223,226,563,565,566,567 more recent studies have failed to confirm
these early findings.568 Issues associated with the FIRM-guided proto-
col that have contributed to uncertainty regarding its clinical value in-
clude difficulties with basket catheter placement and appropriate
electrode contact, and the inability to identify atrial electrogram char-
acteristics expected from rotational activity that differ quantitatively
from surrounding tissue. At the time this document is being written,
the approach of FIRM-guided ablation has not been universally
adopted. Considerable debate continues concerning the efficacy of
this ablation strategy. Further research is clearly needed.223,564,566,569
At the present time, several prospective, randomized clinical trials
are underway to evaluate the long-term safety and efficacy of this
approach.
Several other approaches have recently been developed to identify
rotational activity as a potential target for ablation. One of these sys-
tems involves the use of high-density multipolar recordings with non-
linear analysis of the similarity index and phase mapping of rotational
activity. This approach has resulted in improved ablation outcome
for patients with persistent AF.224,225 Another system that has been
developed to noninvasively map rotational activity is the ECGI map-
ping system.221,570,571,572 This system utilizes a multielectrode vest
that records 224 body surface ECGs; electrical potentials, electro-
grams, and isochrones are then reconstructed on the heart’s surface
using geometrical information from computed tomography (CT). A
mathematical algorithm combines the body surface potentials re-
corded by the electrodes and the geometric information provided by
CT and solves the electrocardiographic inverse problem in order to
noninvasively obtain estimated epicardial electrograms.221,570 An ad-
vantage of this approach is that it is noninvasive, and thus can be used
to provide detailed follow-up information on AF recurrence.
Disadvantages of the system are that it is limited to providing virtual
electrograms of the atrial epicardium; activity on the interatrial sep-
tum, the PV-LAA ridge, etc., is not recorded. Another limitation has
to do with workflow and the fact that CT imaging is required to ob-
tain the torso geometry. An additional limitation of this system is that
it requires the assumption that the torso has uniform electrical prop-
erties when, clearly, thoracic tissue conducts electricity nonuni-
formly. A clinical trial used ECGI combined with phase mapping to
identify the drivers of persistent AF in 103 patients undergoing AF ab-
lation. They observed continuously changing wavefronts and a wide
variety of rotational activity behaviors.222 Reentrant drivers were un-
sustained and meandered substantially, but recurred repetitively
within the same region. Computation of aggregated driver-density
maps over a cumulative registering period allowed identification of a
median of four driver domains per patient and helped to guide the ab-
lation procedure. Of note, the longer the duration of sustained AF,
the larger the number of driver regions. Ablation of driver domains
alone terminated AF in 75% of patients with persistent AF and in 15%
of patients with long-standing persistent AF. The onset or extinction
of drivers during ablation was not assessed; thus, there is room for
improving the ablation results if real-time data are used.222 At the 12-
month follow-up, 83% of the patients with PAF and 75% of the
Guidelines e41
Downloaded from https://academic.oup.com/europace/article-abstract/20/1/e1/4158475
by Erasmus University Rotterdam user
on 29 January 2018
patients with persistent or long-lasting AF were free from AF.222 At
the present time, this system is not widely available, and few mem-
bers of the writing group have clinical experience with this system.
Other investigators have also reported the ability of body surface
potential mapping to detect rotational activity and stable propagation
patterns during AF.573 Phase maps computed from the TQ intervals
in 64 surface potentials showed complex patterns in which rotational
activity could be identified, but they were unstable and lasted for a
very short time. Noninvasive BSM methodology has recently started
to gain momentum for the analysis of activation patterns during
AF.574,575 These investigators used a custom-made 67-electrode vest
that covered the whole torso of the patient; intracardiac signals at
several locations were simultaneously recorded.574 They selected ei-
ther segments without ventricular activity after adenosine infusion, or
applied complex subtraction of QRST if such intervals were not
found. After computing and performing comparisons between intra-
cardiac and surface DF maps, the investigators demonstrated that
high-frequency sources could be reflected on a small area of the
body surface close to the atrium harboring the highest DF.574 More
recently, investigators have used phase mapping to filter the unipolar
signals with a narrow 2-Hz band-pass around the highest DF (HDF fil-
tering) to significantly improve the detection of stable rotational ac-
tivity.575 Prior to HDF band-pass filtering, phase maps displayed
unstable reentries, likely as a result of superposition of the disorgan-
ized electrical activity coming from the rest of the atrial tissue. HDF
filtering accentuated the organized activity of scroll waves, after
which rotational activity was the main pattern of activation during AF
(median of 2.8 rotations, present 73% of the time). Also, computer
simulations showed that epicardial propagation is spatially smooth-
ened when projected on the torso. For example, nearby epicardial
rotational activity with opposing chirality might not be detected on
the torso. This fact and the possibility of temporal intervals in which
AF activity can be affected by ectopic foci, could explain the lack of
detected rotational activity during the remaining 27% of the time.575
Improved understanding of underlying mechanisms improves ther-
apy. High-frequency reentrant sources are an important mechanism
of AF maintenance in humans, even if other mechanisms might also
be involved in AF initiation and maintenance.17 Experimental data and
ablation outcomes are making it increasingly clear that multielectrode
approaches that provide simultaneous acquisition of tens or hun-
dreds of recording sites from the fibrillating atria provide substantial
improvement for the identification and eventual termination of AF
sources. Although there is still substantial room for improvement,
mapping technology is evolving at an accelerating pace, which gives
hope that novel breakthroughs will enable panoramic assessment of
the underlying mechanisms that underlie electrical turbulence in AF.
Simultaneous high-resolution panoramic assessment of wave propa-
gation from the body surface and the endocardium could help in
tracking drifting or more stationary rotational activity trajectories
over wide areas of the atria with better accuracy, and hopefully
should advance ablation therapy. An important issue with these map-
ping forms is that they are critically dependent on electrogram acqui-
sition, electrogram integration, and a variety of signal manipulations
with mathematical techniques, including inverse solution, Hilbert, and
phase transformations that produce an additional level of complexity
in attempting to simplify mapping. Registration of the maps to ana-
tomic structures, or CT or MRI and subsequent navigation, likewise
add complexity to the process and underscore the need for add-
itional translational and clinical studies to validate and clarify their
utility.
A survey of the writing group shows that none of the members
routinely employ ablation of rotational activity during initial or repeat
ablation procedures in patients with PAF; 7% do so during initial abla-
tion of persistent and long-standing persistent AF, and 9% do so dur-
ing repeat ablation of persistent and long-standing persistent AF.
Based on this information and a review of the literature, the writing
group recognizes that the usefulness of ablation of rotational activity
as an initial or repeat ablation strategy for persistent and long-
standing persistent AF is not well established (Class IIb, LOE B-NR,
Table 3).
Localization and Ablation of Left Atrial
Ganglionated Plexi
Recent experimental and clinical studies have shown that the intrinsic
cardiac ANS, which is formed by interconnected clusters of auto-
nomic ganglia, known as GP, plays an important role in the initiation
and maintenance of AF.103,105,114,116,124,355,576,577,578,579,580,581,582
Because the GP are consistently located within areas of highly fractio-
nated atrial potentials (FAPs), also referred to as CFAEs,103,105,
114,116,124,355,576,577,578,579,580,581,582,583,584 it is useful to begin with a
fractionation map of the LA and PVs during AF. The LA FAPs are
usually located in four areas: (1) LAA ridge FAP area (between
LAA and left PVs); (2) superior left FAP area; (3) inferoposterior
FAP area; and (4) anterior right FAP area (Figure 4). GP can be
localized using HFS to identify sites exhibiting transient AV block
during AF. In one approach,124,582 endocardial HFS (cycle length
50 ms, 12–15 V, 10 ms pulse width) is delivered through the distal
pair of the electrodes on a mapping or ablation catheter to sites
within FAPs in the LA. Sites exhibiting a positive HFS response
(transient AV block, increase in mean R-R interval >50% during
AF) identify the 5 major GP (Marshall tract GP, superior left GP,
anterior right GP, inferior left GP, and inferior right GP) (Figure 4).
HFS of a GP generally increases the degree of fractionation in the
adjacent PV and frequently in distant PVs.
For endocardial catheter ablation of the GP, RF energy is applied
to each site exhibiting a positive HFS response (usually 25–35 W for
30–60 seconds, but the RF power and/or time is reduced when close
to the esophagus).105,124,582 HFS is repeated after each RF applica-
tion. If the positive HFS response is still present, RF energy is reap-
plied until the response is eliminated (generally only one or two RF
applications are required). Ablation of each of the five GP areas usu-
ally requires 2–12 (median 6) RF applications.124,582 A positive HFS
response might not identify the entire GP area. HFS-induced transi-
ent AV block is driven by activation of the inferior right ganglionated
plexi (IRGP). Therefore, activating the Marshall tract GP, superior left
GP, inferior left GP, or anterior right GP by HFS is followed by activa-
tion of other GP, including the inferior right GP, which innervates the
AV node. The positive response to HFS (transient AV block) might
not occur, due to ablation of one of the intermediate GP along the
line to the IRGP. To minimize the loss of a positive HFS response, ab-
lation of the GP should be performed in the following order: Marshall
Tract GP, superior left GP, anterior right GP, inferior left GP, and fi-
nally inferior right GP. Other signs of GP activation (such as the onset
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of PV firing other than the PV adjacent to the stimulated GP) are oc-
casionally observed during HFS, which does not produce an AV block
response, suggesting lower sensitivity of HFS in identifying GP. Some
reports targeted GP without HFS, delivering RF applications to the
presumed anatomical locations of the GP.245,576,583,584
The GP (identified by HFS) are consistently located within an area
of FAPs, which is much larger than the GP area, suggesting that al-
though GP ablation consistently produces CFAE (or FAP) ablation,
CFAE ablation is not equivalent to GP ablation. In patients with either
paroxysmal or persistent AF, GP ablation (before PVI) significantly
reduced the inducibility of sustained AF. If AF remains inducible after
GP ablation, GP ablation often eliminates the majority of CFAEs, des-
pite ablating a much smaller area than the overall CFAE area.124,582
One clinical study randomized a total of 242 patients with PAF to
conventional PVI, PVI plus GP ablation, and GP ablation alone.122
Freedom from ATAs (followed for at least 2 years) was achieved in a
similar number of patients in the conventional PVI and GP ablation
alone groups (56% and 48%, respectively), and in a significantly
greater number of patients in the PVI plus GP ablation group (74%;
P = .004). In another randomized study including 264 patients with
persistent or long-standing persistent AF, GP ablation as an adjunct
to PVI resulted in higher rates of sinus rhythm maintenance at 3 years
(49%) compared with PVI plus LA linear lesions (34%).585,586 In add-
ition, LA tachycardias were less common with PVI plus GP ablation
than with PVI plus linear lesions. GP ablation alone was also tested in
patients with drug-refractory long-standing persistent AF, resulting in
a lower success rate (38% sinus rhythm maintenance at
2 years).583,584 A recent, prospective, randomized, surgical AF abla-
tion study reported no improvement of outcomes by ablation of the
autonomic ganglia.123 Again, anchoring the focal ablation of a GP to
other nonconducting tissue produced by PVI or anatomic structures
remains critical to prevent subsequent ATs.
A survey of the writing group showed that 7% of the writing group
members routinely employ ablation of autonomic ganglia during ini-
tial or repeat ablation procedures in patients with PAF, and 7% do so
during initial or repeat ablation of persistent and long-standing per-
sistent AF. Based on this information and a review of the literature,
the writing group recognizes that usefulness of ablation of autonomic
ganglia as an initial or repeat ablation strategy for paroxysmal, persist-
ent, and long-standing persistent AF is not well established (Class IIb,
LOE B-NR, Table 3).
Dominant Frequency Mapping
An emergent property of the complex spatiotemporal dynamics is
that during AF, the local cycle length (atrial fibrillation cycle length
[AFCL]) varies depending on electrode location, with the shortest
AFCLs usually localized in the LA.587,588 The combined use of phase
mapping589 and DF mapping demonstrated that the highest DF cor-
responded with the location of rotational activity that was driving the
arrhythmia.590,591 A subsequent study in patients with paroxysmal or
persistent AF showed that ablation of PVs harboring high DF sites re-
sulted in an increase in the AFCL (>_5 ms) within the CS in 89% of
cases.98 Arrhythmia termination occurred during ablation in 15 of 17
patients (88%) with PAF, but in none with permanent AF. In 87% of
patients with PAF, ablation at a high DF site terminated the arrhyth-
mia. Subsequent studies supported the notion that the high DF
(DFmax) sites play a role in the maintenance of AF in a significant num-
ber of patients.592,593
Based on these mechanistic studies, a small trial of 50 patients with
paroxysmal and persistent AF was performed, combining PVI with ab-
lation of DFmax sites. At a mean of 9.3 ± 5.4 months, freedom from AF
after one or more ablation procedures was achieved in 88% and 56%
of paroxysmal and persistent AF patients, respectively.593 A more re-
cent prospective randomized clinical trial of 232 patients with paroxys-
mal and persistent AF reported no improvement in ablation outcomes
with a DF-based approach compared with PVI alone.594 None of the
writing group members incorporate DF mapping as a routine AF abla-
tion strategy in initial or repeat ablation of PAF. One writing group
member (2%) incorporates a DF-based approach during initial and re-
peat ablation of persistent and long-standing persistent AF. Based on
this information and a review of the literature, the writing group recog-
nizes that a DF-based ablation strategy is of unknown usefulness for AF
ablation (Class IIb, LOE C-LD, Table 3).
Renal Denervation
Arterial hypertension (AH) is the most frequent comorbidity in pa-
tients with AF, and this condition is also an important risk factor for the
triggering and maintenance of AF. The potential antiarrhythmic role of
renal denervation was demonstrated in animal studies suggesting a
beneficial effect on AF inducibility, maintenance, and progres-
sion.307,595,596,597 The positive impact of renal denervation on AF re-
currence was demonstrated in a first-in human study, including 27
patients with paroxysmal or persistent AF and refractory hypertension.
At 12-month follow up, the group of patients who underwent PVI plus
renal denervation had a significantly higher success rate in terms of
freedom from AF compared with PVI alone (69% vs 29%, respectively).
Also, the reduction in BP was much more significant in the PVI-plus-
renal-denervation group.331 Recently, data were reported from a com-
bined analysis of two randomized studies with a large and diverse
group of 80 patients with AF and hypertension. For the entire cohort,
renal artery denervation significantly reduced the rate of AF recur-
rences; however, this result was more pronounced in patients with
persistent AF and refractory hypertension.331 A case report using renal
denervation instead of PVI in a patient with drug-refractory persistent
AF was recently published, with no AF recurrence at 6-month follow-
up. Moreover, the renal denervation resulted in a reduction of LA
size.598 The mechanism by which renal denervation, when combined
with PVI, can impact outcomes of AF ablation has not been well
defined. One potential mechanism is through improved control of
hypertension. An alternate mechanism is through a decrease of central
sympathetic activity by renal denervation.599 The current body of evi-
dence supporting a role of renal denervation in improving outcomes of
AF ablation is extremely limited. This is an area in need of further inves-
tigation. At the present time, we do not advise renal denervation as a
technique to improve outcomes of AF ablation outside of a clinical trial.
This sentiment reflects not only the limited body of literature support-
ing this approach, but also the recent large prospective randomized
SIMPLICITY HTN-3 trial that showed that renal artery denervation
was safe, but was not effective in lowering hypertension.600
Epicardial Ablation of AF
More data concerning thoracoscopic epicardial ablation and com-
bined epicardial-endocardial ablation procedures have been
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published since the last AF ablation consensus statement. In addition
to a potentially more durable lesion set, other advantages of an epi-
cardial approach include access to epicardial structures such as the
ligament of Marshall and GP, management of the LAA, and avoidance
of damaging collateral structures, such as the PN and esophagus.
To date, three randomized prospective trials have compared a
video-assisted thoracoscopic surgical (VATS) approach to percutan-
eous endocardial catheter ablation for the treatment of patients with
paroxysmal and non-PAF, most of whom had failed an initial catheter
ablation.585,586,601,602 A meta-analysis of these and other observa-
tional studies demonstrated a significant improvement of arrhythmia-
free survival for the VATS procedure (78.4 vs 53%; RR 1.54; 95% CI
1.50–2.14; I2 = 0%; P <.0001), with a clearer benefit for patients with
persistent AF.603 Complications were three times more frequent in
the VATS group, mostly due to pneumothorax and pleural effusion.
VATS procedures can also provide a reasonable outcome for pa-
tients with large atria and long-standing persistent AF.604,605
Many observational studies have reported promising results for
so-called hybrid ablation procedures, which combine elements
of VATS and catheter ablation procedures; however, no
randomized controlled trials (RCTs) have been performed to dem-
onstrate effectiveness and safety relative to either procedure
alone.606,607,608,609,610,611,612,613,614,615,616 Before these approaches
are applied more widely, a streamlining of the workflow of the dual
procedure approach will be required.
Nonablative Strategies to Improve
Outcomes of AF Ablation
AAD Therapy
There is evidence that reverse remodeling occurs after cardioversion
of AF. The evidence in support of this conclusion is based on changes
in atrial APD, ERP, CV, and P wave duration when measured
1–4 weeks after achieving sinus rhythm.617,618,619,620 The changes in
P wave duration occur more slowly and do not predict long-term
maintenance of sinus rhythm.619 An important question is whether
AAD therapy can be used to prevent or initiate reverse remodeling
even prior to ablation, thereby improving the success rate for abla-
tion procedures. AAD therapy would be beneficial if it prevented
electrical and structural remodeling by reducing the burden of AF,
but it might also affect the therapeutic endpoints of conduction into
or out of the PVs and the automaticity of PV or non-PV triggers of
AF. The effect of drugs on mapping putative rotational activity or re-
petitive wavelets in humans with AF is unknown.
Four trials have evaluated the effect of preprocedural amiodarone or
dofetilide therapy on outcomes of ablation. One study reported that
the recurrence rate of AF following ablation was lower when treatment
with dofetilide prior to ablation reduced the burden of AF, and was
associated with a decrease in P wave duration.617,618 Another single-
center nonrandomized study found that amiodarone prolonged the
cycle length of AF and reduced the time spent on CFAE ablation, but it
did not have any effect on long-term outcomes.619 A second single-
center study treated patients with Class I or III drugs for long-standing
persistent AF and compared the outcomes of ablation in those who
were successfully converted to sinus rhythm months prior to ablation
as opposed to those who were not. They observed decreases in LA di-
mensions (LADs) in the group that achieved preprocedural sinus
rhythm. Long-term freedom from recurrent atrial arrhythmias was
higher in the group that achieved sinus rhythm prior to ablation.620 The
multicenter randomized Effect of Amiodarone on the Procedure
Outcome in Long-standing persistent AF Undergoing PV Antral
Isolation (SPECULATE) trial studied the effect of preprocedural inter-
ventions in patients with long-standing persistent AF. Termination of AF
was more common in the patients treated with amiodarone, and fewer
non-PV triggers were identified. At 6 months, both groups had similar
recurrence rates; however, at 12 months, arrhythmia-free survival was
higher in the patients who were not treated with amiodarone. A signifi-
cant limitation of the SPECULATE trial is that many patients who were
assigned treatment with amiodarone remained in AF; thus, there was
no opportunity for remodeling to occur.621
From a practical standpoint, patients often require AAD therapy
prior to ablation to reduce the burden of symptomatic AF. Whether
this delays the progression of remodeling or reverses it is not well es-
tablished, although there is evidence from these studies that conver-
sion to sinus rhythm affects the atrial electrophysiological properties.
Studies that showed improved outcomes in patients who regained
sinus rhythm might be interpreted to show that remodeling occurs
and is beneficial, but the alternative interpretation could be that pa-
tients who regain sinus rhythm have less advanced disease and are
better candidates for ablation. The data also suggest that amiodarone
affects the cycle length of AF, has increased conversion rates to sinus
during ablation, and might mask triggers of AF, which could adversely
affect the success of the procedure.
Based on this information, the published literature, and the experi-
ence of this writing group, the writing group recognizes that the use-
fulness of discontinuation of AAD therapy prior to AF ablation in an
effort to improve long-term outcomes is unclear (Class IIb, LOE C-
LD, Table 3). The writing group also recognizes that the usefulness of
initiation or discontinuation of AAD therapy during the postablation
healing phase in an effort to improve long-term outcomes is unclear
(Class IIb, LOE C-LD, Table 3).
Risk Factor Modification
In Section 3 of this document, we have summarized the emerging
data supporting risk factor modification as an approach to improve
outcomes of AF ablation. Based on this information, the published lit-
erature, and the experience of this writing group, for patients with
AF, including those who are being evaluated to undergo an AF abla-
tion procedure, it is felt that that weight loss can be useful as part of a
comprehensive risk factor management strategy (Class IIa, LOE B-R,
Table 3). The writing group also recommends that it is reasonable to
screen for signs and symptoms of sleep apnea when evaluating a pa-
tient for an AF ablation procedure, and recommends a sleep evalu-
ation if sleep apnea is suspected (Class IIa, LOE B-R). And finally, the
writing group recommends that the treatment of sleep apnea can be
useful for patients with AF, including those who are being evaluated
to undergo an AF ablation procedure (Class IIa, LOE B-R, Table 3).
Mechanisms of Nonisthmus-Dependent
Atrial Flutter and Approaches to
Mapping and Ablation
The occurrence of AFL after AF ablation is common enough that all
operators performing AF ablation should be skilled in mapping and
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ablating both typical and atypical AFL. The incidence of AFL after AF
ablation depends on the type of ablation performed during the initial
procedure, varying from 2.6% in centers performing PVI alone to
31% in centers performing linear ablation.622,623,624,625 AFL is less
common after PVI with CB compared with RF-based PVI.489 The
mechanism of AFL is reentry. Reentrant arrhythmias include focal
reentry occurring through gaps in the prior PVI line (PV tachycardia)
or macroreentry around anatomic obstacles created during ablation
(mitral annular flutter, LA roof-dependent flutter, or septal flutters
around areas of scar).447,506,626,627 Typical cavotricuspid isthmus-
dependent flutter can also occur (Figure 5).
Determining the location of the reentry circuit starts with examin-
ation of the 12-lead ECG. A clear isoelectric line in all 12 leads sug-
gests a focal AT involving a small reentrant circuit (e.g.,
microreentry), whereas continuous activation suggests a macroreen-
trant flutter involving a larger circuit.628 Typical cavotricuspid
isthmus-dependent flutter frequently has an atypical appearance on
the 12-lead ECG after prior LA ablation, and this should not be
excluded based on an atypical ECG appearance alone.629 Although
extensive LA ablation can limit interpretation of the 12-lead ECG,
certain rules apply. Tachycardias arising near the PV ostia will typically
have an inferior axis and positive F waves across the precordial leads.
An “m”-shaped F-wave in lead V1 suggests a left PV exit. Right PV
tachycardias are characterized by the ECG amplitude in lead II
greater than that in lead III and a positive F wave in lead I. Mitral annu-
lar flutter has a similar appearance to left PV tachycardias, although
an initial negative component in the precordial leads or amplitude in
lead V2 less than that in V1 and V3 might be suggestive.630 These
rules, however, could be less applicable in patients with extensive
scarring, including that from prior ablations.
Initial localization of an atypical flutter can frequently be facilitated
by simply observing the activation sequence on a CS catheter.
Proximal to distal activation suggests cavotricuspid isthmus-
dependent flutter, right PV tachycardia, or counterclockwise mitral
annular flutter, whereas distal to proximal activation suggests a left
PV tachycardia or clockwise mitral flutter. An “on time” or fused CS
pattern could be suggestive of a roof-dependent flutter.631 When
acquiring an electroanatomical activation map, each acquired point
should be carefully annotated by the operator, taking care to tag and
not include widely split potentials that might indicate a line of block.
Multipoint mapping can decrease the time needed for acquiring a
map, but automated electrogram annotation might lead to errors and
confusing maps. A novel very automated high-density automated
mapping system has recently become available.627,632 Early results
using this system to determine activation sequences and perform ab-
lation based solely on activation rather than entrainment mapping
have been encouraging.627 However, the true clinical value of this
type of system is unknown and will require a prospective randomized
comparison with conventional electroanatomical and entrainment
mapping. When performing ablation of AFL with a conventional 3D
mapping system, scar should be labeled as such to identify anatomic
obstacles. Focal microreentrant tachycardias can also occur and are
typically indicated by centrifugal conduction away from a focal area of
onset and by long fractionated potentials with duration >50% of the
tachycardia cycle-length.628 The main strength of activation mapping
is that it is unlikely that the tachycardia will terminate. The disadvan-
tage is that these activation maps can be extremely difficult to
interpret and might not translate to identifying successful ablation
sites. When performing ablation of atypical AFL with a conventional
3D mapping system, especially when a stable reentrant circuit is pre-
sent that allows entrainment, most operators find that entrainment
mapping from multiple sites is a better and more accurate approach
to localize the reentrant circuit and target ablation lesions. It is for
this reason that entrainment mapping is the gold standard for map-
ping reentrant tachycardias and is the preferred mapping strategy em-
ployed by most writing group members at the present time. For
atypical flutter, because fusion of the F wave can be difficult to inter-
pret, the primary goal is to identify regions with a postpacing interval
within 20 ms of the tachycardia cycle length. Care should be taken to
pace at or near threshold, given high-output pacing can capture adja-
cent tissue that leads to an erroneous postpacing interval. High-
output pacing can also lead to electrode polarization that obscures
the return electrogram. Once the reentry circuit is delineated, an ab-
lation strategy can be designed to connect anatomic obstacles and
interrupt the tachycardia. Despite this current preference, new high-
density automated mapping systems have been developed, as noted
above, which allow development of successful ablation strategies
based on high-density activation mapping alone, without the risk of
entrainment pacing resulting in termination of the flutter under study
or its degeneration into a different flutter or fibrillation. Prospective
randomized clinical trials will need to be performed to determine the
true clinical value of these new automated high-density mapping
systems.627,632
For PV tachycardias, 2 gaps in the PVI line are typically present and
reisolation of the PVs suffices to eliminate the tachycardia.447 For
macroreentrant tachycardias, ablation that connects anatomic obs-
tacles is required. The classic post-PVI macroreentrant tachycardia is
mitral annular flutter; ablation between the mitral annulus and left
lower PV (mitral isthmus) is typically performed (Figure 5), although
an anterior line between the mitral annulus and the LSPV, the RSPV,
or the roof line can also be performed. For mitral isthmus ablation,
epicardial ablation within the CS is required approximately 80% of
the time. The endpoint of linear ablation should be proof of bidirec-
tional block using pacing maneuvers rather than simply tachycardia
termination. Interruption of the clinical tachycardia should be per-
formed first, because burst pacing might induce multiple tachycardias
of unclear significance. After termination of the clinical tachycardia,
reisolation of any reconnected PVs should always be performed.
Anesthesia During AF Ablation
The type of anesthesia used for AF ablation depends in part on the
availability of anesthesia support for ablation procedures. Given the
need to minimize patient movement to improve catheter and map-
ping system stability, deep sedation or general anesthesia is generally
preferred. One prospective randomized clinical trial randomized pa-
tients with general anesthesia or conscious sedation. This study re-
ported that use of general anesthesia increased the single procedure
success rate, lowered the prevalence of PV reconnection among
those who needed a redo procedure, and shortened fluoroscopy
time and procedure time.633 Another nonrandomized clinical trial re-
ported improved efficacy of AF ablation with use of jet ventilation.634
A survey of the writing group members performing AF ablations
found that 73% use general anesthesia, 13% use deep sedation with
an anesthesiologist, and 14% use moderate conscious sedation with
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an electrophysiology nurse. Jet ventilation was used by only 8%. The
major reason cited for not using general anesthesia was lack of anes-
thesiologist availability. Some proponents of not employing general
anesthesia believe that the risk of an atrial esophageal fistula (AEF)
could be higher in patients in whom general anesthesia is
employed.635,636,637,638,639
Recurrent AF with or without PV
Reconnection
Some degree of PV reconnection is observed in more than 80% of
patients who are returned to the electrophysiology laboratory for a
clinically indicated electrophysiology procedure. PV reconnection is
also observed in patients doing well post-PVI. The Gap-AF trial re-
ported PV reconnection at 3 months in 70% of patients randomized
to complete PVI and in 89% of patients in whom a PV “gap” was left
intentionally. AF recurred during the first 3 months postablation in
62% of the patients with complete PVI vs 79% of the patients in
whom a gap was left intentionally.456 When reconnection of the PVs
is observed, it is recommended that the PVs be reisolated. This can
be accomplished by a limited approach, which involves only targeting
those PVs that demonstrate reconnection, and only targeting the seg-
ment of the PV circumference in which the PV reconnection is de-
tected. Among the writing group members, 73% employ this
strategy. An alternate approach is to be more liberal with ablation,
with creation of a new circumferential lesion set around each of the
PVs, which demonstrates reconnection. This approach is employed
by 20% of the writing group members. An even more liberal ap-
proach is to repeat the entire WACA lesion set that was delivered
the first time; this approach is employed by the remaining 7% of the
writing group members. In the small proportion of patients in whom
no PV reconnection is observed, there is agreement that a number of
non-PV-based strategies should be considered, including searching
for non-PV triggers, delivery of one or more linear lesions, isolation
of the CS, isolation of the LAA, ablation of autonomic ganglia, CFAE
ablation, and rotational activity ablation. A recent report suggested
that the best outcomes following ablation of non-PV triggers are
achieved in patients with a well-defined provocable target.640 Each of
these strategies has been described in detail in the rest of this
document.
Endpoints for Ablation of Paroxysmal,
Persistent, and Long-Standing Persistent
AF
PVI is the cornerstone of AF ablation. Among the writing group
members, 95% employ this endpoint during all AF ablation proced-
ures. PVI is demonstrated by entrance block alone by 35%, and both
entrance and exit block by 65%.
Beyond PVI, other endpoints, particularly during ablation for per-
sistent AF, are unclear. It has been suggested that regardless of other
non-PV targets ablated, the endpoint for ablation of persistent AF
should be the termination of AF either to a regular ATA, or to a sinus
rhythm. Although termination of AF has been shown by some to be
predictive of longer-term outcome, other studies have not confirmed
this finding.399,400,401,515,621,641,642 It is unclear whether acute, intra-
procedural termination is a true indication of procedural success, or
simply might indicate patients with less persistent AF who are
destined to do better regardless of the approach used. A substudy of
the STAR AF II trial has suggested this latter point.643 Slowing of AF
cycle length as measured from the CS or the LA or RA appendage
has also been used as a surrogate for acute procedural success.
However, AF cycle length prolongation can be difficult to measure
reliably in AF, and prolongation is often used as a harbinger of acute
termination. Again, longer baseline AF cycle length can be an indica-
tion of AF that is more likely to terminate or respond to ablation ra-
ther than indicating a procedural endpoint in and of itself.643 Thus, AF
termination of cycle length prolongation might not be useful as a sole
procedural endpoint.
Other non-PV targets have been suggested for ablation, particu-
larly for persistent AF. CFAEs have been put forward as an important
target, although many recent randomized studies and meta-analyses
have not concluded that there is any benefit.644 Ablation of non-PV
focal triggers identified via isoproterenol challenge, ablation of atrial
scarred regions, or ablation of localized rotational activations (so-
called rotational activity) have also been reported to have benefit
over PVI alone.140,534,538,645 It appears that regardless of which target
is chosen, complete local elimination of the target should be the goal,
so as not to leave behind partially ablated tissue that could serve as a
site for future AT recurrence. The best method of ablating a localized
rotational activation is as yet unclear. Early descriptions suggested
ablating the center of activation with several lesions and then remap-
ping to confirm that the rotation is terminated.563 Others have sug-
gested that central ablation should be combined with creation of a
short line to an anatomical or ablated boundary that crosses and
interrupts the rotational pathway. The choice at this point is unclear.
Similarly, for scar-based ablation, the best methods of defining scar
are not yet confirmed (late gadolinium enhancement vs voltage map-
ping), and even for voltage mapping, the appropriate voltage cutoffs
have not yet been validated. Furthermore, it is unclear whether such
scar regions should be surrounded by lesions to isolate them from
the rest of the atrium; whether ablation within the scar to eliminate
all residual electrograms (so-called homogenization) should be em-
ployed; or whether these regions should also be tied to anatomical
boundaries by short linear ablations. It follows from earlier com-
ments that these scar ablations should be anchored to other noncon-
ducting anatomical structures. There will need to be much further
research into the best ablative endpoint for these ancillary targets.
Empiric linear ablation likely does not add much to ablation of persist-
ent AF.646,647 However, if linear ablation along the roof or mitral an-
nulus is added to target roof or mitral-dependent flutters, then
bidirectional block is a prerequisite endpoint. Block across a line
must be assessed in sinus rhythm and with differential pacing maneu-
vers, and these are described in detail in the following section.
Section 6: Technology and Tools
In this section, we provide an update on many of the technologies
and tools that are employed for AF ablation procedures. It is import-
ant to recognize that this is not a comprehensive listing and that new
technologies, tools, and approaches are being developed. It is also im-
portant to recognize that RF energy is the dominant energy source
available for ablation of typical and atypical AFL. Although cryoabla-
tion is a commonly employed tool for AF ablation, it is not well suited
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for ablation of typical or atypical AFL. Other energy sources and
tools are available in some parts of the world and/or are in various
stages of development and/or clinical investigation. Shown in Figure 9
are schematic drawings of AF ablation using point-by-point RF energy
(Figure 9A) and AF ablation using the CB system (Figure 9B).
Radiofrequency Energy
Biophysics and Irrigation
The presumed basis of successful AF ablation is production of myo-
cardial lesions that block the propagation of rapidly firing PV triggers
or modification of the arrhythmogenic substrate responsible for
reentry. Successful ablation depends on achieving lesions that are reli-
ably transmural.648,649 The conventional approach employed by car-
diac electrophysiologists to reach the goal of AF ablation is RF energy
delivery by way of a transvenous electrode catheter. RF energy
achieves myocardial ablation by causing resistive heating of the tissue
with subsequent heat conduction to deeper tissue layers. Most RF
energy is delivered in a unipolar fashion between the tip of the abla-
tion catheter and a large surface-area dispersive electrode applied to
the patient’s thorax or thigh. The position of the dispersive electrode
does not greatly affect lesion size or geometry. If a high-power sys-
tem is used, two dispersive electrodes should be employed to avoid
skin burns. With bipolar RF delivery, there is no dispersive electrode,
and both electrodes are active. One commercial system delivers RF
energy simultaneously through multiple electrodes in a unipolar,
blended, or bipolar fashion, using either continuous unipolar delivery
with an offset of the phase of the RF wave between electrodes
(phased RF delivery), or field sequential unipolar and bipolar delivery
between contiguous electrodes in a prespecified ratio.650 Although
bipolar ablation can be effective in heating tissue between contiguous
electrodes, the lesions are not as deep as those using unipolar
ablation.
Factors that will determine the size and depth of RF energy ablative
lesions are power, impedance, temperature, duration, and
CF.651,652,653 High-power delivery and good electrode–tissue contact
promote the formation of larger lesions and improve procedure effi-
cacy. However, if the temperature of the electrode–tissue interface
exceeds 100 C, then blood will boil and the blood proteins will form
char and coagulum. As coagulum adheres to the electrode, less sur-
face area is available for electrical conduction and the current density
rises, resulting in more tissue and blood heating in a positive feedback
spiral leading to a rapid rise in electrical impedance. Higher power de-
livery can be achieved with saline-irrigated tip catheters that cool the
endocardial surface and prevent char and impedance rise. Increased
convective cooling can also be achieved passively by using electrode
material with high thermal conductivity, such as gold.653 The higher
power delivery achieved with tip irrigation results in greater depth of
resistive heating, with significant increase in lesion size. If intramural
temperatures exceed 100 C, steam expansion can suddenly vent
through the endocardium or epicardium (pop lesion) and potentially
cause a perforation.654 Because of more reliable creation of trans-
mural lesions, and reduced risk of formation of endocardial thrombus
and char, AF ablation with RF catheters is most commonly performed
with tip irrigation. Optimal catheter–tissue contact is achieved by a
combination of steerable catheter selection, guide sheath manipula-
tion, operator skill, and monitoring catheter–tissue CF.655 Significant
complications can occur during AF ablation if high RF power is admin-
istered in an uncontrolled fashion. The increased risk of AF ablation
compared with ablation of other arrhythmias can be attributable to
the great surface area of tissue ablated, the large cumulative energy
delivery, the risk of systemic thromboembolism, and the close
Figure 9 Schematic drawing showing catheter ablation of atrial fibrillation using either RF energy or cryoballoon AF ablation. (A) Shows a typical
wide area lesion set created using RF energy. Ablation lesions are delivered in a figure of eight pattern around the left and right PV veins. Also shown
is a linear cavotricuspid isthmus lesion created for ablation of typical atrial flutter in a patient with a prior history of typical atrial flutter or inducible
isthmus-dependent typical atrial flutter at the time of ablation. A multielectrode circular mapping catheter is positioned in the left inferior PV. (B)
Shows an ablation procedure using the cryoballoon system. Ablation lesions have been created surrounding the right PVs, and the cryoballoon abla-
tion catheter is positioned in the left superior PV. A through the lumen multielectrode circular mapping catheter is positioned in the left superior PV.
Illustration: Tim PhelpsVC 2017 Johns Hopkins University, AAM.
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location of structures susceptible to collateral injury, such as the PN,
PVs, and esophagus. Thrombus and char can be minimized by limiting
power and/or target temperature by monitoring the production of
steam microbubbles at the catheter tip with ICE, and by cooling the
electrode–tissue interface with saline-irrigated tips.656,657,658,659
Intramural steam pops can be reduced by limiting both power and
the electrode–tissue contact pressure. Duration of energy delivery
affects the tissue temperature profile. The half-time of lesion growth
is approximately 5–15 seconds, depending on the power used; thus,
maximum lesion size is usually achieved within 1 minute. A long abla-
tion duration will allow the heat generated in the region of resistive
heating to conduct to deeper tissue layers, with maximum lesion size
being achieved when the system has reached steady state. A short
duration will yield maximal heating close to the source, with a steep
drop in temperature in deeper layers, and might be preferred when
ablating thinner regions such as the posterior LA when heating of
contiguous structures (esophagus) needs to be avoided.
Immediately postablation, lesions show typical coagulation necro-
sis, hemorrhage, and edema. Subacute lesions examined 2–7 days
later show infiltration of inflammatory cells, and early chronic lesions
show replacement of myocardium with granulation tissue at
4 weeks.660 Myocardium exposed to temperatures of 50 C or higher
for more than several seconds will show irreversible coagulation ne-
crosis and evolve into nonconducting myocardial scar.652 The mech-
anism of acute injury to myocardium is attributed to thermal injury to
the sarcolemmal membrane with resultant depolarization and intra-
cellular calcium overload.661,662 In the border zone region of lesion
formation, myocytes can become inactive or dormant, but then sub-
sequently reestablish a normal resting membrane potential and nor-
mal electrical conduction. These dormant zones can be reactivated
by the hyperpolarizing effects of adenosine.465 Conversely, the in-
flammatory response to the acute injury and damage to the microvas-
culature can lead to lesion progression.
Various techniques have been proposed to minimize collateral in-
jury. Temperature sensors at the electrode catheter tip can provide
gross feedback of surface temperature, but because of passive con-
vective cooling from circulating blood flow or active cooling in a
cooled tip catheter, temperatures measured at the catheter tip signifi-
cantly underestimate peak tissue temperatures. Limiting power and
shortening duration of energy delivery will limit collateral injury, but
at the expense of reliably creating transmural lesions. ICE has been
used to monitor lesion formation. If the tissue shows evidence of
increased echogenicity, or if small gas bubbles are observed, then
power should be reduced or terminated.663,664
Contact Force-Sensing Catheters and
Systems
Contact Force
During RF catheter ablation, electrode–tissue CF is one of the pri-
mary determinants of lesion size.636,665,666,667 No effective lesion is
formed without adequate CF, and excessive CF is associated with ex-
cessive deep tissue heating and an increased risk of deep steam pop
(and perforation) and injury outside the heart, such as esophageal,
pulmonary, and PN injury.
Ablation catheters using two different technologies have been de-
veloped recently to measure real-time catheter–tissue CF during
mapping and RF ablation. One catheter uses three optical fibers to
measure the microdeformation of a deformable body in the catheter
tip (TactiCath, St. Jude Medical, Inc.), which correlates with tip
force.668,669,670 The second catheter uses a small spring between the
ablation tip electrode and the catheter shaft, with a tiny magnetic
transmitter in the tip and magnetic sensors proximal to the tip to
measure microdeflection of the spring (ThermoCool SmartTouch,
Biosense Webster, Inc.), corresponding to tip force.671,672,673 Both
systems have high resolution (<1 gram) in bench testing and accur-
ately display the direction of force. These two catheters, equipped
with saline-irrigated tip electrodes, underwent extensive preclinical
studies and were introduced for clinical use, beginning in 2010. The
surrogate measures of contact used previously, including the fluoro-
scopic appearance of catheter motion, intracardiac electrogram amp-
litude, and impedance, have been found to be very poor predictors
of CF.668,670,671,672,674
Preclinical experimental studies have shown that (1) at constant
RF power and application time, RF lesion size significantly increases
with increasing CF; (2) the incidence of steam pop and thrombus also
increase with increasing CF; and (3) modulating RF power based on
CF (e.g., high RF power at low CF and lower RF power at high CF) re-
sults in a similar and predictable RF lesion size.668,670,672
AF ablation studies using CFS catheters have provided important
insight into the spatial distribution of CF during PVI. When the oper-
ator was blinded to CF measurements during catheter manipulation
and ablation, sites of high CF were identified to be the RS aspect of
the anterior LA wall, the posterior antrum of the RSPV, the inferior
posterior LA wall, the posterior antrum of the LSPV, and the LA
roof.671 Sites of low CF have been identified to be anterior to the left
PVs and right carina.675,676,677 These low CF sites have correlated
with sites of PV reconnection.677 CFS catheters provide operator
feedback to allow for more homogeneous force delivery and reduce
impedance rise, cardiac perforation, steam pops, and thrombus for-
mation while at the same time improving effective lesion
formation.453,668,671,676,678,679,680
Several clinical studies have compared circumferential antral PVI
using the ThermoCool SmartTouch CFS catheter with ablation using
a non-CFS catheter. The SmartTouch catheter has been shown to re-
duce gaps, prevalence of adenosine-induced dormant conduction,
fluoroscopy time, and AF recurrence.468,673,679,681,682,683 One of the
largest studies was a retrospective, case-control study of 600 patients
followed for mean duration of 11.4 ± 4.7 months. The use of the
SmartTouch CFS catheter predicted freedom from ATA in patients
with PAF (hazard ratio [HR] 2.24; 95% CI 1.29–3.90; P= .004), but
not in those with non-PAF (HR 0.73; 95% CI 0.41–1.30; P= .289).
These findings could be due to differences in the AF substrate in
which recurrence in patients with PAF is attributed to gaps in lesion
sets rather than advanced AF substrate, and CFS improves lesion for-
mation. There was no difference in complication rate between the
CFS and non-CFS catheters. Another evaluation of the SmartTouch
catheter was the ThermoCool SmartTouch Catheter for the
Treatment of Symptomatic Paroxysmal Atrial Fibrillation (SMART-
AF) trial, which was a multicenter, prospective, randomized clinical
trial performed for FDA approval of this catheter.673 The outcomes
were compared with the earlier clinical trial for ThermoCool ap-
proval,684 in which 170 patients were enrolled. The 12-month free-
dom from AF/AT/AFL was 72.5% at 1-year follow-up, compared with
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66% efficacy for the ThermoCool noncontact-force catheter.684 The
average CF per procedure was 18 grams. Four patients experienced
cardiac tamponade. A post hoc analysis revealed that when the CF
employed was between the investigator-selected working ranges
>80% of the time, outcomes were 4.25 times more likely to be suc-
cessful.673 The most recent study to evaluate the efficacy of CF cath-
eters randomized 117 patients with PAF to AF ablation with the
Smart-Touch Catheter. Patients were randomized to having the CF
information available or not available to the operator. The availability
of CF information resulted in a lower incidence of acute reconnec-
tion (22% vs 32%); however, there was no difference in long-term ef-
ficacy, fluoroscopy times, or complications.685
The efficacy of the TactiCath CFS catheter for AF ablation has
been evaluated in a number of clinical trials, one of which resulted in
FDA approval of this device. The TOCCATA study enrolled 35 pa-
tients with PAF and demonstrated that CF predicted freedom from
AF postablation.676 All the patients in whom the average ablation CF
was less than 10 grams (n= 5) had recurrent AF by 1-year follow-up;
whereas, 80% of the patients (n= 8 of 10) were free from AF at
1 year when the average CF was greater than 20 grams. The EFFICAS
I study enrolled 46 patients with PAF and correlated CF with inci-
dence of gaps in PVI lines 3 months after the initial PVI procedure.453
The number of ablation lesions, minimum CF, and minimum force
time integral <400 grams were highly predictive of gap presence and
PV reconnection 3 months postablation.
A small study enrolling 6 patients used late gadolinium-enhanced
(LGE) cardiac MRI to assess scar formation 3 months postablation
following PVI. Increasing force-time integral (FTI) correlated with
increased LGE signal intensity.680 This was particularly so when the
FTI was >1200 grams. Segments with FTI <1200 grams showed less
scar formation 3 months postablation. In addition to being able to
provide feedback to improve durability of AF ablation lesions sets,
the TactiCath catheter has been shown to decrease fluoroscopy
time and reduce the number of RF applications for PVI compared
with a non-CFS catheter.686 The most recent and most important
clinical trial of the TactiCath catheter was the TOCCASTAR clinical
trial performed for FDA approval of this device.655 In this prospect-
ive, randomized clinical trial, 300 patients with PAF were randomized
to ablation with the TactiCath catheter or to the non-CFS
ThermoCool ablation catheter. No difference in efficacy was
observed, with success rates of 67.8% and 69.4% in the CF and con-
trol arms, respectively. When the CF arm was stratified into optimal
CF and nonoptimal CF groups, effectiveness was achieved in 75.9%
vs 58.1%, respectively. There was no difference in the rate of compli-
cations in the two groups. Cardiac tamponade occurred in one pa-
tient in each group.
Despite the absence of prospective clinical trials that have proven
that CF monitoring improves not only the efficacy but the safety of
AF ablation, operators worldwide have quickly adopted these new
advanced ablation tools. Many of these operators who employ CFS
during AF ablation believe that CF monitoring provides important
biomechanical feedback to improve effective lesion formation, dur-
ability of PVI, and clinical outcomes. Future systems combining CF, RF
power, and application time (such as the Force-Power-Time Index)
could provide real-time assessment of lesion formation to increase
the efficacy and safety of RF ablation. It should be remembered that
CF is only one of the surrogate markers of ablative energy delivery.
Power, impedance, temperature, and other factors remain in place
and interact with the CF measurements. Several systems now employ
a monitoring system that uses an integral of two or more of these fac-
tors. It is also possible that when higher CFs are realized, the power
of RF delivery might need to be reduced. Achieving an adequate CF
does not eliminate the user’s responsibility to maintain awareness of
other factors, such as power or other matrix components of
ablation.
A survey of the writing group shows that among those who per-
form AF ablation with RF energy, 70% routinely use CFS. Two-thirds
of the writing group members allow at least 20 seconds at a given ab-
lation site to elapse before moving the ablation catheter to a new
site. The target minimal CF used by the writing group members is > 5
grams by 28%, >10 grams by 62%, >15 grams by 8%, and >20 grams
by 3%. A CF upper limit of <_ 30 grams is employed by 48% of the
writing group members, less than 40 grams by 36%, and <50 grams
by 15%. As noted in Section 5 and Table 3, the writing group recom-
mends that when performing AF ablation with a force-sensing RF
catheter, that a starting point minimum targeted CF of 5 to 10 grams
is reasonable (Class IIa, LOE C-LD, Table 3).
Cryoablation
In recent years, CBA has become the most efficient alternative to RF
catheter ablation (RFCA) for the treatment of AF (Figure 9B).
The CB single shot ablation approach to AF has been designed to
shorten and simplify the ablation procedure for achieving an effective
PVI. Preclinical and clinical studies have shown that CB is effective in
achieving PVI, offering a valid alternative to RF’s point-by-point ap-
proach to PAF treatment.494,687,688 The multicenter, prospective
randomized controlled Sustained Treatment of Paroxysmal Atrial
Fibrillation (STOP-AF) trial has reported that PVI with the first-
generation CB achieved 69.9% freedom from AF at 12 months com-
pared with 7.3% with AADs.462 More recently, the second-
generation CB has become available to overcome some of the limita-
tions of the first CB generation.689 These improvements include ex-
pansion of the cooling zone from the equatorial surface of the
balloon to the entire distal half, leading to a more uniform circumfer-
ential ablation.473,484,690,691,692 Composite circumferential lesion size
could be a second factor in this process.
In a prospective, multicenter registry, there was no difference be-
tween conventional RFCA and CB in terms of acute success rate and
overall complications; however, fluoroscopy times were longer in
CBA procedures.693 Many studies (mostly nonrandomized) showed
that CBA yields similar or higher success rates in comparison to RF in
patients presenting with drug-resistant PAF, and that the procedure
is somewhat less time-consuming and might be associated with a
safer profile.482,694,695,696 More recently, the multicenter randomized
clinical trial FIRE AND ICE, comparing conventional PVI with RFCA
(force-sensing catheters were used in approximately 25% of the pro-
cedures) to CBA (CB-2 in approximately 75% of the procedures) in
drug-refractory PAF has shown that CBA is noninferior to RFCA
with respect to efficacy and overall safety.489,697 More specifically, the
primary efficacy endpoint (any atrial arrhythmia recurrence, use of
AADs, or repeat ablation at 1 year) was not different between the
CBA and RFCA groups; neither was the primary safety endpoint. PN
injury at the time of discharge was the most frequent adverse event
reported in the CBA group (2.7%), but lower than what was
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observed in the STOP-AF trial (13.5%). Permanent PN injury
occurred in 0.3% of patients. A recent analysis of the secondary end-
points of FIRE AND ICE has shown that CBA had significantly fewer
repeat ablations, direct current cardioversions, all-cause rehospitali-
zations, and cardiovascular rehospitalization during the follow-up
compared with RFCA, with a similar improvement in QOL.490
A recent trial reported their pivotal findings on CBA as first-line
therapy in a selected population suffering from PAF; the authors sug-
gest that it might be appropriate to consider CBA therapy for PVI as
first-line therapy in patients with PAF in the absence of significant
structural heart disease.698 Yet, the decision whether to perform a
catheter-based intervention in a symptomatic patient still takes into
account the stage of atrial disease, the presence and severity of any
underlying cardiovascular disease, potential treatment alternatives,
and—in particular—patient preference and operator experience.7
Cryoballoon AF ablation requires a shorter learning curve than
point-by-point RFCA. The results of the currently ongoing Catheter
Cryoablation vs Antiarrhythmic Drug as First-Line Therapy of
Paroxysmal AF (Cryo-FIRST) trial (NCT01803438), expected in
2017, will help answer the question of whether to propose CBA as a
first-line therapy in highly symptomatic patients with PAF.
Laser and Ultrasound Ablation Systems
A laser balloon ablation system transmits light energy through a bal-
loon filled with deuterium oxide (D2O, or “heavy water”) to perform
PVI.498,508,699,700,701 The unique part of this system is that the lumen
of the catheter contains a fiber optic endoscope that allows PVI
under direct visualization. The balloon is compliant, allowing a vari-
able inflation diameter from 25–32 mm, depending on PV size, and is
delivered via a 16 Fr outer-diameter steerable sheath. Once the bal-
loon is inflated, the diode laser emits energy in a 30-degree arc of
overlapping lesions that can be rotated around the circumference of
the PV and tracked visually using special software. The power of the
laser ablation energy can be titrated from 5.5 to 12 W, lasting for 20–
30 seconds for each ablation lesion. Lower power is used when
blood is present in the field of view or when the laser is overlying the
posterior LA wall, and higher power is favored over remaining PV
segments in order to achieve persistent PVI.502 The endoscope has a
115-degree field of view (partially blocked by the lesion generator),
and the balloon catheter is then rotated to complete the isolation.
Each PV is typically individually isolated, as opposed to the individual
or pairwise isolation used during point-by-point RF ablation. A multi-
center, prospective pivotal trial of the laser balloon for treating PAF
found that freedom from AF after a single laser balloon ablation was
noninferior, and nearly identical, to the success rate using irrigated RF
ablation (61.1% laser vs 61.7% RF; P= .003 for noninferiority), with a
similar safety profile.503 PN injury was more common using the laser
balloon (3.5% vs 0.6%; P =.05), but PV stenosis was less common
(0.0% vs 2.9%; P =.03). In a single-center randomized study, AF recur-
rence after ablation was similar using the laser balloon compared
with the first-generation CB (27% vs 37%; P= .18).501,502 The laser
balloon has been used commercially in Europe and has received FDA
approval for use in the United States to treat patients with drug re-
fractory recurrent symptomatic PAF.
A novel automated low-intensity collimated ultrasound ablation
system is in development.702 This system uses low-intensity colli-
mated ultrasound (LICU) to automatically create a 3D anatomical
map of the LA. A graphical interface allows the operator to define a
desired lesion set on the 3D map, then delivers computer-controlled
LICU along the desired ablation path to create a contiguous lesion.
The lesions are created without contacting the atrial wall and are cali-
brated with respect to detected tissue thickness. Ultrasonic power is
varied along the ablation path to achieve transmurality while reducing
the risk of damage to extracardiac structures. Animal studies show
that PVs are electrically isolated with a single planned set of lesions.
Initial phase clinical trials are being performed at this time, and the re-
sults are pending.
Other Balloon Technologies
Balloon-based ultrasound and RF ablation systems have also been de-
veloped for AF ablation.703,704,705 The first of these balloon ablation
systems to be approved for clinical use in Europe was the focused
ultrasound ablation system.703,704,705 Although this balloon-based ab-
lation system was demonstrated to be effective, it was removed from
the market because of a high incidence of AEFs, some of which re-
sulted in patient death.
The hot balloon ablation catheter employs a compliant balloon
filled with saline that is inflated to occlude the PV.706 A central elec-
trode delivers RF energy to the saline in the balloon, and a unique
mixing system creates turbulent flow, promoting uniform distribution
of the heated saline throughout the balloon. The balloon surface dir-
ectly heats the PV wall circumferentially. Tissue heating occurs
through direct conductive heating.707 This technology has been used
to successfully treat patients with PAF, with a reported 65% long-
term single-procedure success rate without AADs. The main re-
ported complication with this technology was PN palsy (3.4%) and
PV stenosis (1.7%).708 A recent prospective multicenter clinical trial
compared the outcomes of hot balloon ablation vs AAD therapy for
PAF. Freedom from atrial arrhythmias was achieved at 12-month
follow-up in 59% of patients undergoing ablation vs 4.7% with AAD
therapy. Serious adverse events occurred in 10% of hot balloon pa-
tients. The incidence of PV stenosis was 5.2%, and the incidence of
PN injury was 3.7%. The clinical availability of this ablation technology
is limited at the present time.709
Multielectrode Circumferential Ablation Catheters
Currently, two multielectrode circumferential catheter systems are
in clinical use: The PV ablation catheter (PVAC) and the nMarq sys-
tem. From a historical standpoint, the first catheter using a circumfer-
ential multielectrode approach for sensing and simultaneous ablation
with the same electrodes was the Mesh ablator.710 However, due to
technical limitations of the system and poor clinical outcome, this sys-
tem is no longer available. The nMARQ catheter is a combined
decapolar irrigated ablation and mapping RF system.711,712,713,714 The
catheter has a circular design and consists of 10 platinum-coated
3 mm electrodes with a 4 mm interelectrode spacing. Irrigation is per-
formed via 10 holes in each electrode. RF ablation can be performed
via all 10 electrodes simultaneously, up to a maximum of 25 W in uni-
polar and 15 W in bipolar mode. In an initial evaluation phase in
smaller patient cohorts, a high acute success rate of PV disconnection
was reported.715,716,717 A multicenter prospective registry reported
data on approximately 180 consecutive patients with paroxysmal
(140 patients) and persistent (40 patients) AF who underwent
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nMARQ AF ablation. Aside from a high acute success rate, acute
complications and rate of AF relapse (e.g., 27% in the PAF group)
were comparable to other ablation techniques after a mean follow-
up of 13.9 months.718 Esophageal injury has been reported in several
studies using the nMARQ AF ablation catheter.719,720 Comparing the
intracardiac signals from the nMARQ to a standard “lasso”-like map-
ping resulted in both underestimation of PV potentials with the
nMARQ postablation (which were still detectable in the lasso) and
overestimation by sensing fragmented electrograms that could not
be verified with a lasso mapping.721 This appears to be an area with a
need for further investigation, because underestimation of remaining
PV potentials can lead to a pseudo-high acute success rate but higher
AF relapses during long-term follow-up. The nMARQ is not currently
available for clinical use in the United States. A prospective clinical
trial is underway to demonstrate the safety and efficacy of this abla-
tion system, needed for FDA approval.722
The PVAC in its first version used 10 platinum-iridium electrodes
in a circular fashion to deliver duty-cycled bipolar or unipolar phased
RF energy via selected or even all electrodes (temperature-con-
trolled and power-limited: 60 C/10 W/60 second delivery time).
Following initial, mostly single-center, experiences that demonstrated
excellent clinical efficacy, several studies reported a high incidence of
asymptomatic cerebral emboli (ACE) lesions after PVI with the
PVAC compared with irrigated focal RF and CBA.650,723,724,725,726,727
These reports triggered an evaluation of the underlying mechanisms;
the Endovascular Revascularization and Supervised Exercise Therapy
in Patients with Peripheral Artery Disease and Intermittent
Claudication trial subsequently demonstrated that through modifica-
tions in the catheter design, including the elimination of overlying
pole 1 and 10 ablation, and protocol for use, it was possible to reduce
the incidence of ACE lesions to 1.7%.722,727,728,729,730 These findings
were confirmed in the PRECISION GOLD trial.731,732 This ablation
system was not approved for clinical use by the FDA due in part to
this initial safety signal and the occurrence of 4 strokes (2.9% of pa-
tients randomized to ablation) following ablation in the pivotal
Tailored Treatment of Permanent Atrial Fibrillation study.733,734 An
additional single-arm study to again elucidate the safety of PVAC
technology, the Evaluation of Multielectrode Phased RF Technology
in Persistent AF (NCT01693120), was subsequently launched but has
recently been closed due to lack of enrollment. In summary, there is
considerable reason and data to believe that PVAC technology in its
redesigned format has achieved at least a similar safety profile as CB
or irrigated tip catheter ablation. The relative efficacy of this ablation
system compared with the CB system or point-by-point RF ablation
will require an adequately powered prospective, randomized clinical
trial.734 Several prospective and randomized data collections are
starting, but results will not soon be available, including the Efficiency
Study Evaluating the Use of the PVAC Catheter Technology for
Performing Ablation in Patients with AF (CAPCOST)
(NCT01562912) and PVAC GOLD Versus Irrigated RF Single Tip
Catheter with Contact FORCE Ablation of the PVs for Treatment of
Drug Refractory Symptomatic Paroxysmal and Persistent AF (GOLD
FORCE) (NCT02463851).
Electroanatomical Mapping Systems
AF is a disease frequently progressing from paroxysmal to persistent
AF. The mechanisms underlying the process of arrhythmia
perpetuation are complex. Major contributions to the understanding
of the initiating and perpetuating factors derive from mapping studies
in both patients and in animal models of AF. Mapping and ablation of
AF require accurate navigation in the LA within the context of the
underlying microstructures and physiology of the electrogram forma-
tion. This can be obtained using standard fluoroscopy or, more com-
monly, with EAM systems that combine anatomical and electrical
information by catheter sequential point-by-point or simultaneous
multielectrode mapping, allowing an accurate anatomical reconstruc-
tion of the 3D shell of the targeted cardiac chamber. There are sev-
eral different EAM systems that are widely used in clinical practice.
The current generation of the CARTO mapping system (CARTO 3;
Biosense Webster, Diamond Bar, CA, USA) relies both on a magnet-
based system for accurate localization of dedicated mapping or abla-
tion catheters and an electrical impedance-based system that allows
for visualization of electrodes and shaft of various types of electro-
physiological catheters. The second EAM system is the electrical
mapping system EnSite NavX (current version, Velocity; St. Jude
Medical, Minneapolis, MN, USA), which uses both voltage and imped-
ance for localization of proprietary and nonproprietary diagnostic
and ablation catheters. This system has now been modified to also
provide magnetic-based navigation, which is anticipated to increase
the precision of this system. Another 3D mapping system that has
been developed is the 3D MediGuide system.735 This sensor-based
electromagnetic navigation system allows real-time catheter tracking
in the environment of prerecorded X-ray loops. This system has
been shown to easily integrate into the workflow of a standard AF
ablation and allows for high-quality catheter tracking. Studies have
shown that this system is useful in reducing fluoroscopy exposure for
patients and staff. A third EAM system that is available for clinical use
is the magnetic electrical Rhythmia mapping system (Boston
Scientific, Marlborough, MA, USA), which is an EAM system that
allows for automated high-density mapping using a dedicated steer-
able 64-electrode mini basket catheter.627,632,736 This system has
only become available in the past several years, and as a result, the ex-
perience with this system is limited. A recent report describes the
value of this system for activation mapping and ablation of complex
left AFLs.627
To further improve the anatomical accuracy of the maps, integra-
tion of 3D images obtained by CT or MRI and of images acquired
with intracardiac ultrasound during the procedure has become avail-
able.737,738 Another approach involves use of 3D rotational angiog-
raphy images that can be merged with live two-dimensional
fluoroscopy.739 This approach is rarely used at the present time. It is
important to recognize that CT and MRI are not real-time images,
and that the accuracy of the use of multiple imaging modalities is de-
pendent on the accuracy of the image fusion. This requires the
matching of fiducial points from both image sets, and not simply their
display in the same user interface space. In addition, the utility of
multimodal approaches to ablation depends on the quality of electro-
gram acquisition and the registration of that physiology onto the 3D
images. Again, as more electrodes are simultaneously used in map-
ping, synthesizing information from that number of electrograms
might require the use of electrogram single processes made simpler
by mathematical manipulations, such as fast Fourier transform, in-
verse solution, Hilbert, and phase transformations. The positive and
negative benefits of these manipulations require increased
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understanding on the part of the user and do not excuse a clear
understanding of the first principles of cardiac electrophysiology.
The use of these 3D mapping systems has been demonstrated to
reduce fluoroscopy duration.740,741,742 However, several studies per-
formed to define the clinical benefit of EAM systems have generated
mixed results: whereas some studies have reported that use of these
mapping systems with or without image integration improves the
safety and efficacy of AF ablation, other studies have reported contra-
dictory findings.743,744,745,746,747 Obviously, the use of 3D mapping
systems will increase the cost of the procedure.
A survey of the writing group members showed that 93% routinely
employ 3D EAM when performing AF ablation with RF energy.
Robotic and Magnetic Catheter
Navigation
The concept of remote catheter navigation is appealing for the oper-
ator because these systems can reduce radiation exposure and the
risk to the physician of developing orthopedic problems related to
prolonged use of protective lead aprons during protracted cases.
They also can facilitate analysis of intracardiac electrograms and 3D
images because the catheter navigation and analysis can be per-
formed from the workstation where the operator is seated. The four
technologies developed to meet these objectives include the mag-
netic navigation system designed by Stereotaxis Inc; a second mag-
netic system referred to as the Catheter Guidance, Control, and
Imaging (CGCI) system, for which there is limited experience; a third
robotic-controlled catheter system manufactured by Hansen
Medical; and the remote catheter system developed by
Catheter Robotics.748,749,750,751 These technologies have been used
to ablate AF, and there is evidence that they are safe, effective, and re-
sult in a significant reduction in fluoroscopy time and radiation
exposure; however, the studies are relatively small, not randomized,
and the populations of patients are not uniform.646,647,748,
749,750,751,752,753,754,755,756,757,758,759 Use of these technologies is a
matter of operator preference. The potential advantages of the sys-
tems are offset by additional costs for the navigation systems, dispos-
ables, and maintenance contracts. A survey of the writing group
members shows that 10% routinely employ a robotic or magnetic
system when performing AF ablation procedures.
Ultrasound
In the electrophysiology lab, ultrasound is a valuable tool, used both
for guiding vascular access and during the procedure. With a linear
probe, central venous access to the femoral, internal jugular, and sub-
clavian veins can be obtained safely, reducing complications, the num-
ber of attempts, and the time required to gain access.760,761 The
impact of real-time ultrasound guidance is even greater in obese pa-
tients, in procedures with less experienced operators, and in patients
undergoing anticoagulation therapy.
ICE, which allows for real-time imaging of cardiac anatomy, is used
in many electrophysiology laboratories throughout the world to fa-
cilitate AF ablation procedures.762,763,764,765,766,767 Advocates of the
use of ICE find it to be of value because it can (1) help identify ana-
tomical structures relevant to ablation, including the PVs and esopha-
gus; (2) facilitate transseptal access and allow selective puncture in
various regions of the fossa; (3) guide accurate placement of the
multielectrode circular ablation catheter and/or balloon-based abla-
tion system; (4) allow titration of the delivered energy; (5) provide
feedback about catheter contact; (6) allow for recognition of throm-
bus formation on sheaths and catheters; and (7) allow early recogni-
tion of cardiac perforation and/or development of a pericardial
effusion.767,768 Some centers also use ICE to screen for the presence
of LAA thrombus, because it has been shown to be comparable to
transesophageal echocardiogram (TEE) when performed by experi-
enced operators. A survey of the writing group members shows that
53% of the members routinely employ ICE imaging during AF abla-
tion. Our survey revealed that ICE was being used routinely by 87%
of the writing group members in the United States and Canada com-
pared with 13% of the writing group members from other countries.
Among those who employ ICE imaging, 37% use ICE to screen for
LA thrombi prior to performing the transseptal stick.
PV Venography
PV venography is commonly performed at the time of AF ablation
procedures.769,770 The purpose of PV venography is to help guide
catheter manipulation, determine the size and location of the PV
ostia, and assess PV stenosis, particularly among patients undergoing
repeat ablation procedures. Among the writing group members, 25%
routinely use PV venography during their AF ablation procedures.
There are three techniques that have been described for PV venog-
raphy. The first technique involves selective delivery of contrast
media into each of the PV ostia. This can be accomplished by pos-
itioning the transseptal sheath in the region of the right and left PV
trunks and injecting contrast, or by selectively engaging each of the
four PV ostia using a deflectable catheter or a multipurpose angiog-
raphy catheter.769 A limitation of the selective PV venography ap-
proach is that noncatheterized PVs can be missed if a preacquired CT
or MRI scan is not available to ensure that all the PVs are identified.
The second technique is performed by injection of contrast medium
into the left and right pulmonary arteries or the pulmonary trunk.
The location of the PVs can then be assessed during the venous phase
of pulmonary arteriography. The third technique involves the injec-
tion of contrast media in the body of the LA or at the roof of the right
or left superior PV ostium immediately after delivery of a bolus of ad-
enosine to induce AV block. The contrast media will fill the LA body,
the PV antrum, and the proximal part of the PV during the phase of
ventricular asystole.
CTand/or MRI Scans and Rotational
Angiography to Define the Anatomy of
the Atrium, PVs, and Antrum
The complex anatomy of the LA plays a major role in the pathophysi-
ology of AF.771 A detailed understanding of this anatomy is essential
for a safe and effective AF ablation procedure.772 There is a significant
inter- and intrapatient variability in the number, size, and bifurcation
of the PVs67,773,774,775,776,777,778 (Figure 2). Common variations in-
clude supernumerary right PVs (18%–29%) and common trunk
(>30%), mainly located on the left side and right middle or right top
PV.69,776 Knowledge of the presence of additional veins prevents
placing ablation lesions over their ostia, which could result in PV oc-
clusion, whereas knowledge of the bifurcation pattern is essential
during CB PVI, in which wiring of various branches might be needed
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to ensure optimal occlusion.779 LA imaging facilitates ablation by pro-
viding detailed anatomical description of the PVs, antrum, and the re-
mainder of the LA, enabling selection of the most suitable ablation
technique prior to the procedure.772,780 During the procedure, inte-
gration of LA images obtained by CT or MRI reduces procedural
time because it enables a more accurate reconstruction of the anat-
omy.41 However, this requires accurate registration. Prior to RF abla-
tion, imaging of LA anatomy with either MRI or CT imaging is
performed routinely by 59% of the writing group members. Prior to
CB, AF ablation imaging of the LA anatomy with either MRI or CT
imaging is performed routinely by 56% of the writing group
members.
Another method of intraprocedural 3D imaging of the LA is rota-
tional angiography. After contrast medium injection in the right heart
chambers, the fluoroscopy c-arm is rapidly rotated around the pa-
tient, and images are acquired throughout the rotation to generate
3D volumetric anatomical rendering of the LA. These images can
then be integrated into an EAM system or superimposed on the
fluoroscopic projections of the heart.781,782 A survey of the writing
group members shows that rotational angiography is routinely per-
formed prior to AF ablation by 0% of the writing group members.
After the procedure, LA imaging is valuable in detection of post-
procedural complications such as PV stenosis or AEF.783
MRI of Atrial Fibrosis and Ablation
Lesions and MRI-Guided AF Ablation
AF is associated with various degrees of structural remodeling of the
atrial myocardium.134,136,139,161,784 In the ventricular myocardium,
MRI is an established modality to visualize myocardial inflammation
and fibrous tissue by using LGE.134,560,561,785,786 However, high-
resolution imaging of atrial fibrosis remains technically challenging,
with limited reproducibility of accuracy of MRI measures of fibrosis
by different centers.787 In a recent study, MRI data of 17% of patients
were excluded due to poor quality.365 MRI may be performed before
catheter ablation of AF to identify atrial fibrosis, or after ablation to
visualize RF lesions.134,784,788,789 Several studies have demonstrated
that the extent of atrial fibrosis evaluated by LGE prior to ablation
can predict the outcomes of catheter ablation of AF.789 Other studies
have reported contradictory results.790 In the multicenter prospect-
ive DECAAF trial, the extent of atrial fibrosis found on preablation
MRI was categorized as stage 1 (<10%), stage 2 (10%–20%), stage 3
(20%–30%), and stage 4 (>30%). AF recurrence 325 days after abla-
tion was independently associated with the extent of atrial fibrosis
(15% for stage 1, 33% for stage 2, 46% for stage 3, and 51% for stage
4).365 These preliminary results suggest that the extent of fibrosis can
be useful to predict arrhythmia recurrences and to guide the decision
to perform catheter ablation in selected patients with AF. Studies
evaluating whether LGE can visualize scar lesions induced by catheter
ablation with RF cryoablation or laser ablation in atrial tissue, or iden-
tify PV reconnection sites have reported conflicting results.784,791
Overall, despite the promise of MRI techniques to improve the out-
comes of AF ablation, further investigation is needed before advocat-
ing the systematic use to assist catheter ablation of AF. The
DECAAF-2 study has just been launched for this purpose. This
randomized, prospective, multicenter clinical trial is designed to test
the hypothesis that PVI plus consolidation of fibrotic areas with RF
ablation is superior to PVI alone.791 A survey of the writing group
members shows that MRI for detection of scar is routinely performed
prior to AF ablation by 8% of the writing group members.
During the past decade, a number of centers have developed the
technology to allow real-time MR-guided electrophysiology interven-
tion. Advantages of this approach include the absence of ionizing radi-
ation and the ability to monitor lesion development in real time.
Although these systems are still under development and are not avail-
able with routine clinical use at this time, this is an area of consider-
able interest that could emerge as an important ablation monitoring
and guidance strategy in the future.792,793,794,795
Section 7: Technical Aspects of
Ablation to Maximize Safety and
Anticoagulation
Prevention of Thromboembolism During
and Following AF Ablation
Patients with AF are at increased risk of thromboembolism during,
immediately following, and for several days to months after their abla-
tion.796,797,798,799 ACE lesions have also been observed after AF abla-
tion.800 The prothrombotic state associated with AF ablation results
in a higher, but transient, thromboembolism risk in patients with AF
who were identified as low-risk before ablation. Careful attention to
anticoagulation of patients before, during, and after ablation for AF is
critical to avoid the occurrence of a thromboembolism event.
Consensus recommendations for anticoagulation prior to, during,
and following ablation are summarized in Table 4. The ablation pro-
cedure leaves patients with substantial areas of damaged LA endothe-
lium that can become a nidus for thrombus formation. Transseptal
sheath placement and insertion of electrode catheters can precipitate
thrombus formation on the catheter or on or within the sheath dur-
ing the procedure.768,801,802,803,804 The atrial tissue can be stunned
for weeks or months postprocedure, leading to impairment of nor-
mal contraction.805 Anticoagulation, in turn, contributes to some of
the most common complications of the procedure, including hemo-
pericardium, pericardial tamponade, and vascular complica-
tions.806,807,808 Therefore, attention must be paid to achieving the
optimal safe level of anticoagulation throughout the process.
Screening for LAAThrombi Prior to
Ablation
Transesophageal Echocardiography
Thromboembolic stroke after AF ablation is a devastating conse-
quence of an invasive procedure. One of the mechanisms could be
dislodgement of a pre-existing clot that could be identified by a
screening TEE. The risk of a thromboembolic event at the time of an
AF ablation procedure varies, depending on a number of factors,
including (1) the type of AF; (2) the presence, absence, and duration
of AF as the presenting rhythm on the day of ablation; and (3) the pa-
tient’s stroke risk profile, including LA size and CHA2DS2-VASc
score. With careful, multiplanar inspection of the LAA and the num-
ber of LAA lobes, the TEE can also provide additional information to
help guide the procedure, such as identification of a pre-existing peri-
cardial effusion, globally impaired cardiac function, presence of an
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atrial septal defect (ASD) or persistent foramen ovale, or fibrosis of
the interatrial septum after previous ablation.809,810,811 In addition,
LA anatomical features, such as a thickened ridge toward the left PVs,
PV stenosis or occlusion, or cor triatriatum, can be identified.
Because many centers perform their procedures on uninterrupted
OAC, one could argue that TEE is unnecessary; however, studies eval-
uating the incidence of LA thrombus on TEE among patients undergo-
ing AF ablation who have been therapeutically anticoagulated have
consistently demonstrated that 1.6% to 2.1% of patients will have a
thrombus or “sludge” in the LAA.796,812,813 The probability of identify-
ing a thrombus was related to the CHA2DS2-VASc score in some but
not in every case. Other risk factors for thrombus were LA size and a
history of persistent AF. Among patients with a CHA2DS2-VASc score
of zero, a thrombus was identified in < 0.3% of patients compared with
>5% of patients with a CHA2DS2-VASc score of >_ 2. The practice of
routine vs selective TEE surveillance for LAA or intracavitary thrombus
prior to PVI varies widely, given evidence to guide this decision is lim-
ited in terms of important clinical outcomes.796,809,810,811,812,813,814
A survey of the writing group members shows that 51% perform a
TEE in all patients presenting for AF ablation regardless of presenting
rhythm and anticoagulation status. This survey also revealed that 71%
of the writing group members perform a TEE in patients presenting
AF who have been therapeutically anticoagulated for 3 or more
weeks prior to ablation. Among patients who present for AF ablation
in sinus rhythm who have not been previously anticoagulated, 78% of
the writing group members routinely perform a TEE. Among patients
presenting for AF ablation who are chronically anticoagulated with
warfarin, 87% of the writing group members perform AF ablation on
uninterrupted warfarin. Among patients undergoing AF ablation who
are chronically maintained on a NOAC, 38% of the writing group
members perform AF ablation on a patient receiving uninterrupted
NOAC without withholding a dose. For patients not anticoagulated
prior to ablation or in whom NOAC therapy is interrupted prior to
ablation, 16% of the writing group members reinitiate the NOAC at
2 hours, 12% at 3 hours, 37% at 4 hours, and 35% at 4 or more hours
after initially achieving hemostasis. It is important to recognize that
this is a rapidly evolving area in AF ablation. The results of the above
survey were obtained prior to publication of the results of the
Randomized Evaluation of Dabigatran Etexilate Compared to
Warfarin in Pulmonary Vein Ablation: Assessment of an
Uninterrupted Periprocedural Anticoagulation Strategy (RE-
CIRCUIT) trial, which demonstrated that performance of AF ablation
on patients receiving uninterrupted dabigatran results in a lower rate
of major bleeds compared with the uninterrupted warfarin strat-
egy.815,841 Shown in Table 4 are the writing group recommendations
concerning anticoagulation strategies prior to ablation. As with the
anticoagulation guidelines for cardioversion of AF, if a thrombus is
identified in the LAA prior to catheter ablation of AF, the AF ablation
procedure should not be performed.
Computer Tomographic Angiography
Data are emerging to suggest that CT imaging can be valuable in de-
tecting thrombi prior to an AF ablation procedure. Several studies
have investigated whether CT imaging can be used to screen for LA
thrombi, with the hope of obviating the need for a screening TEE in
at-risk patients. Compared with TEE as a gold standard, several
studies and one meta-analysis have reported a high diagnostic accur-
acy of CT to detect LAA thrombi.780,816,817 Other studies have re-
ported lower diagnostic accuracy and high inter-reader variability in
detecting LA thrombi with CT imaging.818,819 In a meta-analysis of
studies using delayed imaging protocols, the diagnostic accuracy for
detection of LAA thrombi was reported to be 99%.817 These findings
suggest that cardiac CT (with an acceptable radiation dose) could be
of value in detecting LA thrombi. It is important to note that in many
centers the CT is obtained days to weeks prior to ablation, rendering
this imaging modality of no value because of this time delay.
The writing group members believe that the data are currently in-
sufficient to recommend widespread use of CT imaging as an alterna-
tive to TEE for preablation screening for LA thrombi. This sentiment
reflects in large part a great variability in CT detector imaging equip-
ment and protocols. Further large-scale studies will be required be-
fore CT imaging can be considered an alternative for TEE screening
prior to AF ablation. A survey of the writing group members shows
49% of the members employ CT imaging on a routine basis prior to
AF ablation. Among those who obtain CT imaging, 32% use the CT
image to identify LAA thrombi.
Intracardiac Echocardiography
Data are also emerging to suggest that ICE can be valuable in detect-
ing LAA thrombi prior to an AF ablation procedure. Imaging from the
pulmonary artery is preferred. Whereas the ICE-CHIP study demon-
strated that ICE imaging from the RA had reduced sensitivity in the
detection of LA thrombi compared with standard TEE, other studies
showed that ICE imaging from the pulmonary artery can be used
safely and effectively (compared with TEE) for the evaluation of the
LAA in patients undergoing ablation.768,820,821,822,823 Of interest, ICE
has been shown to have complementary value in rescreening the LA
and the LAA for thrombus after a recent negative or equivocal
TEE.824 These findings suggest that ICE could be of value in detecting
LA thrombi. However, the writing group members believe that the
data are currently insufficient to recommend widespread use of ICE
imaging as an alternative to TEE for preablation screening for LA
thrombi. This sentiment reflects in large part a great variability in the
skills needed to both perform and interpret the results of ICE imaging
for thrombi detection. Further large-scale studies will be required be-
fore ICE imaging can be considered to be a standard and proven al-
ternative for TEE screening prior to AF ablation. A survey of the
writing group members shows that 53% of the members routinely
employ ICE imaging during AF ablation. Our survey revealed that ICE
was being used routinely by 87% of the writing group members in the
United States and Canada compared with 13% of the writing group
members from other countries. Among those who employ ICE imag-
ing, 37% use ICE to screen for LA thrombi prior to performing the
transseptal stick. Based on this information and a review of the litera-
ture, the writing group recommends that use of ICE to screen for
atrial thrombi in patients who cannot undergo TEE imaging may be
considered (Class IIb, LOE C-EO, Table 4).
Anticoagulation
Systemic Anticoagulation Prior to AF Ablation
Many patients who are undergoing AF ablation have an elevated risk
of stroke as assessed using the CHA2DS2-VASc score and are
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therefore systemically anticoagulated with warfarin or with a direct
thrombin or factor Xa inhibitor.825,826,827,828 Most operators initiate
therapeutic anticoagulation for at least 3 weeks prior to ablation in
patients with a CHA2DS2-VASc risk score of 2 or greater, especially
if they are likely to present for the procedure in AF. Because of the
slow offset and onset of warfarin, these patients were historically
transitioned or “bridged” with heparin or low molecular weight hep-
arin before and after the ablation procedure. An increased recogni-
tion of bleeding complications associated with this practice, especially
at the site of vascular access, has led to the use of uninterrupted war-
farin, which has been shown to have a better safety profile, provided
the international normalized ratio (INR) is within the target
range.399,400,401,532,533,829,830,831,832,833,834
Dabigatran and the factor Xa inhibitors (apixaban, rivaroxaban,
edoxaban) have a more rapid onset of action, a shorter half-life, and a
more predictable dose response compared with warfarin.
Accumulating evidence and several meta-analyses have demon-
strated similar efficacy and safety of dabigatran and the factor Xa in-
hibitors compared with warfarin in the setting of catheter
ablation.835,836,837,838,839,840,841,842,843 These data provide reassur-
ance; however, several methodological considerations warrant men-
tion. In most of these studies, one or two doses of the NOACs were
held prior to AF ablation. Nearly all of the included studies were ob-
servational in design, and are therefore subject to confounding and
selection bias. The sample sizes of the individual treatment arms
were small, and study heterogeneity precludes statistically robust
comparisons. In addition, the study populations were predominantly
male, largely characterized by normal renal function, and the mean
patient age was 61 years, a decade younger than the stroke preven-
tion trial populations.
The results of the RE-CIRCUIT study were recently published,
which was a head-to-head comparison of performing AF ablation on
patients receiving uninterrupted dabigatran vs uninterrupted war-
farin.841 This study randomized 704 patients across 104 sites to these
two anticoagulation strategies. The incidence of major bleeding
events during and up to 8 weeks postablation among the 635 patients
who underwent AF ablation was significantly lower with dabigatran
than with warfarin (5 patients [1.6%] vs 22 patients [6.9%]); absolute
risk difference [RD] -5.3%, RR reduction 77%. There were six pa-
tients with cardiac tamponade in the warfarin arm vs one in the dabi-
gatran arm. No strokes or other thromboembolic events occurred in
the dabigatran arm compared with one TIA in the warfarin arm. No
patients in the dabigatran arm required the specific reversal agent
idarucizumab. There has been one other smaller head-to-head com-
parison published of uninterrupted rivaroxaban vs uninterrupted
warfarin (Venture-AF, N= 248).842 This study reported one major
bleeding event, one ischemic stroke, and one vascular death, each of
which occurred in the warfarin arm of the study. A third trial of apixa-
ban vs coumadin is also underway (NCT02227550).
Based on these clinical trials, it is now apparent that a strategy of
performing AF ablation on patients receiving uninterrupted anticoa-
gulation can be performed safely and minimizes the risk of thrombo-
embolic events. Specific recommendations for pre- and
intraprocedure anticoagulation are shown in Table 4. Although fur-
ther studies are needed to further define the efficacy and safety of
performing AF ablation on uninterrupted Factor XA inhibitors or dir-
ect thrombin inhibitors, the writing committee believes that the data
and worldwide experience are now sufficient to provide a Class I rec-
ommendation for performing AF ablation with uninterrupted dabiga-
tran (Class I, LOE A) or rivaroxaban (Class I, LOE B-R), and a 2A
recommendation for the other XA inhibitors for which specific clin-
ical studies have not been performed at this time. Further studies are
needed to determine if a TEE can be omitted in patients with a high
stroke risk profile who present for ablation in AF and are undergoing
ablation on uninterrupted anticoagulation. Data will also be needed
on outcomes and use of specific reversal agents in this setting, par-
ticularly for management of serious procedural bleeding
complications.844,845
Table 4 summarizes the recommendations for anticoagulation pre-,
during, and post-AF ablation, both for warfarin and for the NOACs.
Intraprocedural Anticoagulation
Optimal anticoagulation using heparin with close attention to main-
taining therapeutic dosing during the procedure is important. It is rec-
ommended that heparin be administered prior to or immediately
following transseptal puncture during AF ablation procedures and ad-
justed to achieve and maintain a target activated clotting time (ACT)
of 300 seconds or greater (Class I, LOE B-NR, Table 4). It has
been observed that thrombi can form on the transseptal sheath
and/or the electrode catheter almost immediately after crossing the
septum and that early heparinization substantially decreases this
risk.768,802,803,804,846,847,848 A recent meta-analysis of more than 7000
patients supports this recommendation, showing that performing ab-
lation of AF with a target ACT >300 seconds decreases the risk of
thromboembolic complications without increasing the risk of bleed-
ing.849 Seventy-seven percent of the writing group members adminis-
ter heparin prior to the transseptal puncture. A heparin loading dose
should be administered initially, followed by a standard heparin infu-
sion. The ACT level should be checked at 10–15 minute intervals
until therapeutic anticoagulation is achieved, and then at 15–
30 minute intervals for the duration of the procedure. Patients receiv-
ing a vitamin K antagonist (VKA) require less heparin and reach the
target ACT faster compared with NOACs; thus, when using anticoa-
gulation strategies with the latter, more frequent ACT monitoring
and higher heparin doses should be used.840,849 This recent report
from a large-volume medication center employs an initial heparin
bolus of 50 units per kg in patients who are therapeutically anticoagu-
lated with warfarin, 75 units per kg in patients who are not anticoagu-
lated prior to ablation, and 120 units per kg for patients who are
anticoagulated on a NOAC and have held one to two doses. A sur-
vey of the writing group showed great variability in loading protocols
for heparin prior to an ablation procedure. The heparin dose should
be adjusted to maintain an ACT of at least 300–350 seconds through-
out the procedure. One-third of the writing group members rou-
tinely employ a target ACT of > 350 seconds.820,830,846 Heparinized
saline should be infused continuously through each transseptal sheath
to further reduce the risk of thrombi.802 The risk of systemic embol-
ization of thrombus formed on a sheath can be reduced by withdraw-
ing the sheath to the RA once a catheter is positioned in the LA.
Heparin infusion can be discontinued once all catheters are
removed from the LA, and the sheaths removed from the groin
when the ACT is less than 200–250 seconds. Sheaths can be
removed during full anticoagulation by employing a figure-of-eight
suture.850 Alternatively, the heparin effect can be reversed with
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protamine (Class IIa, LOE B-NR, Table 4).851 This approach is used by
70% of the writing group members.
In the event of persistent bleeding or cardiac tamponade, pro-
tamine should be administered to reverse heparin. If bleeding re-
solves, then reversal of the oral anticoagulant is not
recommended, because this continues to offer protection from
thromboembolic complications postprocedure. However, if peri-
cardial or other bleeding persists with the above measures, fresh
frozen plasma can be administered for reversal of warfarin.
Dabigatran can be reversed with idarucizumab.844 Development
of a reversal agent for Factor Xa inhibitors is underway but is not
yet available on a clinical basis.845 Until these agents are available,
it is recommended that prothrombin complex concentrates
(PCC: Factors II, VII, IX, and X) or recombinant activated factor
VII (rFVIIa) be administered.852 The increasing availability of spe-
cific reversal agents for factor IIa and Xa inhibitors will certainly
encourage the adoption of continuous anticoagulation with the
newer oral anticoagulants during AF ablation.
Early Postprocedural Anticoagulation
There is a prothrombotic milieu following RF ablation for AF due
to reduced contraction of the atria, endothelial damage from abla-
tion lesions, and a thrombogenic state. Therefore, it is the consen-
sus recommendation of the writing group members that patients
should be anticoagulated for at least 2 months postablation, re-
gardless of their CHA2DS2-VASc score or rhythm status (Class I,
LOE C-EO, Table 4). In patients treated with warfarin who have a
subtherapeutic INR the day of the procedure, there are two op-
tions. First, a direct thrombin or Factor Xa inhibitor can be admin-
istered several hours following ablation.826,827,853,854 Second, low
molecular weight heparin (enoxaparin 0.5–1.0 mg per kg twice
daily) or intravenous heparin can be used as a bridge to resump-
tion of INR 2.0–3.0. For most patients, other than those with pros-
thetic valves who will need to remain indefinitely on warfarin,
initiation of a NOAC postablation is a preferred strategy to use in-
stead of heparin or low molecular weight heparin due to the
increased bleeding risk with these agents.
It is expected that patients will have their sheaths removed imme-
diately after ablation, either with or without the use of protamine to
reverse the intravenous heparin used during the procedure.
Hemostasis can be achieved by either direct pressure or the use of a
figure-of-8 suture. Evidence for the safety of uninterrupted NOAC
therapy has increased with the recent publication of Venture AF and
RE-CIRCUIT.841,842 Despite these new data, some centers have the
patient withhold one to two doses of NOACs in the days prior to
their ablation procedure. For these patients, reinitiation of the
NOAC should take place as soon as the clinician is satisfied that there
is no significant pericardial effusion or vascular bleeding following the
ablation. Similarly, for the small subset of low-risk patients who were
not being treated with anticoagulation before the procedure, a
NOAC can be administered immediately following ablation. The
writing group members advise that readministration of a NOAC be
given 3 to 5 hours after completion of the procedure and removal of
the vascular sheaths, provided there is no evidence of ongoing bleed-
ing, or a significant pericardial effusion or cardiac tamponade is rea-
sonable (Class IIa, LOE C-EO, Table 4).
Anticoagulation Considerations Two or
More Months Postablation
Whether elimination of AF or reduction of AF burden by catheter
ablation results in a significant reduction in stroke risk is an important,
and as yet unanswered, question. Until this important question is ad-
dressed by an adequately designed clinical trial, adherence to the AF
anticoagulation guidelines is recommended for patients who have
undergone AF ablation procedures, regardless of the apparent suc-
cess or failure of the procedure (Class I, LOE C-EO, Table 4). The
writing group advises that decisions regarding continuation of sys-
temic anticoagulation more than 2 months postablation should be
based on a patient’s stroke risk profile and not on the apparent suc-
cess or failure of the ablation procedure (Class I, LOE C-EO,
Table 4). And finally, the writing group recommends that for patients
in whom discontinuation of anticoagulation is being considered based
on the patient’s values and preferences, they should consider
undergoing continuous or frequent ECG monitoring to screen for
AF recurrence (Class IIb, LOE C-EO, Table 4). This recommendation
is based on the following: (1) recurrences of AF are common both
early and late following AF ablation; (2) asymptomatic AF is common,
and is more common following AF ablation than prior to AF ablation;
(3) AF ablation destroys a portion of the atria and the impact of this
on stroke risk is uncertain; (4) there have been no large, randomized
prospective trials that have assessed the safety of discontinuing anti-
coagulation in this patient population; (5) studies have shown that
strokes in patients with AF might not be temporaneously related to
an AF event855; and (6) the use of direct thrombin inhibitors or
Factor Xa inhibitors, such as dabigatran, rivaroxaban, edoxaban and
apixaban, is more convenient than warfarin.825,826,827,828
The small subset of writing group members who support the dis-
continuation of systemic anticoagulation in patients with an increased
stroke risk profile make the argument that (1) continuing anticoagula-
tion exposes patients to the risks for hemorrhage and the unfavor-
able effects of anticoagulation on long-term QOL; (2) several large
outcome studies have reported a lower-than-expected stroke risk in
patients who undergo AF ablation compared with control popula-
tions239; and (3) one center has reported a low stroke risk in patients
postablation who screen for recurrence by pulse assessment or ECG
monitoring.238,407,409,545,856,857,858,859,860
In considering these consensus recommendations, it is worth com-
menting that some patients who have multiple stroke risk factors are
highly motivated to discontinue systemic anticoagulation and are will-
ing to accept a possible increased risk of stroke. It is for these patients
that we recommend that some type of continuous monitoring be
performed to screen for silent AF at regular intervals as long as they
remain untreated with systemic anticoagulation. A survey of the writ-
ing group members shows that 77% continue anticoagulation indefin-
itely in patients who have undergone AF ablation and who have a
CHA2DS2-VASc score of 2 or greater. It is possible that the out-
comes of the CABANA and Early Treatment of Atrial Fibrillation for
Stroke Prevention Trial (EAST) (NCT01288352) will help clarify this
issue. In selected patients with ECG, evidence of AF control, and dili-
gent follow-up for AF recurrences, 23% of the writing group mem-
bers indicated that they would consider discontinuing anticoagulation
after a conversation with the patients in which risks and benefits
were discussed. This survey also shows that only 1 writing committee
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member (2%) routinely discontinues anticoagulation in all patients
following AF ablation who are AF-free.
It is important to recognize that the above discussion has focused
on patients at high risk of stroke (i.e., CHA2DS2-VASc score >_2).
There is far greater flexibility as to how anticoagulation is managed in
patients at a low or moderate risk of stroke because current guide-
lines do not mandate systemic anticoagulation. Another important
consideration is that patient preference plays a large role in this deci-
sion. It is our belief that patients should be made aware of the avail-
able data and consensus recommendations, and then should be
encouraged to consider the risks and benefits of continuing vs discon-
tinuing systemic anticoagulation. Some patients who are at increased
risk of stroke are highly motivated to discontinue systemic anticoagu-
lation and are willing to accept an increased risk of stroke. For these
patients, we recommend diligent pulse assessment at least twice daily
and strong considerations that some type of continuous monitoring
be performed to screen for silent AF at regular intervals as long as
they remain free from systemic anticoagulation. A final comment
worth mentioning is that the mechanisms of stroke are not limited to
cardioembolism due to AF; thus, other sources of emboli should also
be considered, such as paradoxical embolism and atheromas from
the aortic arch. In the remainder of this section, we will briefly review
some of the available data.
In multiple randomized trials, AF ablation was superior to AADs in
reducing AF recurrence in drug-refractory patients.861 However,
stroke prevention among these strategies has been largely similar.
One investigator recently undertook a meta-analysis to evaluate
whether AF ablation reduces the long-term risk of stroke compared
with AAD therapy.857 Thirteen RCTs were analyzed, with 1097 pa-
tients treated by catheter ablation and 855 patients receiving AAD
therapy. Overall, seven patients (0.64%) in the catheter ablation
group had ischemic stroke or TIAs vs two patients (0.23%) in the
drug therapy group. No difference was shown in the rate of stroke or
TIA between ablation and drug therapy. To date, however, no AF ab-
lation trial has evaluated whether successful ablation obviates the
need for long-term OAC, but there are reports from large adminis-
trative registries and observational studies addressing this issue.
One study evaluated the long-term results of OAC cessation after
successful catheter ablation of AF.857 OAC and AADs were discon-
tinued irrespective of AF type or baseline CHA2DS2-VASc risk score
in 327 patients with drug-refractory AF after catheter ablation.
Patients with a CHA2DS2-VASc score of 2 (45.4%) and 3 (23.2%) ac-
counted for 68.8% of this cohort. In the patients with a high risk of re-
currence or prior thromboembolic complications, OAC was
continued for up to 6 to 12 months postablation, and antiplatelet
therapy was administered to all patients who maintained sinus
rhythm upon OAC interruption. After a follow-up of 46 months,
82% remained AF-free (free from AADs). No symptomatic ischemic
cerebrovascular events were detected during follow-up, despite
interruption of OAC in 298 (91%) patients and AADs in 293 (89%)
patients.
Another study reported the patterns of anticoagulation use and
cardioembolic risk after catheter ablation for AF.862 They found an
increased use of NOACs after ablation from 0% in 2005 to 69.8% in
2014. OAC discontinuation was high, with only 60.5% and 31.3% of
patients remaining on OAC at 3 and 12 months, respectively. The
rate of discontinuation was higher in low-risk patients (82% vs 62.5%
at 12 months for CHA2DS2-VASc 0–1 vs >_ 2, respectively; P <.001).
Stroke occurred in 1.4% of the patients with CHA2DS2-VASc >_2 and
in 0.3% of those with a CHA2DS2-VASc of 0 or 1 over the study
follow-up. The risk of cardioembolism in the first 3 months after abla-
tion was increased among those with any time free from OAC (HR
8.06; 95% CI 1.53–42.3; P <.05). The risk of cardioembolism beyond
3 months was increased with OAC discontinuation among high-risk
patients (HR 2.48; 95% CI 1.11–5.52; P <.05) but not low-risk pa-
tients, suggesting that continuing OAC for at least 3 months in all pa-
tients and indefinitely in high-risk patients appears to be the safest
strategy in the absence of effective monitoring and AF detection.
An AF ablation registry reported data of patients followed up after
ablation of PAF in a high-risk group (previous stroke; group 1) and a
low-risk group (no previous stroke; group 2) based on data from the
German Ablation Registry, to reveal real-life prescription behav-
ior.412 Between April 2008 and April 2011, 83 patients in group 1 and
377 patients in group 2 with a first ablation of PAF were included in
the registry. The results showed a mean CHA2DS2-VASc score of
4.2 ± 1.4 (group 1) vs 1.6 ± 1.2 (group 2) (P <.0001). OAC was dis-
continued in 38.6% of the patients in group 1 vs 66.3% of those in
group 2 (P <.0001) during follow-up. Thromboembolism occurred
more often in group 1 than in group 2 (4.3% vs 0.3%, P <.05), arguing
against OAC discontinuation in a high-risk population without on-
going pulse assessment and ECG monitoring.
Another study in a large Danish cohort410 evaluated the long-term
risk of thromboembolism and serious bleeding associated with OAC
therapy beyond 3 months after RF ablation of AF. During a median
follow-up of 3.4 years, 71 (1.8%) thromboembolism cases were iden-
tified, in which incidence rates with and without OAC were similar at
0.56 (95% CI 0.40–0.78) and 0.64 (95% CI 0.46–0.89), respectively.
OAC therapy was significantly associated with serious bleeding risk
(HR 2.05; 95% CI 1.25–3.35). Of note, half the patients received
OAC for at least 1 year after catheter ablation, including 56% of the
CHA2DS2-VASc = 0 patients and 67% of the CHA2DS2-VASc = 1 pa-
tients. As expected, bleeding events were higher in the patients who
remained on anticoagulation after AF ablation (HR 2.05).
Another study assessed the feasibility for discontinuation of OAC
after ablation based on the AF burden documented by implantable
cardiac monitors.859 During a follow-up time of 32 ± 12 months (126
patient-years), 41 of the 65 patients (63%) had an AF burden <1 hour
per day and were able to stay off OAC. Twenty-one patients (32%)
had to reinitiate OAC due to an AF burden >1 hour, and three pa-
tients reinitiated OAC due to other reasons. No stroke, TIA, or
other thromboembolic event was observed during follow-up. These
are important data for those patients who decide not to receive
chronic OAC, and we suggest consideration of an anticoagulation
strategy based on AF burden measured by monitoring.
Another single-center report described outcomes in 635 patients
with one or more risk factors for stroke during a mean follow-up of
836 ± 605 days after an AF procedure.545 Anticoagulation was dis-
continued in 434 of 517 patients who remained in sinus rhythm, and
aspirin and/or clopidogrel was prescribed. There were three ischemic
strokes and two TIAs in the anticoagulation discontinuation group.
The estimated 5-year stroke rate in this group was 3%.
An observational study from five large AF ablation centers
included data from 3344 patients who underwent AF ablation.238
Oral anticoagulant therapy was typically discontinued regardless of
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the CHA2DS2-VASc score if patients did not manifest one of the fol-
lowing: (1) any recurrence of ATAs; (2) severe PV stenosis; or (3) se-
vere LA mechanical dysfunction. After discontinuation of
anticoagulation, the patients were treated with aspirin. If AF recurred,
anticoagulation was restarted in those with a CHA2DS2-VASc score
of one or more. There were 347 patients who had a CHA2DS2-VASc
score of >2. Among these 347 patients, no thromboembolic events
occurred.
One of the most recent studies to be published reports data from
the Swedish national health registry.863 Among 1175 individuals
followed for more than a year post-AF ablation, 30% discontinued
warfarin treatment during the first year. In patients with a CHA2DS2-
VASc score >2, the patients discontinuing warfarin had a higher rate
of ischemic stroke (1.6% per year vs 0.3% per year for those who
continued warfarin). Patients with a CHA2DS2-VASc score >2 and
who had had a prior ischemic stroke displayed an especially high risk
of stroke if warfarin was discontinued (HR 4.6). It is important to
note that in this registry, recurrence rates of AF after ablation were
quite high. Sixty percent of the entire cohort and 8 of the 11 patients
with stroke (72.7%) underwent cardioversion of AF or a second PVI.
The study convincingly demonstrated that in patients with recurrent
AF after catheter ablation, a high CHA2DS2-VASc score, and/or a his-
tory of stroke, OAC therapy should not be discontinued. Because
there were so few patients without AF recurrence, the question of
whether “successful” AF ablation might convey a lower risk was not
adequately addressed.
As stated above, there is a lack of randomized trials evaluating this
important clinical challenge; however, there are some ongoing trials,
such as EAST and CABANA, which will address the prognostic im-
pact of rhythm control therapy, including AF ablation and the effect
of rhythm control therapy on stroke. Other trials are needed to de-
fine the optimal anticoagulation during AF ablation procedures in an
era in which novel anticoagulants are increasingly used. We are opti-
mistic about the ongoing Optimal Anticoagulation for Higher Risk
Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial
(NCT02168829), which will effectively determine whether successful
long-term reduction or elimination of AF with catheter ablation will
reduce stroke risk sufficiently to obviate the need for long-term
OAC. Additionally, the ongoing Prevention of Silent Cerebral
Thromboembolism by Oral Anticoagulation With Dabigatran After
PVI for Atrial Fibrillation (ODIn-AF) trial (NCT02067182) will ad-
dress the effect of dabigatran compared with no OAC on the inci-
dence of silent cerebral embolic events in patients with a high risk for
embolic events, but who are free from symptomatic AF after success-
ful PV ablation.
Until the outcomes of such trials are available, our current treat-
ment recommendations to continue OAC after catheter ablation of
AF in patients at high risk for stroke should continue. In patients who
desire to discontinue anticoagulants because of ECG-documented
AF elimination who remain at risk because of high CHA2DS2-VASc
score, an individualized approach after full disclosure is warranted. It
is important that patients who are considering discontinuation of
anticoagulation in the setting of a stroke risk profile have a complete
discussion of the potential risks of this strategy. As noted above, the
writing group recommends that, for patients in whom discontinu-
ation of anticoagulation is being considered based on the patient’s val-
ues and preferences, they should consider undergoing continuous or
frequent ECG monitoring to screen for AF recurrence, although re-
currence of AF is only one of many reasons for stroke events after
discontinuation of anticoagulation (Class IIb, LOE C-EO, Table 4).
Whether this strategy results in a significant reduction of stroke risk
remains uncertain at this time.
Less information is available concerning the optimal approaches to
anticoagulation following surgical ablation of AF. Many variables need
to be considered, including whether the patient underwent ligation
of their LAA and the patient’s stroke risk profile. At the present time,
there is little to no evaluable evidence for or against the merits of
anticoagulation following surgical ablation when the LAA has been
surgically obliterated. In the absence of current evidence, the decision
to anticoagulate and the duration of treatment should be made on an
individual basis weighing the risks and benefits of anticoagulation in
the postsurgical patient. It is, however, not unreasonable to anticoa-
gulate for several months following surgical ablation, provided there
are no other bleeding risks. For patients in whom appendage closure
or ligation was performed at the time of surgical ablation, and in
whom discontinuation of anticoagulation is being considered, TEE-
based assessment of whether complete appendage closure has been
accomplished is recommended because incomplete closure of the
LAA is not uncommon.
Anesthesia or Sedation During Ablation
Patients undergoing catheter ablation of AF are required to lie mo-
tionless on the procedure table for several hours, and repeated stim-
uli from ablation are sometimes painful. For these reasons, most
patients are treated with conscious sedation or general anesthesia.
The choice of approach is determined by the institutional preference
and by assessment of the patient’s suitability for conscious sedation.
General Anesthesia
AF ablation procedures are commonly performed under general an-
esthesia. Not only does use of general anesthesia improve the safety
of the procedure for patients at risk of airway obstruction, but it also
improves patient comfort and might improve efficacy by preventing
patient movement during the procedure. Given the need to minimize
patient movement to improve catheter and mapping system stability,
general anesthesia or deep sedation are generally preferred. One
prospective randomized clinical trial randomized patients with gen-
eral anesthesia or conscious sedation. This study reported that use of
general anesthesia increased the single procedure success rate, low-
ered the prevalence of PV reconnection among those who needed a
redo procedure, and shortened fluoroscopy time and procedure
time.633 General anesthesia is of particular importance for patients at
risk of airway obstruction, those with a history of sleep apnea, and
those at increased risk of pulmonary edema. General anesthesia may
also be employed electively in healthy patients in order to improve
patient tolerance of the procedure. Anesthesia or analgesia needs to
be administered by well-trained and experienced individuals with
monitoring of heart rate, noninvasive or arterial line BP, and oxygen
saturation. Guidelines for assessing levels of anesthesia and training
requirements for administration of intravenous sedation during pro-
cedures have been developed by the American Society of
Anesthesiologists, which can be found on their website. A survey of
the writing group members shows that in the United States and
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Canada, 85% routinely employ general anesthesia. Outside the
United States and Canada, 45% routinely employ general anesthesia.
(Please also see discussion of anesthesia on page e51).
Conscious and Deep Sedation
Deep sedation is a step beyond conscious sedation and just before
general anesthesia. Generally, only anesthesia providers or specially
trained physicians can provide deep sedation because airway and
hemodynamic management might be required. The major limitation
to deep sedation is the need for the patient to lie on the procedure
table with minimal movement during the entire procedure. RF lesions
can be associated with intense pain, resulting in patient movement.
The location of sites eliciting pain with RF lesions are not predictable,
although are most often located on the posterior wall. Monitoring
esophageal temperature during deep sedation is possible, but more
cumbersome, due to intact airway reflexes that are abolished during
general anesthesia. Patient movement with right phrenic stimulation
during CB procedures is also a common occurrence with deep sed-
ation, and is largely absent with the use of general anesthesia.
Jet Ventilation
Catheter stability and catheter contact during LA ablation are crucial
for effective lesion creation. Both catheter stability and catheter–
tissue CF can be further increased by reduced respiratory thoracic
excursions. Data from one institution suggest improved clinical out-
come as a result of enhanced lesion quality and reduction of PV re-
connection when applying high-frequency jet ventilation in general
anesthesia during PVI.634,864,865 Further data from other centers are
needed, however, before final conclusions can be drawn. A survey of
the writing group members reveals that in the United States and
Canada, 14% routinely employ high-frequency jet ventilation.
Outside the United States and Canada, 4% routinely employ high-
frequency jet ventilation during AF ablation procedures.
Summary
The type of anesthesia used for AF ablation depends in part on the
availability of anesthesia support for ablation procedures. Given the
need to minimize patient movement to improve catheter and map-
ping system stability, deep sedation or general anesthesia is generally
preferred.
Approaches to Minimize Risk of an AEF
A rare but potentially devastating complication of AF ablation is injury
to the esophagus, with the possible outcome of AEF or esophageal
perforation leading to mediastinal infection, stroke, and/or
death.866,867,1398 Another complication that is thought to be related
to thermal injury to the periesophageal vagal plexus is gastropare-
sis.868 More information concerning the incidence, presentation, and
management of these complications is presented under Section 10.
Because of the serious consequences of an AEF, it is important to at-
tempt to prevent severe esophageal and periesophageal injury. Some
operators design the ablation lesions to avoid the esophagus. The lo-
cation of the esophagus can be visualized using a variety of
approaches, including multidetector CT, topographic tagging of the
esophageal position with an EAM system, barium paste, and
ICE.869,870,871,872,873,874,875,876 It is important to know that esophagus
location can change during the procedure, and repeated imaging or
visualization is needed to account for the motion of the esophagus.
However, it is difficult to accomplish complete PV ablation without
some ablation in close proximity to the esophagus. Strategies to pre-
vent and treat esophageal injury follow.
Reduced Power Delivery on the Posterior Wall
Higher power and greater depth of tissue heating or cooling are associ-
ated with increased risk of esophageal injury. In order to minimize in-
jury to the esophagus during RF applications on the posterior wall
close to the esophagus, several approaches can be employed, including
(1) reduction of RF power (e.g., <_25 W); (2) shortening RF application
time (e.g., <_20 seconds); and/or (3) decreasing CF (e.g., <_10 grams).
The writing group recommends that RF power be reduced when cre-
ating lesions along the posterior wall near the esophagus (Class I, LOE
C-LD, Table 3). Some reports employed the use of light conscious sed-
ation to use pain to identify potential esophageal injury. However,
there are conflicting data on the specificity of the pain response. It has
been proposed that an alternative energy source, such as the CB for
PVI, could minimize esophageal injury877,878; however, AEF or perieso-
phageal vagal plexus injury after CBA has been reported.879,880 There
are also data that other heat-based energy sources, such as high-
intensity focused ultrasound or laser energy, can damage the esopha-
gus.501,502,700,701,705,881 Although each of these approaches is variously
adopted by different ablation centers, each remains largely unproven
due to the rarity of an AEF as a complication.
Esophageal Temperature Monitoring
A strategy to avoid esophageal injury employed by 65% of the writing
group members is luminal esophageal temperature monitoring, used
to identify potentially dangerous heating of the esophagus.882,883,884,885
Unfortunately, because the esophagus is broad, the lateral position of
the temperature probe or mapping electrode might not align with the
ablation electrode, and the operator could receive a false impression
of safety.1398 There is general agreement among those operators who
employ temperature probes that an increase in esophageal tempera-
ture should trigger interruption of RF energy delivery. Three-quarters
of the writing group members terminate ablation if they observe a
1 C or 2 C rise in temperature from baseline, or a recorded tem-
perature of 39 C–40 C. During CBA, two-thirds of the writing group
members monitor esophageal temperature, and terminate cooling if
the esophageal temperature reaches 20 C–25 C. A variety of
esophageal temperature probes are available for clinical use.886 A re-
cent study has shown the superior thermodynamic profile of multisen-
sor esophageal recording systems; however, no clinical trial has
demonstrated superiority in terms of reducing AEFs.646,647 This type of
study would be impossible to perform due to the very low event rate
of this complication. Among the writing group members who employ
esophageal temperature monitoring, single thermocouple probes are
used by two-thirds and multithermocouple probes are employed by
one-third. The potential benefit of multithermocouple probes must be
weighed against their increased complexity and cost.886,887,888,889 The
writing group recommends that it is reasonable to use an esophageal
temperature probe during RF ablation procedures to monitor esopha-
geal temperature to help guide energy delivery (Class IIa, LOE C-EO,
Table 3).
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Another strategy to protect the esophagus uses active cool-
ing.890,891,892,893 This technique has not been tested on a large scale,
and the data describing this technique are limited. Selected operators
use mechanical displacement of the esophagus.894,895 This technique
appears to be promising, but its use has been limited to a small num-
ber of patients and is therefore an unproven approach.
Pharmacological Prophylaxis
Esophageal ulcers are found in a 5%–40% of patients following AF abla-
tion. It is hypothesized that AEF occurs because there is transmural ne-
crosis of both the atrium and esophagus with subsequent ulcer erosion
from gastroesophageal reflux.896,897 To prevent ulcer erosion, proton
pump inhibitors (PPIs) have been employed, and are used by 65% of
the writing group members after ablation. PPIs are highly effective in
gastroesophageal reflux disease by reducing the acidity of the gastric
juice and healing esophagitis.898,899,900 PPIs are effective in reducing the
size of iatrogenic-induced ulcers, therefore could also be helpful for
ablation-induced ulcers.901 Other mechanisms, such as traumatic injury
of the esophageal wall, could also play a potential role in fistula forma-
tion, although there is no proof of this concept. Prophylactic short-
term use of PPIs after AF ablation is assumed to be effective; however,
further large randomized studies are required to determine whether
PPIs reduce AEFs. Because of the low event rate of AEFs, such a study
will not likely be performed. At the moment, PPI therapy is justified as a
singular preventive treatment.
Role and Indications for Endoscopic Screening for
Ulceration Following AF Ablation
Because AEF can cause septicemia and air embolism leading to death,
early detection of esophageal tissue injuries is essential. Data evaluat-
ing the role of gastrointestinal endoscopy for detection of esophageal
tissue lesions are limited. In 185 patients who underwent gastrointes-
tinal endoscopy after LA RF ablative therapy, ulcer-like or hemor-
rhagic esophageal thermal lesions (diameter: 2–16 mm) were
observed in 14.6% of the patients.902 These lesions only occurred
when the intraluminal esophageal temperature had reached more
than 41 C. The odds of an esophageal lesion increased by a factor of
1.36 (95% CI 1.07–1.74; P= .012) for every 1 C rise in temperature.
Gastrointestinal endoscopy in a cohort of 425 patients 1 to 3 days
after AF catheter ablation, in whom intraluminal esophageal tempera-
tures higher than 41 C were recorded, revealed esophageal tissue le-
sions in 11.6% of asymptomatic patients.903 Hence, these observations
suggest that asymptomatic patients could benefit from routine gastro-
intestinal endoscopy after RF catheter ablative therapy when the intralu-
minal esophageal temperature during the procedure has reached a
certain target temperature, such as 41 C. However, there are no re-
ports on the value of this type of follow-up endoscopic examination after
ablative therapy. Only one study did a follow-up endoscopy at least
7 days after the first examination in patients with an esophageal lesion
diameter >5mm and found regression of all 3168 lesions.903 A PPI was
used in all the patients for 4weeks after ablation.
Role and Indications for CT Imaging for Diagnosis of
Atrioesophageal Fistula
After ablation, symptoms and findings suggesting the possibility of
evolving AEF include chest pain, painful swallowing, fever,
leukocytosis, TIA, and/or stroke typically occurring between
1 and 3 weeks postablation. If esophageal injury is suspected, CT
imaging with intravenous and water-soluble oral contrast is rec-
ommended.904,905,906 Findings on CT imaging on an AEF include
mediastinal or pericardial free air, evidence of free communication
between the esophagus and pericardium or atrium, and inflamma-
tory phlegmon between the esophagus and the heart.
Unfortunately, these CT findings are usually observed late in the
progression of AEF. The appearance of the CT scan early in the
course of this complication can be entirely normal. If esophageal
injury postablation is suspected, but if the CT scan is normal, the
physician must continue to have a high index of suspicion and re-
peat imaging if symptoms or findings do not resolve. Esophageal
ultrasound can also be useful in this setting to disclose muscle and
external injury, beyond a simple ulcer. Although a barium swallow
can detect a fistula, its sensitivity is low. If an AEF is suspected, en-
doscopy with air insufflation should be avoided, given that insuffla-
tion of the esophagus with air can result in a large air embolus,
producing stroke or death. An alternative strategy, which some
members of the writing group employ and which appears to have
lower risk is to use CO2 instead of air for insufflation in this set-
ting. If CO2 were introduced into the LA, there would be little ad-
verse consequence. The early recognition of an AEF can be
missed due to the low awareness of this rare complication. It is im-
portant for patients to be educated as to warning signs and to con-
tact their AF ablation center should any suggestive symptoms
develop.
Management of Atrial Esophageal Fistula
The management of AEF following catheter ablation for AF includes
preventive measures and therapeutic options. If AEF is diagnosed,
available therapeutic options are as follows:
(1) surgical repair of the fistula via thoracotomy (combined LA and
esophageal repair with an intercostal muscle flap inserted in be-
tween to prevent future recanalization of the fistula tract) via
thoracotomy;
(2) the less invasive esophageal stenting, followed by long-term antibi-
otic therapy; and
(3) conservative management with aggressive chest tube drainage and
treatment of sepsis.341,417,907,908,909,910,911
Of the above three, conservative treatment of AEF is associated
with a high mortality rate. 907,1398 Similarly, with esophageal stenting,
earlier studies have reported fatality in the majority and survival in
very few only after undergoing emergency surgical re-
pair.341,417,896,897,907,910,911,912,913,914,1398 Mixed results have also
been shown for surgical repair of AEF complicating RFCA, some with
positive outcome and others with fatal ending.341,417,910,911 However,
the only reported survival in patients thus far underwent surgical fis-
tula repair, and failure of surgery has been mostly attributed to delay
in diagnosis and intervention.341,417,910,911 Thus, based on currently
available clinical information, it is apparent that early surgical interven-
tion is critical for survival in AEF manifesting as a complication of AF
ablation. Of note, there are few reports on successful resolution of
the fistula with stenting in patients with cardioesophageal (connecting
to CS) and esophagopericardial fistula.905,915,916 In cases of
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perforation (not thermal injury) before the fistula has formed, closure
with stent or endoscopic clip can be considered.917,918,919
Summary
Although all of the approaches described above for the prevention of
AEF have been variously adopted by different ablation centers, each re-
mains largely unproven due to the rarity of an AEF as a complication.
Among the writing group members, 67% employ an esophageal tem-
perature probe (single thermocouple for two-thirds, multiple thermo-
couple for one-third), 36% use 3D image integration and import the
esophagus location into the electroanatomical map, 91% decrease RF
power when ablating on the posterior wall of the atrium, 7% use bar-
ium paste, and none (0%) mechanically displace the esophagus. Among
the writing group members, 30% limit power to <_ 20 W on the pos-
terior wall, 45% limit it to 25 W, 18% to 30 W, and 7% use powers
of > 30 W. The writing group recommends that it is reasonable to use
an esophageal temperature probe during RF ablation procedures to
monitor esophageal temperature and to help guide energy delivery
(Class IIa, LOE C-EO, Table 3). The writing group recommends that RF
power be reduced when creating lesions along the posterior wall near
the esophagus (Class I, LOE C-LD, Table 3).
Despite its rarity, the devastating consequences of AEF demand
that the operator maintain a high index of suspicion for this diagnosis.
Presenting symptoms, including fever, dysphagia, and neurological
deficits, often occur in the several weeks after the procedure.918
Therefore, early signs of these symptoms should be reported by pa-
tients to their treating electrophysiologist to avoid the delayed diag-
nosis.908 If AEF is suspected, standard transesophageal endoscopy
should be avoided, because esophageal perforation can be exacer-
bated and air embolism promoted by required air insufflation. An al-
ternative strategy, which some members of the writing group employ
and which appears to have lower risk is to use CO2 instead of air for
insufflation in this setting. If CO2 were introduced into the LA, there
would be little adverse consequence. In patients diagnosed with an
AEF, surgical treatment is recommended.
Section 8: Follow-up
Considerations
Monitoring for Complications in the First
Months After AF Ablation
AF ablation is an invasive procedure that entails risks, most of which
are present during the acute procedural period. However, complica-
tions can also occur in the weeks or months following abla-
tion.920,921,922 Recognizing common symptoms after AF ablation and
distinguishing those that require urgent evaluation and referral to an
electrophysiologist is an important part of follow-up after AF abla-
tion. Symptoms and complications can be divided into those that
occur immediately after ablation (0–3 days), early (1–4 weeks), and
those that can occur late (>4 weeks) after ablation.
Signs and Symptoms of Complications Within 1 Month
Postablation
Shown in Table 5 is a list of signs and symptoms that can occur within
the first several months following ablation. These signs and symptoms
are divided into those that occur within 30 days of AF ablation and
those that occur more than 30 days postablation. Some complica-
tions, such as a stroke or development of an AEF, might present
within the first month or following the first postablation month and
therefore are listed in both sections of this table. The differential diag-
nosis, which should be considered, as well as the recommended
evaluation, are also shown. AF ablation is often performed under gen-
eral anesthesia. Some patients might feel fatigued for several days
after prolonged general anesthesia. Mechanical complications from
endotracheal intubation and transesophageal echocardiography, such
as hoarseness and difficulties swallowing, might also occur and typic-
ally resolve with time.
Tenderness at the vascular access sites is common; hematomas
present after sheath removal will typically extend inferiorly (due to
gravity) and might result in extensive ecchymosis after ablation.
Prompt ultrasound Doppler investigation should be performed if an
AV fistula or pseudoaneurysm is suspected. Worsening of back or
buttock pain is also common from prolonged supine positioning dur-
ing the procedure. However, more severe back pain or flank ecchym-
osis should prompt an evaluation for retroperitoneal hematoma with
CT imaging. Significant bleeding into the leg can also result in com-
partment syndrome.
Shortness of breath soon after ablation might have several causes.
The patient should be examined after ablation for evidence of volume
overload related to irrigated ablation and diuresed as necessary.
Volume overload can be observed in patients with normal or
reduced cardiac function, perhaps due to atrial stunning. If dyspnea
persists or occurs in the absence of volume overload, a chest X-ray
should be obtained to exclude an infectious process or elevation of
the respective hemi-diaphragm. PN injury most commonly occurs
after balloon-based ablation, but can also occur after RF ablation.503
Lack of diaphragmatic movement during inspiration under fluoros-
copy (the sniff test) is diagnostic of PN injury. Right PN injury is much
more common after AF ablation and is due to ablation near the RSPV
or SVC (Figure 1). Left PN injury less commonly occurs when ablating
near the LAA. Although most cases of phrenic injury recover with
reinnervation over a 6–12 month period after ablation, permanent
diaphragmatic paralysis has been reported.
Chest pain is common after ablation; the causes include pericardi-
tis, coronary ischemia, and musculoskeletal pain. Symptoms of peri-
carditis (pleuritic chest pain) are the most common (>75% of
patients) and typically persist for up to a week postablation. In the ab-
sence of evidence of hemodynamic compromise, an ECG is of little
value. It is important to recognize that nearly all patients will demon-
strate a small pericardial effusion following AF ablation as a result of
edema. Nonsteroidal anti-inflammatory agents are recommended for
symptom control. Colchicine can also be used to treat pericardial
symptoms. Oral steroids should be avoided after catheter ablation
unless pericardial symptoms persist or are recurrent. Chest pain that
is associated with ECG changes or that occurs with exertion should
prompt evaluation of coronary ischemia. In particular, if ablation has
been performed inside the CS to target the epicardial portion of the
mitral isthmus, or for isolation of a CS tachycardia, circumflex artery
stenosis should be considered.923
Any unexplained hypotension during or following ablation should
be evaluated promptly. Transthoracic echocardiography or ICE (if
during ablation) should be performed urgently to exclude pericardial
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effusion or cardiac tamponade. A complete blood count should be
performed to exclude bleeding or infection.
Fever might occur early after ablation. We should exclude infec-
tious sources such as a urinary tract infection related to bladder in-
strumentation or pneumonia related to intubation. Low-grade fever
might also be related to pericarditis. In addition, fever might be the
first marker of an impending AEF formation. Chest imaging should be
considered if fever persists, an AEF is suspected, and no other clear
infectious source is identified.
Any neurological symptoms occurring shortly after ablation should
be taken seriously, with brain imaging performed to exclude an em-
bolic event. Migraine-like signs and symptoms have been reported
and are most commonly benign and are attributed to the residual
ASD following transseptal puncture. As noted above, an AEF might
also present with neurological symptoms. It is also important to rec-
ognize that an AEF might present as a neurological event and there-
fore must be considered the differential diagnosis of neurological
symptoms that develop post AF ablation.
Symptoms of pericarditis typically persist up to a week after abla-
tion (Table 5). If symptoms persist for >1 week or are associated with
lightheadedness or shortness of breath, further evaluation is war-
ranted. Groin pain that persists past 7 days or is getting worse should
prompt a physical exam and vascular ultrasound to exclude femoral
access complications. A persistent nagging dry cough might also be
observed for up to 6 weeks after ablation. This complication is more
common with CB than with RF ablation and is likely related to direct
....................................................................................................................................................................................................................
Table 5 Signs and symptoms following AF ablation
Differential Suggested evaluation
Signs and symptoms of complications within a month postablation
Back pain Musculoskeletal, retroperitoneal hematoma Physical exam, CT imaging
Chest pain Pericarditis, pericardial effusion, coronary sten-
osis (ablation related), pulmonary vein sten-
osis, musculoskeletal (after cardioversion),
worsening reflux
Physical exam, chest X-ray, ECG, echocardio-
gram, stress test, cardiac catheterization,
chest CT
Cough Infectious process, bronchial irritation (mechan-
ical, cryoballoon), pulmonary vein stenosis
Physical exam, chest X-ray, chest CT
Dysphagia Esophageal irritation (related to transesophageal
echocardiography), atrioesophageal fistula
Physical exam, chest CT or MRI
Early satiety, nausea Gastric denervation Physical exam, gastric emptying study
Fever Infectious process, pericarditis, atrioesophageal
fistula
Physical exam, chest X-ray, chest CT, urinalysis,
laboratory blood work
Fever, dysphagia, neurological symptoms Atrial esophageal fistula Physical exam, laboratory blood work, chest
CT or MRI; avoid endoscopy with air
insufflation
Groin pain at site of access Pseudoaneurysm, AV fistula, hematoma Ultrasound of the groin, laboratory blood
work; consider CT scan if ultrasound
negative
Headache Migraine (related to anesthesia or transseptal ac-
cess, hemorrhagic stroke), effect of general
anesthetic
Physical exam, brain imaging (MRI)
Hypotension Pericardial effusion/tamponade, bleeding, sepsis,
persistent vagal reaction
Echocardiography, laboratory blood work
Hemoptysis PV stenosis or occlusion, pneumonia Chest X-ray, chest CT or MR scan, VQ scan
Neurological symptoms Cerebral embolic event, atrial esophageal fistula Physical exam, brain imaging, chest CT or MRI
Shortness of breath Volume overload, pneumonia, pulmonary vein
stenosis, phrenic nerve injury
Physical exam, chest X-ray, chest CT, labora-
tory blood work
Signs and symptoms of complications more than a month postablation
Fever, dysphagia, neurological symptoms Atrial esophageal fistula Physical exam, laboratory blood work, chest
CT or MRI; avoid endoscopy with air
insufflation
Persistent cough, atypical chest pain Infectious process, pulmonary vein stenosis Physical exam, laboratory blood work, chest X-
ray, chest CT or MRI
Neurological symptoms Cerebral embolic event, atrial esophageal fistula Physical exam, brain imaging, chest CT or MRI
Hemoptysis PV stenosis or occlusion, pneumonia CT scan, VQ scan
AF, atrial fibrillation; ECG, electrocardiogram; CT, computed tomography; MRI, magnetic resonance imaging; VQ, ventilation-perfusion.
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bronchial or lung injury. This type of cough is generally treated with
antitussives and will typically subside over 4–6 weeks.
Some patients, particularly those with a history of migraines, might
experience migraine headaches in the first few weeks after abla-
tion.924,925 These headaches might be related to the residual ASD
present after transseptal puncture and will typically improve over
several weeks. Hemoptysis is rare but might result from pneumonia
or pulmonary infarction due to an occluded PV, typically occurring
3–6 months after ablation. Dysphagia in the first days after ablation is
most likely related to irritation from transesophageal echocardiog-
raphy or intubation. If dysphagia persists, then imaging (chest CT or
MRI) should be performed to exclude an AEF (see late complica-
tions). The differential diagnosis of dyspnea occurring early after abla-
tion should include volume overload, pneumonia, or PN injury as
outlined above. A chest roentgenogram should be obtained. If symp-
toms persist with a normal chest roentgenogram, we should also
consider PV stenosis (see late symptoms, below). Vagal denervation
of the esophagus or stomach can occur after ablation due to ablation
lesions placed in the vicinity of the esophagus, particularly if extensive
ablation is performed along the LA posterior wall.536,926 Symptoms
can include nausea and early satiety. Patients should be advised to eat
small, frequent meals. Symptoms will typically improve over 4–
6 weeks. If symptoms are profound or persist, a gastric emptying
study can be diagnostic. Pain at the site of sheath insertion can result
from an pseudoaneurysm, an AV fistula, or a hematoma. Evaluation
usually starts with a vascular ultrasound. Bloodwork and a CT scan
might be appropriate.
Signs and Symptoms of Complications More Than a
Month Postablation
Late symptoms of dysphagia and/or fever, particularly in the presence
gastrointestinal bleeding or any neurological symptoms, should
prompt an urgent evaluation for an AEF, a rare but potentially lethal
complication after AF ablation (see Section 10).341,417,866,910 If AEF is
suspected, esophagogastroduodenoscopy should not be performed,
because increased pressure in the esophagus can lead to the intro-
duction of air into the LA and stroke. Imaging with CT or MR is pre-
ferred, with the presence of air in the mediastinum or LA considered
diagnostic. Although barium should not be introduced into the
esophagus, a small amount of water-soluble contrast can help identify
the location of the fistula. The recommended treatment for AEF at
any stage is surgical exploration and resection of the fistulae, typically
requiring resection of the involved esophagus and repair of the pos-
terior LA wall with a pericardial patch. There have been reports of
treatment of early fistulae with covered esophageal stents; however,
surgical treatment is generally preferred. A persistent cough
>6 weeks after ablation, particularly if associated with atypical chest
pain, recurrent pneumonia or hemoptysis, should prompt an evalu-
ation for PV stenosis.927,928 A chest roentgenogram might also show
evidence of atelectasis or infiltrate localized to one lobe of the lung,
which is typically related to focal pulmonary edema. Many patients
have received repeated courses of antibiotics for lung infection be-
fore the correct diagnosis is reached. If PV stenosis is suspected, a
chest contrast CT angiogram or MR angiogram should be performed
to examine PV anatomy and exclude PV stenosis or occlusion. If PV
stenosis or occlusion is detected, a ventilation or perfusion scan is
typically performed to quantify lung perfusion. Referral to a center
with expertise in PV stenting should be recommended early in the
course of PV stenosis, because dilatation is more difficult and has a
higher incidence of pulmonary hypertension, lung infarct, and hemop-
tysis once high grade stenosis has occurred (see Section 10:
Complications). Hemoptysis should trigger an evaluation for PV sten-
osis and usually indicates the presence of complete branch or PV oc-
clusion. Other late complications include a stroke or embolic event
related to recurrent AF or deep vein thrombosis or pulmonary em-
bolus related to femoral vein instrumentation. These complications
are uncommon because anticoagulation is typically reinstated after
ablation.
ECG Monitoring Pre- and Postablation
Arrhythmia monitoring is an important component of the initial
evaluation of patients who are to undergo catheter ablation proced-
ures for AF. Prior to undergoing a catheter ablation procedure, it is
important to confirm that a patient’s symptoms result from AF and
to determine whether a patient has paroxysmal or persistent AF.
The choice of ablation technique, expectations with respect to the
procedure’s outcome, anticoagulation strategies employed, and the
need for TEE prior to the procedure might be impacted by the accur-
ate characterization of the AF type and burden. Preprocedure ar-
rhythmia monitoring is also useful to determine whether a patient
has evidence of regular supraventricular tachycardia that degenerates
into AF as a triggering mechanism or has a pattern of repetitive “focal
firing,” characterized by the presence of frequent atrial premature
beats (>1000 per 24 hours) with frequent rapid salvos of nonsus-
tained AT.458 Focal AF is characterized by localized triggers arising
from the PVs.929 Either of these triggering patterns of AF initiation
identifies a patient in whom a more limited ablation, targeted at only
the triggering arrhythmia focus or PV(s) might be appropri-
ate.406,458,930 An assessment of the adequacy of heart rate control is
particularly important in patients with depressed left ventricular func-
tion who might show evidence of a reversible tachycardia-induced
cardiomyopathy.234
ECG monitoring also plays an important role in the follow-up after
an ablation procedure. Early recurrences of AF are common during
the first 3 months following a catheter ablation procedure.931,932 For
this reason, arrhythmia monitoring to assess the efficacy of catheter
ablation is typically delayed for at least 3 months following catheter
ablation unless required to evaluate arrhythmia symptoms during the
early postablation period. However, recurrences particularly after
the first month following an ablation procedure are predictive of later
recurrence of AF, and therefore monitoring may be used to identify
patients at higher risk of needing a second ablation procedure or on-
going AAD therapy.272,329,933,934,935
The two main reasons to perform arrhythmia monitoring follow-
ing catheter ablation are clinical care and as part of a clinical research
trial. From a purely clinical perspective, arrhythmia monitoring is use-
ful to determine whether a patient’s complaints of palpitations result
from recurrent AF or other ATA. Complaints of palpitations often
result from atrial or ventricular premature beats and are not an ac-
curate predictor of recurrent AF.57,936 Arrhythmia monitoring can
also be of value in asymptomatic patients and can influence decision
making regarding anticoagulant therapy after ablation. Multiple stud-
ies have demonstrated that asymptomatic AF commonly occurs in
Guidelines e63
Downloaded from https://academic.oup.com/europace/article-abstract/20/1/e1/4158475
by Erasmus University Rotterdam user
on 29 January 2018
patients following catheter ablation.56,57,63,413,442,936,937,938 Detection
of these asymptomatic episodes of AF impact the characterization of
the procedure as “successful.” Arrhythmia monitoring is an essential
component of clinical trials aimed at assessing the outcomes of cath-
eter ablation procedures and should be incorporated into all clinical
trials designed to assess the efficacy of AF catheter ablation tools and
techniques. The suggested monitoring strategies and minimum stand-
ards to be used as part of clinical trials are discussed in Section 13:
Clinical Trial Design. These strategies and standards can be useful in
tracking the outcome of clinical care when assessing an institution’s
performance standards related to success and complications of AF
ablation procedures. However, it is recognized that clinical endpoints
and clinical trial secondary endpoints for defining success can include
the elimination of symptomatic AF and control of AF with previously
ineffective AADs after the AF ablation procedure.
Available Methods for Arrhythmia
Monitoring
Use of ECG monitoring tools is essential to assess AF ablation suc-
cess, and the monitored results can have important implications in
terms of clinical care and research outcomes. Arrhythmia monitoring
can be performed with the use of noncontinuous or continuous ECG
monitoring tools (Table 6). The choice of either method depends
on individual needs and the consequences of arrhythmia
detection. More intensive monitoring is associated with a greater like-
lihood of detecting both symptomatic and asymptomatic
AF.57,414,937,938,939,940,941,942,943,944 The proportion of asymptomatic
compared with symptomatic events might be higher after AF abla-
tion; two studies reported that the proportion of AF events that
were asymptomatic was 11%–35% prior to and 53%–65% after abla-
tion.63,945,946 Another study reported that for patients in sinus
rhythm, 53.8% of AF episodes were asymptomatic, with an increase
in asymptomatic episodes changing from the acute to the chronic
period after ablation, demonstrating that AF success cannot be based
on the absence of symptoms alone.936
The identification of AF and the assessment of AF burden with
intermittent monitoring have been shown to depend on a patient’s
actual AF burden and improve with an increasing frequency or dur-
ation of intermittent monitoring.943,947,948,949 Conversely, the more
complex and longer the method of monitoring used, the lower the
patient compliance.
....................................................................................................................................................................................................................
Table 6 Types of ambulatory cardiac monitoring devices
Type of recorder Typical
monitoring
duration
Continuous
recording
Event
recording
Auto
trigger
Unique features
Holter monitor 24–48 hours,
approximately
7–30 days
Yes Yes N/A Short term, provides quantitative data on arrhyth-
mia burden
Patch monitor 1–3 weeks Yes Yes N/A Intermediate term, can provide continuous data for
up to several weeks; improved patient compli-
ance without lead wires
External loop recorder 1 month Yes Yes Variable Good correlation between symptoms and even
brief arrhythmias
External nonloop recorder Months No Yes No May be used long term and intermittently; will not
capture very brief episodes
Smartphone monitor Indefinite No Yes No Provides inexpensive long-term intermittent moni-
toring; dependent on patient compliance; re-
quires a smartphone
Mobile cardiac telemetry 30 days Yes Yes Yes Real time central monitoring and alarms; relatively
expensive
Implantable loop recorder Up to 3 years Yes Yes Yes Improved patient compliance for long-term use;
not able to detect 30-second episodes of AF due
to detection algorithm; presence of AF needs to
be confirmed by EGM review because specificity
of detection algorithm is imperfect; expensive
Pacemakers or ICDs
with atrial leads
Indefinite Yes Yes Yes Excellent AF documentation of burden and trends;
presence of AF needs to be confirmed by elec-
trogram tracing review because specificity of de-
tection algorithms is imperfect; expensive
Wearable multisensor
ECG monitors
Indefinite Yes Yes Yes ECG 3 leads, temp, heart rate, HRV, activity track-
ing, respiratory rate, galvanic skin response
AF, atrial fibrillation; ICD, implantable cardioverter defibrillator; ECG, electrocardiogram; HRV, heart rate variability.
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Traditional AF detection tools for intermittent monitoring after
AF ablation include scheduled or symptom-initiated standard ECGs,
Holter monitors, patient-activated and automatically activated full
disclosure external loop recorders, and transtelephonic recordings.
More recently, implanted loop recorders and external recordings
with wireless connection via smartphone applications have been
used for longer-term monitoring to detect AF after ablation.
The intermittent, scheduled use of continuous short-term ECG
monitors after AF ablation has utilized traditional Holter monitors
and more recently patch ECG monitors. Holter monitors use single-
or multi-lead external recorders connected via wires to small record-
ing devices. Typical Holter monitors record 2 or 3 channels for 24–
48 hours, but some can record continuous 12-lead ECGs or for peri-
ods of 7–30 days. Patients can record symptoms on a diary and/or by
activating an event button. Because Holter monitors are analyzed by
trained technicians and are read by experienced physicians, these
approaches might represent the standard monitoring method against
which other methods should be compared. Newer wearable patch
ECG monitors record from closely spaced electrodes, removing the
need for wires and typically generating up to 2 channel recordings.
These are water resistant, wearable for up to 30 days, and have
enjoyed superior patient acceptance over conventional wired moni-
tor systems. Symptoms can be recorded by an event button. Future
devices are being developed with multiple sensors that can record
body temperature, activity, respiratory rate, and galvanic skin
responses.
Patient- or event-activated external loop recorders can be used
for longer or intermediate duration monitoring, typically over weeks
to months.254 These memory loop recorders can be programmed to
record ECGs for seconds to minutes before and after the detection
of an arrhythmia or a patient-triggered event and thus can detect and
correlate rhythms with even brief symptoms. External loop re-
corders should be worn continuously to capture such events and
typically are connected via wires to skin electrodes.
Nonloop external event recorders can be used for intermittent
transtelephonic recordings that can be initiated by patients with
symptoms or on a schedule. These recorders are applied to the chest
or held by hand. Older conventional transtelephonic monitors
required the recording of rhythm strips while connected in real time
over the phone, but more recent monitors allow the storage of
rhythm strips with transmission at a later time. Event recording
occurs after an event is detected by the patient; the diagnostic yield is
dependent on the recognition of symptoms, the duration of symp-
tomatic episodes, or on scheduled or more frequent use to detect
asymptomatic arrhythmias.
More recently, smartphone-based ECG monitors have been de-
veloped that can be helpful for long-term intermittent surveil-
lance.950,951 Recordings from electrodes embedded in a smartphone
case or a card are connected via low-energy Bluetooth technology to
smartphone applications. These monitors are nonlooping; patients
can record during symptoms that persist long enough to activate the
application. Recordings are stored and can be transmitted via wireless
or cellular networks. In a study conducted after AF ablation, a
smartphone-based single-lead system was compared to transtele-
phonic monitor ECGs with 100% sensitivity and 97% specificity in de-
tecting AF or flutter.951 Multi-lead and reconstructed 12-lead
recording devices are being developed, but have not been studied in
the setting of AF ablation. Continuous ECG monitoring technology
using such applications are also in development.
Mobile cardiac outpatient telemetry devices provide real-time
monitoring and wireless transmission to trained personnel at a cen-
tral monitoring center with activation of alarms to caregivers for
specified significant arrhythmias. These monitors are typically worn
continuously for a period of 2–4 weeks and can record 1–3 leads
connected to a small device via conventional wires or embedded in a
patch. The advantage of these systems is their ability to capture and
identify potentially severe or significant arrhythmias in an immediate
or timely fashion.
Continuous ECG monitoring for longer periods (1–3 years) can be
facilitated with the use of implantable devices. Long-term subcutane-
ous implantable loop monitors can facilitate continuous AF monitor-
ing based on R-R interval analysis over a time period of up to
3 years.952,953 These types of continuous ECG monitoring devices
have been used in several studies to evaluate the results of surgical or
catheter AF ablation.127,607,938,953,954,955,956,957,958,959,960,961 Although
implantable subcutaneous monitors hold promise for the determin-
ation of AF burden in the long term, AF detection algorithms are pri-
marily based on R-R interval regularity, and important limitations
include reduced specificity due to undersensing of beats, oversensing
of myopotentials, and irregular atrial and ventricular premature beats,
as well as limited memory resulting in electrograms not being retriev-
able to verify the correct rhythm diagnosis.941,944,962 Nevertheless,
implantable continuous monitors can ameliorate patient compliance
issues and provide an assessment of long-term AF burden and late re-
currences, including asymptomatic episodes that might have implica-
tions for continuation of anticoagulation. In one study after
concomitant surgical ablation, ILRs compared with conventional
Holter monitoring facilitated more follow-up antiarrhythmic manage-
ment, including cardioversions and catheter ablation procedures,
which were associated with a trend toward higher sinus rhythm rates
at 1 year.942
Implantable pacemakers or defibrillators with atrial leads allow the
burden of AF to be assessed by tracking the number and duration of
mode-switch episodes.963,964 These devices can also assess long-
term AF burden, burden trends, and late or asymptomatic recur-
rences.940,965,966 The ability to record intracardiac atrial electrograms
provides excellent sensitivity and specificity for the diagnosis of atrial
arrhythmias, especially with durations exceeding a few
minutes.937,967,968
Follow-up and Monitoring Guidelines for
Routine Clinical Care
There is a consensus among the writing group members that all pa-
tients who undergo catheter ablation of AF, regardless of whether
they are enrolled in a clinical trial, should be seen in follow-up a min-
imum of 3 months following the ablation procedure. There is also
consensus that all patients who undergo catheter ablation should be
seen by some type of physician (family physician, internist, cardiolo-
gist, or electrophysiologist) on an annual basis thereafter. These on-
going interactions with the medical profession allow the patient’s
clinical status to be evaluated, including an assessment of the pres-
ence or absence of AF as well as their stroke risk profile and anticoa-
gulation needs. These interactions also provide an opportunity to
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focus on the treatment of associated diseases and lifestyle modifica-
tions. These recommendations are slightly modified from the previ-
ous edition of this document, which advised that all patients who
undergo catheter ablation of AF, regardless of whether they are en-
rolled in a clinical trial, should be seen in follow-up at a minimum of
3 months following the ablation procedure, and then every 6 months
for at least 2 years. A 12-lead ECG was recommended at all follow-
up visits and more intense monitoring driven mainly by the clinical im-
pact of AF detection with strict monitoring necessary (suspected
rate-related cardiomyopathy). This modification of our writing group
recommendations reflects, in part, data from real life clinical prac-
tice.969 This European study revealed that one-third of the 12-month
follow-up evaluations were performed by telephonic contact, only
87.2% of the patients had at least one ECG during the follow-up, and
the patients with continuous monitoring of >_ 24 hours (Holter- or
implanted monitoring systems) represented only 57.4% of the
population.
Explanations of this gap between prior expert consensus recom-
mendations and routine clinical practice might reflect the current dis-
connect between indications for catheter ablation and clinical
outcomes of the procedure. Another factor can be cost. On one
hand, the main indication for catheter ablation is symptomatic AF and
decisions regarding continuation of anticoagulation therapy should
be based on the patient’s risk factors for stroke and not on the pres-
ence of or type of AF. At the same time, transtelephonic or long-
term monitoring is at times recommended after ablation to capture
even asymptomatic episodes of AF to evaluate the need to continue
anticoagulation. The majority of writing group members do not be-
lieve that data currently exist to support this common practice of
making decisions regarding anticoagulation based on the presence or
absence of AF (see Section 7).
A significant amount of information has accumulated showing that
cardiac risk factors such as obesity, sleep apnea, and hypertension are
associated with structural and electrical remodeling of the atria,
which forms the substrate leading to AF development and progres-
sion (see Section 3). The recommended indefinite annual follow-up
visits with a health care professional allow for the evaluation and
treatment of associated diseases and lifestyle modification rather
than monitoring of the rhythm itself.
Early Recurrence After Ablation
Definition and Incidence
Early recurrences of AF after AF ablation has been defined as any re-
currence of AF > 30 seconds during the first 3 months of follow-up.
Late recurrence has been defined as any recurrence of
AF > 30 seconds between 3 and 12 months after AF.141,142,143 In using
the term early recurrence of AF (ERAF) it is recognized that the early
recurrence might be AFL or AT. Although we considered defining a
new term, early recurrence of ATAs, post-AF ablation, for simplicity we
have employed the term early recurrence of AF. Throughout the docu-
ment and this section of the document, we note that recurrences can
present in the form of AF, flutter, or tachycardia.
Early recurrences of AF after RF catheter ablation have been re-
ported in up to 50% of patients within the first 3 months of AF abla-
tion.253,329,436,684,932,935,970,971,972 Because these arrhythmias do not
definitively indicate therapy failure over the long term (only half of
these patients will manifest later recurrences), this period is also
referred to as the blanking or therapy stabilization period.935,973 It is
also important to recognize that the later AF recurrences are
observed during the blanking phase, the lower the chance of long-
term success.935
Causes of Recurrences
The pathophysiological mechanisms of these early recurrences are
attributed to various mechanisms: primarily incomplete isolation of
the PVs,973,974 acute inflammatory changes owing to energy deliv-
ery,755 recovery of conduction in a previously isolated PV,448,622,975
modification of the ANS, changes in the atrial substrate, and delayed
effect of RF ablation due to lesion consolidation.257,258
Early Recurrence as a Predictor of
Failure
The occurrence of atrial arrhythmias early after ablation does not ne-
cessarily indicate treatment failure later during follow-up.974
Nevertheless, early recurrences have been shown to predict arrhyth-
mia recurrences late after catheter ablation of AF in some
patients.260,329,935,976,977,978
Management of early recurrences is controversial and has been
treated by AADs, corticosteroids, early cardioversion, or repeat
catheter ablation.
Antiarrhythmic Drugs
Because early AF recurrence usually peaks within the first few weeks
following PVI, the temporary routine administration of AADs in the
immediate postablation period has been proposed as a potential pre-
ventive strategy.1,979 Although the true efficacy of this approach is un-
known, studies have suggested that transient AAD use does not
prevent late arrhythmia relapses.935,980 The 5A study randomized
110 consecutive patients with PAF undergoing ablation to empirical
AAD therapy vs no AAD therapy for the first 6 weeks after RF cath-
eter ablation.980 The authors noted a significantly lower incidence of
clinically significant atrial arrhythmias (AF > 24 hours or associated
with severe symptoms), cardioversions, and arrhythmia-related hos-
pitalization during the 6-week treatment period (13% vs 28% in the
AAD vs non-AAD group; P <.05); however, there was no difference
in the 6-month freedom from recurrent AF (72% vs 68%; P= .84).980
As noted earlier in this document, the writing group also recognizes
that the usefulness of initiation or discontinuation of AAD therapy
during the postablation healing phase in an effort to improve long-
term outcomes is unclear (Class IIb, LOE C-LD, Table 3).
Corticosteroids
Given the association between AF recurrence and RF-induced inflam-
mation, it has been postulated that empiric pretreatment with high-
dose corticosteroids could reduce the incidence of ERAF and long-
term recurrence. One study examined this hypothesis in a population
of 125 patients undergoing PV ablation for symptomatic PAF.981
Corticosteroid therapy resulted in a significant reduction in the early
AF recurrence rate (27% vs 49% at 1 month with corticosteroids vs
placebo, respectively), which was driven by a marked reduction in
the immediate recurrence rate (7% vs 31% within 72 hours, respect-
ively). Interestingly, despite the lack of difference in the rate of recur-
rence between 3 and 30 days (20% vs 18% in the corticosteroid and
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placebo groups, respectively), the long-term freedom from AF with-
out any AAD was significantly higher in the corticosteroid group
(85% vs 71% freedom from AF at 14 months, respectively).
Another study was published recently to evaluate the efficacy of
corticosteroids to prevent early and late recurrence. The authors en-
rolled 138 patients who were randomly assigned to two groups (a
steroid group and a control group). The primary endpoint was ERAF
during the blanking period (3 months postablation). During the blank-
ing period, 51 of the 138 (37.0%) patients experienced ERAF after AF
ablation. The steroid group had a lower rate of ERAF than the con-
trol group (15 of 64 [23.4%] vs 36 of 74 [48.6%]; P =.003). There was
no difference between the two groups in late recurrence during a 24-
month follow-up (log-rank test, P= .918). In a multivariate analysis,
short-term steroid therapy was independently associated with a
lower rate of ERAF during the blanking period (adjusted odds ratio
[OR] 0.45; 95% CI 0.25–0.83; P= .01). The authors concluded that
periprocedural short-term moderate intensity steroid therapy
reduces early recurrence of ATA (approximately 3 months) after
catheter ablation of AF; however, it is not effective in preventing late
(3–24 months) AF recurrence.982
Additional information regarding optimum dosing, and safety and
tolerability of corticosteroid therapy post-AF ablation is needed be-
fore it can be recommended.
Colchicine
Colchicine, an anti-inflammatory agent, has been used post-AF abla-
tion both to reduce pericarditis-related pain, but also to reduce AF.
Colchicine has been shown to reduce postoperative AF following
cardiac surgery,983,984 and has also been studied following AF abla-
tion. The first major study was a prospective randomized trial in 161
patients undergoing ablation of PAF. Patients were randomized to re-
ceive colchicine 0.5 mg bid or placebo.985 At 3 months of follow-up,
AF recurred in 34% of the placebo patients vs 16% of the patients
treated with colchicine. Colchicine led to a reduction in C-reactive
protein and IL-6. A subsequent randomized study of 233 patients
with PAF demonstrated a long-term recurrence rate of 31% among
the patients treated with colchicine vs 49% among the placebo pa-
tients.986 A survey of the writing group members shows that 6% of
the members routinely administer colchicine for 1–3 months posta-
blation. Ninety-four percent of the writing group members do not
routinely administer colchicine.
Cardioversion
Three studies examined long-term outcomes of patients who
required cardioversion for early recurrence of ATAs following RF
catheter ablation. One study examined 55 patients who underwent
cardioversion 2.7 ± 1.4 months after the index procedure.987 Sinus
rhythm was restored in 39 of 45 patients with persistent AF (87%)
and 9 of 10 patients (90%) with AFL (P= .77). After a mean follow-up
of 15 ± 8 months postablation, only eight patients (15%) remained
completely free of AF in the absence of AAD therapy. An additional
11 patients (20%) achieved partial success, as defined by a >_ 90% re-
duction in arrhythmia burden, whereas the remaining 36 patients
(65%) were considered to have failed ablation. Surprisingly, no differ-
ences were noted in acute efficacy or long-term outcomes based on
timing of cardioversion (e.g., cardioversion performed during or fol-
lowing the 90-day blanking period).987 Another study reported on
outcomes of 384 consecutive patients undergoing AF ablation, of
whom 93 had cardioversion at a mean of 88 ± 72 days after ablation
(74 for AF, 19 patients for AFL).988 A mean of 16 ± 10 months after
the index ablation procedure and 15 ± 10 months after cardiover-
sion, 25 of 93 patients (27%) remained free from recurrent atrial ar-
rhythmias in the absence of AAD therapy. In contrast to the earlier
study, the patients in the more recent study who underwent early
cardioversion (within 30 days of arrhythmia recurrence) were more
than 20 times more likely to remain in sinus rhythm than patients
who were cardioverted after 30 days, regardless of the timing of re-
currence or whether concomitant AAD therapy was used. In those
with a delayed cardioversion, only 2 of 47 patients (4%) remained in
sinus rhythm without AAD therapy. In the multivariate analysis, the
time from atrial arrhythmia recurrence to cardioversion was the only
independent predictor of maintenance of sinus rhythm after a single
ablation procedure in the absence of an AAD (P <.001). Interestingly,
these two studies reported similar outcomes for patients who under-
went cardioversion after 30 days, suggesting that if a benefit is to be
gained from early cardioversion, it must be performed within the first
month after arrhythmia recurrence. A larger study included consecu-
tive catheter ablations for AF.989 Prompt electrical cardioversion was
performed if AF or AFL was confirmed and sustained, using a stand-
ard approach with the aim of performing cardioversion within
24 hours of arrhythmia onset. Of the ablations performed, a total of
515 (29%; age: 65.6 ± 11.2 years; male: 57.9%) developed AF or AFL
that required cardioversion. The majority of these arrhythmias first
occurred in the initial 90 days (63.7%) postablation. During this
period, 62.8% were being treated with an AAD. Only 25.1% were
using an AAD at 3 months. The majority of patients postablation
(75.6%) who experienced AF or AFL within the first 90 days after ab-
lation were in sinus rhythm, requiring no AAD at 1 year. Further, 48%
of those patients with the first recurrence from 90 to 180 days were
in sinus rhythm with no AAD at 1 year. Thus, it appears that patients
undergoing their first cardioversion early after ablation (<3 months)
were more likely to remain free from arrhythmia at 1 year (75%).989
An aggressive approach with early electrical cardioversion after LA
catheter ablation appears important to maintain sinus rhythm in
order to minimize late arrhythmia recurrences, reduce chronic AAD
use, and prevent reablation procedures. When comparing an aggres-
sive rhythm control strategy with amiodarone and repetitive use of
cardioversion vs amiodarone and infrequent cardioversion in surgical
RF ablated patients, systematic and repetitive use of cardioversion re-
sulted in a significantly higher portion of patients in sinus rhythm dur-
ing follow-up.990 Although the development of a persistent atrial
arrhythmia post-AF ablation is a sign of poor prognosis, it is currently
recommended to cardiovert those patients preferably within 30 days
of arrhythmia onset. Pathophysiological findings supporting rapid
functional and structural remodeling during AF encourage the clin-
ician to cardiovert persistent arrhythmias early post-AF ablation.
However, the clinical data available supporting this approach remain
limited. The number of electrical cardioversions needed to treat re-
petitive persistent AF recurrences postablation of persistent AF was
investigated.991,992 In this small trial of 40 patients, the number of
electrical cardioversions >_3 was the only independent predictor of
an ablation failure. Therefore, currently, reablation should be con-
sidered in clinical practice after two cardioversions have been per-
formed, because of the high likelihood of recurrent arrhythmias.
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Early Reablation
Performance of early reablation reduces the incidence of further re-
currences, but the overall number of procedures is higher in the
medium-term follow-up. Two studies evaluated the use of early rea-
blation on long-term freedom from AF in patients with
ERAF.141,142,143,989,993 In 302 consecutive patients with RF ablation
for medically refractive AF, 151 experienced an ERAF, 61 of whom
underwent reablation within the first month (e.g., early reablation
group). The remaining 90 patients had a repeat procedure at least
1 month after the index ablation. During a mean follow-up of
11 ± 11 months, patients with early reablation had a lower rate of re-
currences (51% vs 91%, P <.0001), symptomatic improvement, and
improved QOL. However, the total number of procedures required
over the entire duration of follow-up was greater in the patients who
underwent early reablation (2.5 ± 0.7 vs 2.2 ± 0.6, P= .02).993 The
STOP-AF trial randomized 245 patients with PAF to medical therapy
versus CB-based PV ablation. Patients were followed for 12 months.
Of the 163 patients randomized to cryoablation, 84 patients experi-
enced ERAF (51.5%). The only significant factor associated with
ERAF was male sex (HR 2.18; 95% CI 1.03–4.61; P= .041). Late recur-
rence was observed in 41 patients (25.1%), and was significantly
related to ERAF (55.6% late recurrence with ERAF vs 12.7% without
ERAF; P <.001). Among the patients with ERAF, only current tobacco
use (HR 3.84; 95% CI 1.82–8.11; P <.001) was associated with late re-
currence. Conversely, early reablation was associated with greater
freedom from late recurrence (3.3% late recurrence with early rea-
blation vs 55.6% without; HR 0.04; 95% CI 0.01–0.32;
P= .002).141,142,143 Although the clinical benefit of early reablation
was demonstrated, the first month following the procedure might
not be the optimal time for a repeat intervention. On the other hand,
up to 60% of the patients experiencing this event within the first
months postablation will not have any further arrhythmias during
long-term follow-up.253,436,970,971,994 Therefore, reablation is not rec-
ommended in an ERAF that might be a transient phenomenon.2
Conclusions
Theoretically, aggressive treatment of early recurrences of AF might
prevent electrical and structural remodeling and improve long-term
outcome. Larger studies with more reliable follow-up methods are
needed to clarify the relevance and optimal management of early
recurrences.
Atrial Tachycardias After AF Ablation
ATs of new onset make up to 50% of all arrhythmias observed fol-
lowing catheter-based ablation of AF.253,436,507,508,622,623,624,
625,630,870,871,995,996,997,998,999,1000,1001,1002 Most of these tachycardias
originate in the LA, although RA cavotricuspid isthmus (CTI)-depend-
ent flutters might also occur. Patients with a regular AT of new onset
might complain of worsening symptoms due to a faster mean ven-
tricular rate (frequently 2:1 ventricular response) than that during AF
preablation. Rhythm control is often difficult with AADs.
The mechanisms underlying regular LA tachycardias following AF
ablation include focal microreentrant tachycardias originating from
reconnected PV ostia or macroreentrant tachycardias around ana-
tomic obstacles or scar from intrinsic LA disease or prior ablation(s)
(Figure 5).447,508,933,998 Occurrence of early AT within 3 months after
ablation predicts occurrence of both late AT and AF.1003,1004,1005
However, because up to 49% of ATs resolve with time, ablation
should not be undertaken for early AT occurrence unless symptoms
cannot be controlled.1003 Initial treatment should include electrical
cardioversion and AADs. Because Vaughan Williams Class Ic antiar-
rhythmic agents promote slow conduction that can facilitate macro-
reentrant tachycardias, Class III antiarrhythmic agents (dofetilide,
sotalol, or amiodarone), together with negative dromotropic agents,
are typically preferred. For those with intolerable symptoms or con-
tinued late AT recurrence, detailed activation and entrainment map-
ping of the tachycardia results in effective ablation in approximately
90% of patients.447,622,623,624,1006,1007,1008
Antiarrhythmic and Other
Pharmacological Therapy Postablation
AF recurrences during the first 3 months after ablation are rather
common. It is generally believed that the mechanisms of AF in this
setting are different from that of the patient’s clinical arrhythmia.
Acute inflammatory changes owing to energy delivery1009; modifica-
tion of the ANS with consecutive changes in the atrial substrate257;
or delayed effect of radiofrequency ablation due to lesion consolida-
tion have been considered.258 It is also suggested that AF might re-
solve completely upon resolution of the transient factors promoting
early AF recurrences. Accordingly, suppressive antiarrhythmic agents
are frequently prescribed for patients with AF recurrences during the
first 1–3 months following ablation.253,436,988,1010,1011 Because ATs
can also occur shortly after ablation, negative dromotropic agents
(beta or calcium channel blockers) are commonly continued for at
least the first month after ablation. The impact of empirical AAD
therapy for 6 weeks after AF ablation on the occurrence of AF was
investigated in several randomized studies.934,979,980 The drugs em-
ployed for this purpose vary, but most commonly are those that have
been used unsuccessfully prior to ablation; they include flecainide,
propafenone, sotalol, dofetilide, dronedarone, and amiodarone. The
short-term use of AADs after AF ablation decreased early recur-
rences of atrial arrhythmias and need for hospitalization or cardiover-
sion, but had no effect on the prediction or prevention of arrhythmia
recurrence at 6 and 12 months.934,979,980 As noted earlier in this
document, the writing group recognizes that the usefulness of initi-
ation or discontinuation of AAD therapy during the postablation
healing phase in an effort to improve long-term outcomes is unclear
(Class IIb, LOE C-LD, Table 3).
Because an inflammatory process after AF ablation can be one spe-
cific cause leading to early recurrences, the efficacy of corticosteroids
for preventing early postablation atrial arrhythmias was investigated
in several studies.981,982 The prevalence of immediate AF recurrences
(<_3 days after PVI) was significantly lower in the corticosteroid group
compared with the placebo group (7% vs 31%). However, few inves-
tigators routinely administer steroids during or following AF ablation.
The use of PPIs or H2 blockers for 1–4 weeks following ablation has
been suggested to avoid esophageal ulcerations observed on endos-
copy following AF ablation.896,897 However, there are no randomized
data available to demonstrate that this approach reduces the inci-
dence of esophageal symptoms or the development of an AEF. Early
diagnosis of AEF, with early employment of operative intervention, is
the best treatment option for AEF (please refer to Section 10 for
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more information). Attention to the control of hypertension and ad-
dressing other AF risk factors such as sleep apnea and obesity remain
an integral part of AF management after the ablation procedure.929
The impact of angiotensin-converting enzyme inhibitors and angio-
tensin receptor blockers on the long-term outcome of AF ablation
was investigated in a prospective registry of consecutive patients
undergoing catheter ablation of paroxysmal or persistent AF.334 In
that study, however, modulation of the renin-angiotensin aldoster-
one system did not appear to affect maintenance of sinus rhythm
after catheter ablation of AF. Thus, the hypothesis that so-called
medical upstream therapy can positively influence the reverse atrial
remodeling after catheter ablation of AF remains unproven.
Later-Term Repeat Ablation Procedures
Recurrences of AF (or AT) after index AF ablation procedures lead
to repeat ablation in a considerable number of patients. Recent data
show a repeat procedure rate of 15% and 50% depending on the dur-
ation of follow-up and patient characteristics.1012 Since early recur-
rences of AF and/or the development of AT are common during the
first 2–3 months after AF ablation and might resolve spontaneously,
repeat ablation procedures should be deferred for at least 3 months
following the initial procedure if possible. Nevertheless, such early re-
currences are associated with decreased long-term success of the
procedure.260 It is also recognized that some patients will develop
highly symptomatic early recurrence of atrial arrhythmias that cannot
be controlled with antiarrhythmic therapy or slowed with rate con-
trolling medications and are best managed with a reablation proced-
ure within the first 3 months post-AF ablation. Most studies have
reported that patients who fail an initial attempt at ablation and
undergo a repeat ablation procedure demonstrate resumption of
electrical conduction of the previously isolated PVs rather than new
arrhythmogenic foci from nontargeted PVs or outside of the
PVs.263,440,446,1013 This outcome appears to be overwhelmingly the
case for the first reablation procedure, whereas in further redo pro-
cedures (e.g., second or third redo procedure) other mechanisms
also appear to play a more important role.1014
Consequently, the first step when performing a second AF ablation
procedure is to check each PV for reconduction of electrical activity.
If reconduction is found, the primary goal should be reisolation of the
PVs. If, however, there is no evidence of PV reconduction, the deci-
sion on the best ablation technique is more complex. Several targets
have been proposed in this setting, such as LA substrate mapping and
tailored ablation guided by electrogram voltage, ablation with com-
plex fractionated electrograms, ablation of provoked non-PV triggers
or sites commonly associated with non-PVs triggers such as the SVC,
or targeting of focal impulse and rotational activity mapping.
However, definitive evidence of the benefit or superiority of any of
these techniques over the others is lacking.126,223,247,257,567,1015,1016
Data on current clinical practice confirm the prevailing uncertainty
regarding the best reablation technique.540
High-dose isoproterenol infusions have been shown to be helpful
in the provocation of PV and non-PV triggers.440,1013 A recent
randomized trial showed that adenosine administration during the
ablation procedure might unmask dormant PV conduction and re-
duce the recurrence rate of the procedure, but results were not con-
firmed in another trial evaluating ATP.265,1017 The value of adenosine
administration at the time of the redo procedure to demonstrate la-
tent PV conduction has not been demonstrated.461
Autonomic Alterations
Potential side effects of AF ablation include transient and permanent
alterations in autonomic nerve activity. Transient (<6 months) eleva-
tion of heart rate, inappropriate sinus tachycardia and reduction of
heart rate variability have been observed after PVI.223,257 Others re-
ported an immediate decrease in autonomic function such as decel-
eration capacity and acceleration capacity after PVI. Some of
these changes can last for over a year.126,1016 Although most auto-
nomic alterations associated with PVI are transient and are not
associated with significant symptoms, more severe autonomic alter-
ations can occur in cases of periesophageal vagal nerve in-
jury.265,461,868,1017,1018,1019,1020 A prospective observational study
showed a high incidence (33%–48%) of transient (<6 months) new
onset alterations in esophageal motility after AF ablation.536
Although most patients recover within several months, gastric hypo-
motility can persist for over 28 months after the procedure in rare
cases.1020 A case of achalasia cardia has recently been reported to
occur after PVI.252,1021 Another study showed a 7.9% prevalence of
gastric hypomotility after high output (25–30 W) posterior LA abla-
tion. Reduction of the output to 20–25 W at sites where the ablation
line transversed the esophagus eliminated the postablation esopha-
geal hypomotility.1020 In additional to the watts used during ablation,
it is possible that both time and CF are factors that determine perie-
sophageal vagal nerve injury. However, the CF was not evaluated in
the latter study. In summary, most autonomic alterations associated
with AF ablation were self-terminating and asymptomatic. However,
severe symptomatic periesophageal vagal nerve injury can occur after
LA posterior wall ablation.
Very Late Recurrence (More Than
1 Year) After AF Ablation
Many groups have reported the incidence of very late AF recurrences
occurring up to 10 years postablation, even after an initially successful
procedure at 1 year.63,270,536,1022,1023,1024 A recent meta-analysis ana-
lyzed 19 studies including 6167 patients, describing outcomes
>_3 years after AF ablation with a mean follow-up >_24 months after
the index procedure. Single procedure and multiple procedure free-
dom from atrial arrhythmias has been reported to be 53% and 80%,
respectively, with substantial heterogeneity noted for single-
procedure outcomes.
Very late recurrences have been noted after an initial freedom
from AF at 1 year postablation, with an annual recurrence rate esti-
mated at 7.6%, reaching attrition rates of 16%–46% and 30%–54% at
5 and 10 years, respectively. Interestingly, despite the recurrence
rates, a low incidence of progression (0.3% per year) from paroxys-
mal to persistent AF as well as stroke rates <1% have been reported.
Also noteworthy is the fact that time to recurrence might influence
outcomes. Patients with very late recurrences are more likely to
have sporadic episodes and a better response to AADs and repeat
ablation procedures than those with earlier recurrences.
The most consistent predictor of late recurrence is persistent AF.
Other predictors include hypertension, age, LA size, diabetes, valvu-
lar heart disease and left ventricular dysfunction, and higher
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thromboembolic risk scores.63 Recurrences in patients undergoing
repeat ablation procedures have been noted to be due mostly to PV
reconnection. However, recent evidence pointing to the importance
of non-PV foci and gaps in prior ablation lines can also play a role. In
particular, the LAA and LA posterior wall have been shown to con-
tain significant triggers in patients with non-PAF and isolation strat-
egies are suggested to be of benefit in improving long-term
outcomes.
Section 9: Outcomes and Efficacy
Overview
AF ablation is a maturing field. Prior to the publication of the initial
consensus report in 2007, the majority of the published literature on
AF ablation consisted of uncontrolled single- and multicenter re-
ports.1 Further, there had been no standardization in the design of
clinical trials of AF ablation, and the 2007 and 2012 consensus docu-
ments were developed in part to generate standard terminology, def-
initions, and recommendations for end points, follow-up procedures,
and outcome reporting in an effort to make studies more rigorous
and consistent.1,2
Over the past 10–12 years, a large number of randomized trials
have been completed addressing various aspects of AF ablation.
Many have compared AF ablation with AAD therapy in both “first-
line” (AAD-naı¨ve patients) and “second-line” (following the failure of
1 or more drugs) settings.261,377,378,379,462,529,684,733,1025,1026,
1027,1028,1029,1030 In some cases, these trials have supported regula-
tory approval of specific ablation technologies.462,503,655,673,684,733
Some trials have compared AF ablation with other standard pharma-
cological or nonpharmacological approaches to rate con-
trol.235,236,237,390 Many other trials have compared various ablation
techniques or alternative ablation systems with each other. Table 7
provides a summary of the outcomes of a selected group of clinical
trials of AF ablation. This table includes a summary of the clinical trials
that have been performed for FDA approval, clinical trials of AF abla-
tion as first-line therapy, as well as randomized clinical trials of AF ab-
lation for PAF, persistent AF, mixed trials, and randomized trials of
AF ablation in patients with HF.
In this section, we will focus our review of this large and growing
body of literature on trials comparing AF ablation with alternative
treatment approaches—primarily AADs—for AF, to provide sup-
port for recommendations on the role of AF ablation in various pa-
tient groups. Outcomes for specific ablation systems (CBA,
rotational activity ablation, and laser balloon ablation) will also be re-
viewed. Studies comparing ablation techniques or lesion sets with
each other are primarily discussed in Section 5: Strategies,
Techniques, and Endpoints.
Previous versions of the consensus report included a section on
nonrandomized studies of AF ablation. Due to the very large number
of studies reported, the lack of standardization among them, and their
generally early time frame in the evolution of AF ablation, we will not
review that literature in the current document, and instead we refer
readers to the prior consensus documents and to a large meta-
analysis on the topic.262 Useful insights into AF ablation outcomes
outside the setting of RCTs have also been obtained from worldwide
surveys on AF ablation, and these will also be reviewed.
In addition to a broad overview of AF ablation trials among com-
monly treated patient groups, this section will also review outcomes
of AF ablation in populations not well represented in clinical trials
and with specific ablation systems. Additionally, end points beyond
maintenance of sinus rhythm of considerable interest to the field
(e.g., QOL, stroke, cost-effectiveness) will be examined.
Published Literature Review: Clinical
Trials Performed for FDA Approval
When AF ablation began, procedures were performed using stand-
ard 4 mm and later 8 mm tipped, nonirrigated RF catheters that had
been developed and approved for the treatment of other arrhyth-
mias. The first two classes of devices to seek and achieve FDA ap-
proval for ablation of AF were irrigated RF catheters and CBA
catheters (Table 7). In consultation with the FDA, the manufacturers
of these devices were required to conduct randomized trials com-
paring AF ablation to AADs and chose to evaluate patients with PAF
who had previously failed treatment with one or more drugs.
Although the two initial device approval studies had narrow entry
criteria and enrolled primarily young and healthy AF patients, they
were conducted with great rigor and contributed substantially to the
previous literature comparing ablation to AAD therapy.462,684 In
both cases, protocol-defined success with ablation (66% and 70%, re-
spectively) was much higher than with drugs (16% and 7%), and ac-
ceptable rates of serious adverse events occurred.
Given the overwhelmingly superior efficacy of AF ablation in this
patient population, ablation has become the standard of care in many
centers. Accordingly, subsequent FDA-regulated device approval
studies of novel ablation technologies have not required randomiza-
tion against AADs, because doing so would be not be feasible.
Instead, several new technologies have been either compared with a
previously approved device with the same indications for use in a
randomized, controlled noninferiority study or, in the case of a se-
cond generation RF ablation catheter, compared with predefined
performance goals in a single-arm study. Examples of this pathway in-
clude recent trials of force-sensing655,673 and the laser balloon abla-
tion system.503,673 Each of these trials met its prespecified end points,
generally confirming the safety and efficacy of AF ablation in patients
with PAF, but none demonstrated the superiority of new technolo-
gies in the full study populations. Protocol-defined success rates at
12 months in these studies ranged from 61% to 72.5% (primary ef-
fectiveness definitions were not identical across studies). Because
these studies were designed to demonstrate noninferiority to an
approved device with the same indications for use, they have been
subject to the same limitations in terms of patient population, follow-
up duration, etc., as the earlier studies.
An additional study of a phased array multielectrode RF ablation
system performed under regulatory supervision by the FDA in pa-
tients with persistent AF refractory to >_ 1 AAD has also been com-
pleted.733 In this study, patients were randomized to ablation vs
treatment with an alternative AAD or increased dose of a previously
ineffective drug and DC cardioversion. As expected, protocol-
defined success was higher following ablation at 6 months (56% vs
26%). However, the study did not meet its prespecified safety end
point, partly due to the occurrence of 4 strokes (2.9% of the patients
randomized to ablation) that mainly occurred during early
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experience with the ablation system. As a result, this system has not
been approved in the United States.
For the purpose of regulatory approval, it is expected that future
ablation technologies designed to treat PAF will continue to be com-
pared with previously approved ablation systems in randomized stud-
ies. We believe that this is appropriate, although there should be
careful consideration of the possibility of a downward “creep” in ac-
ceptable effectiveness (if each device is numerically inferior but statis-
tically equivalent to the prior comparator device). In the future, we
expect that devices designed to treat patients with symptomatic PAF
might alternatively be evaluated in nonrandomized trials, comparing
prespecified performance goals or objective performance criteria
(OPC), if uniformly established and applied. However, given the rapid
evolution of the field of AF management, it should be understood
that such performance criteria are potentially subject to change over
time. An OPC refers to a numerical target value derived from histor-
ical data from clinical studies and/or registries and can be used in a di-
chotomous (pass or fail) manner by the FDA for the review and
comparison of safety or effectiveness endpoints. Currently, no such
OPC has been validated with respect to catheter ablation of persist-
ent AF or PAF. If an OPC is employed, it is important to clarify the pa-
tient population to which it applies. It is anticipated that the patient
population should be similar to predicate patient populations.
However, in the clinical trials section of this document we have pro-
vided what we believe are acceptable OPC for AF ablation clinical
trials.
Studies seeking regulatory approval for the treatment of persistent
and long-standing persistent AF can follow one of two potential
approaches. As in the past, future studies might compare novel abla-
tion systems against medical management because, at this point, no
ablation system is expressly approved for persistent or long-standing
persistent AF in the United States. Alternatively, a novel ablation sys-
tem could be evaluated in single-arm trials with prespecified OPCs.
AF Ablation as Second-Line Rhythm
Control Therapy
At the time of this writing, at least 16 randomized clinical trials have
been completed comparing AF ablation with AADs in patients with
AF refractory to one or more AADs. Each of these trials is summar-
ized in Table 7. In addition to the trials for FDA approval listed in
Table 7, four of these trials exclusively enrolled patients with paroxys-
mal (or “early persistent”) AF, three trials enrolled only patients with
persistent AF, and three trials enrolled patients with either AF pat-
tern.261,462,684,733,1025,1026,1027,1028,1029,1030 Additional randomized tri-
als in patients with HF and persistent AF have been completed,
comparing ablation with rate control, amiodarone, or AV junction
ablation with biventricular pacing.235,236,237,390,529 The HF trials will
be reviewed in a later section of this document.
In general, the trials involving PAF focused on PVI (although ad-
junctive ablation was allowed or encouraged to varying degrees), and
reported success rates at 12 months ranged from 59%–89%. In all
cases, freedom from arrhythmia at 12 months was significantly higher
than with drug therapy, which had reported success rates of 5%–
23%. Among trials that included patients with persistent AF or com-
bined paroxysmal and persistent populations, the ablation techniques
more frequently incorporated linear lesion sets or ablation with
CFAEs. Reported success rates with ablation ranged from 59%–80%
at 6 or 12 months, whereas success rates with drug therapy ranged
from 9%–58%. In all cases, maintenance of sinus rhythm was signifi-
cantly higher with ablation.
It is difficult to directly compare adverse events from AF ablation
to those from AADs. In most of the above trials, low rates of serious
procedural complications were reported. With the exception of the
HF trials, most of the second-line rhythm control trials enrolled rela-
tively healthy and young patients with AF. Mortality rates in these
relatively small trials have therefore been very low, precluding any
meaningful attempts to determine whether ablation has any impact
on mortality.
The many trials comparing AF ablation with AADs for second-line
rhythm control have been evaluated in a number of meta-analyses
and technology assessments.262,1031,1032 Pooling of results across tri-
als indicates that AF ablation is clearly superior to AAD therapy for
the maintenance of sinus rhythm. The impact of AF ablation on other
key outcomes, including HF, stroke, and QOL, will be reviewed in
subsequent sections of this document.
Outcomes and Efficacy of Catheter
Ablation of AF as First-Line Rhythm
Control Therapy
There have been several studies performed to investigate the role of
AF ablation as first-line therapy, prior to a trial of a membrane-active
antiarrhythmic medication.377,378,379 The Medical ANtiarrhythmic
Treatment or Radiofrequency Ablation in Paroxysmal Atrial
Fibrillation (MANTRA-PAF)494 trial compared catheter ablation with
AAD therapy for the first-line therapy of symptomatic PAF.378 The trial
did not show a reduction in the cumulative AF burden over 2 years;
however, catheter ablation was associated with a lower rate of AF re-
currence (15% vs 29%, P =.004) and a similar rate of complications
(17% vs 15%) compared with AAD. The unexpected result in the
MANTRA-PAF might be explained by the ablation techniques with dis-
cretional circumferential ablation without confirmation of PVI with a
circular mapping catheter as well as by the choice of reduction in AF
burden on 7-day Holter as a primary endpoint. Reductions in AF bur-
den on a short 7-day Holter can be difficult to demonstrate in a parox-
ysmal population. In the Radiofrequency Ablation versus
Antiarrhythmic drugs as First-line Treatment of Paroxysmal AF
(RAAFT-2) trial, PV antrum isolation was performed using irrigated-tip
ablation catheters confirmed by recordings from a circular mapping
catheter.379 The results of the RAAFT-2 demonstrated that AF or AT
recurred in 55% of the catheter ablation group compared with 72% of
the patients in the AAD group after a 2-year follow-up (P= .016).
Moreover, a meta-analysis showed that first-line therapy with cath-
eter ablation was more effective than AAD for long-term mainten-
ance of sinus rhythm and was associated with comparable rates of
adverse events in relatively young patients with PAF and minimal
structural heart disease.380 A preliminary analysis based on the results
of the first RAAFT trial suggests that catheter ablation as a first-line
therapy also has a better cost-effectiveness profile.1033 These results
provide some support for the role of catheter ablation as first-line
therapy for PAF. Whether such benefits extend to elderly patients
with PAF, patients with associated structural heart disease, or non-
PAF is still controversial.
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One small, prospective, multicenter randomized study was per-
formed to evaluate whether catheter ablation is superior to AAD in
patients with HF and persistent AF.529 The main goal of the ablation
procedure was PV antrum isolation and LA posterior wall isolation.
The results showed that catheter ablation was superior to amiodar-
one in achieving freedom from AF at the long-term follow-up (70%
vs 34%, P <.001). Moreover, ablation improved QOL and exercise
capacity, and reduced hospitalization (31% vs 57%, P <.001) and mor-
tality (8% vs 18%, P= .037). These data provide some support for the
notion of AF ablation as first-line therapy; however, further studies
are needed.
Published Literature Review: Survey
Results
A worldwide survey on the methods, efficacy, and safety of catheter
ablation of AF was first published in 2005.806 The outcomes of nearly
9000 AF ablation procedures were reported. More than one ablation
procedure was performed in 27% of patients. The success rate,
defined as freedom from symptomatic AF in the absence of antiarrhythmic
therapy, was 52%. An additional 24% of patients were free of symp-
tomatic AF in the presence of a previously ineffective AAD. The inci-
dence of major complications was 6%.
In a subsequent survey from the same group, the clinical outcome
and safety of AF ablation performed between the years 2003 to 2006
in 85 participating centers proved to be better than in the previous
years.920 During a follow-up of 10 ± 8 months, 192 procedures per
center were reported with a 70% efficacy rate free of AADs, and an
additional 10% efficacy rate in the presence of previously ineffective
AADs. Ablation of PAF was associated with a 35% and 66% larger
probability of success compared with ablation of persistent and long-
standing persistent AF, respectively. Despite a larger prevalence of
centers reporting catheter ablation of persistent and long-standing
persistent AF, the overall complication rate was 4.5%. There were 25
procedure-related deaths (0.15%), 37 strokes (0.23%), 115 TIAs
(0.71%), and 213 episodes of tamponade (1.31%).
In a subsequent report analyzing the risk of periprocedural death
by means of an aggregate calculation from the previous two surveys,
32 fatal events were observed (0.98 per 1000 patients) during 45,115
procedures in 32,569 patients.908 Cardiac tamponade was found to
be the most frequent cause of death, with 8 patients (1 more than 30
days) suffering a fatal outcome as a consequence of this complication.
Stroke was reported as the cause of death in 5 patients (2 more than
30 days), AEF in 5 patients, and massive pneumonia in 2 patients.
More recently, the same authors provided a systematic analysis of
45 delayed tamponade events (e.g., cardiac tamponade occurring at
least 1 hour after procedure termination) in 21,478 patients undergo-
ing 27,921 procedures (0.2%).1034 The median time to tamponade
was 12 days (range: 0.2–45 days) after procedure termination, with
only 4 patients experiencing this event prior to discharge. The mode
of clinical presentation varied, with 39 patients exhibiting gradual pro-
gression to cardiac tamponade and 6 patients experiencing severe
symptoms within minutes. Two patients died from this complication
(risk of death 1 per 10,000 patients).
In January 2014, another survey reported on the first prospective
series providing preprocedural, procedural, and 1-year follow up
data on 72 centers enrolling about 1400 patients undergoing a
median of 1.2 procedures.969 In their registry, the authors reported a
1-year success rate free from AAD therapy of only 40% (44% in PAF;
30% in persistent AF; 37% in long-term persistent AF). Adding AAD
therapy increased the successful control rate to 72%. This result was
achieved with 20% of the patients having undergone at least a second
procedure. Using a multivariate analysis, the authors found that AF
recurrence during the 3-month blanking period was the only pre-
dictor of failure at the 1-year follow-up.
In 2014, the Prospective European Survey on AF Ablation investi-
gators published a prospective consecutive series of 946 consecutive
patients enrolled in 35 centers.1035 AF patterns were paroxysmal,
persistent, and long-standing persistent in 52%, 36%, and 12% of pa-
tients, respectively, with 12% of the centers offering AF ablation as
first-line therapy. PVI was performed in all the centers, with empiric
linear lesions and/or ablation of CFAEs being delivered as adjunctive
approaches in patients with non-PAF. RF was the dominant energy
form used (more than 95% of procedures), with cryoenergy and laser
offered in 4% and less than 1% of procedures, respectively.
In a recent survey led by the EHRA, the strategy used by 30
European centers for treating persistent AF was reported.540 Almost
half of the recruiting centers were performing more than 400 cath-
eter ablations per year and more than 200 LA ablations. PVI was the
main technique in patients undergoing first-time ablation for persist-
ent, but not long-standing persistent, AF in the majority of the centers
(67%), with ablation using fractionated electrograms, either as an add-
ition to PVI or as a stand-alone procedure, in 13% and 3% of centers,
respectively. A stepwise AF ablation technique was used in only 3%
of centers. In patients with long-standing persistent AF, stand-alone
PVI was adopted in only one-third of centers. In the remaining two-
thirds, ablation with fractionated electrograms, stepwise ablation
until AF was terminated, and PVI plus linear lesions at the LA roof or
the mitral isthmus were the most frequently reported techniques.
When PVI was the only technique used in patients with persistent or
long-standing persistent AF, 20% and 10% of procedures were per-
formed with CB, respectively. The 1-year success rate after a single
procedure at 1 year was found to be 50%–60% in 40% of the centers,
with three centers reporting a success rate of less than 40% and three
centers reporting a success rate higher than 80%.
Outcomes of AF Ablation in Populations
Not Well Represented in Clinical Trials
Outcomes of Catheter Ablation of Persistent and Long-
Standing Persistent AF
Persistent AF is quite heterogeneous regarding the pathophysio-
logical mechanisms responsible for electrical and structural remodel-
ing of the atria. In addition, persistent AF itself is an independent
predictor of recurrence, and catheter ablation has reduced success
compared with PAF.268 Success rates vary according to the hetero-
geneity of the patient population and ablation strategies that are en-
compassed under the umbrella “non-PAF.” It is now increasingly well
recognized that the duration of continuous AF is an important pre-
dictor of the efficacy of AF ablation. Patients with continuous AF of
12 months or less duration are very different from patients who have
been in continuous AF for years.
The quality and quantity of data concerning the outcomes of AF
ablation in patients with non-PAF, including both persistent and long-
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standing persistent AF, is limited.529,733,1015,1030 Table 7 shows the
outcomes of four trials of catheter ablation for persistent
AF.245,733,1026,1030 Despite the widespread performance of AF abla-
tion on patients with persistent AF, no ablation catheters have
received FDA or CE Mark labeling specifically for the indication of ab-
lation of persistent AF. One completed clinical trial was performed
with a goal of obtaining FDA labeling for ablation of persistent AF
using a novel, phased RF multielectrode ablation system.733 In this
study, patients were randomized to ablation or to treatment with an
alternative AAD or an increased dose of a previously ineffective drug,
and DC cardioversion. As expected, protocol-defined success was
higher following ablation at 6 months (56% vs 26%). However, the
study did not meet its prespecified safety endpoint, partly due to the
occurrence of 4 strokes (2.9% of the patients randomized to abla-
tion) that mainly occurred during early experience with the ablation
system. As a result, this system has not been approved in the United
States. There have been a number of studies performed comparing
ablation strategies in patients with persistent AF. The largest was the
recently published STAR-AF trial.245 This well-performed and ad-
equately powered study randomized patients with persistent AF to
ablation with PVI alone, PVI alone plus linear ablation, or PVI plus ab-
lation of CFAEs. No difference in efficacy was observed, and there
was a trend toward superiority of PVI alone.
It is important to note, however, that several prospective clinical
trials are planned or have begun in an effort to obtain FDA labeling
for the use of point-by-point RF ablation and cryoablation. Both these
trials have chosen to enroll patients with early persistent AF (and to
exclude patients with long-standing persistent AF) and to employ
OPC. In addition to these trials, there has been one small, prospect-
ive, randomized clinical trial that compared the outcomes of ablation
with AAD therapy in 146 patients with persistent AF. The efficacy of
AF ablation in this study was superior to AAD therapy.1030
The writing group recommendations for techniques to be used for
ablation of persistent and long-standing persistent AF are shown in
Table 3. PVI remains the cornerstone of all AF ablation procedures and
is recommended. Several new ablation strategies are being explored
for use in patients with persistent AF. These approaches include map-
ping and ablation of rotational activity, ablation of areas of low voltage,
ablation of areas identified on MRI as showing fibrosis, ablation of non-
PV triggers, as well as LAA focal ablation, isolation, and/or ligation. Each
of these techniques is described elsewhere in this document.
In this regard, there is considerable debate as to which of these
techniques, if any, should be employed during an initial or repeat AF
ablation procedure in patients with long-standing persistent AF. An
important study was a report of the 5-year outcomes of the “step-
wise” approach to AF ablation515 The single-procedure efficacy of
this approach at 1 year was 35%, falling to 17% at year 5. With re-
peated procedures, the arrhythmia-free survival after the last proced-
ure at the 5-year follow-up was 63%. These and other trials are an
important reminder that new ablation strategies should not be widely
adopted into routine clinical practice until the safety, efficacy, and
true clinical value of these new strategies have been demonstrated in
well-designed and adequately powered prospective randomized clin-
ical trials. As a result of these and other studies, use of the stepwise
ablation strategy, empiric linear ablation, and ablation of CFAEs are
much less commonly performed today than in the past, when this
was a popular ablation strategy for patients with persistent AF.
Outcomes of AF Ablation in Elderly
Patients
Several studies have been published describing the outcomes of AF
ablation in elderly patients. One study compared the safety and effi-
cacy of catheter ablation in three groups of patients: <65 years, 65–
74 years, and >_75 years. Although the total study population included
1165 patients, the group >_75 years only included 32 patients. Over a
mean follow-up of 27 months, AF control defined as no AF on or off
AADs or “rare” AF was comparable in the older and younger patients.
The older patients were less likely to undergo repeat ablation and
were more likely to remain on AADs. Complication rates were simi-
lar.1036 In another study of 174 patients >75 years, 55% of whom had
PAF, 127 (73%) maintained sinus rhythm after a single procedure,
with an acute major complication rate of 1%.1037 Another study eval-
uated catheter ablation for AF in 103 octogenarians with paroxysmal,
persistent, or long-standing persistent AF compared with patients
<80 years.399,400,401 The proportion of patients with the different
types of AF was similar in both groups. A higher rate of non-PV trig-
gers (84% vs 69%, P= .001) was found in the octogenarians. After a
mean follow-up of 18 ± 6 months, 71 (69%) of the octogenarians re-
mained free from AF off AADs after a single procedure vs 71% in pa-
tients <80 years (P= NS). Complication rates did not differ between
the two groups. Other studies of octogenarians have found similar
results.398,1038
In a retrospective cohort study involving Medicare claims for
15,423 patients who underwent ablation procedures associated with
a primary diagnosis of AF, it was found that advanced age was a major
risk factor for all adverse outcomes. However, the overall rate of ad-
verse outcomes was fairly small. Only 11% of patients underwent a
second ablation procedure by 1 year after the index procedure, a
low rate that has been observed in other studies.1039 In another ana-
lysis of a large commercial claims database, acute complications in pa-
tients over and under the age of 65 years were nearly identical.1040
Although comparable rates of periprocedural strokes have generally
been found, late stroke might be more common in older patients.1041
In general, studies have shown similar success rates with catheter
ablation for AF in older patients compared with younger patients,
with comparable complication rates. However, the small number of
elderly patients in most studies compared with the much greater
prevalence of AF in the elderly indicates that ablation is being per-
formed in a highly selected group of older patients. A consistent find-
ing is that older patients are less likely to undergo a second
procedure if the index procedure fails to eliminate the arrhythmia.
The recommendations for AF ablation in elderly patients are shown
in Table 2.
Outcomes of AF Ablation in Patients
with Congestive Heart Failure and the
Impact of Ablation on Left Ventricular
Function
A number of clinical trials have examined the role of catheter ablation
of AF in patients with HF. The initial study to address this important
topic was published in 2004.232,1042 This study examined the role of
catheter ablation in 58 patients with HF with an EF of less than 45%
and 58 controls. During a mean follow-up of 12 ± 7 months, 78% of
patients with HF and 84% of controls remained in sinus rhythm.
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Of particular note is that the EF improved by 21% ± 13%.
Improvements also were seen in exercise capacity and in QOL.
Another study is the Pulmonary Vein Antrum Isolation versus AV
Node Ablation with Bi-Ventricular Pacing for Treatment of AF in
Patients with Congestive Heart Failure (PABA-CHF) study that com-
pared the efficacy of AF ablation with AV node ablation and pace-
maker implantation.235 The primary endpoint of this prospective,
multicenter clinical trial was a composite of EF, distance on a 6-mi-
nute walk, and Minnesota Living with Heart Failure (MLWHF) ques-
tionnaire score after a 6-month follow-up. This study demonstrated
an overall superiority of PVI to AV node ablation and pacing given by
a lower score on the MLWHF questionnaire (60 vs 82), longer walk-
ing distance (340 m vs 297 m), and higher EF (35% vs 28%). A third
case-controlled series reported that the efficacy of AF ablation was
similar in patients with and without LV systolic dysfunction and re-
ported an improvement in EF at the 6-month follow-up.388 Since
publication of the last consensus document, four additional prospect-
ive randomized clinical trials have been published focusing on the out-
comes of AF ablation in patients with HF.236,237,390,529 The first three
were included in a recent meta-analysis.392 The meta-analysis re-
ported data from 4 randomized trials involving a total of 224 patients,
83% of whom had persistent AF. AF ablation was associated with an
increase in LVEF of 8.5% compared with rate control. AF ablation
was also superior in improving QOL as well as peak oxygen con-
sumption and 6-minute walk distance. Major adverse events were
not significantly different. The most recent trial randomized patients
with persistent AF and HF (Ablation vs Amiodarone for Treatment
of Atrial Fibrillation in Patients With Congestive Heart Failure and an
Implanted ICD/CRTD [AATAC] trial) to AF ablation or treatment
with amiodarone. Catheter ablation was more effective than amio-
darone in preventing recurrent AF (70% after a mean of 1.4 proced-
ures vs 34%) and was associated with a lower rate of unplanned
hospitalization.529 Taken as a whole, the results of these studies sug-
gest that catheter ablation of AF is safe and effective in selected pa-
tients with HF. As compared with rate control alone, catheter
ablation results in a greater improvement in EF. The recommenda-
tions for AF ablation in patients with HF are shown in Table 2.
Outcomes of AF Ablation in Patients
with Hypertrophic Cardiomyopathy
AF is a commonly reported complication of hypertrophic cardiomy-
opathy (HCM) with a prevalence and annual incidence of 22.5% and
3.1%, respectively.1043 The substrate for AF is complex and deter-
mined by atrial fibrosis, atrial dilatation, or intrinsic atrial myopathy. In
patients with HCM, development of AF is associated with marked ex-
acerbation of symptoms, increased risk of stroke, and excess HCM-
related mortality.1043
Due to the association of AF with HCM-related morbidity and
mortality, there is general agreement that vigorous maintenance of
sinus rhythm should be attempted.273,274 Randomized data regarding
the efficacy of AADs are not available for patients with HCM; in daily
practice, however, drugs are frequently ineffective in eliminating AF
recurrence. In addition, the efficacy and safety of catheter ablation in
the setting of HCM is poorly characterized, with studies in small pa-
tient cohorts, observational in nature, and providing contradictory
results. A recent systematic review and meta-analysis of these studies
aimed to determine the efficacy and safety of catheter ablation of AF
in patients with HCM.1044 Single-procedure success (freedom from
AF or AT recurrence) was 38.7% in patients with HCM (vs 49.8% in
controls; OR 2.25; 95% CI 1.09–4.64; P= .03). Outcome after >_1
procedure amounted to 51.8% (vs 71.2% in controls; OR 2.62; 95%
CI 1.52–4.51, P= .0006). Repeat procedures (mean difference = 0.16;
95% CI 0.0–0.32, P= .05) and AADs (OR 4.70; 95% CI 2.31–9.55,
P <.0001) were more frequently needed in patients with HCM.
Sensitivity analyses suggested that the outcome in patients with HCM
with less dilated atria and PAF might be more comparable to the gen-
eral population. Overall, the risk of procedure-related adverse events
was low. In summary, even though the likelihood of recurrence is
twofold higher, catheter ablation can be effective in patients with
HCM and AF, particularly in patients with PAF and smaller atria. The
recommendations for AF ablation in patients with HF are shown in
Table 2.
Outcomes of AF Ablation in Young
Patients
As an age-related condition, AF is uncommon in young adults.
However, younger patients with AF are often highly symptomatic
and might have a desire to avoid long-term medical therapy, making
catheter ablation a potentially attractive treatment option.
Limited information is available regarding the outcomes of AF abla-
tion in unusually young patients. At least two single-center studies
and one multicenter study have reported on the outcomes of AF ab-
lation in unusually young patients.405,1045 Two of these three studies
defined young ablation patients as those under the age of 45 years;
the other reported on outcomes of AF ablation for lone AF, defined
as age <65 with no cardiac, pulmonary, or structural heart disease
(mean age 45).
In a 2010 single-center study, 232 patients under age 45 were iden-
tified from an overall ablation cohort.405 The authors reported that
younger patients had lower rates of major complications compared
with more typically aged AF ablation patients. The rate of the author-
defined primary outcome of AF control was similar across age groups,
but a higher proportion of young patients (76%) were AF-free in the
absence of AADs after 1 or more ablation procedures than older pa-
tients (from 53%–68%). A 2016 single-center study reported on abla-
tion outcomes in 76 patients with lone AF (9% of their overall
ablation population). Freedom from atrial arrhythmia after one pro-
cedure was 74%, whereas freedom from atrial arrhythmia after the
last procedure without AADs was 96%. The largest study on AF abla-
tion in younger patients was a multicenter German registry in which
593 patients aged <_45 years were compared with 6650 patients aged
>45 years. In this study, the younger patients had lower rates of com-
plication, shorter hospital stays, and lower rates of AF recurrence
and AAD than older patients. Together, these studies suggest that AF
ablation might be both safer and more effective in younger patients
compared with “average” or older AF patients, although this result
could be due in part to a lower burden of cardiac and noncardiac
comorbid diseases. It has been suggested that AF ablation might
more readily be considered first-line rhythm control therapy in
younger rather than older patients; however the evidence base for
making such a recommendation is not strong. The recommendations
for AF ablation in young patients are shown in Table 2.
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Outcomes of AF Ablation in Women
Multiple studies have found that women are more symptomatic from
AF, have a lower QOL, and are less tolerant of AADs than
men.806,1046,1047,1048,1049 However, the rate of referral of women for
catheter ablation of AF is significantly lower than men, and women
are referred much later after failing more AADs.920 There has not
been consistent evidence to support female sex as a predictor of re-
currence after AF ablation, based on multiple univariate and multi-
variate analyses.252,1050,1051 A systematic review of predictors of AF
recurrence after catheter ablation reported that none of the 23 stud-
ies found female sex to be a predictor of recurrence.1050
At least four major studies have specifically examined outcomes
after ablation of AF in women. A large, retrospective multicenter
study involved 3265 consecutive patients with drug-refractory AF
who underwent PVI.289,290,291 Women constituted a much lower
percentage of the patients referred for ablation, were referred later
for ablation, had failed more AADs, more often had hypertension,
and were older at the time of the procedure. After 24 ± 16 months
of follow-up, the women had significantly lower success rates than
the men, defined as single-procedure freedom from recurrent AF off AADs
(68.5 vs 77.5%; P <.001). Another study also found a lower success
rate in women after a single catheter ablation procedure (35.6% in
women vs 57.1% in men; P= .003); however, once repeat procedures
were taken into account, there was no significant difference in
outcome.1052
Other studies have not shown a difference in outcomes between
men and women.1053,1054 Most recently, a large-scale prospective
analysis of sex-related differences in catheter ablation of AF that en-
rolled 1124 patients with PAF was reported from Japan.1054 After a
mean follow-up of 31.7 ± 24.4 months following the index ablation,
there was no significant difference in success rates or complication
rates between women and men.
Sex-related recurrence rates have been reported as nonprimary
end points in at least 17 other studies, most of which did not reveal
significant sex-related differences.1055
Female sex has been reported as a predictor of complications after
AF ablation, and higher complication rates from AF ablation in
women have repeatedly been found.252,289,290,291,806,808,920,1050,1051,
1052,1053,1054,1056,1057,1058,1059 A multicenter U.S. retrospective study
reported total complications of 3265 (518 in women vs 2747 in
men), with a 5% complication rate in women vs 2.4% in men
(P <.001). This study found more hematomas and pseudoaneurysms
in women.289,290,291 A large multicenter registry from Italy that en-
rolled 2323 patients also reported a significantly higher complication
rate in women (7% vs 4.4%), and female sex was reported to be an in-
dependent predictor of a higher risk of complications by univariate
analysis (OR 2.643; 95% CI 1.686–4.143; P <.0001).1059
Overall, studies have not shown a significant sex-related difference
in outcomes with AF ablation in women compared with men, but
complication rates are consistently higher in women.
Outcomes of Cryoballoon Ablation
Within the past 10 years, CB-based catheter ablation has emerged as
an alternative technique to RF ablation for the treatment of patients
with symptomatic AF, especially for those with PAF. This change is
not only related to the simplified handling of the cryoablation
catheter when compared with point-by-point RF ablation, but also to
technological developments and the steadily increasing number of
clinical trials consistently reporting an overall comparable efficacy to
RF ablation. It is important to note that, as in the whole field of AF ab-
lation, the reported efficacy outcomes must be interpreted with cau-
tion due to differences in the intensity of follow-up and endpoint
definitions.
In 2012, the second-generation CB was introduced. A modified re-
frigerant injection system allows for a more uniform cooling across
the distal balloon hemisphere.489,691,692,1060,1061,1062,1063,1064,1065
Since the 2012 update of this consensus paper, multiple random-
ized and nonrandomized studies including a large-scale registry have
been published that compared CBA against point-by-point RF abla-
tion with respect to rhythm outcome in patients with
PAF.490,492,493,695,696,1066,1067,1068,1069,1070,1071,1072 The majority of
these studies revealed that CBA was similarly effective in the preven-
tion of arrhythmia recurrences, with arrhythmia-free survival ranging
from 54% to 85% in patients undergoing cryoablation and from 55%
to 88% in patients undergoing RF ablation after 1 to 2 years of follow-
up. In particular, there was no difference in efficacy when the second-
generation CB was compared with advanced-generation RF catheters
featuring CF measurements for improved wall contact.1068,1070
In the FREEZE-AF study, 315 patients with PAF were random-
ized to open irrigated radiofrequency ablation or CBA for PVI.1069
Cryoablation was exclusively performed with the first-generation
CB catheter. The primary endpoint was freedom from atrial ar-
rhythmia recurrence with absence of persistent complications. At
12 months, the primary endpoint was met by 70.7% of the patients
in the RF ablation group and by 73.6% of the patients in the cryoa-
blation group after at least one ablation procedure with similar
rates of redo procedures in both groups (19.5% vs 19.9%).
Periprocedural complications occurred more frequently in the
cryoablation group compared with the RF ablation group (12.2%
vs 5.0%), which was largely driven by 9 transient PN injuries
(5.8%) in the cryoablation arm.
The most robust data are provided by the FIRE AND ICE trial that,
to date, is the largest randomized trial comparing both technologies
in patients with symptomatic drug-refractory PAF.490 In this multicen-
ter trial, 762 patients were randomly assigned to undergo PVI by
open irrigated RF (approximately one-fourth with CF) or by CBA
(approximately three-fourths with CB-2). The primary efficacy end-
point was defined as first documented clinical failure, a composite of
recurrent AF, occurrence of AFL or AT, AAD use, or repeat ablation.
After a mean follow-up of 1.5 years, CBA was noninferior to RF abla-
tion with regard to efficacy, with the primary endpoint occurring in
34.6% and 35.9% of patients in the cryoablation group and in the RF
ablation group, respectively. There was no statistically significant dif-
ference in the primary safety endpoint: a composite of death, cere-
brovascular events, and serious treatment-related adverse events
(10.2% vs 12.8% for cryoablation vs RF ablation, respectively). There
were 10 PN injuries (2.7%) in the cryoablation group, with nine of
these injuries resolving by 6 months after ablation. Thus, the inci-
dence of permanent PN paralysis was 0.3%. A subsequent analysis re-
ported that the patients who underwent CBA had fewer repeat AF
ablation procedures, direct current cardioversions, all-cause hospital-
izations, and cardiovascular hospitalizations during follow-up com-
pared with the group randomized to RF ablation.489 Limitations of
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this subsequent analysis, which need to be considered when inter-
preting the results, included the inclusion of nonprespecified end-
points, as well the fact that this analysis was industry sponsored.
The role of cryoablation in patients with persistent AF is less well
established. To date, data are predominantly derived from relatively
small, noncontrolled trials and mostly reflect a single-center experi-
ence.486,1073,1074,1075,1076,1077 Overall, cryoablation appears to be
associated with a favorable long-term outcome in patients with per-
sistent AF, with arrhythmia-free survival ranging from 56% to 82%. In
one non-randomized study, arrhythmia-free survival off AADs
was similar when cryoablation was compared with RF ablation at 1-
year follow-up after a single procedure (60% vs 50%).1078 Preliminary
results from a single-center study demonstrated the feasibility of
extra-PV CBA in patients with long-standing persistent AF.1077
Future prospective randomized trials are needed to more precisely
define the role of CBA in patients with persistent and long-term per-
sistent AF.
Outcome of Rotational Activity Ablation
for AF
Several studies have used phase mapping techniques to identify the
rotational activity in patients with AF. Furthermore, catheter ablation
of AF guided by phase mapping targeting rotational activity has been
found to be effective at eliminating AF in some reports. However, the
prevalence of rotational activity and the outcome of rotational activ-
ity ablation have varied widely, and long-term outcomes of rotational
activity ablation are still lacking. An early investigator used the 64-
pole basket catheter to map rotational activity in patients with parox-
ysmal or persistent AF, and found a high prevalence of rotational ac-
tivity; application of RF energy on the rotational activity eliminated
AF in more than 90% of the patients.563 A more recent study re-
ported favorable results when using an ablation strategy that com-
bined PVI and ablation or rotational activity in patients with non-PAF.
However, another investigator1079 used the same mapping tool and
techniques for AF ablation and identified rotational activity in less
than 20% of AF patients.569 Other investigators could not reproduce
a high percentage of rotational activity in patients with AF and found
disappointing results with rotational activity-based ablation.1080
Another investigator used the body-surface high-density mapping
technique and identified reentrant drivers in 80.5% of paroxysmal
and persistent patients with AF, and AF was eliminated in 75% of the
AF with reentry drivers.222 In another study, high-density activation
mapping identified rotational activity in 15% of the patients with per-
sistent AF.224 Although the Non-Invasive Mapping of Atrial
Fibrillation (AFACART) study also showed an 80% success rate in
terminating AF, the long-term success rate for eliminating AF was sig-
nificantly less. However, the duodecapolar mapping catheter with
phase mapping identified rotational activity in 65% of persistent AF
and long-term persistent AF; application of RF energy on these areas
of rotational activity after PVI rendered 65% of the AF free (mean
follow-up 18 months).497 Although the application of phase mapping
facilitates identification of rotational activity, conventional activation
mapping might not see rotational activity clearly. Due to the contro-
versy around the various ablation techniques for persistent and long-
term persistent AF, the prevalence and outcome of rotational activity
ablations need further investigation.1081
Outcomes of Laser Balloon Ablation
Visually guided PVI using the laser balloon is a recently developed
technology. It was first introduced in Europe and was approved in the
United States in 2016. Since 2010, there have been a number of publi-
cations describing its use.497,498,499,501,502,503,1082,1083,1084,1085 The
number of patients included in these studies has ranged from 50 to
200.498,1084 The patients in all these studies had PAF, except for one
study that included patients with persistent AF.1085
The laser balloon is highly effective in achieving PVI. The rate of
acute PVI ranged from 98% to 100%.498,501,502 Remapping studies
also demonstrated a highly durable rate of isolation of the PVs using
this technology.503 The freedom from AF at follow-up ranged from
60% to 88%, which is comparable to the outcome of PVI using RF en-
ergy in similar populations.503,1085 The patients in all the published
studies were followed for at least 12 months.
The laser beam positioning during PVI is executed under direct
visualization. However, manipulating the catheter in the LA is guided
by X-ray imaging. The fluoroscopy time for laser balloon PVI has
been reported to range between 13 and 36 minutes, with a total pro-
cedure time range of 2–4 hours.498,1082
The FDA-reviewed HeartLight study was a prospective, multicen-
ter randomized trial comparing laser balloon PVI with conventional
RF ablation.503,1082 The 1-year success rate of the laser balloon did
not differ from ablation with the ThermoCool System (61.1% vs
61.7%, respectively). The rates of stroke (1.2%) and tamponade
(1.2%) were similar to RF ablation. Diaphragmatic paralysis secondary
to PN injury occurred in 3.6% of the patients with the laser balloon,
which was more common than with RF ablation. Persistent PN par-
alysis at 1 year occurred in 1.8% of patients. PV stenosis was observed
only in patients randomized to RF ablation (2.9%). There were no
deaths or AEFs in the study. This ablation system is now approved
for clinical use in Europe and the United States.
Long-Term Ablation Efficacy
During the past decade, a large number of studies have been published
that have examined the important issue of the long-term efficacy of AF
ablation. Prior to this time, most clinical studies presented data from
short-term follow-ups, often less than 12 months in duration. The first
of these studies was published 5 years ago and described the long-term
outcomes of a series of 264 patients who were AF-free and off AAD
therapy at the 12-month point following an initial ablation proced-
ure.284 During a mean follow-up of 28 ± 12 months, AF recurred in 23
patients (8.7%). The actuarial recurrence rate of AF at 5 years was
25.5%. Similar findings have been reported in each of the subsequent
trials.266,267,268,1022,1086,1087 The predictors of late recurrence most
commonly identified include persistent AF as well as comorbid condi-
tions. Despite the low single-procedure, long-term success rate re-
ported in virtually all of these clinical trials, they also reveal that with
the use of repeat AF ablation procedures and/or AAD therapy, much
higher rates of freedom from recurrent AF as well as concomitant re-
ductions in AF burden can be achieved.
Impact of Catheter Ablation of AF on
QOL
Because symptomatic improvement is a primary objective in the
treatment of patients with AF, formal assessments of QOL have
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played an increasingly important role in the evaluation of ablation
outcomes.47,63,1088 These measures can provide a more global reflec-
tion of symptom change, symptomatic arrhythmia burden, and the
difference between actual and desired health and function than more
focused endpoints of rhythm status at specific points in time. Generic
tools, such as the SF-36 health survey,1089 which is applicable to a
broad range of disease states and health conditions, and disease-
specific questionnaires1090,1091 developed to assess symptom burden
in patients with arrhythmias, have been most widely employed.
Patients with AF, as reflected by standardized SF-36 scores, have
substantially impaired QOL, below population norms and compar-
able to patients with coronary artery disease and congestive
HF.47,1088,1092 A number of single-center, nonrandomized observa-
tional studies of AF ablation have demonstrated significant and sus-
tained improvements in QOL scores following catheter
ablation.63,1088 Taken alone, these findings need to be interpreted
cautiously, because in the absence of a comparison group or treat-
ment blinding, placebo effects cannot be excluded. Two studies dem-
onstrated that over a 12-month period following treatment, changes
in QOL scores were strongly related to the presence or absence of
documented AF recurrence within the previous 30 days.1093,1094
More important are the results of randomized clinical trials that
compared catheter ablation with AAD therapy in patients with PAF,
and evaluated QOL as an outcome measure.261,377,378,379,684
Investigating catheter ablation as second-line therapy after failed
AAD treatment, catheter ablation was associated with significant im-
provements in SF-36 scores relative to baseline, with restoration to
levels at or above population norms.261,684 QOL scores were signifi-
cantly higher for patients treated with catheter ablation than for pa-
tients treated with drug therapy, in whom there was little change
from baseline scores.
In the three trials investigating catheter ablation as first-line therapy
for AF, QOL improved with both AAD treatment and catheter abla-
tion, and significantly more with catheter ablation, using the SF-
36,377,378,1091 or 4312 EQ-5D379 instruments (EuroQOL five dimen-
sions questionnaire).
A recent meta-analysis included data from 12 RCTs comparing
catheter ablation (as first- or second-line therapy) and AAD treat-
ment, and including a total of 1707 patients with symptomatic AF. In
this analysis, catheter ablation led to greater improvements in several
areas of the SF-36 questionnaire and in the symptom frequency score
from baseline to 3 months follow-up. However, for all QOL metrics
as well as for symptom frequency and severity scores, the differences
between catheter ablation and AAD treatment diminished with
increasing duration of follow-up, and no significant differences re-
mained beyond 9 months of follow-up.1032 In the randomized trials,
an impact of crossover from AAD treatment to catheter ablation
cannot be excluded. However, in an on-treatment analysis of data
from a randomized trial comparing catheter ablation and AAD treat-
ment as first-line therapy, no differences in QOL were observed be-
tween patients treated with catheter ablation, patients treated with
AADs, and patients treated with a combination of both.494
Concerns have been raised that generic QOL instruments such as
SF-36 are not sufficiently sensitive or focused to detect changes in
disease-specific symptoms such as those associated with AF.63,974
AF-specific QOL measures, including the AF Effect on QOL
(AFEQT) questionnaire,1095 the Mayo AF Symptom Inventories,63
and the Arrhythmia-Specific questionnaire in Tachycardia and
Arrhythmia (ASTA),1096 have been developed and are in the process
of validation. A recent study reported that disease-specific assess-
ments of QOL are superior to generic questionnaires.1097
Preliminary findings indicate that these tools also demonstrate sub-
stantial improvements in QOL with ablation, and can more accur-
ately reflect ablation efficacy. However, there is currently no general
agreement that any of the AF-specific QOL instruments are superior
to others or to the general QOL instruments. The use of QOL meas-
ures will be discussed further in the section.
Impact of Catheter Ablation of AF on LA
Size and Function
Experimental and clinical research has demonstrated that in some set-
tings AF results in, or is accompanied by, electrical, structural, and func-
tional remodeling of the atrium.14,587,1098,1099 The results of a subset of
these studies suggest that AF can be viewed, in some patients, as a
rate-related atrial cardiomyopathy. As discussed elsewhere in the
document, AF can also follow and be the consequence of prior atrial
damage and fibrosis (atrial myopathy). To the extent that rate-related
cardiomyopathies lead to reversible chamber dilatation and dysfunc-
tion, it was anticipated that reverse remodeling might also occur in a
subset of patients who underwent AF catheter ablation.
Several studies have examined LA size before and after catheter
ablation.437,1100,1101,1102 These studies have demonstrated a signifi-
cant decrease in the size of the LA after PVI of PAF, regardless of
whether echocardiography, MRI, or CT was used for LA imaging. The
reverse remodeling of LA was more pronounced when sinus rhythm
had been successfully restored.1103 Although the precise mechanism
of this decrease in size is not clear, it appears consistent with reverse
remodeling due to the decreased burden of AF and scar formation
from the ablation procedure.
The impact of catheter ablation of AF on LA transport function
was investigated in patients with paroxysmal and persistent AF, with
conflicting results.1104,1105 A meta-analysis showed a significant de-
crease in LA volume but did not find significant changes in active LA
function, including studies with persistent as well as PAF ablation pro-
cedures.1106 However, because AF eliminates essentially all contract-
ility of the LA, there is general agreement that restoration of sinus
rhythm in patients with persistent AF improves atrial function if sinus
rhythm is maintained.391,1107,1108,1109
However, ablation-related scarring with the risk of causing persist-
ent atrial dysfunction still remains a major concern after extensive ab-
lation for persistent AF. The long-term outcome after stepwise
approach for persistent AF demonstrated the impaired contractility
and compliance of LA, which was related to scar burden.1110
Moreover, a recent study has reported a series of patients who de-
veloped LA diastolic dysfunction and pulmonary hypertension fol-
lowing AF ablation.1111 The precise cause of “stiff LA syndrome” or a
“noncompliant LA” and methods to prevent it will clearly be an area
for further study going forward.
Impact of Catheter Ablation on Stroke
Risk
Conceptually, it appears logical that catheter ablation—by elimin-
ation of or reductions in AF burden—lowers the risk of stroke or
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TIA; initial reports from single-center, nonrandomized studies did
demonstrate a relatively low rate of stroke or TIA after catheter abla-
tion.231,545 To date however, there are no RCTs verifying the hypoth-
esis that ablation lowers the long-term incidence of stroke or TIA.
Please refer to Section 7 for a more detailed discussion of the recom-
mendations made by the writing group for long-term anticoagulation
post-AF ablation.
Indirect evidence stems from four large, health administrative data-
bases using propensity-score matching to create a “control” popula-
tion and to even out differences between patient
groups.239,1112,1113,1114 In a very large, prospectively collected registry
(the Intermountain Healthcare Database in Utah), investigators re-
ported a significantly lower rate of stroke in 4212 ablated patients
(follow-up 3.1 ± 2.4 years), compared with those who did not
undergo ablation.239 Moreover, ablated patients had comparable
stroke rates when compared with age- and sex-matched patients
who did not have a history of AF. Both observations were independ-
ent of baseline stroke risk score. Another propensity score-matched
analysis of medically treated and ablated patients within the U.S.
MarketScan Research Database (n= 805 in each group with follow-
up of up to 3 years), showed that AF ablation was associated with a
reduced risk of stroke or TIA compared with AAD therapy (HR 0.62;
95% CI 0.44–0.86, P= .005).1112 Similarly, data from the Taiwanese
national health insurance claims database reported lower risk of
stroke in 846 ablated patients compared with the control group (HR
0.57; 95% CI 0.35–0.94; P= .026).1113 Recently, a retrospective, pro-
pensity score-matched analysis (using as many as 51 parameters) of
medically treated and ablated patients from Swedish health registries
(n= 2836 in each group during a follow-up period of 4.4 years) con-
firmed that ablation was associated with a lower incidence of ische-
mic stroke than nonablated patients (HR 0.69; 95% CI 0.51–0.93;
P= .016).1114 This association between ablation and stroke was pro-
nounced in patients with a CHA2DS2-VASc score >_2 points, but was
not discernible among patients with low stroke risk.
Three other observational studies determined possible predictors
for stroke-free survival within the ablated patient group.241,242,408
Multivariate analysis in 174 ablated Taiwanese patients showed that
ablation outcome was the strongest independent predictor for sur-
vival free of major adverse cardiovascular events, including stroke
(HR 0.225; 95% CI 0.076–0.671; P= .007).241 A Kaplan-Meier survival
analysis demonstrated that ablation-treated patients without AF re-
currence had a lower incidence of ischemic strokes and TIAs
(P= .015) compared with patients with AF recurrence or medically
treated patients. Of interest, a retrospective analysis of 3058 ablated
low-risk patients from a single-center registry showed only a modest,
non-significant reduction in the risk of cerebrovascular events in pa-
tients who maintained sinus rhythm when compared with those who
had AF recurrence.242
The above studies suggest that catheter ablation can lower the risk
of stroke via maintenance of sinus rhythm. However it is recognized
that the retrospective nature of these studies makes them prone to
bias. The above studies are limited by a lack of detailed data on
rhythm and/or anticoagulation status, selection bias (low stroke risk
at baseline), relatively short follow-up, and the extent to which pa-
tient groups can be matched. Despite the fact that propensity score
matching was successful in creating a control population that was
similar to the ablated group, adjustment is only possible for
observable factors. Unknown confounding factors could account for
why patients treated with ablation had lower rates of stroke or TIA
(post hoc ergo propter hoc). Bias of unmeasured variables can only be
fully neutralized in RCTs. Finally, it should be noted that some of the
above studies made comparisons to historical cohorts whose risk of
stroke appears to be much higher than the risk reported in recent
studies.
Therefore, the above findings cannot be viewed as definitive and
do not provide sufficient evidence that ablation reduces stroke risk.
Instead, they reinforce the hypothesis behind studies like the
CABANA trial or the EAST trial, which will provide more definitive
evidence. However, the results will not be available until 2018, and,
as with most long-term studies in ablation, their relevance could be
challenged by the rapidly evolving nature of the ablation field.
Predictors of Success Following AF
Ablation
A large number of studies have been performed to examine clinical
predictors of the efficacy of AF ablation.328,329,365,1050,1115,1116,1117
Factors that have been identified as predictors of a poorer outcome,
at least in some studies, include (1) non-PAF and particularly long-
term persistent AF; (2) sleep apnea and obesity; (3) increased LA
size; (4) increased age; (5) hypertension; and (6) LA fibrosis as de-
tected by cardiac MRI.365
A systematic review of predictors of AF recurrence after AF abla-
tion analyzed data from 45 studies, 25 of which included a multivari-
able analysis of predictors of recurrence.1050 Among the 17 studies
that examined AF type as a predictor of recurrence, 11 studies re-
ported no impact of AF type on recurrence, whereas six studies re-
ported that the presence of non-PAF was an independent predictor
of a higher rate of recurrence (HR ranging from 1.8 to 22). Seventeen
studies evaluated EF as a predictor of recurrence. Very few patients
in any of these studies had an EF less than 40%. Among these 17 stud-
ies, only five reported a significant association between lower EF and
a higher rate of AF recurrence. Twenty studies examined LA diam-
eter as a predictor of AF recurrence. Very few patients in any study
had LAD >60 mm. Among these 20 studies, four reported a signifi-
cant association between larger LAD and a higher rate of recurrence
of AF. Among 21 studies that examined the presence of structural
heart disease as a predictor, only one reported a significant associ-
ation at 12 months of follow-up. Most studies examined sex, and no
association between recurrence and sex was found. Only one of 22
studies reported an independent association between age and
recurrence.
Cost-Effectiveness of AF Ablation
The cost-effectiveness of AF ablation has been evaluated in a number
of individual studies and several systematic re-
views.1118,1119,1120,1121,1122,1123,1124,1125 The costs of AF ablation pro-
cedures can vary widely, depending on the treatment setting and the
actual equipment used.409,1126 Estimates of the cost-effectiveness of
AF ablation can vary further based on a number of additional factors,
including the patient population, the severity of symptoms, the ana-
lytic time horizon, and assumptions about the impact of AF ablation
on QOL, stroke, and other clinical outcomes. One issue supporting
the potential cost-effectiveness of AF ablation is that the costs of
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ablation are at least partly offset over time by reducing long-term, ar-
rhythmia-related health care resource utilization for patients not
treated with ablation, as supported by some empirical evi-
dence.90,476,1033,1127 However, most formal cost-effectiveness studies
have not found AF ablation to be cost neutral or cost saving in the
short to intermediate term.
The majority of published cost-effectiveness studies have com-
pared AF ablation to AADs as second-line therapy in patients with
PAF.1119,1120,1122,1124,1128,1129 In general, these studies have reported
acceptable cost-effectiveness ratios—in the range of $27,000 to
$59,000 (Canadian) per quality-adjusted life year (QALY) gained
over 5-year time horizons.1122,1128 Results would be more favorable
if ablation were found to significantly reduce the risk of stroke.1118
U.S. experts have recently indicated that cost-effectiveness ratios
below $50,000 per QALY indicate high value, and between $50 and
$150,000 indicate intermediate value.1130
Less is known about the cost-effectiveness of ablation in the first-
line setting or in patients with persistent or long-term persistent AF.
One report based on the First Line Radiofrequency Ablation Versus
Antiarrhythmic Drugs for Atrial Fibrillation Treatment (RAAFT) pilot
study suggested that costs for patients initially treated with drugs
would catch up to those for patients treated with ablation within
2 years due to a very high rate of crossover. However, another more
detailed cost-effectiveness study modeled after the MANTRA-PAF
trial population indicated that AF ablation might only be cost-
effective as first-line therapy in younger patients.1125
Assessments of cost-effectiveness at present rely greatly on ex-
trapolations from clinical trials with limited follow-up duration and
sample sizes, necessitating assumptions about key clinical benefits.
Robust data from larger, longer studies will be needed to refine cost-
effectiveness estimates.
Section 10: Complications
Overview
Catheter ablation of AF is one of the most complex interventional
electrophysiological procedures. AF ablation by its nature involves
catheter manipulation and ablation in the delicate thin-walled atria,
which are in close proximity to other important organs and struc-
tures that can be impacted through collateral damage. It is therefore
not surprising that AF ablation is associated with a significant risk of
complications, some of which might result in life-long disability and/
or death. In this section of the document we will review the compli-
cations associated with catheter ablation procedures performed to
treat AF. The complications are defined and their mechanisms
explored. Emphasis is placed on both those complications that occur
most frequently as well as those very infrequent complications that
have the potential to result in the greatest disability and/or death.
Means of avoiding complications are described and recommenda-
tions are made regarding management should the complications
occur.
It is noteworthy that the publications from which these data are
derived come from high-volume centers where one would expect
the incidence of complications to be lower than in lower-volume
centers. As the practice of AF ablation grows with an increasing num-
ber of low-volume centers performing these procedures, it is likely
that the true complication rate of AF ablation will be higher than
described here. Furthermore, other data such as those derived from
the two worldwide surveys of catheter ablation of AF were provided
voluntarily and, again, are therefore likely to underestimate the true
complication rate.806,920 It is notable that a recent paper reported on
the trends in hospital complication rates associated with AF ablation
between 2000 and 2010 based on the Nationwide Inpatient Sample
involving 93,801 procedures.921 The overall incidence of complica-
tions was 6.29%—increasing from 5.3% in 2000 to 7.5% in 2010. The
in-hospital mortality was 0.46%. Not surprisingly, lower operator and
hospital procedure volume was an important predictor of complica-
tions. These data are a stark reminder that our efforts to eliminate
complications associated with AF ablation are incomplete and there
is more work to do.
As our experience with AF ablation continues to grow, new com-
plications are recognized and are reviewed here. These include stiff
LA syndrome, cough, pulmonary injury, gastric hypomotility, and
sinus tachycardia. Once again, the writing group strongly recom-
mends that standardized reporting of complications be part of all
published reports on AF ablation. In this document, we have pro-
vided definitions of the most important complications associated
with AF ablation (Table 8). We hope these definitions and reporting
standards can be incorporated in the design of future clinical trials of
AF ablation. Shown in Table 9 is an overview of the incidence, preven-
tion, diagnosis, and management of selected complications, and Table
5 presents signs and symptoms associated with various complications
early and late postablation.
Cardiac Tamponade
Cardiac tamponade remains the most common potentially life-
threatening complication associated with AF ablation.921 A recent
paper reported on the trends in in-hospital complication rates associ-
ated with AF ablation between 2000 and 2010 based on the
Nationwide Inpatient Sample involving 93,801 procedures.921 In this
analysis, the overall incidence of a “pericardial complication” was
1.5%. The incidence of pericardial complications increased from
0.74% in 2000 to 2.24% in 2010.921 The markedly higher incidence of
cardiac tamponade during AF ablation compared with routine cardiac
electrophysiology procedures can be attributed to a number of im-
portant procedural differences, including extensive intracardiac cath-
eter manipulation and ablation, the common need for two or more
transseptal punctures, and the need for systemic anticoagula-
tion.806,920,921,1131,1132,1133,1134,1135 The most common causes of car-
diac perforation leading to cardiac tamponade during AF ablation are
(1) misdirected transseptal punctures either with punctures per-
formed too posteriorly exiting the RA into the pericardium before
entering the LA or punctures exiting the LA via the roof, LAA, or the
lateral LA wall; (2) direct mechanical trauma, especially through the
LAA; and (3) overheating during RF energy delivery, with or without
the development of a steam pop. Excessive power, temperatures,
and CF might also be contributory.
The need for periprocedural anticoagulation (with the use of inter-
rupted or uninterrupted OAC strategies) and for intraprocedural
anticoagulation (with the infusion of intravenous heparin to achieve a
stable ACT above 300 seconds throughout the procedure duration)
can exacerbate the bleeding risk and increase the volume of bleeding
following the occurrence of one or more of the causes above.
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Table 8 Definitions of complications associated with AF ablation
Asymptomatic cerebral
embolism
Asymptomatic cerebral embolism is defined as an occlusion of a blood vessel in the brain due to an embolus
that does not result in any acute clinical symptoms. Silent cerebral embolism is generally detected using a dif-
fusion weighted MRI.
Atrioesophageal fistula An atrioesophageal fistula is defined as a connection between the atrium and the lumen of the esophagus.
Evidence supporting this diagnosis includes documentation of esophageal erosion combined with evidence of
a fistulous connection to the atrium, such as air emboli, an embolic event, or direct observation at the time of
surgical repair. A CT scan or MRI scan is the most common method of documentation of an atrioesophageal
fistula.
Bleeding Bleeding is defined as a major complication of AF ablation if it requires and/or is treated with transfusion or re-
sults in a 20% or greater fall in hematocrit.
Bleeding following cardiac
surgery
Excessive bleeding following a surgical AF ablation procedure is defined as bleeding requiring reoperation or >_ 2
units of PRBC transfusion within any 24 hours of the first 7 days following the index procedure.
Cardiac perforation We recommend that cardiac perforation be defined together with cardiac tamponade. See “Cardiac tampon-
ade/perforation.”
Cardiac tamponade We recommend that cardiac tamponade be defined together with cardiac perforation. See “Cardiac tampon-
ade/perforation.”
Cardiac tamponade/perforation Cardiac tamponade/perforation is defined as the development of a significant pericardial effusion during or
within 30 days of undergoing an AF ablation procedure. A significant pericardial effusion is one that results in
hemodynamic compromise, requires elective or urgent pericardiocentesis, or results in a 1-cm or more peri-
cardial effusion as documented by echocardiography. Cardiac tamponade/perforation should also be classified
as “early” or “late” depending on whether it is diagnosed during or following initial discharge from the
hospital.
Deep sternal wound infection/
mediastinitis following cardiac
surgery
Deep sternal wound infection/mediastinitis following cardiac surgery requires one of the following: (1) an organ-
ism isolated from culture of mediastinal tissue or fluid; (2) evidence of mediastinitis observed during surgery;
(3) one of the following conditions: chest pain, sternal instability, or fever (>38 C), in combination with ei-
ther purulent discharge from the mediastinum or an organism isolated from blood culture or culture of medi-
astinal drainage.
Esophageal injury Esophageal injury is defined as an erosion, ulceration, or perforation of the esophagus. The method of screening
for esophageal injury should be specified. Esophageal injury can be a mild complication (erosion or ulceration)
or a major complication (perforation).
Gastric motility/pyloric spasm
disorders
Gastric motility/pyloric spasm disorder should be considered a major complication of AF ablation when it pro-
longs or requires hospitalization, requires intervention, or results in late disability, such as weight loss, early
satiety, diarrhea, or GI disturbance.
Major complication A major complication is a complication that results in permanent injury or death, requires intervention for treat-
ment, or prolongs or requires hospitalization for more than 48 hours. Because early recurrences of AF/AFL/
AT are to be expected following AF ablation, recurrent AF/AFL/AT within 3 months that requires or prolongs
a patient’s hospitalization should not be considered to be a major complication of AF ablation.
Mediastinitis Mediastinitis is defined as inflammation of the mediastinum. Diagnosis requires one of the following: (1) an or-
ganism isolated from culture of mediastinal tissue or fluid; (2) evidence of mediastinitis observed during sur-
gery; (3) one of the following conditions: chest pain, sternal instability, or fever (>38 C), in combination with
either purulent discharge from the mediastinum or an organism isolated from blood culture or culture of me-
diastinal drainage.
Myocardial infarction in the con-
text of AF ablation
The universal definition of myocardial infarction1399 cannot be applied in the context of catheter or surgical AF
ablation procedures because it relies heavily on cardiac biomarkers (troponin and CPK), which are anticipated
to increase in all patients who undergo AF ablation as a result of the ablation of myocardial tissue. Similarly,
chest pain and other cardiac symptoms are difficult to interpret in the context of AF ablation both because of
the required sedation and anesthesia and also because most patients experience chest pain following the pro-
cedure as a result of the associated pericarditis that occurs following catheter ablation. We therefore pro-
pose that a myocardial infarction, in the context of catheter or surgical ablation, be defined as the presence
of any one of the following criteria: (1) detection of ECG changes indicative of new ischemia (new ST-T wave
changes or new LBBB) that persist for more than 1 hour; (2) development of new pathological Q waves on
an ECG; (3) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
Continued
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One initial large study reported that uninterrupted VKA anticoagula-
tion therapy did not result in a higher incidence of tamponade com-
pared with interrupted VKA anticoagulation therapy with bridging
heparin.532,533 This observation was further corroborated by two
meta-analyses.399,400,401,1136 Another study compared the outcomes
of 23 patients who developed pericardial tamponade with an INR <2
to 17 patients on warfarin with an INR >2. No difference was
observed in the initial pericardial drainage, or the duration of
drainage; no patients required surgery.1137 A more recent shift in
periprocedural anticoagulation strategies during AF ablation involves
performing AF ablation on uninterrupted NOAC therapy. The re-
sults of the RE-CIRCUIT study, which was a head-to-head compari-
son of performing AF ablation on uninterrupted dabigatran vs
uninterrupted warfarin, were recently published.841 This study
randomized 704 patients across 104 sites to these two anticoagula-
tion strategies. The incidence of major bleeding events during and up
Pericarditis Pericarditis should be considered a major complication following ablation if it results in an effusion that leads to
hemodynamic compromise or requires pericardiocentesis, prolongs hospitalization by more than 48 hours,
requires hospitalization, or persists for more than 30 days following the ablation procedure.
Phrenic nerve paralysis Phrenic nerve paralysis is defined as absent phrenic nerve function as assessed by a sniff test. A phrenic nerve
paralysis is considered to be permanent when it is documented to be present 12 months or longer following
ablation.
Pulmonary vein stenosis Pulmonary vein stenosis is defined as a reduction of the diameter of a PV or PV branch. PV stenosis can be cate-
gorized as mild <50%, moderate 50%–70%, and severe >_70% reduction in the diameter of the PV or PV
branch. A severe PV stenosis should be considered a major complication of AF ablation.
Serious adverse device effect A serious adverse device effect is defined as a serious adverse event that is attributed to use of a particular
device.
Stiff left atrial syndrome Stiff left atrial syndrome is a clinical syndrome defined by the presence of signs of right heart failure in the pres-
ence of preserved LV function, pulmonary hypertension (mean PA pressure >25 mm Hg or during exercise
>30 mm Hg), and large V waves >_10 mm Hg or higher) on PCWP or left atrial pressure tracings in the ab-
sence of significant mitral valve disease or PV stenosis.
Stroke or TIA postablation Stroke diagnostic criteria
• Rapid onset of a focal or global neurological deficit with at least one of the following: change in level of con-
sciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia or
aphasia, hemianopia, amaurosis fugax, or other neurological signs or symptoms consistent with stroke
• Duration of a focal or global neurological deficit >_24 hours; OR < 24 hours if therapeutic intervention(s) were
performed (e.g., thrombolytic therapy or intracranial angioplasty); OR available neuroimaging documents a
new hemorrhage or infarct; OR the neurological deficit results in death.
• No other readily identifiable nonstroke cause for the clinical presentation (e.g., brain tumor, trauma, infection,
hypoglycemia, peripheral lesion, pharmacological influences).^
• Confirmation of the diagnosis by at least one of the following: neurology or neurosurgical specialist; neuroi-
maging procedure (MRI or CT scan or cerebral angiography); lumbar puncture (i.e., spinal fluid analysis diag-
nostic of intracranial hemorrhage)
Stroke definitions
• Transient ischemic attack: new focal neurological deficit with rapid symptom resolution (usually 1 to 2 hours),
always within 24 hours; neuroimaging without tissue injury
• Stroke: (diagnosis as above, preferably with positive neuroimaging study);
Minor—Modified Rankin score <2 at 30 and 90 days†
Major—Modified Rankin score >_2 at 30 and 90 days
Unanticipated adverse device
effect
Unanticipated adverse device effect is defined as complication of an ablation procedure that has not been previ-
ously known to be associated with catheter or surgical ablation procedures.
Vagal nerve injury Vagal nerve injury is defined as injury to the vagal nerve that results in esophageal dysmotility or gastroparesis.
Vagal nerve injury is considered to be a major complication if it prolongs hospitalization, requires hospitaliza-
tion, or results in ongoing symptoms for more than 30 days following an ablation procedure.
Vascular access complication Vascular access complications include development of a hematoma, an AV fistula, or a pseudoaneurysm. A
major vascular complication is defined as one that requires intervention, such as surgical repair or transfusion,
prolongs the hospital stay, or requires hospital admission.
AF, atrial fibrillation; CT, computed tomography; MRI, magnetic resonance imaging; PRBC, packed red blood cell; AFL, atrial flutter; AT, atrial tachycardia; CPK, creatine phos-
phokinase; ECG, electrocardiogram; LBBB, left bundle branch block.
^Patients with nonfocal global encephalopathy will not be reported as a stroke without unequivocal evidence based on neuroimaging studies.
†
Modified Rankin score assessments should be made by qualified individuals according to a certification process. If there is discordance between the 30- and 90-day modified
Rankin scores, a final determination of major versus minor stroke will be adjudicated by the neurology members of the clinical events committee.
e84 Guidelines
Downloaded from https://academic.oup.com/europace/article-abstract/20/1/e1/4158475
by Erasmus University Rotterdam user
on 29 January 2018
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
.
T
ab
le
9
In
c
id
e
n
c
e
,
p
re
v
e
n
ti
o
n
,
d
ia
g
n
o
si
s,
a
n
d
tr
e
a
tm
e
n
t
o
f
se
le
c
te
d
c
o
m
p
li
c
a
ti
o
n
s
o
f
A
F
a
b
la
ti
o
n
C
o
m
p
li
c
a
ti
o
n
In
c
id
e
n
c
e
S
e
le
c
te
d
p
re
v
e
n
ti
o
n
te
c
h
n
iq
u
e
s
D
ia
g
n
o
st
ic
te
st
in
g
S
e
le
c
te
d
tr
e
a
tm
e
n
t
o
p
ti
o
n
s
R
e
fe
re
n
c
e
s
A
ir
em
bo
lis
m
<
1%
Sh
ea
th
m
an
ag
em
en
t
N
ot
hi
ng
or
ca
rd
ia
c
ca
th
et
er
iz
at
io
n
Su
pp
or
tiv
e
ca
re
w
ith
flu
id
,
ox
yg
en
,h
ea
d
do
w
n
til
t,
hy
pe
rb
ar
ic
ox
yg
en
8
0
3
,1
2
1
8–
1
2
2
3
A
sy
m
pt
om
at
ic
ce
re
br
al
em
bo
li
(A
C
E)
2%
to
15
%
A
nt
ic
oa
gu
la
tio
n,
ca
th
et
er
an
d
sh
ea
th
m
an
ag
em
en
t,
T
EE
Br
ai
n
M
R
I
N
on
e
7
2
3
,7
2
4
,7
2
8
,7
3
1
,8
0
0,
1
2
0
5
–1
2
1
7
A
tr
ia
le
so
ph
ag
ea
lfi
st
ul
a
0.
02
%
to
0.
11
%
R
ed
uc
e
po
w
er
,f
or
ce
,a
nd
R
F
tim
e
on
po
st
er
io
r
w
al
l,
m
on
ito
r
es
op
ha
ge
al
te
m
p,
us
e
pr
ot
on
pu
m
p
in
-
hi
bi
to
rs
;a
vo
id
en
er
gy
de
liv
er
y
ov
er
es
op
ha
gu
s
C
T
sc
an
of
ch
es
t,
M
R
I;
av
oi
d
en
-
do
sc
op
y
w
ith
ai
r
in
su
ffl
at
io
n
Su
rg
ic
al
re
pa
ir
6
3
7
,7
0
5
,8
0
6
,8
6
6
,8
7
7
–
9
2
0,
1
1
6
2
–
1
1
78
,1
3
9
8
C
ar
di
ac
ta
m
po
na
de
0.
2%
to
5%
C
at
he
r
m
an
ip
ul
at
io
n,
tr
an
ss
ep
ta
lt
ec
hn
iq
ue
,r
ed
uc
e
po
w
er
,f
or
ce
,a
nd
R
F
tim
e
Ec
ho
ca
rd
io
gr
ap
hy
Pe
ri
ca
rd
io
ce
nt
es
is
or
su
r-
gi
ca
ld
ra
in
ag
e
4
8
2
,8
0
6
,9
0
8
,9
2
0
,9
2
1,
1
0
3
4
,1
1
3
1
–
1
1
35
,1
1
3
9
–
1
1
4
1
C
or
on
ar
y
ar
te
ry
st
en
-
os
is
/o
cc
lu
si
on
<
0.
1%
A
vo
id
hi
gh
-p
ow
er
en
er
gy
de
liv
er
y
ne
ar
co
ro
na
ry
ar
te
ri
es
C
ar
di
ac
ca
th
et
er
iz
at
io
n
PT
C
A
9
2
3
,1
2
3
3
–
1
2
4
0
D
ea
th
<
0.
1%
to
0.
4%
M
et
ic
ul
ou
s
pe
rf
or
m
an
ce
of
pr
oc
ed
ur
e,
at
te
nt
iv
e
po
st
pr
oc
ed
ur
e
ca
re
N
A
N
A
9
2
1
,8
0
6
,9
0
8
,9
2
0
,1
0
3
9
G
as
tr
ic
hy
po
m
ot
ili
ty
0%
to
17
%
R
ed
uc
e
po
w
er
,f
or
ce
,a
nd
R
F
tim
e
on
po
st
er
io
r
w
al
l
En
do
sc
op
y,
ba
ri
um
sw
al
lo
w
,g
as
-
tr
ic
em
pt
yi
ng
st
ud
y
M
et
oc
lo
pr
am
id
e,
po
ss
ib
ly
in
tr
av
en
ou
s
er
yt
hr
om
yc
in
5
3
6
,1
0
1
7–
1
0
2
1
,1
1
7
9–
1
1
8
5
M
itr
al
va
lv
e
en
tr
ap
m
en
t
<
0.
1%
A
vo
id
ci
rc
ul
ar
ca
th
et
er
pl
ac
em
en
t
ne
ar
or
ac
ro
ss
m
itr
al
va
lv
e;
cl
oc
kw
is
e
to
rq
ue
on
ca
th
et
er
Ec
ho
ca
rd
io
gr
ap
hy
G
en
tle
ca
th
et
er
m
an
ip
ul
a-
tio
n,
su
rg
ic
al
ex
tr
ac
tio
n
1
2
6
3
–
1
2
6
9,
1
3
9
6
Pe
ri
ca
rd
iti
s
0%
to
50
%
N
on
e
pr
ov
en
C
lin
ic
al
hi
st
or
y,
EC
G
,s
ed
im
en
ta
-
tio
n
ra
te
,e
ch
oc
ar
di
og
ra
m
N
SA
ID
,c
ol
ch
ic
in
e,
st
er
oi
ds
9
8
5
,9
8
6
,1
2
5
7
–
1
2
6
2
Pe
rm
an
en
t
ph
re
ni
c
ne
rv
e
pa
ra
ly
si
s
0%
to
0.
4%
M
on
ito
r
di
ap
hr
ag
m
du
ri
ng
ph
re
ni
c
pa
ci
ng
,C
M
A
P
m
on
ito
ri
ng
,p
hr
en
ic
pa
ci
ng
to
id
en
tif
y
lo
ca
tio
n
an
d
ad
ju
st
le
si
on
lo
ca
tio
n
C
X
R
,s
ni
ff
te
st
Su
pp
or
tiv
e
ca
re
4
6
2
,4
8
2
,4
9
0
,5
0
3
,5
3
2,
5
3
3
,5
3
6,
7
0
6
,7
0
7,
7
7
9,
8
0
8
,9
0
3,
9
2
0
,1
0
1
7,
1
0
7
5
,1
1
8
2
–
1
2
0
1
Pu
lm
on
ar
y
ve
in
st
en
os
is
<
1%
A
vo
id
en
er
gy
de
liv
er
y
w
ith
in
PV
C
T
or
M
R
I,
V
/Q
w
av
e
sc
an
A
ng
io
pl
as
ty
,s
te
nt
,s
ur
ge
ry
2
4
4
,4
3
4
,4
6
2
,4
8
2
,4
9
8,
5
0
3
,9
2
7,
9
2
8
,1
1
4
2–
1
1
6
0
R
ad
ia
tio
n
in
ju
ry
<
0.
1%
M
in
im
iz
e
flu
or
os
co
py
ex
po
su
re
,e
sp
ec
ia
lly
in
ob
es
e
an
d
re
pe
at
ab
la
tio
n
pa
tie
nt
s,
X
-r
ay
eq
ui
pm
en
t
N
on
e
Su
pp
or
tiv
e
ca
re
,r
ar
el
y
sk
in
gr
af
t
7
4
7
,7
4
9
,7
6
3
,1
1
8
6,
1
2
4
1
–
1
2
5
6
St
iff
le
ft
at
ri
al
sy
nd
ro
m
e
<
1.
5%
Li
m
it
ex
te
nt
of
le
ft
at
ri
al
ab
la
tio
n
Ec
ho
ca
rd
io
gr
ap
hy
,c
ar
di
ac
ca
th
et
er
iz
at
io
n
D
iu
re
tic
s
1
1
1
0
,1
1
1
1,
1
2
7
0
–
1
2
7
5
St
ro
ke
an
d
T
IA
0%
to
2%
Pr
e-
,p
os
t-
,a
nd
in
tr
ap
ro
ce
du
re
an
tic
oa
gu
la
tio
n,
ca
th
et
er
an
d
sh
ea
th
m
an
ag
em
en
t,
T
EE
H
ea
d
C
T
or
M
R
I,
ce
re
br
al
an
gi
og
ra
ph
y
T
hr
om
bo
ly
tic
th
er
ap
y,
an
gi
op
la
st
y
2
4
2
,4
8
9
,5
0
3
,5
3
2
,6
5
5,
6
7
3
,7
9
6,
7
9
8
,
7
9
9,
8
0
6
,9
2
0,
9
2
1
,1
2
0
2–
1
2
0
4
V
as
cu
la
r
co
m
pl
ic
at
io
ns
0.
2%
to
1.
5%
V
as
cu
la
r
ac
ce
ss
te
ch
ni
qu
es
,u
ltr
as
ou
nd
-g
ui
de
d
ac
-
ce
ss
,a
nt
ic
oa
gu
la
tio
n
m
an
ag
em
en
t
V
as
cu
la
r
ul
tr
as
ou
nd
,C
T
sc
an
C
on
se
rv
at
iv
e
tr
ea
tm
en
t,
su
rg
ic
al
re
pa
ir
,
tr
an
sf
us
io
n
8
0
6
–
8
0
8,
8
3
4
,8
4
0–
8
4
2
,9
2
0
,9
2
1
,1
2
2
4–
1
2
3
2
A
F,
at
ri
al
fib
ri
lla
tio
n;
C
T
,c
om
pu
te
d
to
m
og
ra
ph
y;
M
R
I,
m
ag
ne
tic
re
so
na
nc
e
im
ag
in
g;
T
EE
,t
ra
ns
es
op
ha
ge
al
el
ec
tr
oc
ar
di
og
ra
m
;R
F,
ra
di
of
re
qu
en
cy
;P
T
C
A
,p
er
cu
ta
ne
ou
s
tr
an
sl
um
in
al
co
ro
na
ry
an
gi
op
la
st
y;
N
A
,n
ot
ap
pl
ic
ab
le
;E
C
G
,e
le
ct
ro
-
ca
rd
io
gr
am
;N
SA
ID
,n
on
st
er
oi
da
la
nt
i-i
nfl
am
m
at
or
y
dr
ug
;C
M
A
P,
co
m
po
un
d
m
ot
or
ac
tio
n
po
te
nt
ia
ls
;C
X
R
,c
he
st
X
-r
ay
;T
IA
,t
ra
ns
ie
nt
is
ch
em
ic
at
ta
ck
.
Guidelines e85
Downloaded from https://academic.oup.com/europace/article-abstract/20/1/e1/4158475
by Erasmus University Rotterdam user
on 29 January 2018
to 8 weeks postablation among the 635 patients who underwent AF
ablation was significantly lower with dabigatran than with warfarin (5
patients [1.6%] vs 22 patients [6.9%]; absolute RD -5.3%; RR reduc-
tion 77%). It is notable that there were six patients with cardiac tam-
ponade in the warfarin arm vs one in the dabigatran arm. All the
patients with cardiac tamponade underwent successful pericardio-
centesis with no need for surgical drainage. No strokes or other
thromboembolic events occurred in the dabigatran arm compared
with one TIA in the warfarin arm. No patients in the dabigatran arm
required the specific reversal agent idarucizumab. Another smaller
prospective trial of 250 patients that randomized patients to
undergoing AF ablation on uninterrupted rivaroxaban versus uninter-
rupted warfarin has been published.842 The incidence of major bleed-
ing was low (0.4%), and no patient developed pericardial tamponade.
A recent meta-analysis reported that performance of AF ablation on
NOACs was associated with a lower risk of minor bleeding and no
major differences in the risk of stroke or TIA, cardiac tamponade, or
groin hematomas.1138 Another recent study described the outcomes
of 16 patients who developed a pericardial effusion while taking an
uninterrupted Xa inhibitor. Eleven occurred in the periprocedural
setting and 5 occurred between 1 and 28 days postprocedure. All the
patients underwent pericardiocentesis. Protamine and 4-factor pro-
thrombin complex concentrate were given to all periprocedure
cases. Two patients required surgery. There were no deaths in this
series.
The incidence of tamponade might be as high as 6%1135 and as
low as 0%. The risk factors for tamponade identified in this study
were linear ablation lesions and higher ablation power. A “pop”
was heard during eight of these 10 cases of tamponade. Another
large series reported cardiac tamponade during 15 of 632 ablation
procedures (2.4%).1134 Two of these patients required surgical
intervention. In contrast to the prior study, no “pop” was reported.
The two worldwide surveys of AF ablation reported a 1.2% and a
1.3% incidence of cardiac tamponade, respectively.806,920 A recent
meta-analysis of ablation procedures reported a 0.9% incidence of
tamponade.1139 Women were 1.83-fold more likely to develop
tamponade compared with men. A reciprocal relationship be-
tween center volume and the incidence of outcomes of cardiac
tamponade was observed. Overall, 16% of tamponade cases
required surgery, with lower rates of surgery in high-volume cen-
ters.1139 A meta-analysis of CBA with data on 1308 procedures re-
ported an overall incidence of cardiac effusion or tamponade of
1.5%.482 A more recent prospective RCT of CBA vs RF ablation re-
ported an incidence of tamponade of 1.3% in the RF arm and of
0.3% in the CB arm.489 Although it was hoped the recent introduc-
tion of force-sensing catheters would reduce the rate of tampon-
ade, this has not been confirmed in clinical trials. The incidence of
cardiac tamponade was 2.5% among 161 patients in the safety co-
hort of the recently published SMART-AF trial of the Smart Touch
catheter.673 And in the TOCCASTAR trial, which randomized pa-
tients to ablation with a force-sensing catheter (Endosense) or a
standard irrigated RF catheter, no difference in the incidence of
cardiac tamponade was observed in the two arms (0.66% vs 0.7%,
P= NS).655 It is important to recognize that the presentation of
cardiac tamponade might be delayed and can occur any time from
an hour after the procedure to weeks later.1034,1139 The incidence
of delayed tamponade was 0.2% in the worldwide survey
report.1034 Most, but not all, patients presented with warning
symptoms and 13% of patients presented with hypotension and
shock.
Cardiac tamponade presents either as an abrupt dramatic fall in
BP, or more insidiously, as a gradual decrease in BP. In the latter case,
administration of fluid might return the BP to normal before it subse-
quently declines. However, it is vital that operators and staff be vigi-
lant to the development of cardiac tamponade, as a delay in diagnosis
can be fatal. Sixty percent of the writing group members use an arter-
ial line for BP monitoring during the AF ablation procedure. The de-
velopment of hypotension in any patient should be assumed to
indicate tamponade until proven otherwise by immediate ECG. An
early sign of cardiac tamponade is a reduction in the excursion of the
cardiac silhouette on fluoroscopy with a simultaneous fall in systemic
BP. Ninety percent of the writing group members have an echo ma-
chine in their EP laboratory. Sixty percent of the writing group mem-
bers routinely image the heart with an echocardiogram prior to the
patient leaving the procedure room. Twenty percent of the writing
group members routinely obtain an echocardiogram of the heart
prior to discharge. ICE has been reported to allow earlier detection
of pericardial effusion. It is important to recognize that small, asymp-
tomatic pericardial effusions are commonly observed following AF
ablation procedures. ICE imaging has the potential to detect pericar-
dial effusion earlier. A survey of writing group members reveals that
53% of members routinely employ ICE imaging during AF ablation.
Our survey revealed that ICE was being used routinely by 87% of the
writing group members in the United States and Canada as compared
with 13% of the writing group members from other countries.
Monitoring filling pressures in the LA and RA can be helpful in order
to evaluate progression of the effusion and/or effective drainage of
the pericardial collection. Ninety-three percent of the writing group
members hospitalize their AF ablation patients for at least one night
following their procedure.
The majority of episodes of cardiac tamponade can be managed
successfully by immediate percutaneous drainage and reversal of anti-
coagulation with protamine. In patients anticoagulated with warfarin,
fresh frozen plasma is often administered. And in patients on an Xa
inhibitor, 4-factor prothrombin complex concentrate is often appro-
priate. For patients on dabigatran, the reversal agent idarucizumab is
now available worldwide and provides the opportunity to immedi-
ately reverse the anticoagulant effects of dabigatran.844 Factor Xa in-
hibitors can be reversed with andexanet alfa (currently not approved
for clinical use).845 Percutaneous drainage is best achieved by subxi-
phoid Seldinger puncture of the pericardial sac and placement of an
intrapericardial catheter. The pericardial tap can be performed either
with fluoroscopic guidance based on anatomic landmarks or with
echo guidance.1140 After initial aspiration, the BP promptly returns to
normal. Once the pericardial space has been drained, the patient
needs to be monitored for ongoing bleeding with the drainage cath-
eter. The drainage catheter is typically left in place for at least
12 hours postablation. In rare cases, if there has been a tear, percu-
taneous drainage might be inadequate, and surgical drainage and re-
pair could be necessary.1134 One recent meta-analysis reported that
16% of cases of cardiac tamponade required surgical intervention.1139
It is for this reason that AF ablation procedures should only be per-
formed in hospitals equipped or prepared to manage these types of
emergencies with access to emergency surgical support when
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required. Three cases have been reported of emergent drainage of a
pericardial effusion through a sheath, either inadvertently or pur-
posely placed into the pericardial space using an endocardial ap-
proach, although this would not be considered to be a standard
approach.532,533,1132,1141 Early recognition and rapid appropriate
treatment of cardiac tamponade is mandatory to prevent irreversible
deterioration in perfusion of the brain and other important organs. In
a dedicated worldwide survey, cardiac tamponade was reported to
be the most frequent cause of periprocedural death, with 25% of all
fatalities occurring in association with this complication.908
PV Stenosis
PV stenosis is a well-recognized complication of AF ablation that
results from thermal injury to the PVs, including the media, intima,
adventitia, and PV musculature. Since first reported in 1998, nu-
merous studies have sought to determine the incidence, cause,
diagnostic strategy and treatment approach for PV sten-
osis.434,927,1142,1143,1144,1145 Although the precise pathophysiological
mechanisms are still uncertain, a progressive neointimal proliferation
and myocardial fibrosis resulting in endovascular contraction has
been reported after extensive radiofrequency energy ablation (RFA)
to canine PVs.1146 PV stenosis has been described for both point-by-
point RF ablation as well as CBA.244,462,482,928,1146,1147 To the best of
our knowledge, significant PV stenosis has not been reported with
the laser balloon system.498,503 There are controversial data regard-
ing any impact that RF power output has on the rate of PV sten-
osis.244,1147 The incidence of PV stenosis might be somewhat lower
with CB AF ablation than with RFA.1148,1149 In experienced hands,
however, PV stenosis has become an increasingly uncommon compli-
cation with either ablation technology.489 The highest risk for PV
stenosis is associated with RFA close to the PV orifices and/or within
the PVs, with a 5.6-fold higher incidence in comparison with antral ab-
lation.1147 Ablation within the PVs should be avoided, but can occur
due to shifts in the 3D electroanatomic map, respiratory motion,
poor catheter stability, and/or an inexperienced operator.
The published incidence of PV stenosis varies widely, from 0% to
40%.434,505,778,1142,1144,1150,1151 This variation results from differences
in the ablation technique, definitions of PV stenosis, the intensity of
screening for this complication, and the date the study was per-
formed. When PV ablation for treating AF began in the late 1990s, in-
vestigators were unaware that PV stenosis was a potential
complication. In contrast, operators today understand that PV sten-
osis can be prevented by avoiding RF energy delivery within a PV.
This increased awareness and improvements in imaging modalities
have enabled better identification of the true PV ostium and have re-
sulted in a dramatic reduction in the incidence of PV stenosis.1141,1147
The incidence of symptomatic PV stenosis in experienced hands
approaches zero, although the incidence of asymptomatic PV sten-
osis or PV narrowing might be higher.
Symptoms usually occur weeks to months after the ablation pro-
cedure.927,1152 Prominent symptoms are dyspnea, hemoptysis, cough,
(recurrent) pulmonary infections or pneumonia, and chest
pain.1142,1143,1152 These have often led to a misdiagnosis of pneumo-
nia, pulmonary embolism, or even lung cancer; thus, patients should
be told of the importance of returning to their ablation center if such
signs or symptoms develop. There are data showing a progression of
stenosis during 3 months after RFA despite a normal imaging
examination at 1 month after the index procedure. Furthermore, se-
vere stenosis can also remain asymptomatic.927 According to the per-
centage reduction of the luminal diameter, the severity of PV stenosis
is generally defined as mild (<50%), moderate (50%–70%), or severe
(>70%). In this consensus statement, we recommend that a significant
PV stenosis be defined as a > 70% reduction in luminal diameter. PV
stenosis can develop in any PV; and in some patients, multiple PV
stenoses occur.927,928,1143,1152 It is unclear whether such patients are
more prone to develop PV stenosis compared with others.
PV stenosis can be diagnosed by CT imaging, MRI, perfusion scans,
TEE, or pulmonary venography. The preferred imaging modality is
MRI or CT because location and severity of PV lesions can be pre-
cisely visualized. Advantages of MRI include the fact that pulmonary
perfusion data can be obtained simultaneously and that the diagnostic
procedure is free of radiation. Eleven percent of the writing group
members routinely obtain a CT or MR scan several months postabla-
tion to screen for asymptomatic PV stenosis.
Although the incidence of PV stenosis has decreased over recent
years, it remains a significant complication because it is difficult to
treat and, rarely, it can lead to death. It is notable that 51% of the writ-
ing group members report having had a patient at their center de-
velop PV stenosis requiring intervention. Most of these procedures
were performed more than a decade ago. The indication for inter-
vention is guided predominantly by the presence or absence of symp-
toms. Asymptomatic or mild symptomatic PV stenosis should be
managed conservatively with watchful waiting, given symptomatic
amelioration has been observed after PV stenosis or occlusion with-
out treatment and indicates collateral formation or recruitment.1153
For symptomatic patients, PV angioplasty should be considered. In
patients with more than one PV stenosis, perfusion imaging may be
applied to identify the “culprit” lesion. The dilation procedure is often
complex, especially if the target PV is completely occluded with failed
visualization from direct angiography via the LA as well as antegradely
via pulmonary artery angiography. Electroanatomical 3D mapping
with registration of the anatomy of the LA and the PVs, as well as fu-
sion with the reconstructed LA from the imaging scan before the
index procedure, enables a precise localization of the occluded
PV.1154 Baseline CT or MRI is more helpful in defining the PV
anatomy.
Many PV stenoses are rigid and difficult to dilate. Even after acutely
successful angioplasty, PV restenosis occurs in up to 50% of
cases.927,1142,1143,1152,1155 Stent sizes of 9 mm or more, and especially
drug-eluting stents, revealed significantly better results, although drug-
eluting stents of this size are not available.1142,1143,1144,1156 Whether or
not primary stenting of PV stenosis offers better results than angio-
plasty alone has now been systematically studied by several
groups.1144,1155 The risk of restenosis is significantly less with PV stent-
ing, providing a stent of 8–10 mm in diameter can be used. A further
problem is the small sample size of the published case series.
Complications of interventional treatment of PV stenosis include LA
perforation with or without tamponade, but also PV dissection with
massive bleeding, stent embolization, and stent thrombosis.1142,1143
There are limited data regarding the need for and intensity of anticoa-
gulation and antiplatelet therapy. For cases in which anticoagulation is
otherwise indicated for AF, a regimen including the addition of clopi-
dogrel is most commonly used. Without the indication for anticoagula-
tion, warfarin and clopidogrel should be combined. The duration of
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anticoagulation needed remains unclear. In the case of restenosing PVs,
anticoagulation for life might be necessary. In the setting of stable PV
stents over the course of 1–2 years, clopidogrel and, subsequently,
warfarin can be discontinued. The role of NOACs in PV stenosis has
not been readily studied. Surgical patch repair of primary PV stenosis in
children reveals a 5-year success rate of 67%, with an in-hospital mor-
tality of 10%.1157 Only one case of surgical treatment of severe PV
stenosis with patch implantation after catheter ablation has been re-
ported.1158 Thus, it remains unclear whether the results are better
than with conventional interventional treatment. Connecting the patch
to the proximal end of the stenosis is difficult, because this end is
buried in the lung parenchyma. Given this challenge, and the excessive
risk, there is no foundation for recommending its use in patients with
recurrent PV stenosis after AF ablation, and decision making cannot be
based on a single case report. Even for patients with recurrent severe
and persistent problems due to restenosis despite interventional treat-
ment, recurrent infection and hemoptysis are uncommon, readily man-
ageable, and the need for lobectomy or pneumonectomy is very rare.
In the largest series of PV stenosis to date, both patients who under-
went subsequent pneumonectomy at outside institutions died during
or after surgery.1155 Although lung transplantation can be considered
in a case of congenital PV stenosis,1159 this has never been required in
AF-ablation patients. Dealing with patients with fibrosing mediastinitis
and PV or peripheral artery (PA) stenosis is, in contrast, exceptionally
difficult.1160
Successful PV angioplasty or stenting usually results in a significant
relief of symptoms.1142,1143,1144,1145,1155,1156 Thus, follow-up strat-
egies and intensity should be based on symptoms. Patients with re-
stenosis usually report an increase of complaints existing prior to the
intervention. In such cases, MRI is recommended. There is an add-
itional critical consideration in dealing with PV stenosis. With the de-
cline in follow-up CT scans after AF ablation, the occurrence of
serious stenosis, hemoptysis, permanent PV occlusion, scarring, lung
infarction, and intraparenchymal hemorrhage has increased. Many
such patients are being inappropriately evaluated for lung cancer be-
cause of the appearance of intraparenchymal hemorrhage. Candidate
veins for intervention are also increasingly problematic. These are
more difficult to open and have a higher restenosis rate, requiring re-
petitive reintervention. Because of this, it is recommended that if a
patient does not undergo a routine follow-up 3-month CT or MR, at
a minimum, those with recurrent pulmonary symptoms after AF abla-
tion should be scanned to exclude PV stenosis. Patients should also
be routinely screened for symptoms at the time of follow-up evalu-
ations. The take-home message is to identify PV stenosis before it be-
comes a serious problem.
Atrial Esophageal Fistula, Atrial
Pericardial Fistula, and Esophageal
Hematoma
Esophageal injury is one of the most important complications
associated with catheter and surgical ablation of AF. In this section
of the document we will focus on three types of esophageal injury:
(1) esophageal hematoma, (2) atrial pericardial fistula, and (3)
AEF. We will consider esophagopericardial fistula and AEF as one
topic, and will focus mainly on this serious and often lethal compli-
cation of AF ablation. However, to be complete, we will also
comment on the recently described complication of an esopha-
geal hematoma.
Esophageal Hematoma
The esophagus can be injured directly as a result of trauma from a
transesophageal probe. Esophageal hematoma is a recognized com-
plication after a transesophageal echo study, which can be performed
in association with the ablation procedure.1161 A recent study re-
ported that 0.27% of the patients who underwent an AF ablation
with a preprocedure TEE experienced this complication. The pre-
dominant symptoms were pain on swallowing, regurgitation, and
hoarseness, with an onset within 12 hours of the procedure. Fever
and neurological symptoms were not present. The diagnosis was es-
tablished by a CT scan, which ruled out an AEF and revealed a hema-
toma localized to either the upper esophagus or extending the length
of the esophagus. Endoscopy can further confirm the diagnosis.
Conservative management is advised. Long-term consequences of
this complication include an esophageal stricture, esophageal dysmo-
tility, and vocal cord paralysis.1161
AEF and Atrial Pericardial Fistula
Esophageal ulceration, perforation, or development of a left AEF or
atrial pericardial fistula, have been reported after both catheter abla-
tion of AF and surgical ablation of AF using unipolar RF cur-
rent.806,866,920,1162,1163,1164,1165,1166,1167,1168,1169 It is a possible
complication after catheter ablation using any energy modality that
produces transmural atrial lesions. Although early reports showed
AEF resulting from RF ablation, more recently, AEFs have also been
reported after CBA.877,878,879,1170 An adequately powered study
examining the relative frequency of this complication with the two
primary ablation modalities has not yet been performed. AEFs have
also been reported following ablation with a focal ultrasound balloon
ablation system that is no longer clinically available.705,1167 Esophageal
erosion has also been reported with a circular multielectrode irri-
gated RF ablation system.1171 It is notable that 51% of the writing
group members report having had a patient at their center develop
an AEF following AF ablation. It should be clear, however, that the oc-
currence of an esophageal ulcer is not the same as an AEF. Although
AEFs can be accompanied by ulcers, the presence of an ulcer is not
predictive of an AEF. Occurring in 10%–40% of patients undergoing
an AF ablation, the prevalence of an AEF is closer to one in one thou-
sand in those with an ulcer.
Although the precise mechanism of esophageal tissue injury is not
understood, potential mechanisms include direct thermal injury, acid
reflux, infection from the lumen, and ischemic injury through thermal
occlusion of end arterioles. It has been hypothesized that vagal dam-
age resulting from ablation on the posterior LA wall can cause gastro-
esophageal reflux by damaging the vagal nerves that run along the
esophagus, altering the lower esophageal sphincter pressure. This hy-
pothesis proposes that high esophageal acid production could con-
tribute indirectly to the formation of AEFs.1172,1173 This hypothesis is
attractive; however, one study that attempted to validate it by meas-
uring esophageal acid levels post-AF ablation was negative.1173 The
prevalence of esophageal reflux and an AEF are also very different.
Although the development of an AEF following AF ablation is a
very uncommon complication, its importance rests in the lethality of
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this complication. The Updated Worldwide Survey on the Methods,
Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation
reported an AEF in six patients (0.04%).920 This incidence was similar
to a separate survey of members of the Heart Rhythm Society. In this
survey, an AEF was reported in 6 of 20,425 patients (0.03%).1168 All six
of these patients experienced major cerebrovascular events, and five
(83%) died. In contrast to an AEF, which is very rare, subclinical injury
to the esophagus is extremely common following AF ablation. A
more recent study reported an AEF incidence of 0.11%. In a number
of studies, an endoscopy has been performed to screen for esopha-
geal injury 1–3 days following AF ablation.1174 Esophageal tissue injury
has been reported in up to 50% of patients.637,882,1175 Observed
asymptomatic esophageal ulcers were usually healed on repeat en-
doscopy at 2–3 weeks.1176 One study reported endoscopy per-
formed on 267 patients who underwent RF ablation. The power on
the posterior wall was limited to 25 W. Among these patients, 6
(2.2%) had either erythema (n= 2) or a necrotic ulcer (n= 4) on en-
doscopy. Multivariate analysis revealed that the distance between the
LA and the esophagus was the only independent predictor, although
an LA isthmus line and CS ablation showed a trend.900 After treat-
ment with a PPI (pantoprazole or esomeprazole) and sucralfate, all
recovered without development of an AEF. One study reported a
higher incidence of esophageal injury among patients undergoing AF
ablation with general anesthesia compared with conscious sed-
ation.637 It has been proposed that this relationship reflects the ab-
sence of pain feedback and reduced esophageal motility resulting
from general anesthesia.
The clinical manifestations of an AEF usually present 2–4 weeks
after the ablation procedure. The most common symptoms are fever
and recurrent neurological events (septic emboli), but patients can
present with septic shock, esophageal bleeding, or death. A recent
case series of 53 patients who developed an AEF following AF abla-
tion reported a mean interval between the procedure and presenta-
tion of 20 ± 12 days, ranging from 2 to 60 days. In this series, fever
was the most common presenting symptom, followed by neuro-
logical deficits and hematemesis.1176 The preferred diagnostic modal-
ity is a chest CT scan.1169,1176 It is important to recognize that a
normal chest CT scan does not rule out the presence of an AEF with
100% sensitivity. Ongoing vigilance and evaluation are important if
the clinical suspicion is high. Although a barium swallow can detect a
fistula, its sensitivity is low. IV contrast is much more likely to demon-
strate a lesion passing from the esophagus to the mediastinum, the
pericardium, or the LA. If an AEF is suspected, endoscopy with air in-
sufflation should be avoided, given that insufflation of the esophagus
with air can result in a large air embolus, producing stroke or death.
An alternative strategy, which some members of the writing group
employ and which appears to have lower risk, is to use CO2 instead
of air for insufflation in this setting. If CO2 were introduced into the
LA, there would be little adverse consequence. The early recognition
of an AEF can be missed due to the low awareness of this rare com-
plication. It is important for patients to be educated as to warning
signs and to contact their AF ablation center should any suggestive
symptoms develop.
Considerable efforts have been made to reduce the frequency of
this complication. Approaches that have been proposed include
avoiding ablation on the posterior wall of the atrium (or at least over
the trajectory of the esophagus), reducing RF power on the posterior
wall (to 25 W or less), using ICE to image the esophagus, and using an
esophageal temperature sensor.637,900 Many institutions use an
esophageal temperature probe to prevent thermal injury; however, it
is widely acknowledged that use of an esophageal temperature probe
does not eliminate the risk of esophageal injury.341,417,910 A survey of
the writing group members shows that 87% use lower RF power on
the posterior wall. This survey also reveals that two-thirds routinely
use an esophageal temperature probe. Among those who use a tem-
perature probe, one-third report using a temperature probe with
multiple temperature sensors, whereas two-thirds use a probe with
only one temperature sensor. It is important to recognize that the
temperature probe should be as close as possible to the ablation
catheter at all times during the procedure. Another variable concerns
when to stop power delivery. Whereas some operators ablate until a
predefined temperature has been met (e.g., 39 C or 40 C), other
operators use a more conservative approach and terminate power
when the esophageal temperature increases by as little as 0.2.
Esophageal temperature monitoring is also commonly used during
CB AF ablation. Energy delivery is generally stopped when the
esophageal temperature is lower than -20 C. An alternative ap-
proach to the prevention of this complication is to move the esopha-
gus away from the site of ablation using an endoscope or stylet
positioned through a chest tube.894,895,1177
None of the writing group members employ this strategy. Other
widely used strategies include the use of PPIs; although this approach
is unproven, it has become a common approach. Seventy-two percent
of the writing group members employ a PPI for 1–4 weeks following
AF ablation. Use of PPIs is more common following RF ablation (95%)
compared with CBA (54%). It is important to note, however, that this
practice is based on the observation that esophageal ulcerations can
be observed on endoscopy following ablation. There is no proof that
this approach reduces the development of an AEF.
Treatment of an AEF is a medical emergency that requires urgent
surgical repair.341,417,906,910,911,1169,1176,1178 Recent case series have
reported an 83% to 100% mortality without surgical repair compared
with a 34% mortality with surgical repair.341,417,906,910,1176 Although
several case reports have been published describing favorable out-
comes with esophageal stent placement for treatment of an esopha-
geal perforation or an esophageal pericardial fistula, the mortality
rate for stent placement in a patient with a true AEF approaches
100%.341,417,905,907,910,911
In summary, AEF is a rare but unpredictable complication with se-
vere consequences that might only be mitigated by cautious use of
energy on the posterior wall of the LA, early detection, and interven-
tion. Prompt diagnosis and surgical treatment are typically required.
Support for the use of esophageal stenting is limited, and progression
of the AEF process can still occur despite this stenting procedure.
Gastric Hypomotility and Periesophageal
Vagal Nerve Injury
Injury to the vagal anterior esophageal plexus can occur when RF en-
ergy is applied to the posterior wall of the LA, which can cause acute
pyloric spasm and gastric hypomotility. Common symptoms include
nausea, vomiting, bloating, and abdominal pain developing within a
few hours to a few weeks after the ablation proced-
ure.1018,1020,1179,1180,1181 Some patients also experience sinus
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tachycardia.1180 The incidence of symptomatic gastric problems can
be as high as 17%.1020,1181 One recent study reported that asymp-
tomatic functional impairment of the upper GI tract occurred in 74%
of patients. After AF ablation, although the abnormality is often
asymptomatic, the time to recovery is variable, with some patients
recovering within 2 weeks, but others requiring a much more pro-
tracted time to recovery.536
The initial evaluation can include endoscopy or a barium swallow
study to look for residual food after an overnight fast. CT shows
marked gastric dilation. Solid food labeled with technetium-99 can
demonstrate delayed gastric emptying. The 13C-acetate breath test
has been reported to be a noninvasive alternative to scintigraphy.1182
Real-time MRI has been used to assess gastric motility and pyloric
spasm.1179 In addition, electrogastrography can reveal gastric dys-
rhythmia with bradygastria in patients after ablation.1183 The integrity
of the vagal innervation to the gastrointestinal system can be assessed
by the pancreatic polypeptide response to sham feeding. Patients
with this complication exhibit an abnormal kinetic and peak response.
The normal response is a biphasic increase in pancreatic polypeptide.
Injury to the vagus nerve impairs the first phase of the response.1017
After sham feeding, pancreatic polypeptide level elevation by less
than 50% from baseline was considered as abnormal.
Management of this complication depends on the severity of symp-
toms and whether gastric immotility or pylorospasm predominates.
Small, low-fat, and low-fiber meals can alleviate symptoms.
Intravenous erythromycin can be effective in the acute stage to im-
prove diabetic gastroparesis but has not been evaluated post-AF ab-
lation.1184 Metoclopramide can be used to promote gastric motility
for 1–3 months, but long-term treatment is associated with a risk of
movement disorders. Botulinum injections or surgery might be
required to alleviate pyloric spasm.1185 In severe cases, surgery or
gastric pacing might be required.1185
Although there is no established method to prevent injury to the
vagal nerves, the risk can be reduced by using the same techniques
used to avoid an AEF, described earlier in this document. A recent re-
port identifies higher BMI and limiting the power to 20–25 W on the
posterior LA wall as protective against periesophageal nerve injury
during AF ablation.1020
Phrenic Nerve Palsy
PN palsy is an important complication of AF ablation and results from
direct thermal injury.536,903,1017,1182,1183,1184,1185 The right PN is
most commonly affected, given it descends in close proximity to sites
of ablation in the SVC and both right-sided PVs
(Figure 1).536,903,1184,1185,1187 It courses slightly further from the RIPV
so that injury during treatment of this vein is less common than that
occurring with RSPV ablation. PN palsy is observed with all technolo-
gies for AF ablation, including RF, cryoablation, ultrasound, and laser
ablation.490,536,903,1017,1182,1183,1184,1185,1187 PN palsy can be asymp-
tomatic or can cause dyspnea, tachypnea, cough, hiccups, and thor-
acic pain. The diagnosis is suggested when newly elevated
hemidiaphragm with atelectasis of the ipsilateral lung base is observed
on postprocedure chest radiograph. When suspected, diaphragm ex-
cursion should be evaluated using fluoroscopy (sniff test) or ultra-
sound to confirm the diagnosis. Of the writing group members, 64%
report having had a patient at their center develop permanent PN
palsy, and 36% of the writing group members report having had a
patient at their center develop permanent PN palsy following AF ab-
lation with RF energy.
The most common scenario in which PN injury occurs is with
CBA, with an incidence of transient PN palsy of 3.5%–
11.2%.462,1075,1188,1189 Permanent PN palsy resulting from CBA is far
less common, with an incidence of 0.3% in the recently completed
FIRE AND ICE trial.490 PN palsy has also been reported with the
laser-balloon ablation system. In the HeartLight study of the laser bal-
loon, diaphragmatic paralysis secondary to PN injury occurred in
3.6% of the patients with the laser balloon and was more common
than with RF ablation. Persistent PN paralysis at 1 year occurred in
1.8% of the patients.503 The hot balloon ablation catheter employs a
compliant balloon filled with saline that is inflated to occlude the
PV.706 Because of the mechanism of balloon heating, the possibility of
hot spots forming in deeper tissue planes or in collateral structures
such as the esophagus is unlikely.707 The main reported complica-
tions with this technology were PN palsy (3.4%) and PV stenosis
(1.7%).708 A recent, prospective, multicenter clinical trial compared
the outcomes of hot balloon ablation vs AAD therapy for PAF.706
The incidence of PN injury was 3.7%.
Several mechanisms have been proposed to explain the increased
incidence of balloon-based (CB, laser balloon, hot balloon) AF abla-
tion and PN injury. First, wedging or exerting force to direct the bal-
loon into the RSPV for complete PV occlusion can distort the
anatomy and decrease the distance between the RSPV endocardium
and the right PN.1190 Second, a small balloon size relative to PV diam-
eter can increase the likelihood of distal ablation in the vein.779 Third,
the broader, circumferential thermal gradient and use of additional
freeze cycles can increase risk of dose-dependent nerve palsy.1075
Studies have shown a higher risk of PN injury associated with the
smaller 23-mm balloon compared with the larger 28-mm balloon
with more proximal energy application.462,482 The smaller balloon is
potentially advanced further within the PV, causing distortion of the
anatomy, creating a higher susceptibility to PN thermal injury. PN
palsy can also occur during WACA using RF energy. This likely results
from thermal injury to the PN as it courses anterior to the right PVs.
The second most common scenario of PN palsy is during electrical
isolation of the SVC using point-by-point RF ablation; the reported inci-
dence is 2.1%–10%.1191,1192 Ablation within a persistent left SVC can re-
sult in left PN paralysis, but appears rarely, and has been associated with
the use of CB.1193 Injury to the left PN during isolation of a persistent
left SVC was not observed in several case series using RF en-
ergy.232,1042,1194,1195 Very rarely, ablation at the roof of the LAA can re-
sult in left PN damage1184; however, it was not observed in a large study
in which LAA isolation was performed using RF ablation.532,533 The inci-
dence of PN palsy is 0.17%–0.48% with PV antrum isolation using RF ab-
lation, even though the PN is found within the typical WACA and
carina lines of the right-sided PVs in 30% of patients.808,920,1184,1196 This
highlights the importance of factors other than anatomic proximity
alone contributing to the higher incidence of injury with CB.
A number of strategies have been employed to prevent PN palsy.
These include limiting ablation to antral regions with various balloon
maneuvers; preablation high-output pacing to establish whether the
PN can be captured from the proposed ablation site before ablation;
PN mapping with anatomic tagging of its course using an EAM system
to guide the modification of the ablation lesion set; and monitoring of
diaphragmatic excursion with abdominal palpation, fluoroscopy, or
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intracardiac ultrasound while pacing the PN from the SVC or sub-
clavian vein during ablation.1196 Monitoring the effects of pacing the
right PN is now considered a standard part of CBA and should be
considered during SVC isolation using RF energy. Of the writing
group members, 96% report employing this technique when per-
forming CB AF ablation. Finally, diaphragmatic electromyography for
direct monitoring of diaphragmatic compound motor action poten-
tials (CMAP) during ablation is a technique for early detection of PN
palsy that has been reported to reduce incidence of palsy.1197,1198
CMAPs are recorded using body surface electrodes, esophageal elec-
trodes, or a diagnostic catheter positioned in the hepatic vein. A de-
crease in the amplitude of the myopotential by 30% is more sensitive
than abdominal palpation for predicting the subsequent reduction in
diaphragmatic excursion and nerve palsy.1199 Energy delivery should
be interrupted immediately at the first sign of PN injury. One-third of
the writing group members report employing this technique when
performing CB AF ablation. One-third of the writing group members
also report pacing anterior to the right PVs to tag the PN when per-
forming AF ablation using RF energy.
PN palsy can be asymptomatic or can cause dyspnea, tachypnea,
cough, hiccups, and thoracic pain.903,1017,1184,1187 The diagnosis is sug-
gested when newly elevated hemidiaphragm with atelectasis of the
ipsilateral lung base is observed on postprocedure chest radiograph.
When suspected, diaphragm excursion should be evaluated using
fluoroscopy (sniff test) or ultrasound to confirm the diagnosis.
There are various stages of PN palsy, ranging from detectable de-
crease in CMAP before a reduction in diaphragmatic excursion is per-
ceived to persistent paralysis. With CBA, most PN injuries are
transient and resolve within minutes.903,1184 In patients with persist-
ent nerve palsy, most recover nerve function within weeks and al-
most all by 12 months, although 18–24 months might be required in
some patients.1200 In a large meta-analysis of 22 studies enrolling
1308 patients undergoing CBA, 4.7% had persistent PN paralysis after
the ablation procedure, but only 0.37% had paralysis lasting longer
than 1 year.482 The pathophysiology of the palsy differs by type of ab-
lation energy. With RF ablation, there is a dose-dependent response,
and permanent palsy is characterized acutely by edema, coagulation,
and homogenization of cytoplasmic contents and smearing of nuclear
chromatin.536 With CB, the palsy is also dose-dependent; however,
histopathology studies have shown Wallerian degeneration of large
myelinated axons, and that axonal regeneration accounts for late re-
covery of nerve function.1201 There is no active treatment known to
facilitate PN healing; however, in symptomatic patients with perman-
ent nerve palsy, diaphragmatic plication can improve dyspnea and
functional status.
Stroke, TIA, and Silent Microemboli
Stroke and TIA
Embolism of air or thrombus is one of the most significant complica-
tions of AF ablation, and both are potential causes of cerebral, coron-
ary, and peripheral vascular compromise.
The incidence of thromboembolism associated with AF ablation is
reported to be between 0% and 7%.242,489,503,532,533,655,673,796,798,
799,806,920,921,1202,1203,1204 More than two-thirds of the clinical trials
reviewed for preparation of this document reported one or more
cerebrovascular events. Thromboembolic events typically occur
within 24 hours of the ablation procedure, with the high-risk period
extending for the first 2 weeks following ablation.798,1204 In one series
that surveyed 26 embolic stroke events that occurred in a series of
3060 patients, long-term neurological outcomes were as follows: se-
vere impairment (3 patients, with 2 possibly related deaths); moder-
ate impairment (10 patients); mild impairment (9 patients); and
unknown (4 patients).1202
A number of potential explanations for the development of
thromboembolic complications have been proposed. These include
the development of thrombi on or within stationary sheaths or abla-
tion catheters positioned within the LA, char formation at the tip of
the ablation catheter and at the site of ablation, disruption of a throm-
bus located in the atrium prior to the ablation procedure, and elec-
trical cardioversion during procedures.875 Incidence of these events
can be reduced by a combination of detailed preprocedural imaging,
a strict anticoagulation protocol, meticulous attention to sheath man-
agement, and careful control of RF energy to minimize the risk of
char formation. Of the writing group members, 68% report maintain-
ing a constant heparinized flush through all long sheaths with access
to the LA, and most heparinize to an ACT >300 seconds before
transseptal catheterization.
Diagnosis of a symptomatic thromboembolic event is usually
straightforward when ischemia or infarction results from arterial occlu-
sion interrupting perfusion of dependent tissue. The potential manifest-
ations depend on where the occlusion occurs, whether it be
intracranial, coronary arterial, abdominal, or in other peripheral arterial
beds. We have previously discussed the prevention of thromboembol-
ism by intraprocedural and postprocedural anticoagulation in Section
7: Technical Aspects of Ablation to Maximize Safety and
Anticoagulation. Treatment of a thromboembolic event will vary ac-
cording to the location of the embolus. Peripheral arterial embolization
might be amenable to surgical thrombectomy, whereas cerebral em-
bolization has traditionally been managed conservatively and the con-
sequences accepted. There is growing interest, however, in aggressive
early management of such events, using either thrombolytic drugs or
percutaneous interventional techniques. Some delay in diagnosis of a
thromboembolic event that occurs during an ablation procedure while
a patient is under general anesthesia cannot be avoided.
Asymptomatic Cerebral Emboli
ACE is defined as an occlusion of a blood vessel in the brain due to an
embolus that does not result in any acute clinical symptoms and is
therefore “silent.”800,1205 Emboli can result from a thrombus, air, gas,
tissue, or fat. During an AF ablation procedure, potential sources of
these microemboli include thrombi, which can develop on intracar-
diac catheters; sheath materials; air introduction through a sheath
during catheter insertion or exchanges; dislodgement of thrombi in
the heart; or as a result of thrombi or gas that forms during the abla-
tion process. Diffusion-weighted MRI (DW-MRI), with or without
fluid-attenuated inversion recovery (FLAIR) imaging, is very sensitive
for identifying acute ischemic injury and can detect a cerebral lesion
created by an embolus as early as 30 minutes postablation.
The first report of ACE lesions following AF ablation was pub-
lished in 2006.1206 In this report, 2 of 20 patients developed new
asymptomatic cerebral lesions on MRI, following AF ablation.
Subsequent to this report, multiple studies have reported that DW-
MRI can detect new acute lesions created by emboli, following up to
50% of AF ablation procedures.723,724,800,1205,1207,1208,1209
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The incidence of this complication initially appeared to vary ac-
cording to the system used for ablation, and was reported to be high-
est with the use of nonirrigated circumferential multielectrode
ablation catheters with duty cycled phased RF energy.1209,1210 Based
on these findings, modifications were made in anticoagulation, sheath
management, and energy delivery protocols. Following introduction
of these modifications, two subsequent studies reported a 2% or
lower incidence of ACE lesions with use of this same circular phased
RF ablation catheter.728,731,1211 One study examined the important
question concerning whether these lesions persist on repeat DW-
MRI and T2 FLAIR scanning. In this study, 14 patients who had 50
new silent cerebral emboli detected post-AF ablation had a repeat
MRI a median of 3 months later. It was notable that 47 of the 50 le-
sions (94%) resolved in the interim. The three lesions in three pa-
tients that produced a residual defect at repeat scanning were initially
>10 mm in size, and one of these patients had neurological symp-
toms. When considering the significance of the ACE lesions that have
been observed following AF ablation, it is important to note that
cerebral embolism has also been observed after most types of car-
diac invasive procedures, including coronary angiography, carotid ar-
tery stenting, and cardiac valve replacement.1212,1213 Importantly, as
of now, a direct link between silent cerebral embolism and a decline
in neurocognitive function has not been proven.800,1205,1211,1212
However, one study has reported mild postoperative neurocognitive
dysfunction in 13% of patients undergoing ablation for PAF and in
20% undergoing ablation for persistent AF. The precise mechanism
of this neurocognitive dysfunction and its possible link to ACE lesions
needs to be explored further.1214
A decade after the first description of ACE lesions following AF ab-
lation, a tremendous amount of new knowledge has been generated
concerning this important complication of AF abla-
tion.800,1205,1211,1215,1216 These efforts have resulted in a striking de-
crease in the incidence of this complication. During this period of
time, studies have identified a number of techniques to lower the risk
of ACE lesions, including (1) aggressive anticoagulation prior to, dur-
ing, and following ablation; (2) careful sheath management; (3) modifi-
cations in the delivery of phased RF energy; and (4) choice of ablation
energy source and lesion sets. The long-term prognostic implications
of ACE following AF ablation remain unclear. Because multiple stud-
ies have reported that the majority of acute lesions regress without
evidence of chronic glial scar when reassessed several weeks to
months later, the occurrence of long-term sequelae appears un-
likely.1205 Nevertheless, there is a possibility of long-term sequelae,
given the association between silent cerebral infarcts and an
increased long-term risk of dementia.1217 While further work re-
mains, the amount of progress is striking and will benefit our patients
in the long term.
Air Embolism
The most common cause of air embolism is introduction of air via
the transseptal sheath. Although this can be introduced through the
infusion line, it can also occur with suction when catheters are
removed. Air embolism has been reported with coronary angiog-
raphy, percutaneous interventions requiring access to the LA, and
during ablation procedures.803,1218,1219,1220,1221 Air embolism to the
cerebral vasculature can be associated with altered mental status,
seizure, and focal neurological signs. Central nervous system
dysfunction is attributable to both mechanical obstruction of the ar-
terioles and thrombotic-inflammatory responses of air-injured epi-
thelium.1219,1220 Although immediate diagnosis and treatment is
based on clinical suspicion, prompt MRI or CT scans obtained before
the intravascular air is absorbed might show multiple serpiginous
hypodensities representing air in the cerebral vasculature, with or
without acute infarction.803,1221 Most importantly, AEF should be
ruled out if air embolism is documented after the ablation. A com-
mon presentation of air embolism during AF ablation is acute inferior
ischemia and/or heart block. This reflects the preferential down-
stream migration of air emboli into the right coronary artery (RCA).
The preferential manifestation of air emboli into the RCA territory
might reflect the superior position of the RCA ostium in the supine
patient. Supportive care usually results in complete resolution of
symptoms and signs within minutes. However, pacing and cardiopul-
monary resuscitation might be needed if the hypotension and AV
block persist. A recent study reported the clinical characteristics and
outcomes of 5 out of a series of 2976 patients who underwent AF ab-
lation who experienced a massive air embolism during the proced-
ure. Hemodynamic collapse and hypoxemia occurred in all the
patients and persisted for 10–35 minutes. Despite this, all the patients
had complete recovery.1221 it is imperative, however, that all infusion
lines be monitored closely for bubbles. Whenever catheters are
removed, they should be withdrawn slowly to minimize suction ef-
fects, and the fluid column within the sheath should be aspirated sim-
ultaneously. Particular care is advised when inserting and removing
balloon catheters through large sheaths.1222 Treatment should be ini-
tiated immediately in the laboratory if cerebral air embolism is sus-
pected. The most important initial step is to maximize cerebral
perfusion by the administration of fluids and supplemental oxygen,
which increases the rate of nitrogen absorption from air bubbles. For
large air emboli, it might be beneficial to briefly suspend the patient in
a head-down position.1218,1219 Treatment with hyperbaric oxygen
can reverse the condition and minimize endothelial thromboinflam-
matory injury if it is started within a few hours.1220 Heparin appears
to limit injury in animal models of cerebral arterial air embolism.1223
Vascular Complications
Vascular complications, including groin hematoma, retroperitoneal
bleed, femoral artery pseudoaneurysm, or arteriovenous fistula, are
the most common complications of AF ablation. The incidence of the
more significant of these complications (femoral pseudoaneurysm,
arteriovenous fistula, and retroperitoneal bleeding) varies from 0.2%
to 1.5%.806,808,920,921,1224,1225,1226 The first and updated worldwide
surveys of AF ablation in 2005 and 2010, respectively, reported that
the incidence of vascular complications was 0.95% (84 of 8745 pa-
tients) and 1.5% (240 of 16309 patients), respectively.806,920 A report
from the United States analyzing an estimated 93,801 AF ablations be-
tween 2000 and 2010 showed the overall incidence of vascular com-
plications requiring blood transfusion or surgical repair was 1.53%,
which remained statistically unchanged from year 2000 to 2010.921
More recent reports from Czechia, Belgium, Japan, and the United
States reported the incidence of these complications as 1.1% (13 of
1192 procedures in 959 patients), 1.2% (15 of 1233 procedures in
947 patients), 0.2% (7 of 3373 patients), and 1.5% (18 of 1190 pa-
tients), respectively.808,1224,1225,1226 The incidence of vascular compli-
cations that result from AF ablation is lower than those reported for
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ventricular tachycardia ablation (range, 3.6%–6.9%), in which femoral
arterial access is used in many cases.1227,1228 Most groin hematomas
can be managed conservatively or with ultrasound-guided compres-
sion. However, complications such as femoral pseudoaneurysm, ar-
teriovenous fistula, and retroperitoneal bleeding might require blood
transfusion and/or surgical or percutaneous repair, which leads to
increased morbidity and prolonged hospital stay.1229 Rarely, a large
dense hematoma can lead to femoral neurological sequelae.
The incidence of these complications can be related to the number
and size of the venous sheaths used, insertion of an arterial pressure
line, and perhaps to the intense anticoagulation management before,
during, and after the procedure. Recent studies have suggested un-
interrupted warfarin as an optimal anticoagulation regimen because it
reduces stroke and nonmajor bleeding complications compared with
interrupted warfarin with heparin bridging.834 Further, uninterrupted
or briefly interrupted use of a direct oral anticoagulant was shown to
be as safe and effective as uninterrupted warfarin.840,842,1230 The re-
sults of the RE-CIRCUIT study were recently published, which was a
head-to-head comparison of performing AF ablation on patients
receiving uninterrupted dabigatran vs uninterrupted warfarin.841 This
study randomized 704 patients across 104 sites to these two anticoa-
gulation strategies. The incidence of major bleeding events during
and up to 8 weeks postablation among the 635 patients who under-
went AF ablation was significantly lower with dabigatran than with
warfarin (5 patients [1.6%] vs 22 patients [6.9%]); absolute RD -5.3%,
RR reduction 77%). There has been one other smaller head-to-head
comparison published of uninterrupted rivaroxaban vs uninterrupted
warfarin (Venture-AF, N= 248).842 This study reported one major
bleeding event, one ischemic stroke, and one vascular death, each of
which occurred in the warfarin arm of the study.
The approach used for femoral venous access can impact on the
risk of vascular complications. When an inferior approach to femoral
vein access is used, small medial branches of the femoral artery,
which can run across and superficial to the femoral vein, might be
penetrated before entry to the femoral vein, possibly leading to a
femoral pseudoaneurysm and arteriovenous fistula. When a superior
approach is used, there is an increased risk of retroperitoneal bleed-
ing. To prevent these vascular complications, real-time ultrasound-
guided venipuncture is useful and can be recommended because it
reduces both major and minor vascular complications in patients
undergoing AF ablation and/or electrophysiological proced-
ures.1231,1232 Among the writing group members, two-thirds rou-
tinely use ultrasound imaging to guide vascular access.
Acute Coronary Artery Occlusion and
Stenosis
Injury to the coronary arteries during AF ablation is rare. In a con-
secutive series of 5709 patients undergoing ablation of AF, coronary
arterial injury was observed to occur in eight patients (0.14%).1233
The circumflex artery is in close proximity to the lateral LA and
can potentially be injured during ablation at sites adjacent to its
course within the CS, the lateral mitral isthmus, or the base of the
LAA. Occlusion of the circumflex accounted for three of the eight
cases in the above series, all presenting with ventricular fibrillation 20
and 60 minutes after mitral isthmus ablation and 6 hours after abla-
tion at the LAA base, respectively.1233 Others have also described
features of acute myocardial infarction with ST segment changes
occurring during ablation at the mitral isthmus.923 These patients
have variably undergone unsuccessful intracoronary vasodilators or
thrombectomy and have had to progress to coronary stenting. A sin-
gle case presenting 48 hours after mitral isthmus ablation with total
circumflex occlusion and ventricular arrhythmia storm is described as
having ongoing ventricular arrhythmia requiring ablation and defibril-
lator implantation, highlighting the potential for ongoing conse-
quences as a result of coronary artery injury.1234
The sinus node artery originates from the proximal circumflex ar-
tery in one-third of cases and then courses along the anterior LA and
then the septal SVC, and could therefore be susceptible to injury dur-
ing ablation. In the above series, five of the eight patients presented
with acute sinus node dysfunction.1233 In most of these cases, the cul-
prit site was adjacent to the sinus node artery (per CT) at the anter-
ior LA or septal RA. All these cases presented with sinus arrest
during or within 1 hour of ablation and with no evidence of any other
electrocardiographic changes associated with coronary occlusion.
Two of these patients eventually required permanent pacemaker in-
sertion with significant atrial pacing during follow-up. Others have
described a more transient sinus node dysfunction due to occlusion
of the sinus node artery.1235
The cavotricuspid isthmus can be ablated in conjunction with AF
ablation. This region is in close proximity to the RCA, and injury to
this vessel has been described.1236,1237 These have occurred both
acutely and later during the case, and with both septal and lateral
approaches to the ablation.
In addition to the direct injury and occlusion at the sites of ablation,
a single case of thromboembolic occlusion of the left anterior des-
cending artery the day after ablation has been described.1238 This
case was known to have factor V Leiden mutation, was therapeutic-
ally anticoagulated with an INR of 2, and the activated clotting time
had been maintained between 280 and 390 seconds. Angiography
demonstrated thrombus in the left anterior descending artery,
requiring intervention. This case highlights the need for meticulous
anticoagulation, sheath management, and physician awareness of the
potential for thromboembolism to present as coronary occlusion.
Although presentation with acute coronary artery occlusion is low,
the possibility of thermal injury without occlusion and the possibility
of subsequent remodeling leading to stenosis of a coronary artery
should be considered. The most vulnerable location for this would
appear to be the circumflex vessel during ablation of the mitral isth-
mus. In a series of 54 patients who had undergone mitral isthmus ab-
lation, coronary angiography was performed before and after
ablation.1239 Fifteen patients (28%) had angiographic changes follow-
ing ablation, eight with midcircumflex narrowing, one with circumflex
and obtuse marginal narrowing, one with obtuse marginal narrowing
only, and five with distal circumflex narrowing or occlusion. A further
five had significant narrowing that resolved with intracoronary vaso-
dilators. Patients with such coronary arterial changes had a signifi-
cantly longer ablation time within the CS. Therefore, limiting
excessive ablation, particularly in areas adjacent to the coronary vas-
culature, should be a consideration in planning the ablation strategy.
In the intraoperative setting, late coronary stenosis has been
described at sites of previous ablation.1240
There can be several determining factors in the development of
coronary artery injury during AF ablation. These include the degree
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of protective epicardial adiposity, coronary blood flow, and the inten-
sity and duration of ablation; however, the most predictable is that of
the location of ablation adjacent to the course of the coronary artery.
Careful monitoring and avoiding high-power energy delivery in the
vicinity of these vessels are potentially important in minimizing the
risk of arterial injury.
Radiation Exposure During Catheter
Ablation of AF
An important, less easily recognized, and rarely considered potential
complication of AF ablation is the delayed effect of the radiation
received by the patients, including acute and subacute skin injury, ma-
lignancy, and genetic abnormalities.1,1241,1242,1243,1244,1245,1246,1247
Fluoroscopy is required for most components of the procedure,
including catheter placement, positioning a multielectrode catheter
into the CS, double transseptal catheterization, PV angiography, and
LA ablation. A survey of the writing group members reveals that
two-thirds use single-plane fluoroscopy, whereas one-third employ
biplane. One study reported a mean fluoroscopy time >60 minutes,
with corresponding higher effective radiation doses in obese pa-
tients.1244,1246 By using a vest containing 50–60 dosimeters to meas-
ure peak skin doses (PSDs), another study reported a mean PSD of
1.0 ± 0.5 Gy in the right anterior oblique and 1.5 ± 0.4 Gy in the left
anterior oblique projection, during a mean fluoroscopy time of
67.8 ± 21 minutes.1245 They estimated an overall lifetime risk of ex-
cess fatal malignancies normalized to 60 minutes of fluoroscopy of
0.07% for women and of 0.1% for men.1245 The relatively low radi-
ation exposure to the patients in this study despite the prolonged
fluoroscopy durations was attributable to the state-of-the-art very
low pulsed fluoroscopy frame rate, the avoidance of magnification,
and the optimal adjustments of fluoroscopy exposure rates. The re-
sulting lifetime risk of malignancy was thus within the range previously
reported for ablation of supraventricular tachycardias. However, this
study demonstrated that catheter ablation of AF required significantly
greater fluoroscopy duration and radiation exposure than simpler
catheter ablation procedures. Thus, and especially because AF abla-
tion procedures often need to be repeated, electrophysiologists
should make every attempt to minimize radiation exposure.
Increasing availability and familiarity of electrophysiologists with
3D mapping systems, as well as the availability of CF monitoring, have
significantly reduced fluoroscopy time and the need for fluoroscopy
in recent years.747,1186,1248,1249 This can only be achieved, however,
by an awareness of the importance of reducing fluoroscopy time, and
therefore radiation exposure, by the operator.1250 It has been shown
that use of optimized conventional fluoroscopy and optimized use of
3D mapping can result in a marked reduction in radiation expos-
ure.1251 It is also important to recognize that fluoroscopy time is only
weakly linked to true radiation exposure, because it does not reflect
the fluoroscopy equipment being used, nor patient-specific factors
such as obesity. The use of remote navigation for PVI appears to be
effective, with fewer periprocedural complications and significant re-
ductions in fluoroscopy exposure for both patient and oper-
ator.749,1252,1253 Another interesting option to minimize radiation
exposure to the operator and to alleviate the orthopedic implications
of conventional lead aprons is the use of a radioprotection cabin or a
suspended lead apron.1254
More recently, it has been shown that PVI is feasible without using
fluoroscopy or with extremely limited fluoroscopy. To safely navigate
catheters in the heart with no fluoroscopy, intracardiac ultrasound is
mandatory, as well as imaging integration with preacquired CT or
MRI.763,1255,1256
Pericarditis
More than 50% of the patients who undergo catheter ablation of AF
note some pleuritic chest pain in the first several days following their
procedure. It is also common to observe a “trace” pericardial effu-
sion following AF ablation. These largely self-limited manifestations of
AF ablation-induced pericarditis are so common and of so little con-
sequence that they are considered as part of the standard clinical
course for patients who undergo AF ablation rather than as a compli-
cation of the procedure. A small subset of these patients will go on to
develop more severe and clinically significant manifestations of peri-
carditis. In two recent multicenter registries, pericarditis has been re-
ported to occur in 0.1% and 0.6% of patients, respectively.1059,1257
When transmural lesions are generated during catheter ablation of
AF, some epicardial inflammation, and therefore some pericarditis, is
inevitable. However, more extensive pericarditis can complicate AF
ablation procedures both acutely and at some delay. These presenta-
tions include Dressler syndrome, pericarditis leading to delayed car-
diac tamponade, and constrictive pericarditis.1258,1259,1260 These
severe manifestations and consequences of pericarditis presented be-
tween 18 days and 3 months after their ablation procedures. The
standard international practice for a short hospital stay after AF abla-
tion procedures can contribute to an underappreciation of early
postablation pericarditis.
There is currently no evidence to support the use of nonsteroidal
anti-inflammatory drugs (NSAIDs) or steroids to prevent AF recur-
rences. A single bolus injection of low-dose hydrocortisone (100 mg)
reduced the incidence of pericarditis from 2.5% to 1.1% in one recent
series from Japan, but no difference in early or late recurrences was
found after AF ablation.1261 Another Japanese study also failed to
demonstrate a reduction in immediate, early, or midterm AF recur-
rence with either a low-dose (hydrocortisone 100 mg) or moderate-
dose (methylprednisolone 125 mg) single steroid bolus.
Colchicine is currently the cornerstone of pericarditis treatment
that occurs outside of the AF ablation setting, although specific data
after AF ablation are lacking. In one trial, however, in which patients
were randomized to a 3-month course of colchicine (0.5 mg twice
daily) or placebo, early recurrence was significantly reduced (33.5% of
placebo patients vs 16% for colchicine), and this was strongly associ-
ated with a reduction in inflammatory mediators such as IL-6 and C-re-
active protein. After a 15-month follow-up, a 37% reduction in the RR
of AF recurrence was observed (number needed to treat = 6).985 In a
subsequent randomized study of 233 patients with PAF, these investi-
gators reported that the long-term recurrence rate was 31% among
the patients treated with colchicine vs 49% among the placebo patients.
Colchicine also resulted in an improvement in QOL.986
Mitral Valve Trauma and Curvilinear
Catheter Entrapment
Entrapment of a circular multielectrode mapping catheter by the mi-
tral valve apparatus is an uncommon but established complication of
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AF ablation.1262,1263,1264,1265,1266,1267,1268,1396 It results from inadvert-
ent positioning of a circular electrode catheter close to the mitral
valve or into the left ventricle, often during attempts to position the
catheter into the LIPV or when using such catheters to create elec-
troanatomical maps of the LA. This complication should be suspected
when attempts to reposition the catheter into another PV are met
with resistance. When suspected, it is important to confirm the diag-
nosis with echocardiography. Although successful freeing of the cath-
eter has been reported with gentle clockwise catheter manipulation
and advancing the sheath into the ventricle in two patients, there
have also been a number of cases reported in which the mitral valve
apparatus and/or papillary muscles are torn during attempts to free
the catheter.1263,1264,1268,1269,1396 There have also been several cases
reported in which the distal tip of the circular catheter broke off dur-
ing attempts at catheter removal and had to be subsequently
removed either with a snare or with an open surgical proced-
ure.1263,1265,1266 We recommend that if gentle attempts to free the
catheter fail, elective surgical removal of the catheter should be
performed.
It is important for all electrophysiologists who perform AF ablation
to be aware of this potentially serious complication. Every effort
should be made to be certain that the circular catheter is kept safely
away from the mitral valve and that only clockwise torque be applied
to the catheter, with particular care taken when approaching the
LIPV. The incidence of this rare complication is unknown, but might
have decreased in recent years due to improved awareness.
Limited data are available regarding outcomes of AF ablation in pa-
tients with prosthetic valves. One small, matched cohort study sug-
gested that long-term outcomes might be similar, but ablation
procedures were longer and were associated with a numerically
higher rate of complications in patients with prior mitral or aortic
valve replacement (AVR).908 The development of new perivalvular
leak following AF ablation in a patient with a mitral prosthesis has
been reported, suggesting that care should be taken when ablating
near the annulus in such patients.921
Mortality Risk with AF Ablation
Although AF ablation is generally considered to be safe, devastating
complications can occur rarely, some being fatal. In a recent survey,
death was reported in 32 of 32,569 (or 1 in 1017) patients undergoing
AF ablation procedures worldwide.1039 The most frequent cause of
death was cardiac tamponade, accounting for 25% of the deaths, of
which 3% occurred later than 30 days after the procedure. Stroke
was responsible in 16% of the cases, of which 6% occurred later than
30 days. AEF also accounted for 16% of the deaths, with extensive
pneumonia responsible for 6%. Less common causes of death
observed in the periprocedural phase included myocardial infarction,
irreversible torsades de pointes, septicemia, sudden respiratory ar-
rest, extrapericardial PV perforation, occlusion of both lateral PVs,
hemothorax, and anaphylaxis, which were each responsible for 3% of
early deaths.
Twenty-two percent of all deaths occurred more than 30 days
after the procedure. Among the identified causes of late death were
asphyxia from tracheal compression secondary to subclavian hema-
toma, intracranial bleeding, acute respiratory distress syndrome, and
esophageal perforation by the intraoperative TEE probe, with each
cause contributing to 3% of all late deaths.
It should be noted that these reported mortality risks of AF abla-
tion came mostly from experienced operators and centers. In the
community setting, the mortality risk of AF ablation can be much
higher. Indeed, one study of 93,801 patients undergoing AF ablation in
the United States between 2000 and 2010 showed that one in
238 AF ablation patients were never discharged alive following their
procedure. These mortality risks were due primarily to inexperi-
enced operators who performed fewer than 25 procedures annually,
and to low-volume hospitals that performed fewer than 50 proced-
ures annually.921
When a 30-day all-cause mortality definition is used for AF abla-
tion, AF ablation mortality rises to 1 in 125 patients within the
Medicare population (mean age of 72).921 Awareness about the risk
of death and the possible causes might help physicians set more ap-
propriate and efficient standards for procedural safety, and need to
be considered in the patient’s decision-making process.
Stiff Left Atrial Syndrome
First described after mitral valve surgery in 1988, stiff LA syndrome
was recognized as a rare complication of LA catheter ablation in
2011.1110,1111,1270,1271,1272,1273 One early report described a series of
three patients with unexplained exertional dyspnea, LA hypertension,
and large V waves on LA pressure or pulmonary capillary wedge
pressure (PCWP) tracings after multiple surgical LA ablation proced-
ures.1271 A subsequent study prospectively collected 1380 consecu-
tive patients undergoing ablation, obtaining echocardiograms before
and after ablation to assess for pulmonary hypertension.1272
Excluding patients with PV stenosis or significant mitral valve disease,
there were 19 patients (1.4%) with new or worsening pulmonary
hypertension, LA diastolic abnormalities, and clinical findings of dys-
pnea, HF, pulmonary hypertension (mean PA pressure >_25 mm Hg
or during exercise >_30 mm Hg), and large V waves (>_10 mm Hg and
higher than mean LA pressure tracings) on PCWP or LA pressure
tracings. Other authors reported worsened pulmonary hypertension
(echocardiographic right ventricular systolic pressure (RVSP)
>35 mm Hg with increases of > 10 mm Hg) in 41 of 499 patients
(8.2%) by 3 months after ablation.1110 These studies were flawed,
however, by the low cutoff for diagnosing PA hypertension, particu-
larly after an ablation with excess volume delivery. Stiff LA syndrome
was also reported in 9 patients after surgical maze procedures, pre-
senting with unexplained dyspnea, severe pulmonary and LA hyper-
tension, giant LA V waves, absent LA or LV A waves, blunted X
descents, and elevated left ventricular end-diastolic pressure attrib-
uted to abnormal LA compliance and contractility.1274
Studies have identified small LA size (<_45 mm), high mean LA pres-
sure, severe LA scarring (>60%), diabetes mellitus (DM), and OSA as
independent predictors of pulmonary hypertension or stiff LA syn-
drome postablation.1272 The potential importance of scar burden
and the extent of RF ablation to LA stiffness or function has also been
noted by other investigators. In another study of 26 patients with
mean follow-up of 80 months, LA scar by MRI was related to the
number of procedures, total RF duration, LAA EF, and expansion
index.1275 LAA EF correlated with exercise capacity at follow-up, and
LA scar extent had a negative correlation with exercise capacity.
Another study reported that LA stiffness index, derived from invasive
pressure measurements and cardiac MRI volumes during sinus
rhythm (DP/DV) was higher in patients with persistent rather than
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PAF, older age, and prior LA ablation.1276 A subsequent study re-
ported that in 70 patients with 12-month follow-up, LV diastolic dys-
function worsened in 27% and correlated with total ablation time,
concluding that more aggressive ablation might aggravate diastolic
dysfunction.1145
The stiff LA syndrome fortunately appears to be largely responsive
to diuretic therapy. One study reported that all 19 of their patients
had symptomatic improvement after diuretic therapy, noting that di-
uretics appeared more effective for this syndrome than for other
forms of pulmonary hypertension.1272 In contrast, another study re-
ported a case of stiff LA syndrome after two AF catheter ablation
procedures that failed with furosemide and spironolactone, but
which responded to sildenafil.927
In summary, stiff LA syndrome or worsened pulmonary hyperten-
sion appears to occur in 1.4%–8% of patients after AF RF catheter ab-
lation. The diagnosis of stiff LA syndrome after AF or LA ablation
should be sought for patients who present with unexplained dyspnea
with signs of right HF. Diagnosis can be made by signs of right HF in
the presence of preserved left ventricular function, pulmonary hyper-
tension (mean PA pressure >_25 mm Hg or during exercise >_30 mm
Hg), and large V waves (>_20 mm Hg and higher than mean LA pres-
sure tracings) on PCWP or LA pressure tracings in the absence of sig-
nificant mitral valve disease or PV stenosis. We also recommend that
to reduce the risk of stiff LA syndrome, judicious use of extensive LA
ablation be considered in patients with small LA size, high LA pres-
sures, preexisting severe LA scarring, DM, or OSA. Patients with stiff
LA syndrome usually respond well to diuretics.
Cough
Cough is a specific respiratory symptom that can occur after catheter
ablation of AF. It might be a sign of underlying PV stenosis, PN injury,
direct bronchial injury, stiff LA syndrome, gastroesophageal reflux,
pulmonary embolism, pericarditis, or other iatrogenic respiratory
complications such as ventilator-associated pneumonia or postpro-
cedure aspiration pneumonia. Although there is a paucity of data on
the incidence and mechanisms of postprocedure cough, the underly-
ing mechanisms can vary according to the ablation technology.
After RF ablation, cough might point to the presence of RF-
induced PV stenosis. Whereas mild PV stenosis is frequently asymp-
tomatic, patients with more extensive and severe PV narrowing can
present with cough, dyspnea, chest pain, or hemoptysis.1152,1200
Similarly, another study reported that in 18 patients with severe PV
stenosis, 7 (39%) reported cough.462 Cough might also be a sign of
RF-induced PN injury. Although a rare complication (0.48%), RF-
induced PN injury is frequently (9 of 22 patients) associated with im-
mediate features of dyspnea, cough, hiccup, and/or sudden diaphrag-
matic elevation.1277
Cough following CBA is more frequent. In fact, as many as 1 in 6 pa-
tients can develop a dry cough following CBA, which is usually self-
limiting in 91%.1278 Whereas the most evident mechanism for post-
procedure cough is that of CBA-induced PN injury (up to 11%), some
reports suggest that the cough is caused by direct upper airway irrita-
tion during CBA (bronchial or pulmonary injury).1278 In an experimen-
tal model, Aryana et al showed that CBA can elicit direct and acute
bronchial inflammation, bleeding, and mucosal injury.1277 A recent
study reported ice formation within the left main-stem bronchus using
real-time bronchoscopy during CBA.583,584 Given the increasing
number of case reports detailing respiratory complaints after CBA, a
systematic examination of the short- and long-term consequences of
CBA on normal bronchial tissue during PVI is warranted.
Increase in Heart Rate and/or Sinus
Tachycardia
A subset of patients will experience a significant increase in their resting
sinus heart rate following AF ablation.110 Although this typically results
in a 10–20 beats per minute (bpm) increase in heart rate (well below
the 100 bpm threshold to classify the increase as sinus tachycardia),
the resulting increase in heart rate can exceed 100 bpm in a very small
subset of patients. This phenomenon is related to shifts in autonomic
tone following ablation and is predictive of ablation success. This shift
in autonomic tone results from ablation of GP that are commonly
located near the PV antra, as previously discussed.110,121 Stimulation of
GP has been shown to elicit AF by producing repetitive bursts of rapid
focal PV firing, and ablation of GP can play a role in AF treat-
ment.257,577,1279 Following ablation of GPs, signs of parasympathetic
withdrawal such as increased heart rate and attenuated heart rate vari-
ability can be observed, and these signs have been associated with im-
proved procedural outcomes.118,126,577,1280,1281 Although the increase
in heart rate and reduction in heart rate variability after ablation typic-
ally follow a transient time course, with resolution within 3 months,
some studies have shown that the long-term persistence of these auto-
nomic changes is associated with improved clinical outcomes.126
These clinical data are consistent with experimental findings demon-
strating a reduction in stellate ganglion nerve activity and subsequent
AF with continuous low-level vagal nerve stimulation.1200 Thus, the ob-
servation of increased heart rate following ablation can be a normal
finding with potential positive prognostic implications regarding out-
comes and is not necessarily a procedural complication per se.
Section 11: Training
Requirements
Overview
The strategies, specific methods, and technology pertaining to AF ab-
lation are evolving. Accordingly, the guidelines for training to perform
this procedure must be flexible in recognition of various approaches
and technologies that will change with advances in the field. Training
for AF ablation should encompass six fundamental principles: (1) ap-
propriate selection of patients; (2) knowledge of the anatomy of the
atria and adjacent structures; (3) conceptual knowledge of strategies
to ablate AF; (4) technical competence; (5) recognition, prevention,
and management of complications; and (6) appropriate follow-up and
long-term management.
The training required in each of these areas differs from other abla-
tion procedures because, in comparison, ablation of AF is technically
more difficult, is associated with greater risks, and requires more
careful follow-up.
Appropriate Selection of Patients
Trainees should recognize clinical attributes that can increase the dif-
ficulty of a transseptal puncture, increase the risk of the procedure,
and affect short- and long-term outcomes. These factors are
e96 Guidelines
Downloaded from https://academic.oup.com/europace/article-abstract/20/1/e1/4158475
by Erasmus University Rotterdam user
on 29 January 2018
discussed in Sections 8 and 9 of this document. The trainee should
also develop the judgment to decide whether conscious sedation or
general anesthesia would be most appropriate for the case under
consideration. It is also important to assess the severity of symptoms
related to AF and the potential benefit of an ablation procedure.
Trainees should be experienced in counseling patients about the po-
tential risks and benefits of, as well as the alternatives to, an ablation
procedure and should be able to apply this knowledge for recom-
mendations specific to the needs of individual patients. They should
also take into consideration the prior use of AADs and pharmaco-
logical alternatives to AF ablation.
It is also important for electrophysiologists involved with catheter ab-
lation to be knowledgeable about surgical ablation techniques for AF. In
particular, electrophysiologists who perform AF ablation procedures
must be aware of the indications, techniques, and outcomes of surgical
approaches for AF ablation. This applies both to the new minimally inva-
sive surgical approaches, AF surgery combined with other cardiac surgi-
cal procedures, and the Cox-Maze III procedure (see Section 12).
Anatomy of the Atria and Adjacent
Structures
Detailed knowledge about the anatomy of the LA and its adjacent
structures is crucial for performing the technical aspects of transsep-
tal puncture and cannulation, LA mapping, and isolation of the PVs or
modification of the substrate that sustains AF. The trainee must rec-
ognize the anatomic relationship of the atria, SVC, and PVs to the pul-
monary arteries, aorta, mitral annulus, PNs, sympathetic and
parasympathetic innervation, esophagus, and other mediastinal struc-
tures (Figure 1). These anatomic relationships affect the ability to per-
form the procedure successfully and to avoid complications.
Conceptual Knowledge of Strategies to
Ablate AF
Trainees should understand the pathophysiology of AF and its impli-
cations for strategies to ablate AF. This includes the role of the PVs,
the SVC, the musculature of the LA, and the potential impact of auto-
nomic stimulation. They should understand the rationale for isolation
of the PVs and elimination of the foci that trigger AF, as well as the
basis for broad circumferential ablation of tissue or elimination of
fractionated potentials or other technologies that appear to alter the
substrate that sustains AF.
Technical Competence
The technical skills needed for ablation of AF are substantial. These
include anticoagulation management, transseptal needle puncture
and cannulation of the LA, precise manipulation of the catheter for
mapping and ablation, identification of the pulmonary ostia, adjust-
ment of the energy used for ablation, and the appropriate use of
fluoroscopy, radiographic contrast for imaging, 3D mapping systems
and/or ICE. Simulation technologies are evolving that could help
trainees gain experience with fundamental techniques in the early
phase of learning procedural skills or the recognition and manage-
ment of acute complications such as cardiac tamponade.1250,1282,1283
There are substantial differences among laboratories in the use of
radiographic contrast imaging, EAM or echocardiography, and the
number and types of catheters used to identify electrical endpoints
and to perform ablation. The degree of expertise gained in the use of
a specific technology will depend on where training is completed, as
well as the duration of training. Nonetheless, trainees should be ex-
pected to understand the potential advantages and limitations of
these systems and should have the ability to interpret basic images
and electrical recordings obtained from these various methodologies.
They should be well versed in the principles of radiation safety for pa-
tients and the medical personnel who perform ablation procedures.
Training programs should emphasize the interpretation of intracar-
diac electrograms for recognition of PV potentials and determination
of when electrical isolation of a PV has been achieved, the role of CS
and LAA pacing in the differentiation of far field electrograms from PV
potentials, identification of fractionated low-amplitude LA potentials,
and techniques required to map and ablate right and/or LA tachycar-
dias or AFL. Concepts related to entrainment are especially important.
Trainees need to be skilled in identifying the presence, mechanism, ori-
gin, and ablation of other supraventricular tachycardias that could act
as triggering mechanisms for AF, such as AV nodal reentrant tachycar-
dia and AV reentrant tachycardia. Training and competence in RF cath-
eter ablation are essential because this ablation technology is needed
for ablation of typical and atypical AFL. Many electrophysiology labora-
tories also use RF energy as the preferred energy source for ablation
of AF. Many other electrophysiologists prefer CBA for their AF abla-
tion procedures. Other ablation technologies that are currently avail-
able in some parts of the world include laser balloon ablation and
ablation using circular multielectrode RF ablation catheters. Trainees
should be familiar with the advantages and limitations of each energy
source and associated delivery system.
Procedural Experience
The 2015 American College of Cardiology/American Heart
Association/Heart Rhythm Society Advanced Training Statement on
Clinical Cardiac Electrophysiology proposed a minimum of 5 five
focal ATs, 30 macroreentrant ATs (including 20 isthmus- and 10
nonisthmus-dependent/complex macroreentry) and 50 AF ablation
procedures for those who undergo fellowships in clinical cardiac
electrophysiology.1284 The writing group members are supportive of
the requirement that trainees perform at least 50 AF ablation pro-
cedures and at least 30 macroreentrant ATs (including 20 isthmus-
and 10 nonisthmus-dependent/complex macroreentry) during fel-
lowship training. Furthermore, the writing group recommends that
those performing the procedure perform at least several AF ablation
procedures per month to maintain competence.
These numbers underestimate the experience required for a high
degree of proficiency.991,992,1082,1285,1286 Exact numerical values are
difficult to specify because technical skills develop at different rates.
Nonetheless, comparisons of high- and low-volume centers suggest
that outcomes are better at centers that have performed more than
100 procedures.806 Other data report improved outcomes for oper-
ators with an annual procedure volume of at least 25 cases and for
centers with an annual procedure volume of at least 50 cases.921
Moreover, the selection of patients and interpretation of AFL and
other ATs that are often observed in patients with AF require training
that is unique to electrophysiology fellowships. Trainees who intend
to perform AF ablation independently should receive additional train-
ing after the standard fellowship is completed if they performed
fewer than 50 AF ablation procedures during training.
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Recognition, Prevention, and
Management of Complications
As previously discussed, ablation of AF is associated with substantial
risks that must be recognized. Training programs must emphasize tech-
niques that reduce these risks. This includes careful manipulation of
catheters, appropriate use of anticoagulation, modification of energy
delivered on the posterior wall of the LA, and the risk of applying en-
ergy within the PVs or LAA. Fellows should be trained to suspect car-
diac tamponade or internal bleeding as a common cause of
hypotension. Training should also include management of these com-
plications. The skills to perform an emergent echocardiogram when
cardiac tamponade is suspected are important. It is preferable for fel-
lows to undergo training in pericardiocentesis. If trainees do not gain
proficiency in pericardiocentesis, they must be able to recognize and
diagnose cardiac tamponade and have immediate access to a physician
who can perform an emergency pericardiocentesis. They should
understand the risks of conscious sedation, which include hypoventila-
tion, aspiration, and respiratory arrest. They should also recognize the
delayed time course associated with the development of AEFs or PV
stenosis, as well as the appropriate steps needed to diagnose and man-
age these complications.
Appropriate Follow-up and Long-Term
Management
Management of patients after hospital discharge can be complex
and requires commitment from the physician (cardiologist or in-
ternist) who will be following the patient on an ongoing basis.
Individuals undergoing training in AF ablation should participate in
a longitudinal clinic in which these patients are followed.
Experience must be gained in diagnosis and management of post-
procedure complications, including esophageal injury, PV stenosis,
and late tamponade, pseudoaneurysm, or arteriovenous fistula.
Because the prevalence of some of these complications is very
low, it is possible that the trainee will not have first-hand experi-
ence with patients. Therefore, supplementation of clinical experi-
ence with didactic presentations on diagnosis and management of
postablation complications is required. Prophylaxis against and
management of postprocedure atrial arrhythmias, including timing
of repeat ablation and use of concomitant AADs, must be taught
to trainees. Finally, the training experience must address the risk-
benefit decision-making regarding the use of intermediate and
long-term anticoagulation therapy. Given the complexity of these
issues, it would be ill-advised for cardiologists who are not trained
in electrophysiology to consider performing ablation procedures
for AF. Due to these issues and prerequisites for obtaining and
maintaining competency, this statement should also extend to the
performance of cryoablation or other balloon ablation.
Section 12: Surgical and Hybrid
AF Ablation
Historical Considerations and
Development of the Cox-Maze Procedure
There is a rich history of surgery for AF. Initial procedures were
aimed at controlling the ventricular response rate. Later procedures
were directed at converting AF to a normal sinus rhythm. Following
experimental investigation, the Maze procedure was introduced for
the surgical treatment of AF in 1987 by James Cox. This procedure
was designed to interrupt macroreentrant circuits, thereby reducing
the ability of the atrium to fibrillate. Fortuitously, the surgery also iso-
lated all of the PVs and the posterior LA. In contrast to previous pro-
cedures, such as the corridor procedure and LA transection
procedures, the Cox-Maze procedure successfully restored both AV
synchrony and sinus rhythm and decreased the incidence of late
stroke.1287 This effect was attributed to both AF control and amputa-
tion of the LAA. The surgery involved creating multiple strategically
placed incisions across both the RA and LA. The surgical incisions
were placed so that the sinus node could “direct” the propagation of
the sinus impulse throughout both atria. It also allowed most of the
atrial myocardium to be activated, resulting in preservation of atrial
transport function in most patients.1288 The final iteration of this pro-
cedure, the Cox-Maze III, became the standard for the surgical treat-
ment of AF.
Long-term outcomes of 198 patients who underwent the Cox-
Maze III procedure for treatment of paroxysmal (n= 113) or persist-
ent or long-standing persistent AF (n= 85) have been reported.1289
The mean follow-up was 5.4 ± 2.9 years. Among the 112 patients
who underwent surgery only for AF treatment, 96% were in sinus
rhythm with or without AAD therapy and 80% were in sinus rhythm
and free of AAD therapy at the last follow-up. Among the 86 patients
who underwent AF surgery in conjunction with other cardiac sur-
gery, 97% were in sinus rhythm with or without AAD therapy and
73% were in sinus rhythm free of AAD therapy. The incidence of
major complications among the 112 patients who only underwent
AF surgery was 11%. Among these were two perioperative deaths
and two perioperative strokes or TIAs. Nine patients (8%) required
pacemaker placement. The incidence of major complications among
the 86 patients who underwent AF surgery at the time of other car-
diac surgical procedures was 14%. Among these were one periopera-
tive death and one perioperative stroke. Twenty patients (23%)
required pacemaker placement.
In considering the results of these early reports of cardiac sur-
gery for treatment of AF, it is now recognized that these patients
did not undergo rigorous follow-up by present standards.
Rhythms were documented by means of a mailed questionnaire,
telephone interview, and/or an ECG for documentation. It is clear
that the pioneering work of Cox and his team paved the way for
the current, less invasive Cox-Maze IV surgery and other surgical
approaches for AF ablation, as well as the field of endocardial cath-
eter ablation of AF.
The term lone AF holds different meanings in EP jargon com-
pared with surgical jargon. Electrophysiologists refer to lone AF
when there is no other structural heart disease present. Surgeons
often refer to a lone AF procedure as one in which the only surgi-
cal procedure performed is the ablation as opposed to a concomi-
tant procedure. To eliminate confusion, we recommend that
surgeons avoid using lone AF to describe populations of AF pa-
tients, and furthermore, we recommend the term stand-alone abla-
tion when no other concomitant procedure is performed at the
same operative encounter. As noted earlier in the document, the
writing group recommends that the term lone AF not be used in
any context related to AF or AF ablation.
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Surgical Ablation Technology
Despite its efficacy, the Cox-Maze procedure did not gain widespread
application due to its complexity, technical difficulty, and morbidity.
The development and subsequent availability of technology to perform
atrial ablation allowed surgeons to replace some of the traditional cut-
and-sew lesions with ablation lines using this technology. The simplified
Cox-Maze procedure lessened procedural morbidity, thus leading to
wider adoption and extending its benefits to more patients. Although a
variety of energy sources for ablation were initially developed, only cry-
othermy and RF energy delivery have emerged as practical and effica-
cious. The only surgical ablation system approved and specifically
labeled for surgical AF ablation is the Atricure Ablation System, which
includes a number of ablation tools, including a bipolar RF clamp.1290
Cryothermy can be thought of as nondirectional (although shield-
ing mechanisms can be employed), whereas RF is a directional
source. The RF technologies can be organized into two major groups:
unipolar and bipolar. Bipolar RF can be directional bipolar or con-
strained bipolar. The directional bipolar devices have two side-by-
side poles that are applied to the tissue surface, with the energy pass-
ing through the tissue between them. As the tissue between the
poles desiccates and the impedance rises, the energy passes deeper
into healthy tissue, with the goal of tissue transmurality.
The constrained bipolar devices consist of a clamp with two jaws,
which are applied on opposite sides of the atrial tissue. The energy
passes through the tissue between the two jaws. When conductance
falls, transmurality is inferred. The unipolar devices do not provide
the surgeon with a transmurality indicator. Since most of these abla-
tion systems were released clinically without dose-response studies,
their use has led to occasional collateral cardiac and extracardiac
damage.1162,1291,1292 Moreover, both unipolar and directional bipolar
energy sources have had difficulty creating transmural lesions when
used from the epicardial surface on the beating
heart.1293,1294,1295,1296,1297,1298 This difficulty occurs because the cir-
culating intracavitary blood pool produces convective cooling, which
makes transmural lesions difficult to achieve.1299 In an attempt to ob-
viate this problem, one device provides suction to pull two walls of
atrial tissue into apposition in a shallow trough, thus excluding the cir-
culating heat sink of intracavitary blood while the energy is applied.
All of these energy sources have a fixed depth of penetration, which
makes their use in pathologically thickened atria problematic.
Bipolar RF ablation has overcome some of these shortcomings.
Because energy is delivered between two closely approximated elec-
trodes embedded in the jaw of a clamp device, the energy is focused
and results in discrete lesions. The energy is confined to between the
jaws of the clamp, reducing the possibility of collateral cardiac or
extracardiac damage. By measuring the tissue conductance between
the two electrodes, algorithms have been developed that help pre-
dict lesion transmurality in the experimental laboratory. The weak-
ness of these devices is that they can only ablate tissue that can be
clamped within the jaws of the device. This problem has limited the
potential lesion sets, particularly in the beating heart. Moreover, in
the clinical situation, multiple ablations have often been required to
achieve entrance and exit block. These devices have been incapable
of fully ablating the RA and LA isthmus and have required adjunctive
cryothermy, or unipolar or directional bipolar RF ablation to perform
a complete Cox-Maze III lesion set.
Nevertheless, the development of these new ablation technologies
has benefited the surgical treatment of AF by making a technically dif-
ficult and time-consuming surgery easier for all cardiac surgeons to
perform. At present, more than 50% of the patients undergoing
open-heart surgery who have AF are offered concomitant AF sur-
gery.1300 Replicating the full Cox-Maze lesion set with linear lines of
ablation has been shown to be both feasible and clinically effective. A
number of groups have reported excellent results with ablation-
assisted Cox-Maze procedures.1301,1302,1303,1304,1305,1306
The largest of these experiences included 282 patients who under-
went the Cox-Maze IV procedure over a 7-year period with either
paroxysmal (n= 118), persistent (n= 28), or long-standing persistent
AF (n= 135).1301 A total of 124 patients (44%) underwent surgery
only for AF treatment, and 158 patients (56%) had other cardiac sur-
gery performed, which included mitral valve surgery in approximately
50% of patients. Among the entire patient cohort, 89% of the patients
were in sinus rhythm with or without AAD therapy, and 78% were in
sinus rhythm and free of AAD therapy at 12 months of follow-up. In
contrast to early studies on surgical AF ablation, more intensive
monitoring was performed with Holter monitors every 3 months in
70% of the patients. The incidence of major complications was 11%,
including an operative mortality of 2% and a 1.7% incidence of stroke.
Pacemakers were implanted in 9% postoperatively. A propensity ana-
lysis, matching patients who underwent an ablation-assisted Cox-
Maze with those having had a traditional cut-and-sew Cox-Maze III,
showed no differences in freedom from AF at 3, 6, and 12 months of
follow-up.1307 Further recent work has shown significantly improved
results when the entire posterior LA is excluded by the so-called box
lesion.1306,1308
A long-term study followed 576 patients from 2002 to 2014 with
long-term monitoring.1306 At 5 years, freedom from ATAs was 73%
(102 of 139) and freedom from ATAs off AADs was 61% (80 of 135).
There was no difference in outcomes between patients with PAF or
the more persistent forms. There was also no difference between
outcomes for those patients who had stand-alone procedures and
those who had concomitant procedures. Because outcomes were
significantly better at 12 months of follow-up (92% freedom from
ATAs overall and 88% freedom from ATAs off AADs), this paper
highlights the importance of long-term follow-up. Currently, the limi-
tations of the energy delivery devices and the attempt to deploy
them through minimal access incisions or ports place constraints on
the location and number of ablation lesions that can be performed.
The impact on results of these alternative lesion patterns and the less
invasive surgical approaches requires further observational prospect-
ive analysis and randomized trials.
There has only been one completed trial of concomitant surgical
AF ablation that has resulted in specific FDA labeling for clinical treat-
ment of AF.1290 This was the Atricure Synergy Ablation System trial
intended for the ablation of persistent and long-standing persistent
AF in patients who are undergoing open concomitant coronary ar-
tery bypass grafting (CABG) and/or valve replacement or repair. The
principal device used in this trial was an Atricure Synergy Ablation
clamp. This system had originally been approved by the FDA for soft
tissue ablation without specifically labeling for AF ablation. This pro-
spective nonrandomized clinical trial, using a Bayesian adaptive design
with prespecified early stopping rules, enrolled 55 patients between
February 2008 and June 2009. Along with concomitant cardiac
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surgery, investigators performed the Cox-Maze IV lesion set. The
median patient age was 72 years, the median EF was 50%, and the me-
dian LA size was 6 cm. 56% of patients underwent valve surgery alone
or in conjunction with CABG. The incidence of major adverse events
was 9%, including death in 2 patients (3.6%), major bleeding in 2 pa-
tients (3.6%), and stroke in one patient (1.8%). In addition to these
major complications, 25% of the patients required implantation of a
permanent pacemaker for AV node dysfunction (8.3%) or sinus node
dysfunction (17%). The effectiveness of the procedure was assessed
in 50 evaluable patients, excluding four patients who died and one
withdrawal. At 6 months of follow-up, 74% of the patients were AF-
free and off AAD therapy, and 84% of the patients were free of AF
on or off AAD therapy. The freedom from AF at 12 months of
follow-up was also 75%. The results of this study were reviewed at
an FDA panel meeting, leading to approval for clinical use in 2011.
This surgical ablation system is currently the only system specifically
labeled for treatment of AF.
We recommend that the term Maze procedure is appropriately
used only to refer to the biatrial lesion set of the Cox-Maze surgery.
It requires ablation of the RA isthmus and the LA isthmus. Less exten-
sive lesion sets should not be referred to as a Maze procedure, but
rather as a surgical AF ablation procedure. In general, surgical ablation
procedures for AF can be grouped into three different groups: (1) a
full biatrial Cox-Maze procedure, (2) PVI alone, and (3) PVI combined
with LA lesion sets.
Surgical Technology for Appendage
Ligation or Removal and Outcomes of
These Procedures
The LAA is a site of thrombus formation in patients with AF.
Retrospective evaluation has suggested that the LAA is responsible
for up to 90% of the strokes in patients with AF and nonrheumatic
heart disease.1309 Accordingly, it has been the target of elimination in
the original Cox-Maze, as well as in the majority of its modifications.
Early evaluation of the cut-and-sew Cox-Maze suggested a reduction
of stroke late after surgery.1287 Other small, retrospective series sub-
sequently suggested a lower-than-expected incidence of late neuro-
logical event (stroke or TIA) after a Maze, possibly independent of
CHA2DS2-VASc score.
1287,1310,1311 The reduction in stroke has been
attributed to a combination of sinus restoration and LAA elimination.
The role of the LAA has been clouded by small numbers of patients
and the continuation of anticoagulation in a minority of postoperative
patients, as well as a retrospective series suggesting a persistent
stroke risk in postoperative patients who are in sinus rhythm, with
large atria, and poor atrial contraction leading to effective LA
asystole.1312
The strongest evidence that LAA elimination decreases stroke
comes from the WATCHMAN Left Atrial Appendage System for
Embolic Protection in Patients With Atrial Fibrillation (PROTECT
AF) and WATCHMAN LAA Closure Device in Patients With Atrial
Fibrillation Versus Long Term Warfarin Therapy (PREVAIL) trials
that randomized patients to either anticoagulation or implantation of
a WATCHMAN device in the LAA. The 4-year results of the
PROTECT AF trial suggested that elimination of the LAA was super-
ior to anticoagulation for the composite endpoint of cardiovascular
death, all stroke, and systemic embolization.1313,1314
An important concern for surgical excision has been the complica-
tion of bleeding. This complication is especially important in older pa-
tients and those with enlarged atria in whom the tissue may be more
friable. This has led to several different techniques for LAA elimination
at the time of surgery. The most common have been internal ligation
(e.g., sewing the LAA orifice closed from the inside) and stapled exci-
sion. There is a paucity of data that examines effectiveness of any surgi-
cal technique. However, with stapled excision, reported rates of tears
requiring repair have been approximately 10%.1315,1316
Another issue is the potential for arrhythmia generation from the
LAA. One study demonstrated LAA firing in 29% of patients and the
only site of recurrence in 8.7% of patients who had undergone cath-
eter ablation of paroxysmal or persistent AF; additional LAA isolation
could increase the freedom from AF.532,533 Thus, the isolation or sur-
gical excision of the LAA could influence procedure efficacy and re-
duce the risk of thromboembolic events.
However, a randomized study including 176 patients with persist-
ent AF who were undergoing surgical ablation via thoracoscopic ap-
proach reported that additional LAA amputation did not reduce the
rate of any atrial arrhythmias compared with the standard surgical ab-
lation set. The follow-up period of this study was 18 months and the
results cannot be extrapolated to the long-term maintenance of sinus
rhythm or thromboembolic events prevention.1317
An emerging concern is the effectiveness of these alternative tech-
niques. Most evidence is anecdotal and revolves around case reports
because the LAA is not routinely evaluated late after surgery unless
there is a clinical indication. In a series of 137 such patients, the LAA
was incompletely ligated (either leaving a stump greater than 1 cm or
a gap with flow) in 27% of patients after surgical excision. In internally
ligated patients, the failure rate was 77%. There were no successes
when the LAA was stapled without amputation of the distal rem-
nant.1318 One limitation of this small series is that it only looked at
the 5% of patients who received intervention who had an indication
for late TEE, which included only 12 in the stapled group. A more re-
cent small, randomized trial of internal ligation, surgical excision, and
stapled excision reported that, at TEE evaluation in follow-up of
5 months, all three of these techniques left either a stump or a gap at
least 50 percent of the time.1319
Epicardial LAA ligation with a LARIAT device has been developed
through the combined transseptal and subxiphoid approach.1320 The
results from the multicenter registry demonstrated a high acute clos-
ure rate, but procedural success was limited by bleeding.1321 More
recent results showed that LARIAT device implantation was associ-
ated with a lower rate of leaks at 1 year of follow-up and a 1.1% rate
of TIA or stroke.1322
Newer techniques include an external clip (Atriclip) that was
approved by the FDA in 2011 for the occlusion of the LAA under dir-
ect visualization in patients undergoing other open cardiac surgical
procedures, as indicated in the approved Indication statement of the
AtriClip device. This study reported 98% success in 60 of 71 patients
available for follow-up.1323 A longer-term study followed 36 patients
with annual CT scans.1324 At 3.5 years of follow-up, all the clips were
stable with no thrombi, no LAA perfused, no neck >1 cm, and no
neurological events. The use of an endoloop has been described, as
well as a silicone fastener, which is not currently available (Tiger
paw). The true efficacy of any single technique is unknown and will re-
quire more investigation before any recommendations can be made.
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There are data that suggest that despite the limitations of all these
techniques, a reduction in strokes might occur. One series of 773 pa-
tients undergoing surgery for AF compared surgical excision with al-
ternative techniques. The annual rates of late neurological events was
approximately 1% using alternative techniques, and only one event
was fatal.1325 This suggested at least a reduction of clot burden even
in incompletely successful techniques. Our understanding of surgical
elimination continues to rapidly evolve, and current studies are inad-
equate to make a distinction between LAA excision or exclusion
techniques. It is reasonable and probably helpful to eliminate the LAA
with any technique at the time of AF surgery, but late evaluation
should be performed prior to cessation of anticoagulation. We have
elected not to make recommendations regarding appendage occlu-
sion, resection, or ligation in this document, because this is beyond
the scope of this document and available data.
Concomitant Surgical Ablation
Historical Considerations
Surgical ablation is most commonly applied as a concomitant proced-
ure during valve or CABG surgeries. Prior consensus recommenda-
tions referred to cardiac surgery as a whole, grouping data from
multiple studies to derive IIa LOE C recommendations.2 However,
that document went on to say, “It is advisable that all patients with
documented AF referred for other cardiac surgeries undergo a left
or biatrial procedure for AF at an experienced center, unless it. . .
will add significant risk. . ..”2
More recent AHA/ACC/HRS Guidelines continued this proced-
ural grouping but included more recent randomized comparisons to
determine that surgical ablation at the time of another surgery is a IIa
LOE B recommendation. The frequencies of surgical ablation per-
formance and durable rhythm success have steadily increased.
Furthermore, as noted above, the FDA has now approved an ablation
system for treatment of persistent AF in patients undergoing con-
comitant cardiac surgical procedures.1290 Recently, more information
has become available on AF mechanisms and the potential influence
of specific structural heart abnormalities on outcome. Therefore, this
surgical section provides updated recommendations for three oper-
ation categories for which more data are now available: primary
open atrial operations, primary closed atrial operations, and stand-
alone operations for AF.
Concomitant Surgical Ablation
Open concomitant cardiac surgical operations, in which a left atriot-
omy is being performed for the primary procedure, commonly in-
clude patients receiving mitral valve repair or replacement (MVRR),
with or without concomitant tricuspid valve repair or replacement,
or closure of an ASD. Closed concomitant surgical ablation oper-
ations, in which a left atriotomy is not otherwise performed, com-
monly include patients undergoing prosthetic AVR, CABG, or
AVRþCABG.
The prevalence of preoperative AF and frequency of concomitant
cardiac surgical operations varies between these procedure classes.
AF is found in one-third of patients presenting for mitral valve sur-
gery, but in only 6% of patients undergoing isolated CABG, and in
14% of patients at the time of AVR. Mitral valve repair for primary re-
gurgitation has largely supplanted mitral valve replacement and does
not require lifelong anticoagulation. Thus, successful surgical ablation
concomitant to mitral repair can mitigate the need for long-term anti-
coagulation or medicinal therapy for AF. The performance rate of
concomitant cardiac surgery in patients with AF at the time of mitral
operations has risen from 52% to 62%. In an analysis of operations
performed in the early 2000s, the likelihood of surgical ablation per-
formed for AF at the time of AVR was 31%, and only 26% at the time
of CABG. Although differential application of surgical AF ablation
exists among operative procedures, more recent information sug-
gests an acceleration of surgical AF ablation, especially in the mitral
subgroup.
Surgical Ablation at the Time of Concomitant Open
Atrial Operations
At the time of a primary atriotomy, AF surgery can be performed
during concomitant MVRR with or without tricuspid surgery, with or
without closure of ASD, and with or without other concomitant pro-
cedures such as CABG.1326 The results of the only prospective study
performed to achieve FDA labeling for AF ablation reported a 9%
major complication rate, a 25% rate of pacemaker implantation, and a
75% freedom from AF at 12 months of follow-up among 54 consecu-
tive patients with persistent AF undergoing other types of cardiac
surgery who were enrolled in this clinical trial.1290 Several other
RCTs and meta-analyses are available to evaluate AF surgery at the
time of concomitant mitral procedures.1327,1328,1329,1330,1331,
1332,1333,1334 Large LA, AF duration, advanced age, and failure to iso-
late the entire posterior LA are common predictors of reduced long-
term efficacy. High baseline comorbid risk is a common reason cited
for not performing surgical ablation, though many institutional studies
note that this is not a contraindication to surgical ablation. The safety
of concomitant surgical ablation has been established in the literature
and in updated valve risk models from the STS database.
A multivariable regression and propensity matched cohort, com-
posed of 52% mitral procedures from the STS database, demon-
strated no impact on 30-day mortality with surgical AF ablation.1300
However, patients undergoing surgical AF ablation had a 26% higher
chance of requiring a permanent pacemaker (OR 1.26). In a recent
randomized trial of mitral valve operations, there was no increase in
major complications associated with the addition of surgical ablation
other than a doubling of pacemaker risk.1331,1333 Conversely, recent
large meta-analyses confirmed the safety of concomitant surgical ab-
lation, but did not find a significant increase in pacemaker use. The in-
cidence and outcome relevance of pacemaker implantation remains a
point of controversy. In analyses of more recent STS data, risk-
adjusted mortality was either not impacted or actually decreased
with surgical AF ablation in the mitral and multiple valve popula-
tions.1335 A longitudinal study (up to 120 months) demonstrated that
restoration of sinus rhythm by a Cox-Maze procedure combined
with heart surgery markedly increased long-term survival.1336
Despite previously published variability of efficacy of surgical ablation
in heterogeneous populations, the longitudinal benefits of concomitant
surgical AF ablation at the time of MVRR are now becoming clearer.
Several recent RCTs and meta-analyses indicate that concomitant
surgical ablation at the time of MVRR reduces the longitudinal inci-
dence of postoperative AF greater than 50% for at least 1 year, with re-
sults ranging from 60%–90%.1327,1328,1329,1330,1331,1333,1334,1337,1338
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In addition to LA size and preoperative AF duration, there is a proced-
ural learning curve that can impact efficacy, and thus surgeons should
seek appropriate training prior to performing surgical ablation.
Therefore, based on the literature and the experience of the writ-
ing group members, surgical ablation for AF is recommended at the
time of concomitant open atrial procedures, such as mitral valve sur-
gery in patients with symptomatic AF (Class I, LOE B-NR) (Table 2,
Figure 8).
Surgical Ablation at the Time of Concomitant Closed
Atrial Operation
Concomitant surgical ablation of AF at the time of primary nonatriot-
omy operations includes patients undergoing isolated AVR, isolated
CABG, or AVRþCABG. The presence of AF at the time of these op-
erations, especially if left untreated, is associated with increased risk
of early and late mortality and morbidity. When no intracardiac path-
ology exists in the setting of AF, further surgical decision-making is
required. Although full open Cox-Maze IV has been shown to be safe
and effective in these cases, surgeons are reluctant to add a left atriot-
omy to address AF. If less aggressive approaches, such as epicardial
PVI or the Dallas lesion set are to be applied, care should be taken to
note the mechanism and type of AF being treated.1339,1340,1341
Recent randomized and matched cohort studies of surgical ablation
and concomitant AVR, AVRþCABG, and isolated CABG all consist-
ently show no differences in 30-day or in-hospital morbidity or
mortality.1342,1343,1344
We have known that at the time of isolated CABG operations, the
open atrial Cox-Maze procedure is effective upwards of 90% at
5 years of follow-up.1345 The application of bipolar RF clamps to per-
form PVI has shown variable 50%-89% 1-year success superior to
AAD alone in patients with paroxysmal and persistent
AF.1346,1347,1348,1349,1350 A recent meta-analysis of 16 RCTs of surgical
ablation and concomitant operations evaluated predominantly mitral
operations, but included both AVR and CABG operations.1333 There
were no significant differences in mortality, stroke, or pacemaker re-
quirement between surgical ablation compared with no ablation;
however, the surgical ablation groups demonstrated superior 1-year
freedom from AF in AVR and AVRþCABG.
Therefore, based on the literature and the experience of the writ-
ing group members, surgical ablation for AF is recommended at the
time of concomitant closed atrial procedures such as isolated AVR,
isolated CABG, and AVRþCABG in patients with symptomatic AF
refractory or intolerant to at least one Class I or III antiarrhythmic
medication (Class I, LOE B-NR) (Table 2, Figure 8). For symptomatic
patients with AF who have not previously been treated with antiar-
rhythmic therapy, concomitant closed AF surgery is recommended
with a Class IIa indication, LOE B-NR (Table 2, Figure 8).
At the time of a planned cardiac operation for symptomatic struc-
tural pathology, it should be noted that interpreting symptoms of
concomitant AF as distinct might or might not be feasible because
these could be masked by symptoms prompting the primary cardiac
operation (i.e., valvular or coronary disease). Therefore, in the setting
of existing symptomatic surgical pathology, the presence or absence
of AF symptoms should not be the only factor involved in surgical de-
cision making on the concomitant performance of surgical ablation. It
should be noted that the surgeon members of the writing committee,
as well as other surgeon reviewers, felt that the evidence might war-
rant a Class I indication for this patient subgroup; however, among
the larger group, consensus was attained for a level IIA
recommendation.
Stand-Alone Surgical Ablation of AF
Stand-Alone Operations for AF and Their Outcomes
The primary indication for stand-alone surgery that was described in
the 2012 Consensus Document was the presence of symptomatic
AF, refractory or intolerant to at least one Class I or Class III AAD.2
In current practice, most patients also have experienced at least one
unsuccessful catheter ablation before referral, unless the patient has
a strong preference for a cure with a single procedure.
There has been over two decades of experience with operations
performed solely for treatment of AF (stand-alone operations). The
wide use of these procedures has been limited by a reluctance to
refer patients to surgery for AF, procedural complexity, and limited
data regarding outcomes. Moreover, the types of procedures and the
technologies used to perform them have multiplied and are variable
between operators. This has led to relatively modest-sized single-site
case series, or at best multicenter series without comparison groups.
In addition, the rigor and methodology of follow-up have changed
dramatically over time and have further limited comparisons of out-
comes. Lastly, the development of hybrid procedures, especially
when staged, make comparisons even more difficult. This section will
focus only on single-stage surgeries as sole AF therapies. A discussion
of hybrid procedures will follow. Perhaps the best way to distinguish
the types of surgeries is by those that require cardiopulmonary by-
pass and cardiac arrest and those that do not. In order to effectively
create a lesion down to the mitral annulus, an open heart is required.
The earliest—and one of the largest—reported study of stand-
alone operations for AF has been the 112 patients who underwent
the cut-and-sew Cox-Maze III procedure by James Cox.1351 This pro-
cedure is performed through a sternotomy on cardiopulmonary by-
pass on an arrested heart and physically cuts and re-sews the atria to
create a collection of lines of block. Cryothermia is used to destroy
the tissue down to the mitral annulus. Among the 112 patients, 96%
were in sinus rhythm with or without AAD therapy, and 80% were in
sinus rhythm and free of AAD therapy at last follow-up. There was
one late stroke in this group, and 88% of the patients were off chronic
anticoagulation at last follow-up. The only risk factor for late recur-
rence was the preoperative duration of AF.1351 There have been sev-
eral other published series with similar results that combine both
stand-alone and concomitant patients with smaller numbers of pa-
tients. This procedure requires a sophisticated level of training and
skill. As such, it is performed rarely, and only by experienced sur-
geons. Ideal patients for stand-alone AF ablation have failed other
therapies, want definitive cures, or have clots in the LAA, making
other approaches not using cardiopulmonary bypass risk prohibitive.
With the introduction of new ablation technology, including bipo-
lar RF energy and new cryoablation systems, there has been renewed
interest in less invasive procedures for stand-alone AF ablation.
These new tools can be used in the open chest or through small inci-
sions between the ribs. When used in the open chest with a full bia-
trial Cox-Maze lesion set performed, the procedure has been
termed the Cox-Maze IV procedure. Techniques for a Cox-Maze IV
procedure through a small, right inframammary incision have also
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been perfected. As noted in the earlier section on new surgical abla-
tion technology, the outcomes achieved with the Cox-Maze IV pro-
cedure are similar to those achieved with the earlier Cox-Maze
procedure. Importantly, the cross-clamp times are shorter with the
Cox-Maze IV procedure.1301 The advantage of these approaches in-
cludes the ability to reliably create the endocardial lesions of the
Maze, down to the mitral annulus. Late evaluation of this procedure
in 146 stand-alone patients has shown a 72% freedom from AF at
5 years of follow-up and a 59% freedom from AF off antiarrhythmic
medications.1306 Cryothermia alone has been used and described in a
series of 77 patients, with a 6-month result of 88% freedom from AF,
antiarrhythmic medications, and anticoagulants, but late follow-up is
lacking.1306,1352
Other approaches have limited the lesions to only those that can
be created from the epicardium without the need to open the heart,
and use both cardiopulmonary bypass and cardiac arrest. This ap-
proach has limited the extent of lesions from the Maze that can be
created, because the mitral line is buried by an epicardial fat pad that
makes destruction of tissue in this area unreliable. The minimally inva-
sive surgical approach using video-assisted PV ablation and exclusion
of the LAA was first described in 2005.1353 A bipolar RF clamp was
used for PVI on the beating heart in 27 patients, among whom 18 had
PAF. Among the 23 patients followed for more than 3 months, 21
(91%) were free of AF and 65% were off all AADs. There were four
major complications, but no deaths, and no pacemakers were im-
planted. An additional ablation strategy that has been reported is min-
imally invasive PVI and partial autonomic denervation.1354 In a study
of 74 patients undergoing this approach, 84% of the patients with
PAF were free of AF and 57% of patients with persistent or long-
standing persistent AF were free of AF at 6 months. There was one
death, one hemothorax, one case of transient renal insufficiency, and
one patient with a transient brachial plexopathy. A second, larger re-
port from this group in 114 patients reported that 72%, 46.9%, and
32% of patients with paroxysmal, persistent, and long-standing per-
sistent AF, respectively, were free of AF and off antiarrhythmic medi-
cations at 195 days of follow-up.1355 Another multi-center series of
100 patients with a similar approach and mean follow-up of
13.6 months reported a sinus restoration rate of 87%, with 64% of pa-
tients free from AADs.1356 The results of these and other trials cited
earlier in this section have made it clear that a more extensive lesion
set than PVI alone is required for successful surgical treatment of per-
sistent and long-standing persistent AF. Most surgeons who still per-
form this type of procedure have moved toward a hybrid approach
in either a single or staged operation. However, a PVI alone remains a
reasonable approach for patients with PAF.
The Dallas Lesion Set was developed to create a complete ap-
proach, which can be performed on a beating heart without cardio-
pulmonary bypass.1339,1340,1341 The set replicates the LA lesions of
the Cox-Maze III, but changes the connection of the PVI to the aortic
annulus in continuity with the mitral. Early results have been pub-
lished on 30 patients.1339,1340 The group included 10 patients with
persistent AF and 20 patients with long-standing persistent AF.
Electrocardiographic long-term monitoring and the use of AAD data
were collected 6 months postprocedure, and follow-up was 100%.
Procedure-related complications did not occur during follow-up, nor
were there any deaths. At 6 months of follow-up, 90% of the patients
with persistent AF and 75% of the patients with long-standing
persistent AF were in sinus rhythm. AAD therapy was continued in
22% of the patients with persistent AF and 53% of the patients with
long-standing persistent AF. In a series of 100 paroxysmal patients
randomized to include the Dallas Lesion Set or not, the additional le-
sion, as expected in a paroxysmal population, did not impact success
at 16 months of follow-up.520 Much like the results of catheter abla-
tion, this suggests that the type of AF will influence the success of the
procedure. Persistent AF is likely to require a more extensive lesion
set. An important area of interest is the decision to offer a patient
surgery or catheter ablation.
The AF Catheter Ablation Versus Surgical Ablation Treatment
(FAST) trial sought to compare catheter ablation with minimally inva-
sive surgery.601 A total of 124 patients who had drug-refractory AF
with dilated atria or failed catheter ablation were randomized to ei-
ther catheter ablation or minimally invasive surgery using bipolar
clamps, with or without additional connecting lesions. At 1 year of
follow-up, freedom from AF was 37% in the catheter ablation group
and 66% in the surgical group. Although this was somewhat offset by
the increased adverse events in the surgical group (34% vs 16%), the
only death was in the catheter ablation group.601 A different analysis
of 7 studies, including two RCTs, suggested superior freedom from
AF in the surgical group, with similar complication rates, except for
an increase in pacemaker implantation in surgical patients.1357
However, the technologies and groups were fairly heterogeneous.
Other approaches, such as epicardial box lesions with suction-
assisted unidirectional uni- and bipolar RF and a complete box lesion
with bipolar clamps, have been described in numbers insufficient to
draw any conclusion. As the new techniques have been introduced,
there has been appropriate concern regarding the safety of minimally
invasive stand-alone surgery. Although safety is dependent on pro-
cedure and site, it has been examined in a systematic review that
compiled results from 23 observational studies with 752 patients
who underwent minimally invasive stand-alone procedures.1349
Operative mortality was 0.4%. Complication rates attributed to sur-
gery were only 3.2%. Reports from the STS National Database
showed an operative mortality rate of 0.74%. The complication rate
was considerably higher at 16.43%, although major morbidities such
as stroke (0.72%), renal failure (2.45%), and bleeding (0.99%) were
low. Pacemakers were implanted in 1.03% of patients.
The outcomes of stand-alone AF ablation from the STS database
were recently reported.1358 Between 2005 and 2010, a total of 91,801
surgical AF ablations were performed, of which 4893 (5.3%) were
stand-alone. During this period of time, the number of stand-alone
AF surgeries increased from 552 cases in 2005 to 1041 cases in 2010.
The mean age of the stand-alone group was 60 years, and 71% were
men. Some 80% of the stand-alone procedures were off pump. The
overall operative mortality was 0.74% (1.7% on pump vs 0.5% off
pump), the rate of pacemaker implantation was 1%, and the overall
complication rate was 16% (28% on pump vs 13% off pump).1358
The Atrial Fibrillation Ablation and Autonomic Modulation via
Thoracoscopic Surgery (AFACT) study compared the outcomes of
thoracoscopic surgical AF ablation in 240 patients with advanced AF
at a single European center.123 A total of 59% of the patients had per-
sistent AF and 68% had an enlarged LA. One-fourth of these patients
had previously failed catheter AF ablation. Patients were randomized
to undergo surgical AF ablation alone or combined with epicardial ab-
lation of the four major GP. At 12 months follow-up, no recurrences
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of AF were observed in 71% and 68% in the GP and control groups,
respectively; the incidence of major complications was greater in the
group that underwent GP ablation (19% vs 8%, respectively). Major
bleeding occurred in nine patients in the GP group, one of whom
required sternotomy. Sinus node dysfunction occurred in 12 patients
in the GP group and in 4 controls. The authors concluded that GP ab-
lation during thoracoscopic surgery for advanced AF is associated
with higher risk and no appreciable improvement in AF control. This
center also recently examined the 5-year outcomes of thoracoscopic
surgery for AF in 66 patients. A total of 50% of patients experienced
no AF recurrences and discontinued AAD therapy at the 5-year
follow-up, and 88% of the patients were in sinus rhythm. In this co-
hort, persistent AF and previous failure of catheter ablation were in-
dependently associated with AF recurrence.1359
Superior efficacy of a single approach has also been difficult to es-
tablish. A systematic review of 48 studies including 3832 patients sug-
gested that the efficacy of bipolar RF was equivalent to the cut-and-
sew Maze III technique for stand-alone surgical ablation, as long as
both were applied meticulously.1360 Another meta-analysis of 16
published randomized trials indicated that the cut-and-sew Maze III
produced slightly better recovery of SR and stroke prevention, but
with increased perioperative risk.1361 Definitive recommendations
for a surgical approach with or without cardiopulmonary bypass
await more data.
Using a surgical approach with or without cardiopulmonary bypass
that creates all, some, or a modification of the maze is reasonable, es-
pecially in patients in whom catheter ablation has failed or who are at
high risk for an unsuccessful catheter-based result. However, a stand-
alone operation should have the ability to create the complete full
Maze lesion set, whether it is in a single operation or staged. This ap-
proach is especially important for those patients who have persistent
AF.
Therefore, based on the literature and the experience of the writ-
ing group members, stand-alone surgical ablation of paroxysmal
AAD-refractory AF can be considered for patients who have failed
one or more attempts at catheter ablation, and after review of the
relative safely and efficacy of catheter ablation vs a stand-alone surgi-
cal approach for those who are intolerant or refractory to AAD ther-
apy and prefer a surgical approach (Class IIb, LOE B-NR). For
patients with persistent and long-standing persistent AF, stand-alone
surgical ablation is reasonable for patients who have failed one or
more attempts at catheter ablation, and after review of the relative
safely and efficacy of catheter ablation vs a stand-alone surgical ap-
proach for those who are intolerant or refractory to AAD therapy
and prefer a surgical approach (Class IIa, LOE B-NR, Figure 8). Stand-
alone surgical AF ablation is not recommended for patients who have
not failed a trial of at least one antiarrhythmic medication.
Catheter Ablation After AF Surgery
The idea of a “touch-up” ablation for AF recurrence is not new to
catheter ablation. It is, however, relatively new to the treatment algo-
rithms of failure after cardiac surgery for AF, which has historically
been considered the end of the road for sinus restoration. Now,
catheter ablation can be a critical adjuvant for patients who undergo
surgical AF ablation yet still suffer from residual AF. The potpourri of
surgical AF treatment—ranging from PVI through complete LA to
complete biatrial lesions and combinations in between—makes
standardized conclusions difficult in this area. This endpoint is further
obscured by the myriad of technologies used to create the lines of
block, as well as the underlying type of fibrillation treated and the lim-
ited number of patients in published series. However, there are sev-
eral publications that offer some guidance, which will be reviewed
below. What has become clear over time is that, as with redo-
catheter AF ablation procedures, finding a reconnection of the PVs is
also to be expected in a patient undergoing a catheter-based AF abla-
tion procedure following a surgical AF ablation procedure.
Because the cut-and-sew Maze was the earliest described pro-
cedure, initial reports focused on patients who underwent that
specific procedure. One of the earliest studies reported on 23 pa-
tients who presented a mean 14 months after a cut-and-sew Maze.
In this report, 8 patients had only undergone a Maze, and 15 had
undergone a concomitant procedure.1361 The most common site
of failure was around the PVs, which occurred in eight (35%) pa-
tients. Five patients had focal tachycardia (3 in the CS and 1 each
in the posterior lateral RA and LA septum). Four patients had RA
incisional flutter and six had left AFL, which mapped around the
mitral valve annulus in four patients and around the PVs in two.
One year after ablation, 19 of the 23 patients were both
arrhythmia-free and off AADs.
The vulnerability of PVI was supported by another study that fol-
lowed 20 patients with arrhythmias after surgical ablation.1362 This
group, however, was much more heterogeneous: alternative energy
sources were used to create the initial lines of block, including micro-
wave, RF, cryothermy, and laser; most patients had only LA lesion
sets at the time of initial surgery, and nearly half the patients had
more than one mechanism of tachycardia. This report also high-
lighted the involvement of the mitral isthmus, including the CS and
the LAA. The vulnerability of the mitral isthmus, especially at the CS,
was also highlighted in a series of 22 patients failing after the Cox-
Maze III.1363 Of note, this outcome represented a 15% failure rate
among a total of 143 patients in whom lesions were created using a
combination of cut-and-sew and cryothermy. Frequently, out of con-
cern for injury to the circumflex, cryothermy is used at the mitral an-
nulus and is often used to connect the PVs in a small area so that
reapproximation of the tissue is easier.
In a series of patients with five different surgical types, various rates
of failure were identified.1364 High-intensity focused ultrasound was
associated with a 37.5% need for touch-up catheter ablation, which
was much more frequent than the other groups. This group had fail-
ures primarily around the PVs, suggesting an incomplete lesion cre-
ation at initial operation. The other groups—consisting of cut-and-
sew Maze, biatrial Maze using primarily RF, LA maze alone, and PVI
alone—had no significant difference in success, ranging from 90% for
the cut-and-sew to 69% for PVI alone. When the RA was not ad-
dressed at the time of initial operation, it was the site of failure in 75%
of those who had recurrent AF. In the other groups, the mitral isth-
mus was again identified as an area for failure. Successful ablation was
achieved in approximately 70% of patients.
These findings have relevance as new paradigms for treatment
evolve. Using hybrid strategies with technology that replaces cut-
and-sew and new lesion sets might require a more individualized ap-
proach to each patient. New technology can introduce an area of vul-
nerability around the PVs. In one series of 154 patients undergoing
minimally invasive PVI, eight failures were studied. Half had gaps in
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the lesions created with new enabling technology.1365 The remainder
had flutters around the mitral isthmus. In a series that compared a
cut-and-sew Maze to a hybrid approach, only 8% of the patients
needed ablation after a cut-and-sew Maze.1366 However, after PVI
using bipolar RF, 7 of 25 (29%) patients needed a second-stage cath-
eter ablation. All seven had at least one failure around the PVs, for a
total of 15 veins. Reconnection was most common in the RI region.
Interestingly, there were no RA failures in this group.
These reports suggest that there are many factors for surgical fail-
ures after AF treatment. It is likely that catheter ablation can help se-
lected patients restore sinus rhythm after failures. These treatments
should be performed at experienced centers by experienced individ-
uals who will tailor the procedure to the individual patient based on
initial lesion set, the ablation technology and strategy used during ini-
tial AF surgery, and the results of extensive mapping and provocative
testing at the time of the redo ablation procedure. As the experience
with new hybrid approaches evolve, more definitive conclusions
should arise.
Hybrid Epicardial and Endocardial AF
Ablation Procedures
Background
Forward-thinking practitioners view catheter AF ablation and minimal
access surgical ablation as complementary rather than competitive
techniques, having found that patients who fail a surgical ablation usu-
ally fail as paroxysmal with a relatively low burden of AF. Whereas
they might not have been candidates for catheter AF ablation pre-
operatively, they are now ideal candidates for a “touch-up” catheter
AF ablation. The electrophysiologist will frequently find a single small
break in a line, which is easily completed with a catheter; thus, the
procedure is converted to a success. This realization of the comple-
mentary nature of these disciplines has led some to believe that per-
haps combining these approaches could lead to better outcomes
than either approach alone.
There are other reasons why surgical (epicardial) and catheter
(endocardial) ablation can be viewed as complementary. Surgical de-
vices can fail to penetrate the endocardium; catheter devices can fail
to penetrate to the epicardium. Surgeons are skilled at making lines;
the tools are designed for it, the smooth epicardial surface is ideal for
it, and visual imaging can reveal breaks in a line. Electrophysiologists
excel at “spot welding.” The catheter tip is punctuated by design, so
it can slip off of endocardial ridges or trabeculations, resulting in
breaks, and nonvisual imaging does not show continuity of burns.
Surgeons might have difficulty mapping for completeness; they are
constrained by pericardial reflections, they might lack formal training,
and their tools are first- or second-generation. Electrophysiologists
excel at mapping for success; they have full access to the entire endo-
cardial surface, they are formally trained in the techniques, and they
have mature enabling technology. In addition, each specialty has its
own unique contributions. Surgeons can fully divide the ligament of
Marshall, eliminate the atrial appendage, perform targeted ablation of
GP, and isolate the SVC with little risk of injury to the PN.
Electrophysiologists can easily make a cavotricuspid isthmus line, map
for flutters, ablate within the CS, and map and ablate focal trig-
gers.1367,1368 Recognition of the complementary nature of these
techniques has led some centers to explore “hybrid” procedures
(combined surgical and catheter ablation), with early promising
results.606
The advent of minimal access surgical ablation laid the groundwork
for hybrid ablation. Seeking to advance the success of the Cox-Maze
III yet lessen the morbidity, surgeons began exploring minimal-access
approaches. Three things led to the expansion of minimal-access
techniques: First was the focus on the PVs as the seminal goal of abla-
tion; second, advances in enabling technology allowed lesion creation
using RF energy and cryothermy; and third was the published data re-
vealing modest success for catheter ablation of the persistent forms
of AF.2,931
Thus, with the focus on the PV triggers, surgeons began perform-
ing an increasing number of minimal-access PVI proced-
ures.197,1369,1370,1371 However, investigators showed that this
treatment was inadequate for patients with persistent and long-
standing persistent AF.1355 This led to the belief that the persistent
forms of AF needed both substrate modification and trigger isolation,
and this provided the impetus to develop the Dallas lesion set, which
replicated all the LA lesions of the Cox-Maze III, yet allowed them to
be placed on the surface of the full-beating LA. Although it was a
major step forward, with a success rate of 79%, this approach failed
to reach the success rates of the Cox-Maze III.1339,1340 To enhance
the robustness of lesion formation, the complementary processes of
performing a catheter-based endocardial ablation in combination
with surgical epicardial ablation were contemplated, and this led to
hybrid approaches.1372,1373,1374
Though these hybrid techniques are under active investigation, the
published literature is limited to a few early feasibility studies. Early in-
vestigators used a unilateral right thoracoscopic approach to isolate
the PVs with a single encircling box lesion. The energy source for the
surgical ablation was monopolar RF (Cobra Adhere, Estech, San
Ramon, CA). Nineteen consecutive patients underwent a right unilat-
eral minimally invasive hybrid procedure. Ten patients (52.6%) had
long-standing persistent AF, whereas four (21.1%) had persistent and
five (26.3%) PAF.1375 In 17 patients, one or more PVs (mostly the
LSPV) were not isolated, and an endocardial touch-up was needed. It
was possible to complete all the procedures as planned, without any
conversion to cardiopulmonary bypass. No patient died during the
follow-up. At 1 year, 7 of 19 (36.8%) patients were in sinus rhythm
with no episode of AF and off AADs. Among the patients with long-
standing persistent AF, 20% (2 of 10) were in sinus rhythm and off
AAD, 50% (2 of 4) in persistent and 60% (3 of 5) in PAF.
Disappointing 1-year results were attributed to an inadequate energy
source. Thus, the surgical portion of the procedure was converted to
use a bipolar RF clamp (AtriCure Inc., West Chester, OH), which
had been shown to be more effective.1376 This approach provided
improved results, and in most cases, gaps in surgical lesions could be
completed by endocardial catheter ablation during the same proced-
ure.608 A sequential hybrid approach was subsequently developed.606
There are advantages and disadvantages to simultaneous and staged
hybrid procedures.
An important concern of single-stage hybrid is that edema and
stunning induced by surgical ablation might produce block on testing,
but these areas might recover later, when edema has subsided. This
presence of an incomplete block at delayed catheter mapping was re-
ported by an investigator who performed bilateral PVI box lesion and
an additional roofline and LAA exclusion with clips in 30 patients
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with persistent AF. At staged catheter hybrid 3 months later, they
found gaps in 77%–87% of the PVI lesions, nearly 70% of the rooflines,
and 40% of the floor lines, requiring endocardial touch-up ablation.
Nevertheless, they were able to obtain a 1-year freedom from AF
and AAD by 7-day Holter of 90% (27 of 30). Other surgeons com-
pared 25 staged hybrid procedures using bipolar RF with 38 classic
cut-and-sew Maze III procedures.1366 At 1 year of follow-up, freedom
from AF and antiarrhythmic medication was 52% for the staged hy-
brid and 87.5% for the Maze III (P= .004). Other approaches included
a unilateral thoracoscopic approach using the monopolar RF suction
Estech Cobra Adhere XL device (AtriCure Inc., West Chester, OH)
without atrial appendage occlusion, applied to 19 patients.1375 At im-
mediate hybrid catheter ablation, every lesion required touch-up and
1-year freedom from AF and AAD was 36%.
An innovative approach has been the passage of a scope from the
subxiphoid, transperitoneal and transdiaphragmatic region to ap-
proach the posterior LA (the convergent procedure). The surgeon
uses the nContact monopolar RF coagulation system to produce a
comprehensive biatrial lesion pattern on the outside of a beating
heart while eliminating chest incisions. Then, the electrophysiologist
uses an ablation catheter endocardially to finish the lesion pattern
and ensure that all reentrant circuits are interrupted.
Reported success rates have varied, from 16.7% to 100%; how-
ever, there has been an elevated adverse event rate in most published
series, with an associated mortality of up to 12.5%, mostly related to
AEF and sudden death.607,609,613,1368,1377,1378,1379,1380,1381,1382,1383
This procedure has been largely redesigned to prevent these adverse
results, and two papers have reported no mortality and no
AEF.613,1381
A recent meta-analysis compared the Cox-Maze to hybrid pro-
cedures. The overall freedom from AF and freedom from AF off
AAD at 1-year of follow-up was 87% vs 71%, respectively, but the
complication rates were higher with hybrid procedures.1384 Based
on current literature, the hybrid approach with the most effective
outcomes and safety profile appears to be the bilateral PVI pro-
cedures with LAA management. Available published data on the
monopolar convergent procedure do not indicate an adequate
safety and efficacy profile.
Currently, there is investigation into both simultaneous and
staged hybrid procedures, with no clinical trials showing one strat-
egy superior to the other. The Dual Epicardial Endocardial
Persistent Atrial Fibrillation trial is a prospective randomized
staged hybrid study using bipolar RF. The CONVERGE trial is a set
of prospective randomized simultaneous hybrid trials using
monopolar RF. These trials also use different operative
approaches. There are a number of other ongoing multicenter tri-
als that are likely to define the roles and lesion sets for treatment
of patients with persistent AF using these strategies.
The hybrid approach could hold significant promise for those pa-
tients with persistent or long-standing persistent, drug-resistant AF
to offer improved results over minimal access surgical ablation or
catheter ablation alone. Based on the literature and the experience
of the writing group members, we believe that it might be reasonable
to apply the indications for stand-alone surgical ablation described
above to patients being considered for hybrid surgical ablation (Class
IIb, LOE C-EO, Table 2).
The Future
The most successful programs in the future might be those that em-
ploy an interdisciplinary, collaborative team approach to the treat-
ment of AF, resulting in higher success rates for patients. Many of
these patients are well read and mobile and will seek out such cen-
ters, thus increasing both catheter and surgical volumes. Practitioners
in the future will likely find value to working as part of a multidisciplin-
ary team. The precedent is set for this type of collaboration. The STS,
the ACC, the FDA, and the Centers for Medicare and Medicaid
Services have joined together to collaboratively introduce transcath-
eter AVR as a mandatory multidisciplinary team approach with man-
datory long-term follow-up. More work is needed in the area of
collaborative ablation of AF.
Section 13: Clinical Trial Design
Overview
Although there have been many advances made in the field of catheter
and surgical ablation of AF, there is still much to be learned about the
mechanisms of initiation and maintenance of AF and how to apply this
knowledge to the still-evolving techniques of AF ablation. Although
single-center, observational reports have dominated the early days of
this field, we are quickly moving into an era in which hypotheses are
put through the rigor of testing in well-designed, randomized, multi-
center clinical trials. It is as a result of these trials that conventional
thinking about the best techniques, success rates, complication rates,
and long-term outcomes beyond AF recurrence—such as thrombo-
embolism and mortality—is being put to the test. The ablation litera-
ture has also seen a proliferation of meta-analyses and other aggregate
analyses, which reinforce the need for consistency in the approach to
reporting the results of clinical trials. This section will review the min-
imum requirements for reporting on AF ablation trials. It will also ac-
knowledge the potential limitations of using specific primary outcomes
and emphasize the need for broad and consistent reporting of second-
ary outcomes to assist the end-user in determining not only the scien-
tific, but also the clinical relevance of the results.
Types of Clinical Trials, Strengths, and
Weaknesses
Mortality Trials
Large, randomized, controlled multicenter trials are considered the
“gold standard” for many therapies in cardiovascular medicine. They
are most likely to provide an unbiased understanding of the out-
comes of specific aspects of ablative intervention. Although AF is
associated with increased mortality and morbidity from stroke, HF,
and recurrent hospitalization, most of the AF ablation literature is
focused on AF recurrence and symptomatic improvement. It remains
unclear whether ablation can affect AF burden sufficiently to have a
positive outcome with respect to mortality and stroke endpoints.
Trials powered to demonstrate a benefit for ablation with regard to
these “hard” endpoints require large numbers of patients with exten-
sive follow-up and its accompanying expense; however, the need for
such trials cannot be understated. The CABANA trial was powered
to examine stroke and mortality outcomes of AF ablation compared
with pharmacological rate and rhythm control strategies. CABANA,
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which recently completed enrollment, requires a minimum of 5 years
of follow-up; thus, results will not be available until 2018. In the mean-
time, EAST is a study that is currently enrolling and is designed to com-
pare standard care vs a strategy of early rhythm control with ablation
and/or AADs with endpoints including a composite outcome of car-
diovascular death, stroke, and hospitalization due to worsening of HF
or acute coronary syndrome. Although it is unclear whether these tri-
als will demonstrate a mortality benefit of AF ablation, both are de-
signed to examine a host of prespecified secondary endpoints.
Secondary endpoints such as HF hospitalizations are especially import-
ant for patients with uncontrolled rates and HF with preserved EF or
tachycardia-induced cardiomyopathy. Finally, because both trials will
include larger numbers of patient ablations with more novel technolo-
gies such as cryoablation and CFS than have been available in any other
study to date, significant advances in the understanding of ablation pro-
cedure with these systems should be possible. Nevertheless, it remains
imperative to continue with designs of large mortality trials that reflect
shifting global ablation techniques, technologies, and patient selection.
There are currently 45 trials that meet the search criteria of “ablation
mortality AF” on ClinicalTrials.gov; however, fewer than 10 have mor-
tality as part of the primary endpoint.
Stroke and Thromboembolism Trials
Reductions in stroke and thromboembolism remain the most im-
portant goals of AF treatment. It is unclear, however, if elimination of
or reductions in AF will necessarily reduce the associated risk of
stroke, and whether such outcomes exceed those possible with
NOAC agents. Although an increased risk of stroke appears to be
associated with brief episodes of AF detected by implanted cardiac
devices, multiple large randomized trials have demonstrated that
there might be no temporal relationship between AF episodes and
AF thromboembolic events. This possibility has cast significant doubt
regarding the direct causal role that AF plays in stroke. On the other
hand, some cohort studies of AF ablation have reported a lower risk
of stroke postablation compared with matched, nonablated AF popu-
lations. The impact of AF ablation on stroke and thromboembolism
is an important topic of future study and will likely require a combin-
ation of very large studies with long durations of follow-up akin to
CABANA and EAST. The OCEAN study is currently getting started,
and will examine the optimal strategy for ongoing antithrombotic
therapy 1 year after successful ablation in a moderate-risk profile
population with a primary endpoint of overt and covert stroke. It is
important to stress that until the results of these trials are known, the
current recommendations are to continue anticoagulation indefin-
itely in patients with CHA2DS2-VASc >_2, regardless of the success of
the ablation procedure.
Periprocedural stroke reduction is an important topic that is ac-
tively being studied, with various strategies of anticoagulation, par-
ticularly continuous administration of VKA and non-VKA oral
anticoagulants through the ablation procedure.834,841,842 In addition,
concomitant LAA occlusion is being tested. In percutaneous proced-
ures, there are few if any studies powered for stroke alone; most pri-
marily evaluate AF recurrence.
Finally, multiple studies have demonstrated small ACE on MR brain
imaging after ablation.724,728,1207 The clinical significance of such ACE
lesions is not known, and many will resolve to the point of being
undetectable after weeks or months. The impact on cognitive func-
tion, if any, is not clear. At this point, there are no mandates for per-
forming periprocedural brain imaging for novel technologies to
evaluate the incidence of silent cerebral embolism, in large part be-
cause of its unknown clinical significance and the cost and burden of
MRI on patients. However, further evaluation of the significance of
such findings remains an important area of study.
Screening substudies could be reasonable for high-risk devices and
should be combined with clinical neurological and cognitive assess-
ments. These silent cerebral emboli are to be distinguished from cov-
ert embolic strokes secondary to long-term AF, which have been
linked with long-term cognitive decline, and are much larger than the
silent emboli seen periprocedurally.1385,1386,1387,1388
Multicenter Outcome Studies
There has been a proliferation of multicenter, randomized studies
primarily geared toward the outcome of AF recurrence in the last
several years. Many of these studies have had the appropriate size
and power to make some important statements on the appropriate
techniques for AF ablation. Because of the endpoint of AF recur-
rence, these studies can be performed with smaller sample sizes and
shorter follow-up periods compared with mortality- or stroke-
driven trials. A number of randomized trials have demonstrated the
superiority of AF ablation over AADs in drug-refractory patients.
First-line catheter ablation has shown mixed results over first-line
drug therapy in the MANTRA-PAF and RAAFT-2 studies.378,379
STAR AF 2, Adenosine Following Pulmonary Vein Isolation to Target
Dormant Conduction Elimination (ADVICE), FIRE AND ICE, and
TOCCASTAR are just a few examples of multicenter randomized
studies that have included hundreds of patients per study and added
important contributions to the daily practice of AF abla-
tion.245,265,378,379,489,655 STAR AF 2, for example, challenged the long-
held belief that additional ablation beyond PVI is important for abla-
tion of persistent AF and has launched a new search for alternative
targets to CFAE and empiric lines. It remains possible that incomplete
ablation in these arenas is more problematic than the ablation format
itself. As reported recently, the FIRE AND ICE trial has shown an
equivalence of evolving cryoablation technologies to traditional RF.
The ADVICE trial showed that systematic use of adenosine to search
for dormant conduction can improve durability of PVI and associated
1-year outcome, although studies reported earlier in this document
raise questions about the overall utility of adenosine or iso-
proterenol. There are many more studies planned to examine vari-
ous aspects of AF ablation, primarily around the comparison of
techniques in certain patient populations to improve ablation out-
comes. As expected, a criticism of all such trials is that the technology
and techniques are outdated prior to trial completion. STAR AF 2
did not use CFS and FIRE AND ICE used a mixture of first- and
second-generation CB technologies. Therefore, ongoing trials com-
paring the most up-to-date technologies will always be required.
Larger-scale surgical ablation trials are lacking, and the consensus
group believes that the development of well designed, highly agile,
large-scale multicenter surgical trials with similar monitoring regi-
mens need to be encouraged and performed. As with catheter-based
studies and registries, the use of patient-reported outcome measures
as part of the study endpoints is highly recommended.
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Industry-Sponsored Device Approval Studies
There have been a number of prospective randomized studies per-
formed to evaluate the safety and efficacy of investigational devices
used for AF ablation. These studies, such as THERMOCOOL IDE
and STOP AF, have all provided important, high-quality data demon-
strating the superiority of catheter ablation over drug therapy in drug
refractory patients.462,684 Now that the utility of ablation over drug
therapy in such patients has been accepted, many of the current stud-
ies are focused on comparing new technologies against approved de-
vices in a noninferiority design. Although these studies are important
from a safety and efficacy perspective and are often mandated by
health approval bodies such as the FDA, the incremental yield in
knowledge could be limited. Prespecified subgroup analyses, or the
use of novel endpoints. could therefore be important to determine
whether incremental value is added by the newer technology.
TOCCASTAR, for example, demonstrated statistical noninferiority
of CF-driven RF ablation to traditional RF. However, only in a post-
hoc analysis did the trial show that optimal CF was associated with
better outcomes, findings which should be viewed with caution due
to the limitations of post hoc analyses. Testing of the durability of le-
sion sets such as PVI either after delayed waiting, drug (adenosine)
challenge, or repeat electrophysiology study after 3 months might
also help assess comparative efficacy more accurately. Industry must
also look to see whether safety and efficacy parameters demon-
strated in PAF also apply to nonparoxysmal populations. Several
industry-sponsored studies are either being planned or are in pro-
gress to assess outcomes in this challenging population.
Registry Studies
AF ablation registries offer a unique opportunity to collect data from
large numbers of patients to examine outcomes. In particular, regis-
tries might help assess how ablation is being performed in the “real
world” compared with controlled clinical trials that are often per-
formed on a highly selected patient population in very experienced
centers. The definition of real world remains problematic, however,
because recent studies have shown reasonable congruence between
the outcomes of RCTs and registries. Registries are well suited to
determining early complication rates of ablation, particularly for less
common ones such as PV stenosis, esophageal injury, or mortality.
Appropriateness of patient selection and outcomes in patient sub-
groups that are underrepresented in studies, such as women or pa-
tients with underlying structural heart disease, can also be assessed in
sizable registries. The collection of this kind of information, by itself,
makes registries worthwhile if they can be performed with sufficient
representation of a majority of centers. Still, well-controlled efforts
such as the STS database have shown an even-handed approach to
collecting this kind of material. Worldwide surveys of AF ablation
have been published, and ongoing efforts are being made to harmon-
ize various centers or national databases to pool ablation informa-
tion. Many countries are now setting up provincial or national
registries to examine the use and outcomes of AF ablation. In the
United States, for example, the older Safety of Atrial Fibrillation
Ablation Registry Initiative registry project was discontinued, but an-
other started by the National Cardiovascular Data Registry (NCDR)
has been launched nationally, with voluntary participation. The HRS
is also collaborating with the AHA to develop an additional AF
ablation registry. Surgical data are currently being collected in the
STS database; however, although data on safety and outcome are
available, lesion-specific information for surgical ablation remains pre-
liminary. Collection of longitudinal data, particularly longer-term out-
comes, can be limited by a lack of patient follow-up at the same
center and a lack of consistent monitoring protocols. The need for in-
formed consent to collect follow-up data also remains an obstacle to
obtaining outcome data. The burden of data entry can also lead to in-
adequate reporting, and the cost of auditing data can be very expen-
sive and tedious. The purpose of establishing a registry and the
realistic goals of data collection must be stated outright upon estab-
lishment, because the opportunity and financial costs could be alter-
natively spent on well-designed clinical trials. Comparison of
performance among sites, for example, must be based on the stated
purposes and strengths of the registry. If the main purpose is to re-
port acute complications, then long-term outcomes cannot be com-
pared. Comparisons must also be corrected for patient
characteristics, referral patterns to the institution, and community-
based versus advanced academic practices. Finally, once the stated
goals of the registry are accomplished, there should be specific time-
frames for termination of the registry to avoid indefinite data collec-
tion with no specific stated purpose.
Clinical Endpoint Considerations
Early data in the field of AF ablation were limited by the multitude of
different endpoints used in the trials, including multiple definitions of
success, complications, and minimum monitoring postablation. Prior
consensus statements sought to create consistency in the reporting
of clinical trials by adopting standardized definitions for AF type,
blanking periods, definitions of success, recommendations for min-
imal monitoring postablation, major complications, and device-
related complications.1,2 Again, this document outlines the definitions
of various types of AF (Table 1), definitions of efficacy (Table 10),
QOL measures (Table 11), non-AF recurrence endpoints (Table 12),
and definitions of complications (Table 8).
Clinical endpoints for AF ablation trials may either consist of clin-
ical events like mortality, stroke, re-initiation of AAD treatment,
need for cardioversion, reablation and rehospitalization, or of
patient-reported outcomes such as symptom severity or QOL. AF
recurrence or change in AF behavior is a very important endpoint to
report in trials targeting AF elimination. The following section will
focus on recommendations and definitions for AF-related measure-
ments used in clinical ablation trials.
Blanking Period
It has long been recognized that in the weeks immediately following
AF ablation, early recurrences of atrial arrhythmia can occur that sub-
sequently subside over time.253,254,255,436 Whether this is due to an
early “inflammatory” response in the atrium or pericardium remains
hypothetical. Based on these observations, prior consensus state-
ments, and the present consensus document, the writing group rec-
ommends the use of a 3-month blanking period immediately
postablation, during which arrhythmia recurrences are not counted
toward the primary recurrence endpoint (Table 10). The use of a
blanking period is not without limitations. Although half of all early re-
currences might subside, early recurrence remains a very significant
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Table 10 Definitions for use when reporting outcomes of AF ablation and in designing clinical trials of catheter or sur-
gical ablation of AF
Acute procedural suc-
cess(pulmonary vein
isolation)
Acute procedural success is defined as electrical isolation of all pulmonary veins. A minimal assessment of electrical iso-
lation of the PVs should consist of an assessment of entrance block. If other methods are used to assess PVI, including
exit block and/or the use of provocative agents such as adenosine or isoproterenol, they should be prespecified.
Furthermore, it is recommended that the wait time used to screen for early recurrence of PV conduction once initial
electrical isolation is documented be specified in all prospective clinical trials.
Acute procedural success
(not related by pulmonary
vein isolation)
Typically, this would apply to substrate ablation performed in addition to PVI for persistent AF. Although some have
proposed AF termination as a surrogate for acute procedural success, its relationship to long-term success is contro-
versial. Complete elimination of the additional substrate (localized rotational activation, scar region, non-PV trigger,
or other target) and/or demonstration of bidirectional conduction block across a linear ablation lesion would typic-
ally be considered the appropriate endpoint.
One-year success* One-year success is defined as freedom from AF/AFL/AT after removal from antiarrhythmic drug therapy as assessed
from the end of the 3month blanking period to 12 months following the ablation procedure. Because cavotricuspid
isthmus-dependent atrial flutter is easily treated with cavotricuspid isthmus ablation and is not an iatrogenic arrhyth-
mia following a left atrial ablation procedure for AF, it is reasonable for clinical trials to choose to prespecify that oc-
currence of isthmus-dependent atrial flutter, if confirmed by entrainment maneuvers during electrophysiology
testing, should not be considered an ablation failure or primary effectiveness endpoint.
Alternative one-year success Although the one-year success definition provided above remains the recommended end point that should be reported in
all AF ablation trials, and the endpoint for which the objective performance criteria listed below were developed, the
Task Force recognizes that alternative definitions for success can be used if the main goal of therapy in the study is to
relieve AF-related symptoms and to improve patient QOL. In particular, it is appropriate for clinical trials to define suc-
cess as freedom from only symptomatic AF/AFL/AT after removal from antiarrhythmic drug therapy as assessed from
the end of the 3-month blanking period to 12 months following the ablation procedure if the main goal of therapy in the
study is to relieve AF-related symptoms and to improve patient QOL. However, because symptoms of AF can resolve
over time, and because studies have shown that asymptomatic AF represents a greater proportion of all AF postablation
than prior to ablation, clinical trials need to continue to report freedom from both symptomatic and asymptomatic AF
even if this alternative one year success definition is used as the primary trial endpoint.
Clinical/partial success* It is reasonable for clinical trials to define and incorporate one or more secondary definitions of success that can be
referred to as “clinical success” or “partial success.” If these alternative definitions of success are included, they
should be defined prospectively. In prior Consensus Documents the Task Force has proposed that clinical/partial
success be defined as a “75% or greater reduction in the number of AF episodes, the duration of AF episodes, or the
% time a patient is in AF as assessed with a device capable of measuring AF burden in the presence or absence of pre-
viously ineffective antiarrhythmic drug therapy.” Because there is no firm scientific basis for selecting the cutoff of
75% rather than a different cutoff, this prior recommendation is provided only as an example of what future clinical
trials may choose to use as a definition of clinical/partial success.
Long-term success* Long-term success is defined as freedom from AF/AFL/AT recurrences following the 3-month blanking period through
a minimum of 36-month follow-up from the date of the ablation procedure in the absence of Class I and III antiar-
rhythmic drug therapy.
Recurrent AF/AFL/AT Recurrent AF/AFL/AT is defined as AF/AFL/AT of at least 30 seconds’ duration that is documented by an ECG or device
recording system and occurs following catheter ablation. Recurrent AF/AFL/AT may occur within or following the
post ablation blanking period. Recurrent AF/AFL/AT that occurs within the postablation blanking period is not con-
sidered a failure of AF ablation.
Early recurrence of AF/AFL/
AT
Early recurrence of AF/AFL/AT is defined as a recurrence of atrial fibrillation within three months of ablation. Episodes
of atrial tachycardia or atrial flutter should also be classified as a “recurrence.” These are not counted toward the
success rate if a blanking period is specified.
Recurrence of AF/AFL/AT Recurrence of AF/AFL/AT postablation is defined as a recurrence of atrial fibrillation more than 3 months following AF
ablation. Episodes of atrial tachycardia or atrial flutter should also be classified as a “recurrence.”
Late recurrence of AF/AFL/
AT
Late recurrence of AF/AFL/AT is defined as a recurrence of atrial fibrillation 12 months or more after AF ablation.
Episodes of atrial tachycardia or atrial flutter should also be classified as a “recurrence.”
Blanking period A blanking period of three months should be employed after ablation when reporting efficacy outcomes. Thus, early re-
currences of AF/AFL/AT within the first 3 months should not be classified as treatment failure. If a blanking period of
less than 3 months is chosen, it should be prespecified and included in the Methods section.
Continued
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Stroke screening A risk-based approach to determine the level of postablation stroke screening in clinical trials is recommended by the
Task Force. For ablation devices with a lower risk of stroke and for which a stroke signal has not been reported, a
minimum standardized neurological assessment of stroke should be conducted by a physician at baseline and at hos-
pital discharge or 24 hours after the procedure, whichever is later. If this neurological assessment demonstrates new
abnormal findings, the patient should have a formal neurological consult and examination with appropriate imaging
(i.e., DW-MRI), used to confirm any suspected diagnosis of stroke. For devices in which a higher risk of stroke is sus-
pected or revealed in prior trials, a formal neurological examination by a neurologist at discharge or 24 hours after
the procedure, whichever is later, is recommended. Appropriate imaging should be obtained if this evaluation reveals
a new neurological finding. In some studies in which delayed stroke is a concern, repeat neurological screening at 30
days postablation might be appropriate.
Detectable AF/AFL/AT Detectable AF is defined as AF/AFL/AT of at least 30 seconds’ duration when assessed with ECG monitoring. If other
monitoring systems are used, including implantable pacemakers, implantable defibrillators, and subcutaneous ECG
monitoring devices, the definition of detectable AF needs to be prespecified in the clinical trial based on the sensitiv-
ity and specificity of AF detection with the particular device. We recommend that episodes of atrial flutter and atrial
tachycardia be included within the broader definition of a detectable AF/AFL/AT episode.
AF/AFL/AT burden It is reasonable for clinical trials to incorporate AF/AFL/AT burden as a secondary endpoint in a clinical trial of AF abla-
tion. In stating this it is recognized that there are no conclusive data that have validated a rate of AF burden reduction
as a predictor of patient benefit (i.e. reduction in mortality and major morbidities such as stroke, CHF, QOL, or hos-
pitalization). If AF burden is included, it is important to predefine and standardize the monitoring technique that will
be used to measure AF burden. Available monitoring techniques have been discussed in this document. Should AF
burden be selected as an endpoint in a clinical trial, the chosen monitoring technique should be employed at least a
month prior to ablation to establish a baseline burden of AF.
Entrance block Entrance block is defined as the absence, or if present, the dissociation, of electrical activity within the PV antrum.
Entrance block is most commonly evaluated using a circular multielectrode mapping catheter positioned at the PV
antrum. Entrance block can also be assessed using detailed point-by-point mapping of the PV antrum guided by an
electroanatomical mapping system. The particular method used to assess entrance block should be specified in all
clinical trials. Entrance block of the left PVs should be assessed during distal coronary sinus or left atrial appendage
pacing in order to distinguish far-field atrial potentials from PV potentials. It is recommended that reassessment of
entrance block be performed a minimum of 20 minutes after initial establishment of PV isolation.
Procedural endpoints for AF
ablation strategies not tar-
geting the PVs
Procedural endpoints for AF ablation strategies not targeting the PVs: The acute procedural endpoints for ablation
strategies not targeting the PVs vary depending on the specific ablation strategy and tool. It is important that they be
prespecified in all clinical trials. For example, if a linear ablation strategy is used, documentation of bidirectional block
across the ablation line must be shown. For ablation of CFAEs, rotational activity, or non-PV triggers, the acute end-
point should at a minimum be elimination of CFAEs, rotational activity, or non-PV triggers. Demonstration of AF
slowing or termination is an appropriate procedural endpoint, but it is not required as a procedural endpoint for AF
ablation strategies not targeting the PVs.
Esophageal temperature
monitoring
Esophageal temperature monitoring should be performed in all clinical trials of AF ablation. At a minimum, a single
thermocouple should be used. The location of the probe should be adjusted during the procedure to reflect the lo-
cation of energy delivery. Although this document does not provide formal recommendations regarding the specific
temperature or temperature change at which energy delivery should be terminated, the Task Force does recom-
mend that all trials prespecify temperature guidelines for termination of energy delivery.
Enrolled subject An enrolled subject is defined as a subject who has signed written informed consent to participate in the trial in
question.
Exit block Exit block is defined as the inability to capture the atrium during pacing at multiple sites within the PV antrum. Local
capture of musculature within the pulmonary veins and/or antrum must be documented to be present to make this
assessment. Exit block is demonstrated by a dissociated spontaneous pulmonary vein rhythm.
Nonablative strategies The optimal nonablative therapy for patients with persistent and long-standing persistent AF who are randomized to
the control arm of an AF ablation trial is a trial of a new Class I or III antiarrhythmic agent or a higher dose of a previ-
ously failed antiarrhythmic agent. For patients with persistent or long-standing persistent AF, performance of a dir-
ect-current cardioversion while taking the new or dose adjusted antiarrhythmic agent should be performed, if
restoration of sinus rhythm is not achieved following initiation and/or dose adjustment of antiarrhythmic drug ther-
apy. Failure of pharmacological cardioversion alone is not adequate to declare this pharmacological strategy
unsuccessful.
Noninducibility of atrial
fibrillation
Noninducibility of atrial fibrillation is defined as the inability to induce atrial fibrillation with a standardized prespecified
pharmacological or electrical stimulation protocol. The stimulation protocol should be prespecified in the specific
clinical trial. Common stimulation approaches include a high-dose isoproterenol infusion protocol or repeated atrial
burst pacing at progressively more rapid rates.
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Patient populations for inclu-
sion in clinical trials
It is considered optimal for clinical trials to enroll patients with only one type of AF: paroxysmal, persistent, or long-
standing persistent. If more than one type of AF patient is enrolled, the results of the trial should also be reported
separately for each of the AF types. It is recognized that “early persistent” AF responds to AF ablation to a similar de-
gree as patients with paroxysmal AF and that the response of patients with “late persistent AF” is more similar to
that in those with long-standing persistent AF.
Therapy consolidation
period
Following a 3-month blanking period, it is reasonable for clinical trials to incorporate an additional 1- to 3-month ther-
apy consolidation period. During this time, adjustment of antiarrhythmic medications and/or cardioversion can be
performed. Should a consolidation period be incorporated into a clinical trial design, the minimum follow-up duration
should be 9 months following the therapy consolidation period. Performance of a repeat ablation procedure during
the blanking or therapy consolidation period would “reset” the endpoint of the study and trigger a new 3-month
blanking period. Incorporation of a therapy consolidation period can be especially appropriate for clinical trials evalu-
ating the efficacy of AF ablation for persistent or long-standing persistent AF. The challenge of this approach is that it
prolongs the overall study duration. Because of this concern regarding overall study duration, we suggest that the
therapy consolidation period be no more than 3 months in duration following the 3-month blanking period.
Recommendations regarding
repeat ablation
procedures
It is recommended that all clinical trials report the single procedure efficacy of catheter ablation. Success is defined as
freedom from symptomatic or asymptomatic AF/AFL/AT of 30 seconds or longer at 12 months postablation.
Recurrences of AF/AFL/AT during the first 3-month blanking period post-AF ablation are not considered a failure.
Performance of a repeat ablation procedure at any point after the initial ablation procedure should be considered a
failure of a single procedure strategy. It is acceptable for a clinical trial to choose to prespecify and use a multiproce-
dure success rate as the primary endpoint of a clinical trial. When a multiprocedure success is selected as the primary
endpoint, efficacy should be defined as freedom from AF/flutter or tachycardia at 12 months after the final ablation
procedure. In the case of multiple procedures, repeat ablation procedures can be performed at any time following
the initial ablation procedure. All ablation procedures are subject to a 3-month post blanking window, and all ablation
trials should report efficacy at 12 months after the final ablation procedure.
Cardioversion definitions
Failed electrical
cardioversion
Failed electrical cardioversion is defined as the inability to restore sinus rhythm for 30 seconds or longer following elec-
trical cardioversion.
Successful electrical
cardioversion
Successful electrical cardioversion is defined as the ability to restore sinus rhythm for at least 30 seconds following
cardioversion.
Immediate AF recurrence
postcardioversion
Immediate AF recurrence postcardioversion is defined as a recurrence of AF within 24 hours following cardioversion.
The most common time for an immediate recurrence is within 30–60 minutes postcardioversion.
Early AF recurrence
postcardioversion
Early AF recurrence postcardioversion is defined as a recurrence of AF within 30 days of a successful cardioversion.
Late AF recurrence
postcardioversion
Late AF recurrence postcardioversion is defined as recurrence of AF more than 30 days following a successful
cardioversion.
Surgical ablation definitions
Hybrid AF surgical ablation
procedure
Hybrid AF surgical ablation procedure is defined as a joint AF ablation procedure performed by electrophysiologists
and cardiac surgeons either as part of a single “joint” procedure or performed as two preplanned separate ablation
procedures separated by no more than 6 months.
Surgical Maze ablation
procedure
Surgical Maze ablation procedure is defined as a surgical ablation procedure for AF that includes, at a minimum, the fol-
lowing components: (1) line from SVC to IVC; (2) line from IVC to the tricuspid valve; (3) isolation of the PVs; (4) iso-
lation of the posterior left atrium; (5) line from MV to the PVs; (6) management of the LA appendage.
Stand-alone surgical AF
ablation
A surgical AF ablation procedure during which other cardiac surgical procedures are not performed such as CABG,
valve replacement, or valve repair.
Nomenclature for types of
surgical AF ablation
procedures
We recommend that the term “Maze” procedure is appropriately used only to refer to the biatrial lesion set of the
Cox-Maze operation. It requires ablation of the RA and LA isthmuses. Less extensive lesion sets should not be
referred to as a “Maze” procedure, but rather as a surgical AF ablation procedure. In general, surgical ablation pro-
cedures for AF can be grouped into three different groups: (1) a full biatrial Cox-Maze procedure; (2) PVI alone; and
(3) PVI combined with left atrial lesion sets.
Hybrid epicardial and endo-
cardial AF ablation
This term refers to a combined AF ablation procedure involving an off-pump minimally invasive surgical AF ablation as
well as a catheter-based AF ablation procedure designed to complement the surgical lesion set. Hybrid ablation pro-
cedures may be performed in a single-procedure setting in a hybrid operating room or a cardiac catheterization la-
boratory environment, or it can be staged. When staged, it is most typical to have the patient undergo the minimally
invasive surgical ablation procedure first following by a catheter ablation procedure 1 to 3 months later. This latter
approach is referred to as a “staged Hybrid AF ablation procedure.”
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Minimum AF documentation, endpoints, TEE performance, and success rates in clinical trials
Minimum documentation for
paroxysmal AF
The minimum AF documentation requirement for paroxysmal AF is (1) physician’s note indicating recurrent self-termi-
nating AF and (2) one electrocardiographically documented AF episode within 6 months prior to the ablation
procedure.
Minimum documentation for
persistent AF
The minimum AF documentation requirement for persistent AF is (1) physician’s note indicating continuous AF > 7
days but no more than 1 year and (2) a 24-hour Holter within 90 days of the ablation procedure showing continuous
AF.
Minimum documentation for
early persistent AF
The minimum AF documentation requirement for persistent AF is (1) physician’s note indicating continuous AF > 7
days but no more than 3 months and (2) a 24-hour Holter showing continuous AF within 90 days of the ablation
procedure.
Minimum documentation for
long-standing persistent
AF
The minimum AF documentation requirement for long-standing persistent AF is as follows: physician’s note indicating
at least 1 year of continuous AF plus a 24-hour Holter within 90 days of the ablation procedure showing continuous
AF. The performance of a successful cardioversion (sinus rhythm >30 seconds) within 12 months of an ablation pro-
cedure with documented early recurrence of AF within 30 days should not alter the classification of AF as long-
standing persistent.
Symptomatic AF/AFL/AT AF/AFL/AT that results in symptoms that are experienced by the patient. These symptoms can include but are not lim-
ited to palpitations, presyncope, syncope, fatigue, and shortness of breath. For patients in continuous AF, reassess-
ment of symptoms after restoration of sinus rhythm is recommended to establish the relationship between
symptoms and AF.
Documentation of AF-
related symptoms
Documentation by a physician evaluating the patient that the patient experiences symptoms that could be attributable
to AF. This does not require a time-stamped ECG, Holter, or event monitor at the precise time of symptoms. For pa-
tients with persistent AF who initially report no symptoms, it is reasonable to reassess symptom status after restor-
ation of sinus rhythm with cardioversion.
Minimum effectiveness end-
point for patients with
symptomatic and asymp-
tomatic AF
The minimum effectiveness endpoint is freedom from symptomatic and asymptomatic episodes of AF/AFL/AT recur-
rences at 12 months following ablation, free from antiarrhythmic drug therapy, and including a prespecified blanking
period.
Minimum chronic acceptable
success rate: paroxysmal
AF at 12-month follow-up
If a minimum chronic success rate is selected as an objective effectiveness endpoint for a clinical trial, we recommend
that the minimum chronic acceptable success rate for paroxysmal AF at 12-month follow-up is 50%.
Minimum chronic acceptable
success rate: persistent AF
at 12-month follow-up
If a minimum chronic success rate is selected as an objective effectiveness endpoint for a clinical trial, we recommend
that the minimum chronic acceptable success rate for persistent AF at 12-month follow-up is 40%.
Minimum chronic acceptable
success rate: long-standing
persistent AF at 12-month
follow-up
If a minimum chronic success rate is selected as an objective effectiveness endpoint for a clinical trial, we recommend
that the minimum chronic acceptable success rate for long-standing persistent AF at 12-month follow-up is 30%.
Minimum follow-up screen-
ing for paroxysmal AF
recurrence
For paroxysmal AF, the minimum follow-up screening should include (1) 12-lead ECG at each follow-up visit; (2) 24-
hour Holter at the end of the follow-up period (e.g., 12 months); and (3) event recording with an event monitor
regularly and when symptoms occur from the end of the 3-month blanking period to the end of follow-up (e.g.,
12 months).
Minimum follow-up screen-
ing for persistent or long-
standing AF recurrence
For persistent and long-standing persistent AF, the minimum follow-up screening should include (1) 12-lead ECG at
each follow-up visit; (2) 24-hour Holter every 6 months; and (3) symptom-driven event monitoring.
Requirements for transeso-
phageal echocardiogram
It is recommended that the minimum requirement for performance of a TEE in a clinical trial should be those require-
ments set forth in ACC/AHA/HRS 2014 Guidelines for AF Management pertaining to anticoagulation at the time of
cardioversion. Prior to undergoing an AF ablation procedure a TEE should be performed in all patients with AF
of > 48 hours’ duration or of unknown duration if adequate systemic anticoagulation has not been maintained for at
least 3 weeks prior to AF ablation. If a TEE is performed for this indication, it should be performed within 24 hours of
the ablation procedure.
AF, atrial fibrillation; DW-MRI, diffusion-weighted magnetic resonance imaging; CHF, congestive heart failure; QOL, quality of life; ECG, electrocardiogram; CABG, coronary ar-
tery bypass grafting; PV, pulmonary vein; SVC, superior vena cava; IVC, inferior vena cava; CFAE, complex fractionated atrial electrogram; PVI, pulmonary vein isolation; AFL,
atrial flutter; AT, atrial tachycardia; ACC, American College of Cardiology; AHA, American Heart Association; HRS, Heart Rhythm Society.
*When reporting outcomes of AF ablation, the development of atrial tachycardia or atrial flutter should be included in the broad definition of recurrence following AF ablation.
All studies should report freedom from AF, atrial tachycardia, and atrial flutter. These endpoints can also be reported separately. All studies should also clearly specify the type
and frequency of ECG monitoring as well as the degree of compliance with the prespecified monitoring protocol.
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Table 11 Quality-of-life scales, definitions, and strengths
Scale Definition/Details Strengths/Weaknesses
Short Form (36) Health
Survey (SF36)38
Consists of 8 equally weighted, scaled scores in the fol-
lowing sections: vitality, physical functioning, bodily
pain, general health perceptions, physical role func-
tioning, emotional role functioning, social role func-
tioning, mental health. Each section receives a scale
score from 0 to 100.
Advantages: extensively validated in a number of dis-
ease and health states. Might have more resolution
than EQ-50 for AF QOL.(General)
Physical component summary (PCS) and mental compo-
nent summary (MCS) is an average of all the physically
and mentally relevant questions, respectively.
Disadvantages: not specific for AF, so might not have
resolution to detect AF-specific changes in QOL.
The Short Form (12) Health Survey (SF12) is a shorter
version of the SF-36, which uses just 12 questions
and still provides scores that can be compared with
SF-36 norms, especially for summary physical and
mental functioning.
Gives more precision in measuring QOL than EQ-5D
but can be harder to transform into cost utility
analysis.
EuroQol Five Dimensions
Questionnaire (EQ-5D)39
(General)
Two components: Health state description is measured
in five dimensions: mobility, self-care, usual activities,
pain/discomfort, anxiety/depression. Answers may be
provided on a three-level (3L) or five-level (5L) scale.
In the Evaluation section, respondents evaluate their
overall health status using a visual analogue scale (EQ-
VAS). Results can easily be converted to quality-ad-
justed life years for cost utility analysis.
Advantages: extensively validated in a number of dis-
ease and health states. Can easily be converted into
quality-adjusted life years for cost-effectiveness
analysis.
Disadvantages: might not be specific enough to detect
AF-specific changes in QOL. Might be less specific
than SF-36.
AF effect on Quality of Life
Survey (AFEQT)40 (AF
specific)
20 questions: 4 targeting AF-related symptoms, 8 evalu-
ating daily function, and 6 assessing AF treatment con-
cerns. Each item scored on a 7-point Likert scale.
Advantages: brief, simple, very responsive to AF inter-
ventions. Good internal validity and well validated
against a number of other global and AF-specific
QOL scales. Used in CABANA.
Disadvantages: validation in only two published studies
(approximately 219 patients).
Quality of Life
Questionnaire for Patients
with AF
18-item self-administered questionnaire with three do-
mains: psychological, physical, and sexual activity.
Each item scores on a 5-point Likert scale.
Advantages: brief, simple, responsive to AF interven-
tions; good internal validity; used in SARA trial.
(AF-QoL)41 Disadvantages: external validity compared only to SF-
36; formal validation in 1 study (approximately 400
patients).
(AF specific)
Arrhythmia-Related
Symptom Checklist
(SCL)42 (AF specific)
16 items covering AF symptom frequency and symptom
severity.
Advantages: most extensively validated in a number of
arrhythmia cohorts and clinical trials.
Disadvantages: time-consuming and uncertain
generalizability.
Mayo AF Specific Symptom
Inventory (MAFSI)43 (AF
specific)
10 items covering AF symptom frequency and severity.
Combination of 5- point and 3-point Likert scale
responses.
Advantages: validated in an AF ablation population and
responsive to ablation outcome; used in CABANA
trial.
Used in CABANA trial. Disadvantages: external validity compared only to SF-
36; 1 validation study (approximately 300 patients).
University of Toronto Atrial
Fibrillation Severity Scale
(AFSS) (AF specific)44
10 items covering frequency, duration, and severity. 7-
point Likert scale responses.
Advantages: validated and reproducible; used in CTAF
trial.
Disadvantages: time-consuming and uncertain
generalizability.
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predictor of late recurrence of AF.141,142,143,255 Furthermore, some
studies have shown that recurrences occurring early in the blanking
period (within 1–2 months) are less predictive of late recurrence,
whereas those occurring in the third month have a very high
predictive value for later recurrence.933,977,1389 Blanking periods can
also be applied inconsistently, typically after the initial ablation, but
not typically after repeat procedures, particularly when there is only
a limited duration of follow-up. Despite these limitations, the writing
....................................................................................................................................................................................................................
Table 11 Continued
Scale Definition/Details Strengths/Weaknesses
Arrhythmia Specific
Questionnaire in
Tachycardia and
Arrhythmia (ASTA)45 (AF
specific)
Records number of AF episodes and average episode
duration during last 3 months. 8 symptoms and 2 dis-
abling symptoms are recorded with scores from 1–4
for each.
Advantages: validated in various arrhythmia groups; ex-
ternal validity compared with SCL, EQ5D, and SF-36;
used in MANTRA-PAF; brief; simple.
Disadvantages: one validation study (approximately 300
patients).
European Heart Rhythm
Association (EHRA)46
(AF specific)
Like NYHA scale. I, no symptoms, II, mild symptoms not
affecting daily activity, III, severe symptoms affecting
daily activity, and IV, disabling symptoms terminating
daily activities.
Advantage: very simple, like NYHA.Disadvantages: not
used in studies and not well validated; not very spe-
cific; unknown generalizability.
Canadian Cardiovascular
Society Severity of Atrial
Fibrillation Scale (CCS-
SAF)47 (AF specific)
Like NYHA scale. O, asymptomatic, I, AF symptoms
have minimal effect on patient’s QOL, II, AF symp-
toms have minor effect on patient QOL, III, symp-
toms have moderate effect on patient QOL, IV= AF
symptoms have severe effect on patient QOL.
Advantages: very simple, like NYHA; validated against
SF-36 and University of Toronto AFSS.
Disadvantages: poor correlation with subjective
AF burden; not very specific.
AF, atrial fibrillation; QOL, quality of life; CABANA, Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation; SARA, Study of Ablation Versus antiaRrhythmic
Drugs in Persistent Atrial Fibrillation; CTAF, Canadian Trial of Atrial Fibrillation; MANTRA-PAF, Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal
Atrial Fibrillation; NYHA, New York Heart Association; AFSS, atrial fibrillation severity scale.
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Table 12 Non-AF recurrence–related endpoints for reporting in AF ablation trials
Stroke and bleeding
endpoints
Definitions/Details
Stroke (2014 ACC/AHA Key
Data Elements)
An acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury
as a result of hemorrhage or infarction. Symptoms or signs must persist >_24 hours, or if documented by CT, MRI
or autopsy, the duration of symptoms/signs may be less than 24 hours. Stroke may be classified as ischemic
(including hemorrhagic transformation of ischemic stroke), hemorrhagic, or undetermined. Stroke disability
measurement is typically performed using the modified Rankin Scale (mRS).
Transient ischemic attack
(2014 ACC/AHA Key
Data Elements)
Transient episode of focal neurological dysfunction caused by brain, spinal cord, or retinal ischemia without acute
infarction and with signs and symptoms lasting less than 24 hours.
Major bleeding (ISTH
definition)
Fatal bleeding AND/OR symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular,
retroperitoneal, intraarticular, pericardial, or intramuscular with compartment syndrome AND/OR bleeding
causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units
of blood.
Clinically relevant nonmajor
bleed (ISTH definition)
An acute or subacute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical
response such that it leads to one of the following: hospital admission for bleeding; physician-guided medical or
surgical treatment for bleeding; change in antithrombotic therapy (including interruption or discontinuation).
Minor bleeding (ISTH
definition)
All nonmajor bleeds. Minor bleeds are further divided into clinically relevant and not.
Incidence and discontinu-
ation of oral
anticoagulation
The number of patients receiving oral anticoagulation and the type of oral anticoagulation should be documented at
the end of follow-up. If patients have their oral anticoagulation discontinued, the number of patients discontinu-
ing, the timing of discontinuation, and the reasons for discontinuation of oral anticoagulation, as well as the clinical
characteristics and stroke risk profile of the patients should be reported.
AF, atrial fibrillation; CT, computed tomography; MRI, magnetic resonance imaging.
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group consensus continues to recommend the use of a 3-month
blanking period for atrial arrhythmia recurrences post-initial ablation
for AF. If alternate durations of blanking are employed, they should
be prespecified in the trial methodology. Clinical trials should also
consider routine discontinuation of AADs after the blanking period
to determine off-drug success rates of ablation. Large clinical trials
such as CABANA have also employed extensive ongoing monitoring,
which could shed light on more robust blanking period definitions.
The currently recommended definitions of the blanking periods,
monitoring standards, complications, and other AF ablation clinical
trial definitions are provided in Tables 8 and 10.
AF Recurrence Endpoints
The selection of a primary endpoint depends on the objectives of the
trial. As mentioned earlier in this section, trials with mortality, stroke,
or hospitalization outcomes are of particular interest in advancing the
field of AF ablation. However, now and in the foreseeable future, re-
currence of AF will remain of primary interest for most clinical trials.
A summary of AF-related endpoints is listed in Table 13, along with
the advantages and disadvantages of each endpoint.
The consensus statement reaffirms the use of freedom from any
atrial arrhythmia (e.g., AF, AT, or AFL) greater than 30 seconds off
antiarrhythmic therapy as the gold standard for reporting the efficacy
of AF ablation (Table 10). The writing group also believes that all trials
should report single-procedure, off AAD therapy efficacy for ablation
with a minimum of 12 months follow-up. Slight variations in this end-
point have been used in several clinical trials, but ideally, all categories
of recurrence should be reported transparently, such as freedom
from AF separately from other atrial arrhythmia, one- and multiple-
procedure success rates, and success on and off antiarrhythmic ther-
apy. By reporting all of these variations, the reader can determine the
most relevant outcome for themselves and can also easily compare
results between clinical trials. A recent study that reported outcomes
using a wide variety of endpoints can serve as an excellent example
of this approach to reporting outcomes.245 The inclusion of all atrial
arrhythmias compared with AF in isolation recognizes the fact that
ablation can result in iatrogenic macro- and microreentrant tachycar-
dias caused by incomplete scar formation from the procedure itself.
Furthermore, patients might present with mixed pictures of both
AFL and fibrillation, and elimination of one but not the other will not
improve patient outcomes.
The consensus statement recognizes that the 30-second cutoff for
arrhythmia recurrence is stringent and might not accurately reflect
more clinically relevant endpoints, such as reduction in total AF bur-
den, symptom abatement, and improvement in QOL. A strict cutoff
might also underestimate the true benefit of ablation, especially when
presented in the format of a Kaplan-Meier analysis. Isolated, brief re-
currences can result in a patient being considered a “procedural fail-
ure,” although the overall reduction in AF burden has been
substantial. Patients with preablation high-burden PAF might con-
tinue to experience AF episodes, but with a reduced frequency and
duration and a significant improvement in QOL. More liberal cutoff
points have been suggested based on implantable monitoring tech-
nology detection limits (>2 minutes) or based on hypothesized
thresholds for stroke risk (>6 minutes or > 5–6 hours). However, se-
lection of any other cutoff would be as arbitrary as the initial selection
of 30 seconds, which has now been in place since 2007. Keeping the
same endpoint threshold will therefore allow for comparison of fu-
ture studies against those performed in the past. It also remains un-
clear whether the selection of a somewhat more generous threshold
would actually significantly alter reported success rates in a time to
event analysis.
Arrhythmia recurrence is often reported as time to first AF episode
of a particular type, such as any episode of an ATA lasting more than
30 seconds, verified by surface ECG (loop recorder) or an intracar-
diac electrogram. This parameter might best reflect differences in le-
sion quality around PVs for electrical isolation. Ineffective ablation
and early gap formation could result in an earlier time to first recur-
rent AF. Even the time to the second or third AF recurrence might
further allow insights into such ablation effects and could therefore
be used as a secondary outcome measurement.
Cutoffs of more than 30 seconds can be reported in addition to
the 30-second primary endpoint to show how procedural success
might change. In fact, the consensus group encourages such reporting
routinely in all clinical trials to better assess the most clinically rele-
vant outcomes for future clinical trials. In particular, higher cutoffs
can be used for patients with persistent or long-standing persistent
AF because of the very high burden of preablation AF and the lower
likelihood that ablation will result in a full “cure” of the arrhythmia. It
is strongly suggested that other cutoffs be prespecified and reported
in secondary outcomes of trials so the true effects of catheter abla-
tion on various types of AF can be put into proper context outside of
the 30-second cutoff.
A cutoff that can be used in addition to 30 seconds would be the
time to first clinical or stroke-relevant AF duration (e.g., more than
1 hour or 5.5 hours). As already described, the SOS trial revealed AF
activity of more than 1 hour per day as a cutoff for an increased risk
of stroke, whereas other investigation revealed various AF burden
levels, such as a marker of an increased risk for thromboembolism.
This parameter might be used preferentially in studies in which the
potential of ablation to reduce outcomes such as thromboembolism
might be the primary interest. “Time to first persistent AF” could be
considered for trials of persistent AF ablation in which time to the
first episode of more than 7 days might be a relevant parameter while
investigating substrate modifying ablation therapies such as atrial lines
or localized rotational activity elimination.
AF Burden Endpoints
Rather than report time to an AF recurrence of a specific duration,
many feel that AF burden is a more optimal endpoint for assessing ab-
lation efficacy. AF burden can be estimated based on serial long-term
monitoring results and patient symptom reporting, but only continu-
ous monitoring through a cardiac implantable electronic device
(loop, pacemaker, ICD) can truly define the burden. Furthermore,
placement of such an implantable recording device should ideally be
performed preablation so that pre- and postablation outcomes can
be compared. Use of such devices, however, can be quite costly and
impose undue difficulty in performing clinical trials. AF burden can be
used in various ways in AF ablation trials. Freedom from relevant AF—
classically defined as an absence of any ATA of more than
30 seconds—might be defined, for example, as a low daily AF burden
less than 1%–2%. This approach would recognize the fact that
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Table 13 Advantages and disadvantages of AF-related endpoints in AF ablation trials
Endpoint Advantages Disadvantages Relevance and Comments
Freedom from AF/AFL/AT re-
currence “gold standard” is
30 seconds
Has been in use for many years
Can be used to compare results
of new trials with historical
trials
Sets a high bar for AF elimination
Can systematically underestimate
the efficacy of AF ablation, par-
ticularly for persistent AF, if 30-
second cutoff is used
Particularly well suited for parox-
ysmal AF outcomes
Reporting of cutoffs other than
30 seconds encouraged as sec-
ondary endpoints to better
contextualize results
May be reported as proportion
of patients free from arrhythmia
or time to recurrence
Freedom from stroke-relevant
AF/AFL/AT-duration cutoff of
1 hour
Useful for trials in which interest
is more for prognostic change
conferred by ablation rather
than elimination of all
arrhythmias
No consistent definition of what
a stroke-relevant duration of
AF is: ranges from 6 minutes to
24 hours in literature
More than 1 hour could be a use-
ful cutoff based on results of
505 trial
May be reported as proportion
of patients free from arrhythmia
or time to recurrence
Freedom from AF/AFL/AT
requiring intervention (emer-
gency visits, cardioversion, ur-
gent care visit, reablation,
etc.)
Can provide an endpoint more
relevant to systemic costs of AF
recurrence
Clinically relevant
Will overestimate efficacy of ab-
lation by ignoring shorter epi-
sodes not requiring
intervention that still might be
important to quality of life or
stroke
Determination of what is an
“intervention” must be prespe-
cified in protocol and biases
mitigated to avoid over- or
underintervention in the trial
Freedom from persistent AF/
AFL/AT-duration cutoff of 7
days
Useful for trials assessing add-
itional substrate modification in
persistent AF
Can systematically overestimate
the efficacy of AF ablation, par-
ticularly for persistent AF
Can require continuous monitor-
ing to definitively assess if epi-
sode is > 7 days
Freedom from AF/AFL/AT on
previously ineffective antiar-
rhythmic therapy
If patient maintains sinus rhythm
on previously ineffective drug
therapy, this may be considered
a clinically relevant, successful
outcome
Will increase the success rate
compared with off-drug success
May not be relevant to patients
hoping to discontinue drug
therapy
Postablation drug and dosage of
drug should be identical to pre-
ablation drug and dosage
Significant reduction in AF bur-
den: >75% reduction from
pre- to postablation and/or
total postablation burden
<12%
Can be useful in persistent AF
studies, but might not be suited
for early, paroxysmal AF
studies
Ideally requires continuous moni-
toring using an implantable
device
No scientific basic exists showing
that a 75% reduction in AF bur-
den impacts hard endpoints,
including heart failure, stroke,
and mortality
AF burden can be estimated by
intermittent monitoring and re-
porting of patient symptoms
and recurrences like a “time in
therapeutic range” report for
oral anticoagulation; see text
Could also see 75% reduction in
number and duration of AF
episodes
Because there is no firm scientific
basis for selecting the cutoff of
75%, this prior recommenda-
tion is provided only as an ex-
ample of what future clinical
trials may choose to use as a
definition of clinical/partial
success
Prevention in AF progression:
time to first episode of per-
sistent AF (>7 days)
Does not assume that total elim-
ination of AF is required
Well suited for paroxysmal or
“early” AF studies in which goal
is to prevent progression to
persistent AF
Prevention in progression might
be irrelevant for stroke or
thromboembolic outcomes
Long follow-up time might be
required unless population is
“enriched”
Can ideally require continuous
implantable monitoring
Might be useful for specific popu-
lations such as heart failure or
hypertrophic cardiomyopathy,
in which progression to persist-
ent AF can lead to increased
hospitalization
Continued
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occasional and short-lasting atrial arrhythmias over a few minutes
might be an acceptable outcome. It should be noted, however, that
there is a substantial difference between long-term, daily monitoring
of AF burden versus a detection period of 3 months, as in the
Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker
Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial, in
which short-lasting AF was likely a marker for future long-lasting AF
outside the monitoring period.1390 Reduction in AF burden more than
75% could be considered as clinical success just as much as reduction
in both the number and duration of AF episodes. However, the num-
ber and duration of episodes are significantly more sensitive to
under- or oversensing with subcutaneous devices but also implanted
pacemakers or defibrillators for various technical reasons. In contrast,
the number of episodes necessitating urgent or emergency care visits might
not only be clinically relevant, but might also help demonstrate the
cost-effectiveness of the procedure. Furthermore, because there is
no firm scientific basis for selecting the cutoff of 75%, this prior rec-
ommendation is provided only as an example of what future clinical
trials might choose to use as a definition of clinical or partial success.
In recognition that AF ablation may not be curative, particularly for
patients with persistent or long-standing persistent AF, the concepts
of AF progression and regression, while unproven, could be of inter-
est. Many patients might initially present with very infrequent epi-
sodes of PAF that could be quite manageable with minimal drug
therapy. Ablation in this setting might help delay progression to
higher burden paroxysmal or persistent AF, which could be associ-
ated with decreased functioning but also increased risks of stroke,
HF, or death. On the other hand, patients with persistent AF who
can be converted into infrequent, paroxysmal forms of AF (so-called
AF regression) might experience not only QOL benefits but also a
potential reduction in morbidity and mortality. In order for these
endpoints to be widely implemented, thresholds of AF must be es-
tablished under which patient QOL and risk of adverse outcomes are
reliably improved, which has yet to be done. For example, one sub-
study of the STAR AF 1 trial showed that patients with very high-
burden paroxysmal or persistent AF could continue to experience
up to 2 or more hours of AF per month postablation and still report
an improvement in QOL.1391 The patient-reported symptoms did
not deteriorate until they experienced more than 27 hours of AF per
month. This outcome remains an important focus for ongoing clinical
investigation.
When an implanted device is not used, many trials have attempted
to estimate changes in AF burden by using various methods. If careful
recording of patient symptoms and clinically apparent recurrences is
performed, including duration and frequency of episodes over a spe-
cific period of time, then these could be used to estimate AF burden
pre- and postablation.1391 Total AF detected on intermittent continu-
ous monitoring (like intermittent 7 day Holters) could be used,
....................................................................................................................................................................................................................
Table 13 Continued
Endpoint Advantages Disadvantages Relevance and Comments
Regression of AF: reduction in
burden to a given threshold
or conversion of persistent to
paroxysmal AF
Does not assume that total elim-
ination of AF is required
Well suited for persistent “late”
AF studies in which goal is to
regress to paroxysmal AF,
which might be easier to con-
trol with drug therapy
Regression endpoint will over-
estimate efficacy of AF ablation
Might ideally require continuous
implantable monitoring
Patients will require ongoing drug
therapy
Could be particularly useful for
long-standing persistent AF
populations with structural
heart disease, heart failure, etc.
Acute AF termination during ab-
lation procedure
Could provide indication of suc-
cessful modification of sub-
strate responsible for
maintaining AF, most relevant
to persistent or long-standing
persistent AF
Limited studies have linked acute
AF termination to long-term
success
Relevance of acute AF termin-
ation has not consistently been
shown to correlate to long-
term success
Endpoint might not be relevant
to paroxysmal AF patients in
whom AF might terminate
spontaneously
Some studies employ administra-
tion of intravenous or oral anti-
arrhythmics during ablation that
could cause spontaneous
termination
Studies consider termination as
reversion to sinus rhythm,
whereas others consider rever-
sion to any regular tachycardia
as termination
Intraprocedural administration of
preprocedural oral antiarrhyth-
mics or intraprocedural intra-
venous antiarrhythmics are
discouraged
If antiarrhythmics are used, their
use and dosage before and dur-
ing the ablation should be
clearly documented
Termination to sinus rhythm and
termination to another regular
tachycardia (AT or AFL) should
be separately reported
AF, atrial fibrillation; AFL, atrial flutter; AT, atrial tachycardia.
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although the accuracy is somewhat limited depending on the duration
and frequency of monitoring.378 Intermittent, but frequent, transtele-
phonic or other portable monitors can provide brief strips of rhythm
status. Time in sinus rhythm could be estimated by the number of
weeks (for example), with sinus transmissions divided by the total
number of weeks of the monitoring period, akin to a time in thera-
peutic range for OAC with VKA.245 A combination of symptom re-
porting and ECG status at various time points can also be used to
calculate estimated time in sinus rhythm, as was employed in a sub-
study of the Atrial Fibrillation and Congestive Heart Failure study.1392
Endpoint Differences for Paroxysmal vs Nonparoxysmal
AF Ablation Studies
Important consideration should be given to differences in AF recur-
rence endpoint reporting in trials of paroxysmal versus persistent AF.
For patients with PAF, the burden might not be well suited for deter-
mining the outcome of ablation. Because the preablation burden can
be relatively low in the months preceding ablation, with a large range
in the burden, it might be hard to realize a statistically significant
change postablation or between treatment arms. This was demon-
strated in the MANTRA-PAF trial, in which total AF burden (meas-
ured on 7-day Holters) did not differ between drug and ablation
therapy, but the total number of patients free from any AF recur-
rence was significantly higher in the ablation arm.378 For these pa-
tients, a time to recurrence or proportion free from arrhythmia
endpoint might be a better option. Other statistical concerns that
need to be considered for AF burden as an outcome measure for ab-
lation in PAF patients include regression to the mean and the clus-
tered, nonrandom pattern of PAF episodes. For persistent AF,
reduction in burden can be much more relevant because the preabla-
tion burden will be high (close to 100%), with little standard devi-
ation, making a statistical reduction postablation easier to define. On
the other hand, the use of freedom from 30-second endpoints could
underestimate the true clinical effect of ablation in the persistent
population. The consensus group still maintains that the 30-second
endpoint should be reported, but secondary endpoints such as
changes in AF burden and/or AF progression or regression should
also be described. Both CABANA and EAST, with more extensive
monitoring, should both shed additional light on these issues.
The writing group members encourage reporting of other second-
ary endpoints that might better represent clinically relevant out-
comes of the ablation procedure. Improvements in patient QOL are
very important to assessing the clinical success of AF ablation, but as
with any intervention, the magnitude of the improvements might be
confounded by expectancy bias (“placebo effect”). A detailed discus-
sion of QOL measurements and potential benefits and limitations ap-
pears later in this section.
Symptomatic vs Asymptomatic Recurrence
Even in patients with highly symptomatic AF, as many as half of all epi-
sodes can occur without associated symptoms.56 The ratio of asymp-
tomatic to symptomatic episodes increases up to 4-fold postablation,
perhaps due to shorter durations, slower rates, or autonomic modu-
lation after the procedure.58 In highly symptomatic AF patients,
asymptomatic episodes often coexist with the symptomatic; thus,
patient reporting of symptoms can still serve as a rough surrogate for
procedural success. For clinical trial purposes, however, reporting of
only symptomatic AF recurrences could overestimate procedural
success by 20% or more by missing asymptomatic recurrences. The
importance of asymptomatic AF detection depends in part on the
purpose of the clinical trial. If patient QOL and symptom abatement
is the primary goal of therapy in the study, then underdetection of
asymptomatic AF could be of little relevance. However, if the study
goal is to reduce the associated risks of AF (stroke, HF) and to change
potential therapy, including OAC, then the detection of asymptom-
atic AF is much more critical. Typically, the detection of asymptom-
atic AF recurrence is accomplished by longer-term, frequent, or
implantable monitoring approaches.
AF Monitoring Postablation
Arrhythmia monitoring can be performed with the use of noncontin-
uous or continuous ECG monitoring tools. The choice of either
method depends on individual need and consequence of arrhythmia
detection. Basically, more intensive monitoring is associated with a
greater likelihood of detecting both symptomatic and asymptomatic
AF.56,58,937 Identification of patients with AF and assessment of AF
burden with intermittent monitoring have been shown to depend on
a patient’s actual AF burden, and improve with an increasing fre-
quency or duration of intermittent monitoring. Conversely, the more
complex and longer the method of monitoring that is used, the lower
the patient compliance.
Available noncontinuous detection tools include scheduled or
symptom-initiated standard ECGs, Holter (24 hours to 7 days), trans-
telephonic recordings, patient- and automatically activated devices,
and external loop recorders (Table 6). Scheduled 7-day Holter ECG
recordings or daily plus symptom-activated event recordings are esti-
mated to document approximately 70% of AF recurrences, with an
estimated negative predictive value for absence of AF between 25%
and 40%.947,1393
Continuous ECG monitoring is permanent monitoring for a long
time period (1, 2, or more years). Continuous ECG monitoring can
be facilitated with the use of implantable devices. Implantable pace-
makers or defibrillators with atrial leads allow the burden of AF to be
assessed by tracking the number and duration of mode switch epi-
sodes, particularly when an arrhythmia duration of >_5 minutes is
used as the cutoff value.1394 More recently, a long-term subcutaneous
implantable loop monitor has become available to facilitate continu-
ous AF monitoring based on R-R interval analysis over a period of
2 years.58,952 These types of continuous ECG monitoring devices can
be used to evaluate the results of AF ablation. Although implantable
subcutaneous monitors hold promise for determination of AF bur-
den long term, important limitations include less than 100% specificity
due to myopotentials, atrial and ventricular premature beats, as well
as limited memory resulting in electrograms not being retrievable to
verify the correct rhythm diagnosis. Another major limitation for the
performance of clinical trials is cost. If the consensus mandated ILR
monitoring for all clinical trials, the cost of performing such trials
would likely become prohibitive. There are also a number of patients
who might refuse long-term devices.
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Again, the purpose of the trial should be married to the type of
monitoring performed. If the ultimate goal is to improve patients’
QOL, then excessive monitoring for asymptomatic AF might not be
worth the effort. However, if the goal is to reduce AF burden, or
change prognosis, particularly from a stroke point of view, then con-
tinuous monitoring should be required.
In the past, the consensus statement has provided minimum clinical
requirements for postablation monitoring for clinical trials. Initially,
these were quite stringent, and in the last consensus statement, the
requirements were made more flexible. The current consensus rec-
ommends the following minimum monitoring requirements: For PAF,
follow-up screening should include a minimum of three visits (e.g., at
3, 6, and 12 months), with a 12-lead ECG at each visit, a 24-hour
Holter at the end of the follow-up period (e.g., 12 months), and more
limited event recording from the end of the 3-month blanking period
to the end of follow-up (e.g., 12 months), both at regular periods and
with patient activated recordings obtained at the time of symptoms
(or equivalent). Follow-up beyond 1 year is encouraged and might
occur every 6 months with Holter and ECG (or equivalent). For per-
sistent and long-standing persistent AF, follow-up screening should
include a minimum of three visits (e.g., at 3, 6, and 12 months), with a
12-lead ECG at each visit, a 24-hour Holter every 6 months, and
event recording from the end of the 3-month blanking period to the
end of follow-up (e.g., 12 months), as well as at the time of symptoms
(or equivalent). Follow-up beyond 1 year is encouraged and might
occur every 6 months with Holter and ECG (or equivalent) (Table
10). In making these recommendations, it is important to recognize
that the writing group views these as minimal monitoring recommen-
dations. More intensive follow-up with more frequent Holters and/or
extended ECG monitoring is encouraged. Similarly, follow-up beyond
1 year is encouraged and might occur every 6 months with Holter
and ECG (or equivalent). It is acknowledged that this recommenda-
tion falls short of continuous monitoring and will largely detect symp-
tomatic recurrences with only a limited ability to detect
asymptomatic recurrences. However, this minimum standard will at
least provide some consistency in trial reporting, and trials are
encouraged to exceed this standard where possible. Details are
specified in Table 10.
QOL Measurement
QOL should remain an important endpoint for AF ablation studies,
but not necessarily the primary endpoint. QOL is limited by treat-
ment expectancy bias. Although sham procedures have not been
performed to assess the true magnitude of this bias, it is unlikely that
such studies will be performed because they would be extremely
challenging.
QOL can be measured both using well-established scales like the
SF-36 and EQ5D, but also using more specific scales like the Atrial
Fibrillation Effect on QualiTy-of-Life (AFEQT), University of Toronto
Atrial Fibrillation Severity Scale, Mayo AF-Specific Symptom
Inventory, or Symptom Severity Score. The advantages of the gener-
alized scales is their wide usage in medicine, the ability to compare
improvements in QOL with other medical interventions, and in the
case of the EQ5D, converts QOL changes to cost-effectiveness
measures through the use of QALYs; however, these scales can lack
sensitivity to changes with reductions in AF burden. AF-specific
scales, on the other hand, might improve sensitivity and discriminate
more effectively between patients with successful and failed ablation.
At present, the true value of AF-specific scales requires validation
through randomized studies using standard of care therapy as a con-
trol arm, given the comorbidity associated with AF can impact the
same symptoms that affect the EHRA score and the Canadian
Cardiovascular Society Severity in Atrial Fibrillation scale. Finally, we
still need to know how these changes compare with other medical
interventions and if the changes would result in substantial reductions
in health care cost or patient morbidity.
The consensus group recommends that all clinical trials incorpor-
ate some measure of patient-reported outcomes and preferably
measure them using both a general and an AF-specific measurement
scale. A summary of QOL scales is provided in Table 11.
Other Endpoint Reporting
There are important subgroups of patients and clinical outcomes that
need to be studied, but are unlikely to be addressed by any one study
alone. To facilitate pooled data analysis, the consensus recommends
routine reporting of additional subgroup analyses, particularly around
modifiable lifestyle risk factors. BMI and OSA should be reported in
the baseline characteristics and subgroup analysis, comparing high vs
average BMI and those with and without sleep apnea, which should
be ideally reported in recognition that modifiable risk factors are an
important contributor to AF progression and ablation outcome.
The need for a better understanding of the most appropriate post-
ablation anticoagulation strategy is particularly recognized by the
consensus group. Due to the rarity of stroke, TIA, and peripheral
thromboembolism, it is unlikely that sufficiently powered studies will
ever be conducted to conclusively resolve this relevant aspect of clin-
ical practice. In the absence of a clear strategy, it is possible that post-
ablation patients are exposed to an excess stroke risk if untreated, or
to an excess bleeding risk if treated with no real need. As a reason-
able surrogate to an evidence-based demonstration, the consensus
group recognizes the value of careful reporting of secondary out-
comes in which individual data are made available for (1) baseline risk
factors; (2) postablation anticoagulation strategy (e.g., if continued,
and if so, which drug, or discontinued); and (3) postablation
thromboembolic and/or bleeding events. An effort of this type would
not only enhance the quality of the single studies, but it would also
allow for pooled analyses in the future. Examples of specific second-
ary outcomes that could be reported are summarized in Tables 10
and 12.
Unanswered Questions in AF Ablation
There is still much to be learned about the mechanisms of AF, tech-
niques of AF ablation, and long-term outcomes. The following are un-
answered questions for future investigation:
(1) AF ablation and modification of stroke risk and need for ongoing
OAC: The CHA2DS2-VASc score was developed for patients with
clinical AF. If a patient has received a successful ablation such that
he/she no longer has clinical AF (subclinical, or no AF), then what is
the need for ongoing OAC? Are there any patients in whom suc-
cessful ablation could lead to discontinuation of OAC?
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(2) Substrate modification in catheter-based management of AF—
particularly for persistent AF: What is the proper lesion set required
beyond PVI? Do lines and CFAE have any remaining role? Are these
approaches ill-advised or simply discouraged?
What is the role of targeting localized rotational activations? How
do we ablate a localized rotational activation? How can scar be char-
acterized and targeted for ablation? Do we need to replicate the
MAZE procedure? Does the RA need to be targeted as well as the
LA?
(3) Autonomic influence in AF: Is clinical AF really an autonomic medi-
ated arrhythmia? Is elimination of GP required? Is there a role for
autonomic modulation, for example, spinal cord or vagal
stimulation?
(4) Contribution and modulation of risk factors on outcomes of AF ab-
lation: Obesity reduction has been shown to reduce AF burden and
recurrence in patients undergoing ablation. What is the role of bari-
atric surgery?
Does the modulation of other risk factors influence outcome such
as hypertension, sleep apnea, and diabetes?
(5) Outcomes in ablation of high-risk populations: Do high-risk popula-
tions benefit from AF ablation?
Congestive HF has been assessed in smaller trials, but larger trials
are required. Outcome data are needed in patients with very
enlarged LAs, HCM, patients with renal failure on dialysis, and the
very elderly.
(6) Surgical vs catheter-based vs hybrid ablation: There should be more
comparative work between percutaneous and minimally invasive
surgical approaches. Both report similar outcomes, but there is a
dearth of comparative data. Is there any patient benefit to hybrid
procedures?
(7) How do we characterize patients who are optimal candidates for
ablation? Preablation LGE-MRI might identify patients with heavy
burdens of scar who are unlikely to respond to ablation. These
techniques must become reproducible and reliable and must be as-
sessed in multicenter trials. Other markers need to be investigated,
including genetic markers, biochemical markers, and clinical
markers based on aggregated risk scores.
(8) The incremental role of new technologies: As newer and often
more expensive technologies are produced for AF ablation, their
definitive incremental value must be determined in order to justify
change in practice or case cost. These technologies include global
(basket) mapping techniques, newer ablation indices for assessing
lesion durability, advanced imaging for viewing lesions in the myo-
cardium, etc. New energy sources, including laser, low-intensity
ultrasound, photonic particle therapy, external beam ablation, and
MRI-guided ablation, must be assessed in comparative fashion.
(9) Outcomes of AF ablation: We need to better understand the clin-
ical relevance of ablation outcomes. What is the significance of time
to recurrence of 30 seconds of arrhythmia? How do we best quan-
tify AF burden?
How do these outcomes relate to QOL and stroke risk?
(10) What is the role of surgical LA reduction? Does LAA occlusion or
obliteration improve outcome of persistent AF ablation with an ac-
companying reduction in stroke? Does ablation work through atrial
size reduction? What is the incidence of “stiff atrial” syndrome and
does this mitigate the clinical impact of ablation?
(11) Working in teams: What is the role of the entire heart team in AF
ablation? Does a team approach achieve better outcomes than a
“silo” approach?
(12) Improving the safety of catheter ablation: As ablation extends to
more operators and less experienced operators, the statistical oc-
currence of complications will increase. We need newer techniques
to minimize complications and institute standards for operators to
improve the reproducibility of ablation results and safety profiles at
a variety of centers worldwide.
(13) How does catheter ablation affect mortality, stroke, and hospitaliza-
tion in broad and selected patient populations receiving catheter ab-
lation for AF?
(14) Management of patients who fail initial attempts at catheter abla-
tion: Should there be specific criteria for repeat ablations (e.g.,
atrial size, BMI)? Should patients be referred for surgery for re-
peat ablation?
In order to address these and other important questions in the
field of catheter and surgical AF ablation, we urge investigators to cre-
ate and participate in multisite collaborations and electrophysiology
research networks with involvement of senior and junior investiga-
tors on the steering committees to push forward the next phase of
AF research. We also urge funding bodies to support these important
initiatives.
Section 14: Conclusion
Catheter ablation of AF is a very commonly performed procedure
in hospitals throughout the world. Surgical ablation of AF, al-
though less widely available than catheter-based AF ablation, is
also an important therapeutic option for patients with AF at many
major medical centers. This document provides an up-to-date re-
view of the indications, techniques, and outcomes of catheter and
surgical ablation of AF. Areas for which a consensus can be
reached concerning AF ablation are identified, and a series of con-
sensus definitions have been developed for use in future clinical
trials of AF ablation. Also included within this document are rec-
ommendations concerning indications for AF ablation, technical
performance of this procedure, and training. It is our hope to im-
prove patient care by providing a foundation for those involved
with care of patients with AF as well as those who perform AF ab-
lation. It is recognized that this field continues to evolve rapidly
and that this document will need to be updated. Successful AF ab-
lation programs optimally should consist of a cooperative team of
cardiologists, electrophysiologists, and surgeons to ensure appro-
priate indications, procedure selection, and follow-up.
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